	
In	O
general	O
,	O
adverse	O
events	O
reported	O
by	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
hepatitis	O
C	O
virus	O
co-infection	O
were	O
similar	O
to	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
subjects	O
without	O
hepatitis	O
B	O
and/or	O
hepatitis	O
C	O
virus	O
co-infection	O
.	O
	
There	O
was	O
a	O
6-fold	O
increase	O
in	O
the	O
risk	O
of	O
CTCAE	O
Grade	O
3-4	O
hyperglycemia	B
in	O
patients	O
with	O
diabetes	O
or	O
glucose	O
intolerance	O
and	O
a	O
2-fold	O
increase	O
in	O
patients	O
taking	O
corticosteroids	O
.	O
	
In	O
patients	O
who	O
develop	O
serious	O
allergic	O
reactions	O
,	O
discontinue	O
Zydelig	O
permanently	O
and	O
institute	O
appropriate	O
supportive	O
measures	O
.	O
	
Approximately	O
81	O
%	O
of	O
these	O
local	O
reactions	O
resolved	O
without	O
intervention	O
within	O
4	O
weeks	O
of	O
XIAFLEX	O
injections	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
signs	O
of	O
peripheral	O
motor	O
and	O
sensory	O
neuropathy	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
AdreView	O
administration	O
.	O
	
Monitor	O
liver	O
function	O
tests	O
before	O
treatment	O
and	O
before	O
the	O
start	O
of	O
each	O
cycle	O
.	O
	
Rupture	B
of	I
hepatic	I
adenomas	I
may	O
cause	O
death	B
through	O
intra-abdominal	B
hemorrhage	I
.	O
	
Diarrhea	B
due	O
to	O
Zydelig	O
responds	O
poorly	O
to	O
antimotility	O
agents	O
.	O
	
Interrupt	O
Ferriprox	O
therapy	O
if	O
neutropenia	O
develops	O
(	O
ANC	O
<	O
1.5	O
x	O
10	O
9	O
/L	O
)	O
.	O
	
5.4	O
QT	O
Prolongation	O
In	O
an	O
uncontrolled	O
open-label	O
ECG	O
study	O
in	O
26	O
patients	O
,	O
QT	B
prolongation	I
was	O
observed	O
on	O
Day	O
8	O
,	O
independent	O
of	O
eribulin	O
concentration	O
,	O
with	O
no	O
QT	B
prolongation	I
observed	O
on	O
Day	O
1	O
.	O
	
Patients	O
whose	O
baseline	O
ALT	O
or	O
AST	O
were	O
elevated	O
were	O
more	O
likely	O
to	O
experience	O
liver	B
test	I
elevation	I
than	O
those	O
beginning	O
with	O
normal	O
values	O
.	O
	
These	O
include	O
cases	O
of	O
Stevens-Johnson	B
syndrome	I
,	O
toxic	B
epidermal	I
necrolysis	I
and	O
erythema	B
multiforme	I
.	O
	
Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
from	O
first	O
drug	O
intake	O
to	O
event	O
date	O
,	O
date	O
of	O
last	O
drug	O
intake	O
+	O
2	O
,	O
death	O
date	O
(	O
whatever	O
occurred	O
first	O
)	O
across	O
all	O
treated	O
subjects	O
divided	O
by	O
365.25	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
to	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Febrile	B
neutropenia	I
has	O
been	O
reported	O
with	O
treatment	O
with	O
ADCETRIS	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
CIGARETTE	O
SMOKING	O
AND	O
SERIOUS	O
CARDIOVASCULAR	B
EVENTS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Discontinuation	O
of	O
therapy	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
10	O
%	O
of	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
Patients	O
received	O
placebo	O
(	O
N=1393	O
)	O
,	O
FARXIGA	O
5	O
mg	O
(	O
N=1145	O
)	O
,	O
or	O
FARXIGA	O
10	O
mg	O
(	O
N=1193	O
)	O
once	O
daily	O
.	O
	
At	O
one	O
year	O
after	O
transplantation	O
these	O
values	O
were	O
183	O
mg/dL	O
,	O
50	O
mg/dL	O
,	O
102	O
mg/dL	O
,	O
and	O
151	O
mg/dL	O
,	O
respectively	O
,	O
in	O
401	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
and	O
196	O
mg/dL	O
,	O
48	O
mg/dL	O
,	O
108	O
mg/dL	O
,	O
and	O
195	O
mg/dL	O
,	O
respectively	O
,	O
in	O
405	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
Follow	O
instructions	O
for	O
preparation	O
(	O
including	O
admixing	O
)	O
and	O
administration	O
strictly	O
to	O
minimize	O
medication	O
errors	O
(	O
including	O
underdose	O
and	O
overdose	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
(	O
2.4	O
)	O
]	O
.	O
	
Anyone	O
considering	O
prescribing	O
ONFI	O
or	O
any	O
other	O
AED	O
must	O
balance	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
or	O
behavior	O
with	O
the	O
risk	O
of	O
untreated	O
illness	O
.	O
	
The	O
desired	O
therapeutic	O
response	O
was	O
achieved	O
at	O
doses	O
of	O
4-6	O
mg/hour	O
.	O
	
These	O
were	O
commonly	O
dyspepsia	B
(	O
including	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
pain	I
,	O
abdominal	B
discomfort	I
,	O
and	O
epigastric	B
discomfort	I
)	O
and	O
gastritis-like	O
symptoms	O
(	O
including	O
GERD	B
,	O
esophagitis	B
,	O
erosive	B
gastritis	I
,	O
gastric	B
hemorrhage	I
,	O
hemorrhagic	B
gastritis	I
,	O
hemorrhagic	B
erosive	I
gastritis	I
,	O
and	O
gastrointestinal	B
ulcer	I
)	O
.	O
	
Based	O
on	O
the	O
severity	O
of	O
the	O
adverse	O
drug	O
reaction	O
,	O
withhold	O
ZYKADIA	O
with	O
resumption	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Patients	O
with	O
alanine	O
aminotransferase	O
or	O
aspartate	O
aminotransferase	O
>	O
3	O
*	O
ULN	O
(	O
upper	O
limit	O
of	O
normal	O
)	O
experienced	O
a	O
higher	O
incidence	O
of	O
Grade	O
4	O
neutropenia	B
and	O
febrile	B
neutropenia	I
than	O
patients	O
with	O
normal	O
aminotransferase	O
levels	O
.	O
	
Among	O
patients	O
in	O
Study	O
3	O
who	O
reported	O
no	O
prior	O
exposure	O
to	O
XIAFLEX	O
,	O
97	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-I	O
and	O
AUX-II	O
after	O
two	O
concurrent	O
doses	O
of	O
XIAFLEX	O
0.58	O
mg	O
(	O
total	O
dose	O
of	O
1.16	O
mg	O
)	O
in	O
the	O
same	O
hand	O
.	O
	
In	O
other	O
XIAFLEX-treated	O
patients	O
(	O
9	O
of	O
1044	O
;	O
0.9	O
%	O
)	O
,	O
a	O
combination	O
of	O
penile	B
ecchymoses	I
,	O
sudden	O
penile	B
detumescence	I
,	O
and/or	O
a	O
penile	B
``	O
popping	B
''	O
sound	B
was	O
reported	O
,	O
and	O
in	O
these	O
cases	O
,	O
a	O
diagnosis	O
of	O
corporal	B
rupture	I
can	O
not	O
be	O
excluded	O
.	O
	
The	O
mean	O
time	O
to	O
nadir	O
was	O
13	O
days	O
and	O
the	O
mean	O
time	O
to	O
recovery	O
from	O
severe	O
neutropenia	B
(	O
<	O
500/mm	O
3	O
)	O
was	O
8	O
days	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
20	O
%	O
)	O
reported	O
in	O
the	O
two	O
randomized	O
clinical	O
trials	O
that	O
occurred	O
more	O
commonly	O
(	O
>	O
=2	O
%	O
)	O
in	O
the	O
abiraterone	O
acetate	O
arm	O
were	O
anemia	B
,	O
elevated	B
alkaline	I
phosphatase	I
,	O
hypertriglyceridemia	B
,	O
lymphopenia	B
,	O
hypercholesterolemia	B
,	O
hyperglycemia	B
,	O
elevated	B
AST	I
,	O
hypophosphatemia	B
,	O
elevated	B
ALT	I
and	O
hypokalemia	B
.	O
	
The	O
information	O
below	O
is	O
derived	O
from	O
a	O
clinical	O
trial	O
database	O
for	O
FANAPT	O
consisting	O
of	O
2070	O
patients	O
exposed	O
to	O
FANAPT	O
at	O
doses	O
of	O
10	O
mg/day	O
or	O
greater	O
,	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
*	O
The	O
most	O
common	O
adverse	O
reactions	O
are	O
(	O
incidence	O
>	O
=	O
5	O
%	O
)	O
chromaturia	B
,	O
nausea	B
,	O
vomiting	B
and	O
abdominal	B
pain	I
,	O
alanine	B
aminotransferase	I
increased	I
,	O
arthralgia	B
and	O
neutropenia	B
.	O
	
Comparisons	O
between	O
placebo	O
and	O
SIMPONI	O
ARIA	O
were	O
based	O
on	O
the	O
first	O
24	O
weeks	O
of	O
exposure	O
.	O
	
Controlled	O
Studies	O
with	O
Rheumatoid	O
Arthritis	O
CIMZIA	O
was	O
studied	O
primarily	O
in	O
placebo-controlled	O
trials	O
and	O
in	O
long-term	O
follow-up	O
studies	O
.	O
	
POTIGA	O
was	O
discontinued	O
in	O
3	O
of	O
the	O
5	O
patients	O
who	O
required	O
catheterization	O
,	O
and	O
all	O
were	O
able	O
to	O
void	O
spontaneously	O
;	O
however	O
,	O
1	O
of	O
the	O
3	O
patients	O
continued	O
intermittent	O
self-catheterization	O
.	O
	
Table	O
1	O
:	O
Change	O
in	O
Fasting	O
Glucose	O
FANAPT	O
Placebo	O
24	O
mg/day	O
Mean	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
n=114	O
n=228	O
Serum	O
Glucose	O
Change	O
from	O
Baseline	O
-0.5	O
6.6	O
Proportion	O
of	O
Patients	O
with	O
Shifts	O
Serum	O
Glucose	O
Normal	O
to	O
High	O
2.5	O
%	O
10.7	O
%	O
(	O
<	O
100	O
mg/dL	O
to	O
>	O
=126	O
mg/dL	O
)	O
(	O
2/80	O
)	O
(	O
18/169	O
)	O
Pooled	O
analyses	O
of	O
glucose	O
data	O
from	O
clinical	O
studies	O
including	O
longer	O
term	O
trials	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
54	O
(	O
49	O
%	O
)	O
subjects	O
treated	O
with	O
Zydelig	O
+	O
rituximab	O
.	O
	
*	O
Palmar-plantar	B
Erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
:	O
Interrupt	O
COMETRIQ	O
,	O
decrease	O
dose	O
.	O
	
Steroids	O
should	O
be	O
used	O
with	O
caution	O
in	O
the	O
presence	O
of	O
glaucoma	O
.	O
	
S	O
A	O
medically	O
important	O
event	O
that	O
may	O
be	O
life-threatening	O
or	O
result	O
in	O
death	B
or	O
hospitalization	O
or	O
prolongation	O
of	O
existing	O
hospitalization	O
.	O
	
Serious	O
adverse	O
events	O
that	O
may	O
be	O
associated	O
with	O
CRS	B
included	O
pyrexia	B
,	O
headache	B
,	O
nausea	B
,	O
asthenia	B
,	O
hypotension	B
,	O
increased	B
alanine	I
aminotransferase	I
,	O
increased	B
aspartate	I
aminotransferase	I
,	O
and	O
increased	B
total	I
bilirubin	I
;	O
these	O
events	O
infrequently	O
led	O
to	O
BLINCYTO	O
discontinuation	O
.	O
	
Tuberculosis	B
and	O
herpes	B
infections	I
were	O
reported	O
more	O
frequently	O
in	O
patients	O
receiving	O
NULOJIX	O
than	O
cyclosporine	O
.	O
	
(	O
2.3	O
)	O
,	O
(	O
5.2	O
)	O
5	O
.	O
	
5.4	O
Bacterial	O
Infections	O
Prolonged	O
use	O
of	O
corticosteroids	O
may	O
suppress	B
the	I
host	I
response	I
and	O
thus	O
increase	O
the	O
hazard	O
of	O
secondary	B
ocular	I
infections	I
.	O
	
Orthostatic	B
hypotension	I
was	O
reported	O
in	O
5	O
%	O
of	O
patients	O
given	O
20	O
to	O
24	O
mg/day	O
,	O
3	O
%	O
of	O
patients	O
given	O
10	O
to	O
16	O
mg/day	O
,	O
and	O
1	O
%	O
of	O
patients	O
given	O
placebo	O
.	O
	
In	O
this	O
study	O
13	O
patients	O
experienced	O
bone	B
fractures	I
for	O
treatment	O
durations	O
up	O
to	O
104	O
weeks	O
.	O
	
The	O
rate	O
of	O
withdrawals	O
due	O
to	O
adverse	O
events	O
in	O
placebo-controlled	O
monotherapy	O
and	O
combination	O
therapy	O
trials	O
was	O
2.4	O
%	O
(	O
19/801	O
)	O
for	O
placebo	O
,	O
2.2	O
%	O
(	O
24/1072	O
)	O
for	O
Edarbi	O
40	O
mg	O
,	O
and	O
2.7	O
%	O
(	O
29/1074	O
)	O
for	O
Edarbi	O
80	O
mg	O
.	O
	
Abrupt	O
discontinuation	O
or	O
dose	O
reduction	O
has	O
been	O
associated	O
with	O
the	O
appearance	O
of	O
new	O
symptoms	O
that	O
include	O
dizziness	B
,	O
nausea	B
,	O
headache	B
,	O
irritability	B
,	O
insomnia	B
,	O
diarrhea	B
,	O
anxiety	B
,	O
fatigue	B
,	O
abnormal	B
dreams	I
,	O
and	O
hyperhidrosis	B
.	O
	
*	O
Macrovascular	O
outcomes	O
:	O
There	O
have	O
been	O
no	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TRULICITY	O
or	O
any	O
other	O
antidiabetic	O
drug	O
(	O
5.7	O
)	O
.	O
	
(	O
5.4	O
)	O
item	O
{	O
Viral	O
infections-	O
Employment	O
of	O
a	O
corticosteroid	O
medication	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
a	O
history	O
of	O
herpes	O
simplex	O
requires	O
great	O
caution	O
.	O
	
Caution	O
should	O
be	O
exercised	O
in	O
treating	O
patients	O
with	O
pre-existing	O
hypertension	O
,	O
cardiovascular	O
,	O
or	O
cerebrovascular	O
conditions	O
that	O
might	O
be	O
compromised	O
by	O
increases	O
in	O
blood	O
pressure	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
New-Onset	O
Diabetes	O
After	O
Transplantation	O
The	O
incidence	O
of	O
new-onset	B
diabetes	I
after	I
transplantation	I
(	O
NODAT	B
)	O
was	O
defined	O
in	O
Studies	O
1	O
and	O
2	O
as	O
use	O
of	O
an	O
antidiabetic	O
agent	O
for	O
>	O
=30	O
days	O
or	O
>	O
=2	O
fasting	O
plasma	O
glucose	O
values	O
>	O
=126	O
mg/dL	O
(	O
7.0	O
mmol/L	O
)	O
post-transplantation	O
.	O
	
5.14	O
Glaucoma	O
and	O
Cataracts	O
Glaucoma	B
,	O
increased	B
intraocular	I
pressure	I
,	O
and	O
cataracts	B
have	O
been	O
reported	O
in	O
patients	O
with	O
COPD	O
or	O
asthma	O
following	O
the	O
long-term	O
administration	O
of	O
inhaled	O
corticosteroids	O
.	O
	
Because	O
of	O
the	O
observed	O
ophthalmologic	O
adverse	O
reactions	O
,	O
POTIGA	O
should	O
only	O
be	O
used	O
in	O
patients	O
who	O
have	O
responded	O
inadequately	O
to	O
several	O
alternative	O
treatments	O
and	O
for	O
whom	O
the	O
benefits	O
outweigh	O
the	O
risk	O
of	O
retinal	O
abnormalities	O
and	O
potential	O
vision	O
loss	O
.	O
	
While	O
all	O
atypical	O
antipsychotic	O
drugs	O
have	O
been	O
shown	O
to	O
produce	O
some	O
metabolic	O
changes	O
,	O
each	O
drug	O
in	O
the	O
class	O
has	O
its	O
own	O
specific	O
risk	O
profile	O
.	O
	
Advise	O
patients	O
with	O
myelosuppression	O
following	O
TREANDA	O
treatment	O
to	O
contact	O
a	O
physician	O
if	O
they	O
have	O
symptoms	O
or	O
signs	O
of	O
infection	O
.	O
	
Causality	O
can	O
not	O
be	O
excluded	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Pharmacyclics	O
at	O
1-877-877-3536	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
In	O
a	O
monotherapy	O
study	O
comparing	O
NESINA	O
to	O
a	O
sulfonylurea	O
in	O
elderly	O
patients	O
,	O
the	O
incidence	O
of	O
hypoglycemia	B
was	O
5.4	O
%	O
with	O
NESINA	O
compared	O
to	O
26	O
%	O
with	O
glipizide	O
(	O
Table	O
2	O
)	O
.	O
	
Patients	O
who	O
experience	O
Grade	O
3	O
or	O
worse	O
allergic-type	O
reactions	O
should	O
not	O
be	O
rechallenged	O
.	O
	
Adjunctive	O
Therapy	O
Controlled	O
Trials	O
In	O
the	O
controlled	O
adjunctive	O
therapy	O
epilepsy	O
trials	O
(	O
Study	O
3	O
,	O
Study	O
4	O
,	O
and	O
Study	O
5	O
)	O
,	O
the	O
rate	O
of	O
discontinuation	O
as	O
a	O
result	O
of	O
any	O
adverse	O
reaction	O
was	O
14	O
%	O
for	O
the	O
800	O
mg	O
dose	O
,	O
25	O
%	O
for	O
the	O
1200	O
mg	O
dose	O
,	O
and	O
7	O
%	O
in	O
subjects	O
randomized	O
to	O
placebo	O
.	O
	
(	O
6.1	O
)	O
*	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
for	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
are	O
pyrexia	B
,	O
chills	B
,	O
fatigue	B
,	O
rash	B
,	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
abdominal	B
pain	I
,	O
peripheral	B
edema	I
,	O
cough	B
,	O
headache	B
,	O
arthralgia	B
,	O
night	B
sweats	I
,	O
decreased	B
appetite	I
,	O
constipation	B
,	O
and	O
myalgia	B
.	O
	
In	O
the	O
clinical	O
trials	O
,	O
blood	O
counts	O
were	O
monitored	O
every	O
week	O
initially	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Anaphylaxis	O
and	O
Angioedema	O
TECFIDERA	O
can	O
cause	O
anaphylaxis	B
and	O
angioedema	B
after	O
the	O
first	O
dose	O
or	O
at	O
any	O
time	O
during	O
treatment	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Valeant	O
Pharmaceuticals	O
North	O
America	O
LLC	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Patients	O
were	O
randomized	O
to	O
three	O
treatment	O
groups	O
:	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
(	O
n=58	O
)	O
,	O
Vimizim	O
2	O
mg/kg	O
once	O
every	O
other	O
week	O
(	O
n=59	O
)	O
,	O
or	O
placebo	O
(	O
n=59	O
)	O
.	O
	
The	O
role	O
of	O
lymphopenia	B
in	O
this	O
case	O
is	O
unknown	O
.	O
	
Gastrointestinal	O
disorders	O
Diarrhea	B
37	O
0	O
Nausea	B
21	O
0	O
Stomatitis	B
16	O
0	O
Gastroesophageal	B
reflux	I
disease	I
13	O
0	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
Rash	B
22	O
0	O
Bruising	B
16	O
0	O
Pruritus	B
11	O
0	O
General	O
disorders	O
and	O
administrative	O
site	O
conditions	O
Fatigue	B
21	O
0	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Muscle	B
spasms	I
21	O
0	O
Arthropathy	B
13	O
0	O
Infections	O
and	O
infestations	O
Upper	B
respiratory	I
tract	I
infection	I
19	O
0	O
Sinusitis	B
19	O
0	O
Pneumonia	B
14	O
6	O
Skin	B
infection	I
14	O
2	O
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
Epistaxis	B
19	O
0	O
Cough	B
13	O
0	O
Nervous	O
system	O
disorders	O
Dizziness	B
14	O
0	O
Headache	B
13	O
0	O
Neoplasms	O
benign	O
,	O
malignant	O
,	O
and	O
unspecified	O
(	O
including	O
cysts	O
and	O
polyps	O
)	O
Skin	B
cancer	I
11	O
0	O
Table	O
8	O
:	O
Treatment-EmergentBased	O
on	O
laboratory	O
measurements	O
.	O
	
The	O
safety	O
of	O
INLYTA	O
has	O
been	O
evaluated	O
in	O
715	O
patients	O
in	O
monotherapy	O
studies	O
,	O
which	O
included	O
537	O
patients	O
with	O
advanced	O
RCC	O
.	O
	
Renal	B
function	I
abnormalities	I
can	O
occur	O
after	O
initiating	O
INVOKANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
the	O
clinical	O
study	O
of	O
7808	O
postmenopausal	O
women	O
with	O
osteoporosis	O
,	O
the	O
incidence	O
of	O
infections	B
resulting	O
in	O
death	B
was	O
0.2	O
%	O
in	O
both	O
placebo	O
and	O
Prolia	O
treatment	O
groups	O
.	O
	
Increases	O
in	O
Serum	O
Magnesium	O
Dose-related	O
increases	B
in	I
serum	I
magnesium	I
were	O
observed	O
early	O
after	O
initiation	O
of	O
INVOKANA	O
(	O
within	O
6	O
weeks	O
)	O
and	O
remained	O
elevated	O
throughout	O
treatment	O
.	O
	
Approximately	O
50	O
%	O
of	O
the	O
subjects	O
were	O
male	O
and	O
the	O
ethnic	O
distribution	O
was	O
60	O
%	O
Caucasian	O
,	O
30	O
%	O
Asian	O
,	O
6	O
%	O
Hispanic	O
,	O
2	O
%	O
Black	O
,	O
and	O
3	O
%	O
patients	O
of	O
other	O
ethnic	O
groups	O
.	O
	
Dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
were	O
required	O
in	O
16	O
%	O
of	O
XALKORI-treated	O
patients	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
ENTEREG	O
12	O
mg	O
in	O
1,793	O
patients	O
in	O
10	O
placebo-controlled	O
studies	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
and	O
at	O
least	O
twice	O
the	O
rate	O
of	O
placebo	O
)	O
reported	O
with	O
acute	O
monotherapy	O
treatment	O
of	O
manic	O
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	O
I	O
disorder	O
in	O
adults	O
were	O
somnolence	B
,	O
dizziness	B
,	O
extrapyramidal	B
symptoms	I
other	O
than	O
akathisia	B
,	O
and	O
increased	B
weight	I
and	O
during	O
the	O
adjunctive	O
therapy	O
trial	O
in	O
bipolar	O
I	O
disorder	O
in	O
adults	O
were	O
somnolence	B
and	O
oral	B
hypoesthesia	I
.	O
	
This	O
finding	O
with	O
salmeterol	O
is	O
considered	O
a	O
class	O
effect	O
of	O
LABA	O
,	O
including	O
indacaterol	O
,	O
the	O
active	O
ingredient	O
in	O
ARCAPTA	O
NEOHALER	O
.	O
	
After	O
the	O
Cleansing	O
Gel	O
has	O
been	O
wiped	O
off	O
,	O
wash	O
the	O
area	O
with	O
soap	O
and	O
water	O
.	O
	
Monitor	O
and	O
manage	O
patients	O
using	O
standards	O
of	O
care	O
,	O
including	O
antidiarrheals	O
,	O
antiemetics	O
,	O
and	O
fluid	O
replacement	O
.	O
	
Tables	O
3	O
and	O
4	O
summarize	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
in	O
XALKORI-treated	O
patients	O
.	O
	
At	O
the	O
end	O
of	O
treatment	O
,	O
0.8	O
%	O
,	O
4.0	O
%	O
,	O
and	O
2.7	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
,	O
had	O
hemoglobin	B
above	I
the	I
upper	I
limit	I
of	I
normal	I
.	O
	
The	O
incidence	O
of	O
all-cause	O
mortality	B
was	O
2.3	O
%	O
(	O
n	O
=	O
90	O
)	O
in	O
the	O
placebo	O
group	O
and	O
1.8	O
%	O
(	O
n	O
=	O
70	O
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
QT	O
Prolongation	O
*	O
QT	B
prolongation	I
can	O
occur	O
with	O
SIRTURO	O
.	O
	
(	O
5.1	O
)	O
QT	O
Prolongation	O
*	O
QT	B
prolongation	I
can	O
occur	O
with	O
SIRTURO	O
.	O
	
Antipsychotic	O
treatment	O
,	O
itself	O
,	O
however	O
,	O
may	O
suppress	O
(	O
or	O
partially	O
suppress	O
)	O
the	O
signs	O
and	O
symptoms	O
of	O
the	O
syndrome	O
and	O
thereby	O
may	O
possibly	O
mask	O
the	O
underlying	O
process	O
.	O
	
Other	O
adverse	O
reactions	O
reported	O
in	O
patients	O
receiving	O
Besivance	O
occurring	O
in	O
approximately	O
1-2	O
%	O
of	O
patients	O
included	O
:	O
blurred	B
vision	I
,	O
eye	B
pain	I
,	O
eye	B
irritation	I
,	O
eye	B
pruritus	I
and	O
headache	B
.	O
	
This	O
rare	B
type	I
of	I
T-cell	I
lymphoma	I
has	O
a	O
very	O
aggressive	O
disease	O
course	O
and	O
is	O
usually	O
fatal	B
.	O
	
Monitor	O
LDL-C	O
and	O
treat	O
if	O
appropriate	O
after	O
initiating	O
INVOKANA	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
The	O
potency	O
Units	O
of	O
DYSPORT	O
(	O
r	O
)	O
are	O
not	O
interchangeable	O
with	O
other	O
preparations	O
of	O
botulinum	O
toxin	O
products	O
and	O
,	O
therefore	O
,	O
units	O
of	O
biological	O
activity	O
of	O
DYSPORT	O
(	O
r	O
)	O
can	O
not	O
be	O
compared	O
to	O
or	O
converted	O
into	O
units	O
of	O
any	O
other	O
botulinum	O
toxin	O
products	O
(	O
5.1	O
)	O
*	O
Recommended	O
dose	O
and	O
frequency	O
of	O
administration	O
should	O
not	O
be	O
exceeded	O
(	O
5.4	O
)	O
*	O
Immediate	O
medical	O
attention	O
may	O
be	O
required	O
in	O
cases	O
of	O
swallowing	B
difficulties	I
(	O
5.3	O
)	O
*	O
Concomitant	O
neuromuscular	O
disorder	O
may	O
exacerbate	O
clinical	O
effects	O
of	O
treatment	O
(	O
5.5	O
)	O
*	O
DYSPORT	O
(	O
r	O
)	O
contains	O
human	O
albumin	O
.	O
	
(	O
2.4	O
,	O
5.10	O
)	O
*	O
Hepatic	B
Toxicity	I
and	O
Hepatic	B
Failure	I
:	O
Monitor	O
liver	O
enzymes	O
.	O
	
The	O
safety	O
of	O
SAPHRIS	O
was	O
evaluated	O
in	O
403	O
pediatric	O
patients	O
with	O
bipolar	O
I	O
disorder	O
who	O
participated	O
in	O
a	O
3-week	O
,	O
placebo-controlled	O
,	O
double-blind	O
trial	O
,	O
of	O
whom	O
302	O
patients	O
received	O
SAPHRIS	O
at	O
fixed	O
doses	O
ranging	O
from	O
2.5	O
mg	O
to	O
10	O
mg	O
twice	O
daily	O
.	O
	
Table	O
1	O
Table	O
2	O
6.2	O
Immunogenicity	O
As	O
with	O
most	O
therapeutic	O
proteins	O
,	O
patients	O
may	O
develop	O
anti-drug	O
antibodies	O
(	O
ADA	O
)	O
to	O
ERWINAZE.In	O
a	O
study	O
with	O
ERWINAZE	O
treatment	O
by	O
intramuscular	O
administration	O
(	O
Study	O
1	O
)	O
,	O
6	O
of	O
56	O
(	O
11	O
%	O
)	O
patients	O
treated	O
with	O
ERWINAZE	O
developed	O
antibodies	O
to	O
ERWINAZE	O
.	O
	
(	O
5.9	O
)	O
*	O
Monitor	O
for	O
proteinuria	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
.	O
	
Other	O
important	O
considerations	O
in	O
the	O
differential	O
diagnosis	O
include	O
central	O
anticholinergic	O
toxicity	O
,	O
heat	O
stroke	O
,	O
drug	O
fever	O
,	O
and	O
primary	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
pathology	O
.	O
	
Merkel	B
cell	I
carcinoma	I
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF-blocking	O
agents	O
.	O
	
Cases	O
of	O
syncope	B
were	O
also	O
reported	O
after	O
the	O
first	O
dose	O
of	O
GILENYA	O
.	O
	
Because	O
of	O
the	O
risk	O
of	O
seizure	O
associated	O
with	O
XTANDI	O
use	O
,	O
patients	O
should	O
be	O
advised	O
of	O
the	O
risk	O
of	O
engaging	O
in	O
any	O
activity	O
where	O
sudden	O
loss	O
of	O
consciousness	O
could	O
cause	O
serious	O
harm	O
to	O
themselves	O
or	O
others	O
.	O
	
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
less	O
than	O
10	O
%	O
of	O
AFINITOR	O
-treated	O
patients	O
:	O
epistaxis	B
(	O
9	O
%	O
)	O
,	O
decreased	B
appetite	I
(	O
6	O
%	O
)	O
,	O
otitis	B
media	I
(	O
6	O
%	O
)	O
,	O
depression	B
(	O
5	O
%	O
)	O
,	O
abnormal	B
taste	I
(	O
5	O
%	O
)	O
,	O
increased	B
blood	I
luteinizing	I
hormone	I
(	I
LH	I
)	I
levels	I
(	O
4	O
%	O
)	O
,	O
increased	B
blood	I
follicle	I
stimulating	I
hormone	I
(	I
FSH	I
)	I
levels	I
(	O
3	O
%	O
)	O
,	O
hypersensitivity	B
(	O
3	O
%	O
)	O
,	O
ovarian	B
cyst	I
(	O
3	O
%	O
)	O
,	O
pneumonitis	B
(	O
1	O
%	O
)	O
,	O
and	O
angioedema	B
(	O
1	O
%	O
)	O
.	O
	
The	O
symptoms	O
are	O
consistent	O
with	O
the	O
mechanism	O
of	O
action	O
of	O
botulinum	O
toxin	O
and	O
may	O
include	O
asthenia	B
,	O
generalized	B
muscle	I
weakness	I
,	O
diplopia	B
,	O
blurred	B
vision	I
,	O
ptosis	B
,	O
dysphagia	B
,	O
dysphonia	B
,	O
dysarthria	B
,	O
urinary	B
incontinence	I
,	O
and	O
breathing	B
difficulties	I
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
age	O
>	O
60	O
years	O
,	O
hypertension	O
or	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
has	O
occurred	O
in	O
patients	O
with	O
impaired	O
elimination	O
of	O
GBCAs	O
.	O
	
Of	O
the	O
14	O
patients	O
receiving	O
GILENYA	O
,	O
7	O
patients	O
had	O
2:1	B
AV	I
block	I
(	O
5	O
patients	O
within	O
the	O
first	O
6	O
hours	O
postdose	O
and	O
2	O
patients	O
after	O
6	O
hours	O
postdose	O
)	O
.	O
	
Somnolence	B
includes	O
the	O
following	O
events	O
:	O
somnolence	B
,	O
sedation	B
,	O
and	O
hypersomnia	B
.	O
	
In	O
Study	O
2	O
,	O
1	O
of	O
871	O
(	O
0.1	O
%	O
)	O
chemotherapy-naive	O
patients	O
treated	O
with	O
XTANDI	O
and	O
1	O
of	O
844	O
(	O
0.1	O
%	O
)	O
patients	O
treated	O
with	O
placebo	O
experienced	O
a	O
seizure	B
.	O
	
Most	O
patients	O
(	O
>	O
70	O
%	O
)	O
in	O
both	O
trials	O
were	O
enrolled	O
in	O
Eastern	O
Europe	O
and	O
were	O
White	O
.	O
	
5.3	O
Congestive	O
Heart	O
Failure	O
Cases	O
of	O
worsening	B
congestive	I
heart	I
failure	I
)	O
and	O
new	B
onset	I
CHF	I
have	O
been	O
reported	O
with	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
.	O
	
Adverse	O
events	O
that	O
led	O
to	O
treatment	O
discontinuation	O
and	O
occurred	O
in	O
more	O
than	O
1	O
%	O
of	O
patients	O
taking	O
GILENYA	O
0.5	O
mg	O
were	O
serum	B
transaminase	I
elevations	I
(	O
4.7	O
%	O
compared	O
to	O
1	O
%	O
on	O
placebo	O
)	O
and	O
basal	B
cell	I
carcinoma	I
(	O
1	O
%	O
compared	O
to	O
0.5	O
%	O
on	O
placebo	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
3	O
%	O
;	O
2	O
or	O
more	O
patients	O
)	O
observed	O
in	O
alglucosidase	O
alfa-treated	O
patients	O
were	O
hypersensitivity	B
reactions	I
and	O
included	O
anaphylaxis	B
,	O
headache	B
,	O
nausea	B
,	O
urticaria	B
,	O
dizziness	B
,	O
chest	B
discomfort	I
,	O
vomiting	B
,	O
hyperhidrosis	B
,	O
flushing/feeling	O
hot	B
,	O
increased	B
blood	I
pressure	I
,	O
paresthesia	B
,	O
pyrexia	B
,	O
local	B
swelling	I
,	O
diarrhea	B
,	O
pruritus	B
,	O
rash	B
,	O
and	O
throat	B
tightness	I
.	O
	
If	O
hypertension	O
can	O
not	O
be	O
adequately	O
controlled	O
,	O
withhold	O
Kyprolis	O
and	O
evaluate	O
.	O
	
5.6	O
Embryofetal	O
Toxicity	O
Based	O
on	O
its	O
mechanism	O
of	O
action	O
,	O
GILOTRIF	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
NMS	B
is	O
an	O
uncommon	O
but	O
life-threatening	O
syndrome	O
characterized	O
by	O
fever	B
or	O
hyperthermia	B
,	O
muscle	B
rigidity	I
,	O
involuntary	B
movements	I
,	O
altered	B
consciousness	I
,	O
and	O
mental	B
status	I
changes	I
.	O
	
(	O
5.2	O
)	O
*	O
HORIZANT	O
is	O
not	O
interchangeable	O
with	O
other	O
gabapentin	O
products	O
.	O
	
Inform	O
patients	O
of	O
the	O
risk	O
and	O
of	O
symptoms	O
and	O
to	O
contact	O
a	O
physician	O
immediately	O
if	O
symptoms	O
of	O
an	O
infusion	O
reaction	O
occur	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17	O
)	O
]	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
Similar	O
adverse	O
reactions	O
have	O
been	O
observed	O
in	O
postmarketing	O
use	O
as	O
compared	O
to	O
the	O
clinical	O
trials	O
.	O
	
Although	O
the	O
overall	O
incidence	O
of	O
FD	O
&	O
C	O
Yellow	O
No	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
2	O
%	O
and	O
more	O
common	O
than	O
placebo	O
)	O
are	O
cough	B
,	O
oropharyngeal	B
pain	I
,	O
nasopharyngitis	B
,	O
headache	B
and	O
nausea	B
.	O
	
Evaluate	O
dyspnea	O
to	O
exclude	O
cardiopulmonary	O
conditions	O
including	O
cardiac	O
failure	O
and	O
pulmonary	O
syndromes	O
.	O
	
In	O
some	O
cases	O
of	O
anaphylactic	B
reactions	I
,	O
epinephrine	O
was	O
administered	O
.	O
	
The	O
safety	O
of	O
DYSPORT	O
(	O
r	O
)	O
for	O
the	O
treatment	O
of	O
hyperhidrosis	O
has	O
not	O
been	O
established	O
.	O
	
Creatinine	B
increases	I
were	O
comparable	O
by	O
background	O
NRTIs	O
and	O
were	O
similar	O
in	O
treatment-experienced	O
subjects	O
.	O
	
5.7	O
Risk	O
of	O
Serious	O
Adverse	O
Reactions	O
in	O
Pancreatic	O
and	O
Gastric	O
Anastomoses	O
ENTEREG	O
has	O
not	O
been	O
studied	O
in	O
patients	O
having	O
pancreatic	O
or	O
gastric	O
anastomosis	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
DOTAREM	O
exposure	O
in	O
2813	O
patients	O
,	O
representing	O
2672	O
adults	O
and	O
141	O
pediatric	O
patients	O
.	O
	
Table	O
4	O
displays	O
the	O
mean	O
changes	O
in	O
serum	O
creatinine	O
and	O
eGFR	O
levels	O
at	O
Week	O
144	O
and	O
the	O
percentage	O
of	O
subjects	O
with	O
elevations	B
in	I
serum	I
creatinine	I
(	O
All	O
Grades	O
)	O
.	O
	
(	O
5.13	O
)	O
*	O
Potential	O
for	O
motor	B
impairment	I
:	O
Use	O
caution	O
when	O
operating	O
machinery	O
.	O
	
In	O
the	O
clinical	O
trials	O
,	O
2	O
subjects	O
who	O
received	O
placebo	O
committed	O
suicide	B
compared	O
to	O
none	O
in	O
OTEZLA-treated	O
subjects	O
.	O
	
b	O
Includes	O
diarrhea	B
,	O
enteritis	B
,	O
enterocolitis	B
,	O
colitis	B
,	O
defecation	B
urgency	I
,	O
and	O
steatorrhea	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
1	O
%	O
and	O
more	O
common	O
than	O
with	O
placebo	O
)	O
:	O
ocular	B
irritation	I
,	O
application	B
site	I
irritation	I
,	O
and	O
application	B
site	I
anesthesia	I
.	O
	
Patients	O
with	O
neuromuscular	O
disorders	O
may	O
be	O
at	O
increased	O
risk	O
of	O
clinically	O
significant	O
effects	O
including	O
severe	O
dysphagia	B
and	O
respiratory	B
compromise	I
from	O
typical	O
doses	O
of	O
XEOMIN	O
[	O
See	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.5	O
Keratitis	O
Keratitis	B
,	O
characterized	O
as	O
worsening	B
eye	I
inflammation	I
,	O
lacrimation	B
,	O
light	B
sensitivity	I
,	O
blurred	B
vision	I
,	O
eye	B
pain	I
,	O
and/or	O
red	B
eye	I
occurred	O
in	O
0.8	O
%	O
of	O
patients	O
treated	O
with	O
GILOTRIF	O
among	O
3865	O
patients	O
across	O
clinical	O
trials	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
chronic	O
infections	O
.	O
	
Some	O
patients	O
had	O
residual	O
visual	B
acuity	I
loss	I
even	O
after	O
resolution	O
of	O
macular	B
edema	I
.	O
	
In	O
2-year	O
,	O
double-blind	O
,	O
placebo-controlled	O
studies	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
,	O
macular	B
edema	I
with	O
or	O
without	O
visual	B
symptoms	I
occurred	O
in	O
1.5	O
%	O
of	O
patients	O
(	O
11/799	O
)	O
treated	O
with	O
fingolimod	O
1.25	O
mg	O
,	O
0.5	O
%	O
of	O
patients	O
(	O
4/783	O
)	O
treated	O
with	O
GILENYA	O
0.5	O
mg	O
and	O
0.4	O
%	O
of	O
patients	O
(	O
3/773	O
)	O
treated	O
with	O
placebo	O
.	O
	
The	O
proportion	O
of	O
subjects	O
with	O
psoriasis	O
who	O
discontinued	O
treatment	O
due	O
to	O
any	O
adverse	O
reaction	O
was	O
6.1	O
%	O
for	O
subjects	O
treated	O
with	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
and	O
4.1	O
%	O
for	O
placebo-treated	O
subjects	O
.	O
	
Infections	B
,	O
stomatitis	B
,	O
and	O
pneumonitis	B
were	O
the	O
most	O
common	O
reasons	O
for	O
treatment	O
delay	O
or	O
dose	O
reduction	O
.	O
	
No	O
cases	O
of	O
transmission	O
of	O
viral	O
diseases	O
or	O
CJD	O
have	O
ever	O
been	O
reported	O
for	O
albumin	O
.	O
	
It	O
is	O
recommended	O
that	O
patients	O
being	O
considered	O
for	O
FANAPT	O
treatment	O
who	O
are	O
at	O
risk	O
for	O
significant	O
electrolyte	O
disturbances	O
have	O
baseline	O
serum	O
potassium	O
and	O
magnesium	O
measurements	O
with	O
periodic	O
monitoring	O
.	O
	
5.4	O
Risk	O
of	O
Serious	O
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Severe	O
Hepatic	O
Impairment	O
Patients	O
with	O
severe	O
hepatic	O
impairment	O
may	O
be	O
at	O
higher	O
risk	O
of	O
serious	O
adverse	O
reactions	O
(	O
including	O
dose-related	O
serious	O
adverse	O
reactions	O
)	O
because	O
up	O
to	O
10-fold	O
higher	O
plasma	O
levels	O
of	O
drug	O
have	O
been	O
observed	O
in	O
such	O
patients	O
compared	O
with	O
patients	O
with	O
normal	O
hepatic	O
function	O
.	O
	
Mean	O
percentage	O
decreases	B
in	I
BMD	I
from	O
baseline	O
to	O
Week	O
144	O
in	O
the	O
STRIBILD	O
group	O
were	O
comparable	O
to	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
at	O
the	O
lumbar	O
spine	O
(	O
-1.43	O
%	O
versus	O
-3.68	O
%	O
,	O
respectively	O
)	O
and	O
at	O
the	O
hip	O
(	O
-2.83	O
%	O
versus	O
-3.77	O
%	O
,	O
respectively	O
)	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
PRADAXA	O
is	O
contraindicated	O
in	O
patients	O
with	O
mechanical	O
prosthetic	O
valves	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
(	O
2.1	O
,	O
5.7	O
,	O
14.1	O
)	O
*	O
Immunizations	O
:	O
avoid	O
use	O
of	O
live	O
vaccines	O
during	O
treatment	O
.	O
	
If	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
do	O
not	O
modify	O
the	O
dose	O
of	O
TAFINLAR	O
.	O
	
5.3	O
Local	O
Skin	O
Reactions	O
Severe	O
skin	B
reactions	I
in	I
the	I
treated	I
area	I
,	O
can	O
occur	O
after	O
topical	O
application	O
of	O
Picato	O
(	O
r	O
)	O
gel	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
*	O
Oral	B
ulceration	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
hypotension	O
after	O
initiating	O
therapy	O
and	O
increase	O
monitoring	O
in	O
clinical	O
situations	O
where	O
volume	O
contraction	O
is	O
expected	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
DaTscan	O
administration	O
and	O
,	O
following	O
administration	O
,	O
observe	O
patients	O
for	O
symptoms	O
or	O
signs	O
of	O
a	O
hypersensitivity	O
reaction	O
.	O
	
Rehydrate	O
and	O
treat	O
with	O
anti-emetics	O
and	O
anti-diarrheals	O
as	O
needed	O
.	O
	
Avoid	O
use	O
of	O
PRADAXA	O
and	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
(	O
CrCl	O
15-30	O
mL/min	O
)	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Symptomatic	O
treatment	O
employed	O
in	O
clinical	O
trials	O
included	O
steroid	O
and	O
mydriatic	O
ophthalmic	O
drops	O
.	O
	
Promptly	O
evaluate	O
signs	O
and	O
symptoms	O
of	O
blood	O
loss	O
.	O
	
In	O
the	O
randomized	O
trial	O
,	O
five	O
patients	O
(	O
1.3	O
%	O
)	O
experienced	O
fatal	B
infectious	B
adverse	I
events	I
(	O
sepsis	B
or	O
septic	B
shock	I
)	O
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
peginterferon	O
alfa	O
and	O
ribavirin	O
for	O
pre-treatment	O
,	O
on-treatment	O
and	O
post-treatment	O
laboratory	O
testing	O
recommendations	O
including	O
hematology	O
,	O
biochemistry	O
(	O
including	O
hepatic	O
function	O
tests	O
)	O
,	O
and	O
pregnancy	O
testing	O
requirements	O
.	O
	
Treatment	O
of	O
SJIA	O
A	O
total	O
of	O
201	O
SJIA	O
patients	O
aged	O
2	O
to	O
less	O
than	O
20	O
years	O
have	O
received	O
ILARIS	O
in	O
clinical	O
trials	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
important	O
adverse	O
reactions	O
are	O
described	O
elsewhere	O
in	O
labeling	O
:	O
*	O
Anaphylaxis	B
and	O
Angioedema	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
*	O
e	O
Rate	O
of	O
documented	O
symptomatic	O
hypoglycemia	B
for	O
active	O
controls	O
18	O
%	O
(	O
glimepiride	O
)	O
and	O
2	O
%	O
(	O
sitagliptin	O
)	O
.	O
	
The	O
adverse	O
drug	O
reactions	O
associated	O
with	O
ILARIS	O
treatment	O
in	O
SJIA	O
patients	O
were	O
infections	B
,	O
abdominal	B
pain	I
,	O
and	O
injection	B
site	I
reactions	I
.	O
	
Liver	O
Enzyme	O
Abnormalities	O
In	O
the	O
pool	O
of	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
a	O
similar	O
proportion	O
of	O
patients	O
experienced	O
at	O
least	O
one	O
event	O
of	O
ALT	B
)	I
increase	I
of	O
3-fold	O
or	O
greater	O
above	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
0.9	O
%	O
and	O
0.9	O
%	O
for	O
all	O
comparators	O
versus	O
TANZEUM	O
)	O
.	O
	
In	O
Study	O
1	O
,	O
VORAXAZE-related	O
adverse	O
reactions	O
were	O
collected	O
on	O
a	O
flow	O
sheet	O
with	O
a	O
daily	O
log	O
of	O
adverse	O
reactions	O
characterized	O
as	O
``	O
glucarpidase	O
toxicity	O
.	O
''	O
	
Monitor	O
patients	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
tuberculosis	O
including	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
,	O
patients	O
who	O
are	O
on	O
treatment	O
for	O
latent	O
tuberculosis	O
,	O
or	O
patients	O
who	O
were	O
previously	O
treated	O
for	O
tuberculosis	O
infection	O
.	O
	
(	O
5.6	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Post-Transplant	B
Lymphoproliferative	I
Disorder	I
(	O
PTLD	B
)	O
:	O
increased	O
risk	O
,	O
predominantly	O
involving	O
the	O
CNS	O
;	O
monitor	O
for	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
and	O
symptoms	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
Clinical	O
Trials	O
of	O
Vizamyl	O
(	O
N	O
=	O
761	O
subjects	O
)	O
Adverse	O
Reaction	O
N	O
(	O
percent	O
of	O
patients	O
)	O
Flushing	B
16	O
(	O
2	O
%	O
)	O
Increased	B
blood	I
pressure	I
13	O
(	O
2	O
%	O
)	O
Headache	B
10	O
(	O
1	O
%	O
)	O
Nausea	B
8	O
(	O
1	O
%	O
)	O
Dizziness	B
8	O
(	O
1	O
%	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
reactions	I
:	O
Ask	O
patients	O
about	O
prior	O
reactions	O
to	O
Vizamyl	O
.	O
	
(	O
5.4	O
)	O
*	O
Elderly	O
patients	O
:	O
Patients	O
>	O
=	O
65	O
years	O
of	O
age	O
were	O
more	O
likely	O
to	O
experience	O
fatal	B
outcomes	O
not	O
related	O
to	O
disease	O
progression	O
and	O
certain	O
adverse	O
reactions	O
,	O
including	O
neutropenia	B
and	O
febrile	B
neutropenia	I
.	O
	
5.6	O
Drug	O
Interactions	O
See	O
Table	O
2	O
for	O
a	O
listing	O
of	O
drugs	O
that	O
are	O
contraindicated	O
for	O
use	O
with	O
VICTRELIS	O
due	O
to	O
potentially	O
life-threatening	O
adverse	O
events	O
,	O
significant	O
drug	O
interactions	O
or	O
loss	O
of	O
virologic	O
activity	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
These	O
two	O
trials	O
also	O
included	O
a	O
total	O
of	O
403	O
patients	O
treated	O
with	O
a	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
6.1.1	O
Safety	O
Experience	O
with	O
Kyprolis	O
in	O
Combination	O
with	O
Lenalidomide	O
and	O
Dexamethasone	O
in	O
Patients	O
with	O
Multiple	O
Myeloma	O
The	O
safety	O
of	O
Kyprolis	O
in	O
combination	O
with	O
lenalidomide	O
and	O
dexamethasone	O
(	O
KRd	O
)	O
was	O
evaluated	O
in	O
an	O
open-label	O
randomized	O
study	O
in	O
patients	O
with	O
relapsed	O
multiple	O
myeloma	O
.	O
	
*	O
Hepatitis	B
B	I
reactivation	I
-	O
Monitor	O
HBV	O
carriers	O
during	O
and	O
several	O
months	O
after	O
therapy	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Hepatic	O
Decompensation	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	O
C	O
In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
PROMACTA	O
in	O
combination	O
with	O
interferon	O
and	O
ribavirin	O
may	O
increase	O
the	O
risk	O
of	O
hepatic	B
decompensation	I
.	O
	
Hepatobiliary	O
disorders	O
:	O
hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)	O
]	O
.	O
	
In	O
patients	O
with	O
a	O
pre-existing	O
low	O
WBC/ANC	O
or	O
drug-induced	O
leukopenia/neutropenia	O
,	O
perform	O
a	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
were	O
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
:	O
hyperkeratosis	B
,	O
headache	B
,	O
pyrexia	B
,	O
arthralgia	B
,	O
papilloma	B
,	O
alopecia	B
,	O
and	O
palmar-plantar	B
erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
.	O
	
In	O
several	O
cases	O
,	O
these	O
reactions	O
occurred	O
after	O
the	O
first	O
dose	O
.	O
	
How	O
do	O
I	O
store	O
DUAVEE	O
?	O
	
Consider	O
the	O
risks	O
and	O
benefits	O
of	O
treatment	O
prior	O
to	O
initiating	O
SIMPONI	O
ARIA	O
in	O
patients	O
:	O
*	O
with	O
chronic	O
or	O
recurrent	O
infection	O
;	O
*	O
who	O
have	O
been	O
exposed	O
to	O
tuberculosis	O
;	O
*	O
with	O
a	O
history	O
of	O
an	O
opportunistic	O
infection	O
;	O
*	O
who	O
have	O
resided	O
or	O
traveled	O
in	O
areas	O
of	O
endemic	O
tuberculosis	O
or	O
endemic	O
mycoses	O
,	O
such	O
as	O
histoplasmosis	O
,	O
coccidioidomycosis	O
,	O
or	O
blastomycosis	O
;	O
or	O
*	O
with	O
underlying	O
conditions	O
that	O
may	O
predispose	O
them	O
to	O
infection	O
.	O
	
The	O
following	O
events	O
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
in	O
the	O
three	O
placebo-controlled	O
3-month	O
clinical	O
trials	O
and/or	O
the	O
open-label	O
,	O
long-term	O
extension	O
study	O
lasting	O
12	O
months	O
.	O
	
SPRINT-2	O
(	O
subjects	O
who	O
were	O
previously	O
untreated	O
)	O
and	O
RESPOND-2	O
(	O
subjects	O
who	O
had	O
failed	O
previous	O
therapy	O
)	O
evaluated	O
the	O
use	O
of	O
VICTRELIS	O
800	O
mg	O
three	O
times	O
daily	O
in	O
combination	O
with	O
PegIntron/REBETOL	O
with	O
a	O
four-week	O
lead-in	O
period	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
PegIntron/REBETOL	O
alone	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
ALT	B
elevations	I
with	O
DALVANCE	O
treatment	O
were	O
reported	O
in	O
clinical	O
trials	O
.	O
	
Consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
is	O
recommended	O
to	O
aid	O
in	O
the	O
decision	O
of	O
whether	O
initiating	O
anti-tuberculosis	O
therapy	O
is	O
appropriate	O
for	O
an	O
individual	O
patient	O
.	O
	
5.2	O
Acute	O
Pancreatitis	O
In	O
clinical	O
trials	O
,	O
acute	B
pancreatitis	I
has	O
been	O
reported	O
in	O
association	O
with	O
TANZEUM	O
.	O
	
(	O
N=134	O
)	O
40	O
mg	O
daily	O
(	O
N=757	O
)	O
80	O
mg	O
daily	O
(	O
N=1279	O
)	O
(	O
N=1277	O
)	O
Liver	B
Function	I
Abnormalities	I
0.7	O
%	O
6.6	O
%	O
4.6	O
%	O
4.2	O
%	O
Nausea	B
0.7	O
%	O
1.1	O
%	O
1.3	O
%	O
0.8	O
%	O
Arthralgia	B
0	O
%	O
1.1	O
%	O
0.7	O
%	O
0.7	O
%	O
Rash	B
0.7	O
%	O
0.5	O
%	O
1.6	O
%	O
1.6	O
%	O
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
discontinuation	O
from	O
therapy	O
was	O
liver	B
function	I
abnormalities	I
in	O
1.8	O
%	O
of	O
ULORIC	O
40	O
mg	O
,	O
1.2	O
%	O
of	O
ULORIC	O
80	O
mg	O
,	O
and	O
in	O
0.9	O
%	O
of	O
allopurinol-treated	O
subjects	O
.	O
	
The	O
addition	O
of	O
VICTRELIS	O
to	O
peginterferon	O
alfa	O
and	O
ribavirin	O
is	O
associated	O
with	O
an	O
additional	B
decrease	I
in	I
hemoglobin	I
concentrations	I
.	O
	
5.2	O
Increase	O
in	O
Intraocular	O
Pressure	O
Acute	B
increases	I
in	I
intraocular	I
pressure	I
have	O
been	O
seen	O
within	O
60	O
minutes	O
of	O
intravitreal	O
injection	O
,	O
including	O
with	O
EYLEA	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
Toxic	B
epidermal	I
necrolysis	I
,	O
including	O
fatal	B
outcomes	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)	O
]	O
.	O
	
5.4	O
Cataracts	O
In	O
the	O
three	O
controlled	O
clinical	O
trials	O
in	O
adults	O
with	O
chronic	O
ITP	O
,	O
cataracts	B
developed	O
or	O
worsened	O
in	O
15	O
(	O
7	O
%	O
)	O
patients	O
who	O
received	O
50	O
mg	O
of	O
PROMACTA	O
daily	O
and	O
8	O
(	O
7	O
%	O
)	O
placebo-group	O
patients	O
.	O
	
You	O
can	O
ask	O
your	O
pharmacist	O
or	O
healthcare	O
provider	O
for	O
information	O
about	O
DUAVEE	O
that	O
is	O
written	O
for	O
health	O
professionals	O
.	O
	
Do	O
not	O
restart	O
if	O
confirmed	O
.	O
	
Before	O
prescribing	O
STENDRA	O
,	O
it	O
is	O
important	O
to	O
note	O
the	O
following	O
:	O
EXCERPT	O
:	O
*	O
Patients	O
should	O
not	O
use	O
STENDRA	O
if	O
sexual	O
activity	O
is	O
inadvisable	O
due	O
to	O
cardiovascular	O
status	O
or	O
any	O
other	O
reason	O
(	O
5.1	O
)	O
*	O
Use	O
of	O
STENDRA	O
with	O
alpha-blockers	O
,	O
other	O
antihypertensives	O
,	O
or	O
substantial	O
amounts	O
of	O
alcohol	O
(	O
greater	O
than	O
3	O
units	O
)	O
may	O
lead	O
to	O
hypotension	B
(	O
2.3,5.6,5.7	O
)	O
*	O
Patients	O
should	O
seek	O
emergency	O
treatment	O
if	O
an	O
erection	O
lasts	O
greater	O
than	O
4	O
hours	O
(	O
5.3	O
)	O
*	O
Patients	O
should	O
stop	O
STENDRA	O
and	O
seek	O
medical	O
care	O
if	O
a	O
sudden	O
loss	O
of	O
vision	O
occurs	O
in	O
one	O
or	O
both	O
eyes	O
,	O
which	O
could	O
be	O
a	O
sign	O
of	O
Non	O
Arteritic	O
Ischemic	O
Optic	O
Neuropathy	O
(	O
NAION	O
)	O
.	O
	
Cases	O
of	O
MTC	B
in	O
patients	O
treated	O
with	O
liraglutide	O
,	O
another	O
GLP-1	O
receptor	O
agonist	O
,	O
have	O
been	O
reported	O
in	O
the	O
postmarketing	O
period	O
;	O
the	O
data	O
in	O
these	O
reports	O
are	O
insufficient	O
to	O
establish	O
or	O
exclude	O
a	O
causal	O
relationship	O
between	O
MTC	B
and	O
GLP-1	O
receptor	O
agonist	O
use	O
in	O
humans	O
.	O
	
Table	O
4	O
presents	O
the	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=	O
2	O
%	O
of	O
subjects	O
treated	O
with	O
STENDRA	O
.	O
	
If	O
anemia	O
develops	O
during	O
or	O
after	O
treatment	O
with	O
Teflaro	O
,	O
drug-induced	O
hemolytic	O
anemia	O
should	O
be	O
considered	O
.	O
	
The	O
most	O
serious	O
adverse	O
reactions	O
reported	O
with	O
alglucosidase	O
alfa	O
treatment	O
included	O
anaphylaxis	B
and	O
acute	B
cardiorespiratory	I
failure	I
.	O
	
Renal	O
and	O
Urinary	O
Disorders	O
:	O
Interstitial	B
nephritis	I
.	O
	
Hepatotoxicity	B
may	O
reoccur	O
if	O
PROMACTA	O
is	O
reinitiated	O
.	O
	
Risk	O
factors	O
for	O
arterial	O
vascular	O
disease	O
(	O
for	O
example	O
,	O
hypertension	O
,	O
diabetes	O
mellitus	O
,	O
tobacco	O
use	O
,	O
hypercholesterolemia	O
,	O
and	O
obesity	O
)	O
and/or	O
VTE	O
(	O
for	O
example	O
,	O
personal	O
history	O
or	O
family	O
history	O
of	O
VTE	O
,	O
obesity	O
,	O
and	O
systemic	O
lupus	O
erythematosus	O
)	O
should	O
be	O
managed	O
appropriately	O
.	O
	
With	O
the	O
interventions	O
used	O
for	O
anemia	O
management	O
in	O
the	O
clinical	O
trials	O
,	O
the	O
average	O
additional	O
decrease	O
of	O
hemoglobin	O
was	O
approximately	O
1	O
g	O
per	O
dL	O
.	O
	
Hypertoxin-producing	O
strains	O
of	O
C.	O
difficile	O
cause	O
increased	O
morbidity	O
and	O
mortality	O
,	O
as	O
these	O
infections	O
can	O
be	O
refractory	O
to	O
antibacterial	O
therapy	O
and	O
may	O
require	O
colectomy	O
.	O
	
Hemodialysis	O
does	O
not	O
appear	O
to	O
have	O
a	O
substantial	O
impact	O
on	O
apixaban	O
exposure	O
[	O
seeClinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
corticosteroids	O
or	O
methotrexate	O
)	O
may	O
be	O
at	O
a	O
greater	O
risk	O
of	O
infection	B
.	O
	
In	O
a	O
trial	O
of	O
TANZEUM	O
in	O
patients	O
with	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
the	O
frequency	O
of	O
such	O
gastrointestinal	B
reactions	I
increased	O
as	O
renal	B
function	I
declined	I
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
If	O
the	O
potential	O
benefit	O
for	O
reinitiating	O
treatment	O
with	O
PROMACTA	O
is	O
considered	O
to	O
outweigh	O
the	O
risk	O
for	O
hepatotoxicity	O
,	O
then	O
consider	O
cautiously	O
reintroducing	O
PROMACTA	O
and	O
measure	O
serum	O
liver	O
tests	O
weekly	O
during	O
the	O
dose	O
adjustment	O
phase	O
.	O
	
Sixty-two	O
percent	O
of	O
these	O
patients	O
had	O
at	O
least	O
one	O
sample	O
that	O
was	O
positive	O
for	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
.	O
	
BRAF	O
V600E	O
or	O
V600K	O
Unresectable	O
or	O
Metastatic	O
Melanoma	O
:	O
The	O
safety	O
of	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
was	O
evaluated	O
in	O
Trial	O
2	O
and	O
other	O
trials	O
consisting	O
of	O
a	O
total	O
of	O
202	O
patients	O
with	O
BRAF	O
V600	O
mutation-positive	O
unresectable	O
or	O
metastatic	O
melanoma	O
who	O
received	O
TAFINLAR	O
150	O
mg	O
orally	O
twice	O
daily	O
in	O
combination	O
with	O
trametinib	O
2	O
mg	O
orally	O
once	O
daily	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
requiring	O
intervention	O
in	O
clinical	O
trials	O
were	O
hypersensitivity	B
reactions	I
,	O
occurring	O
in	O
20	O
of	O
39	O
(	O
51	O
%	O
)	O
patients	O
treated	O
with	O
alglucosidase	O
alfa	O
,	O
and	O
included	O
rash	B
,	O
pyrexia	B
,	O
urticaria	B
,	O
flushing	B
,	O
decreased	B
oxygen	I
saturation	I
,	O
cough	B
,	O
tachypnea	B
,	O
tachycardia	B
,	O
hypertension/increased	O
blood	B
pressure	I
,	O
pallor	B
,	O
rigors	B
,	O
vomiting	B
,	O
cyanosis	B
,	O
agitation	B
,	O
and	O
tremor	B
.	O
	
Diagnostic	O
studies	O
including	O
a	O
direct	O
Coombs	O
'	O
test	O
,	O
should	O
be	O
performed	O
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
>	O
=	O
2	O
%	O
of	O
Patients	O
Treated	O
with	O
STENDRA	O
in	O
a	O
Placebo-Controlled	O
Clinical	O
Trial	O
Lasting	O
2	O
Months	O
to	O
Determine	O
the	O
Time	O
to	O
Onset	O
of	O
Effect	O
(	O
Study	O
3	O
)	O
Adverse	O
Reaction	O
Placebon=143	O
STENDRA	O
100	O
mgn=146	O
STENDRA	O
200	O
mgn=146	O
Headache	B
0.7	O
%	O
1.4	O
%	O
8.9	O
%	O
Nasal	B
congestion	I
0.0	O
%	O
0.7	O
%	O
4.1	O
%	O
Gastroenteritis	B
viral	I
0.0	O
%	O
0.0	O
%	O
2.1	O
%	O
Across	O
all	O
trials	O
with	O
any	O
STENDRA	O
dose	O
,	O
1	O
subject	O
reported	O
a	O
change	B
in	I
color	I
vision	I
.	O
	
TANZEUM	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
or	O
in	O
patients	O
with	O
MEN	O
2	O
.	O
	
Because	O
these	O
reactions	O
may	O
worsen	O
renal	O
function	O
,	O
use	O
caution	O
when	O
initiating	O
or	O
escalating	O
doses	O
of	O
TANZEUM	O
in	O
patients	O
with	O
renal	O
impairment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
A	O
specific	O
antidote	O
for	O
ELIQUIS	O
is	O
not	O
available	O
.	O
	
In	O
clinical	O
trials	O
with	O
VICTRELIS	O
,	O
the	O
proportion	O
of	O
subjects	O
who	O
experienced	O
hemoglobin	B
values	I
less	I
than	I
10	I
g	I
per	I
dL	I
was	O
higher	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron	O
(	O
r	O
)	O
/REBETOL	O
(	O
r	O
)	O
than	O
in	O
those	O
treated	O
with	O
PegIntron/REBETOL	O
alone	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
Across	O
8	O
Phase	O
III	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
pancreatitis	B
adjudicated	O
as	O
likely	O
related	O
to	O
therapy	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
TANZEUM	O
(	O
6	O
of	O
2,365	O
[	O
0.3	O
%	O
]	O
)	O
than	O
in	O
patients	O
receiving	O
placebo	O
(	O
0	O
of	O
468	O
[	O
0	O
%	O
]	O
)	O
or	O
active	O
comparators	O
(	O
2	O
of	O
2,065	O
[	O
0.1	O
%	O
]	O
)	O
.	O
	
Tuberculosis	O
should	O
be	O
strongly	O
considered	O
in	O
patients	O
who	O
develop	O
a	O
new	O
infection	O
during	O
CIMZIA	O
treatment	O
,	O
especially	O
in	O
patients	O
who	O
have	O
previously	O
or	O
recently	O
traveled	O
to	O
countries	O
with	O
a	O
high	O
prevalence	O
of	O
tuberculosis	O
,	O
or	O
who	O
have	O
had	O
close	O
contact	O
with	O
a	O
person	O
with	O
active	O
tuberculosis	O
.	O
	
(	O
5.3	O
)	O
*	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
with	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
DALVANCE	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
drug	O
TUDORZA	O
PRESSAIR	O
.	O
	
STENDRA	O
should	O
be	O
used	O
with	O
caution	O
,	O
and	O
only	O
when	O
the	O
anticipated	O
benefits	O
outweigh	O
the	O
risks	O
,	O
in	O
patients	O
with	O
a	O
history	O
of	O
NAION	O
.	O
	
Consider	O
other	O
antidiabetic	O
therapies	O
in	O
patients	O
with	O
a	O
history	O
of	O
pancreatitis	O
.	O
	
If	O
you	O
would	O
like	O
more	O
information	O
,	O
talk	O
with	O
your	O
healthcare	O
provider	O
.	O
	
6.3	O
Immunogenicity	O
Patients	O
with	O
classical	O
HL	O
and	O
sALCL	O
in	O
Studies	O
1	O
and	O
2	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
were	O
tested	O
for	O
antibodies	O
to	O
brentuximab	O
vedotin	O
every	O
3	O
weeks	O
using	O
a	O
sensitive	O
electrochemiluminescent	O
immunoassay	O
.	O
	
Sustained	B
increases	I
in	I
intraocular	I
pressure	I
have	O
also	O
been	O
reported	O
after	O
repeated	O
intravitreal	O
dosing	O
with	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
inhibitors	O
.	O
	
The	O
population	O
studied	O
had	O
a	O
mean	O
age	O
of	O
49	O
years	O
(	O
3	O
%	O
of	O
subjects	O
were	O
older	O
than	O
65	O
years	O
of	O
age	O
)	O
,	O
39	O
%	O
were	O
female	O
,	O
82	O
%	O
were	O
white	O
and	O
15	O
%	O
were	O
black	O
.	O
	
Patients	O
greater	O
than	O
65	O
years	O
of	O
age	O
,	O
patients	O
with	O
co-morbid	O
conditions	O
and/or	O
patients	O
taking	O
concomitant	O
immunosuppressants	O
such	O
as	O
corticosteroids	O
or	O
methotrexate	O
may	O
be	O
at	O
greater	O
risk	O
of	O
infection	O
.	O
	
A	O
causal	O
relationship	O
to	O
STENDRA	O
is	O
uncertain	O
.	O
	
Ask	O
your	O
healthcare	O
provider	O
for	O
ways	O
to	O
lower	O
your	O
chances	O
of	O
getting	O
heart	O
disease	O
.	O
	
These	O
hypersensitivity	B
reactions	I
included	O
:	O
anaphylaxis	B
,	O
angioedema	B
,	O
hypotension	B
,	O
tachycardia	B
,	O
swollen	B
tongue	I
,	O
dyspnea	B
,	O
wheezing	B
and	O
rash	B
.	O
	
*	O
Cardiac	B
arrest	I
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
(	O
NSF	B
)	O
*	O
Hypersensitivity	B
reactions	I
(	O
anaphylactic	B
shock	I
,	O
circulatory	B
collapse	I
,	O
respiratory	B
arrest	I
,	O
pulmonary	B
edema	I
,	O
bronchospasm	B
,	O
cyanosis	B
,	O
oropharyngeal	B
swelling	I
,	O
laryngeal	B
edema	I
,	O
blood	B
pressure	I
increased	I
,	O
chest	B
pain	I
,	O
angioedema	B
,	O
conjunctivitis	B
,	O
hyperhidrosis	B
,	O
cough	B
,	O
sneezing	B
,	O
burning	B
sensation	I
,	O
and	O
pallor	B
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
MI	O
and	O
stroke	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
,	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
medical	O
practice	O
.	O
	
In	O
Study	O
1	O
and	O
Study	O
2	O
,	O
NULOJIX	O
was	O
studied	O
at	O
the	O
recommended	O
dose	O
and	O
frequency	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
in	O
a	O
total	O
of	O
401	O
patients	O
compared	O
to	O
a	O
cyclosporine	O
control	O
regimen	O
in	O
a	O
total	O
of	O
405	O
patients	O
.	O
	
If	O
such	O
an	O
acute	O
reaction	O
occurs	O
,	O
combination	O
therapy	O
should	O
be	O
discontinued	O
and	O
appropriate	O
medical	O
therapy	O
immediately	O
instituted	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
In	O
such	O
patients	O
,	O
consider	O
discontinuation	O
of	O
SAPHRIS	O
at	O
the	O
first	O
sign	O
of	O
a	O
clinically	O
significant	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
Infections	O
:	O
PML	B
[	O
see	O
Boxed	O
Warning	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)	O
]	O
,	O
serious	O
infections	B
and	O
opportunistic	B
infections	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Monitor	O
platelet	O
counts	O
regularly	O
.	O
	
The	O
immunogenicity	O
data	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
considered	O
positive	O
for	O
antibodies	O
to	O
EYLEA	O
in	O
immunoassays	O
.	O
	
*	O
Invasive	B
fungal	I
infections	I
-	O
For	O
patients	O
who	O
develop	O
a	O
systemic	O
illness	O
on	O
SIMPONI	O
ARIA	O
,	O
consider	O
empiric	O
antifungal	O
therapy	O
for	O
those	O
who	O
reside	O
in	O
or	O
travel	O
to	O
regions	O
where	O
mycoses	O
are	O
endemic	O
(	O
5.1	O
)	O
.	O
	
5.6	O
Increased	O
Low-Density	O
Lipoprotein	O
Cholesterol	O
(	O
LDL-C	O
)	O
Increases	B
in	I
LDL-C	I
can	O
occur	O
with	O
JARDIANCE	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Consider	O
tuberculosis	O
in	O
the	O
differential	O
diagnosis	O
in	O
patients	O
who	O
develop	O
a	O
new	O
infection	O
during	O
SIMPONI	O
ARIA	O
treatment	O
,	O
especially	O
in	O
patients	O
who	O
have	O
previously	O
or	O
recently	O
traveled	O
to	O
countries	O
with	O
a	O
high	O
prevalence	O
of	O
tuberculosis	O
,	O
or	O
who	O
have	O
had	O
close	O
contact	O
with	O
a	O
person	O
with	O
active	O
tuberculosis	O
.	O
	
For	O
these	O
reasons	O
,	O
the	O
incidence	O
of	O
antibodies	O
to	O
albiglutide	O
can	O
not	O
be	O
directly	O
compared	O
with	O
the	O
incidence	O
of	O
antibodies	O
of	O
other	O
products	O
.	O
	
The	O
protocol	O
specified	O
that	O
patients	O
continue	O
receiving	O
intravenous	O
hydration	O
,	O
urinary	O
alkalinization	O
and	O
leucovorin	O
,	O
and	O
that	O
leucovorin	O
administration	O
be	O
adjusted	O
to	O
ensure	O
that	O
it	O
was	O
not	O
administered	O
within	O
two	O
hours	O
before	O
or	O
after	O
VORAXAZE	O
.	O
	
Monitor	O
closely	O
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
occurring	O
in	O
at	O
least	O
1	O
%	O
of	O
subjects	O
)	O
in	O
Vizamyl-treated	O
subjects	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
(	O
Boxed	O
Warning	O
,	O
4	O
,	O
5.1	O
,	O
5.6	O
)	O
*	O
Other	O
malignancies	B
:	O
increased	O
risk	O
with	O
all	O
immunosuppressants	O
;	O
appears	O
related	O
to	O
intensity	O
and	O
duration	O
of	O
use	O
.	O
	
*	O
d	O
Event	O
requiring	O
another	O
person	O
to	O
administer	O
a	O
resuscitative	O
action	O
.	O
	
The	O
safety	O
of	O
ILARIS	O
compared	O
to	O
placebo	O
was	O
investigated	O
in	O
two	O
phase	O
3	O
studies	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Doses	O
ranged	O
from	O
6	O
to	O
189	O
Units/kg	O
,	O
with	O
a	O
median	O
dose	O
of	O
50	O
Units/kg	O
.	O
	
5.2	O
Thyroid	O
Accumulation	O
The	O
DaTscan	O
injection	O
may	O
contain	O
up	O
to	O
6	O
%	O
of	O
free	O
iodide	O
(	O
iodine	O
123	O
)	O
.	O
	
(	O
5.2	O
)	O
*	O
?	O
	
Uveitis	B
(	O
including	O
iritis	B
)	O
occurred	O
in	O
1	O
%	O
(	O
6/586	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
and	O
uveitis	B
occurred	O
in	O
1	O
%	O
(	O
2/202	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Treatment	O
and	O
Reduction	O
in	O
the	O
Risk	O
of	O
Recurrence	O
of	O
Deep	O
Venous	O
Thrombosis	O
and	O
Pulmonary	O
Embolism	O
Avoid	O
use	O
of	O
PRADAXA	O
and	O
concomitant	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
CrCl	O
<	O
50	O
mL/min	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
The	O
long-term	O
consequences	O
of	O
the	O
degree	O
of	O
suppression	B
of	I
bone	I
remodeling	I
observed	O
with	O
Prolia	O
may	O
contribute	O
to	O
adverse	O
outcomes	O
such	O
as	O
osteonecrosis	B
of	I
the	I
jaw	I
,	O
atypical	B
fractures	I
,	O
and	O
delayed	B
fracture	I
healing	I
.	O
	
If	O
experiencing	O
Grade	O
>	O
=	O
3	O
diarrhea	O
,	O
dosage	O
should	O
be	O
modified	O
.	O
	
Perform	O
ophthalmological	O
evaluation	O
at	O
any	O
time	O
a	O
patient	O
reports	O
visual	O
disturbances	O
and	O
compare	O
with	O
baseline	O
,	O
if	O
available	O
.	O
	
(	O
5.8	O
)	O
5.1	O
Post-Transplant	O
Lymphoproliferative	O
Disorder	O
NULOJIX-treated	O
patients	O
have	O
an	O
increased	O
risk	O
for	O
developing	O
post-transplant	B
lymphoproliferative	I
disorder	I
(	O
PTLD	B
)	O
,	O
predominantly	O
involving	O
the	O
CNS	O
,	O
compared	O
to	O
patients	O
on	O
a	O
cyclosporine-based	O
regimen	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
Table	O
2	O
]	O
.	O
	
The	O
use	O
of	O
PRADAXA	O
for	O
the	O
prophylaxis	O
of	O
thromboembolic	O
events	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
in	O
the	O
setting	O
of	O
other	O
forms	O
of	O
valvular	O
heart	O
disease	O
,	O
including	O
the	O
presence	O
of	O
a	O
bioprosthetic	O
heart	O
valve	O
,	O
has	O
not	O
been	O
studied	O
and	O
is	O
not	O
recommended	O
.	O
	
*	O
Renal	B
failure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
In	O
CAPS	O
Study	O
1	O
,	O
no	O
pattern	O
was	O
observed	O
for	O
any	O
type	O
or	O
frequency	O
of	O
adverse	O
events	O
throughout	O
the	O
three	O
study	O
periods	O
.	O
	
Administration	O
of	O
Picato	O
(	O
r	O
)	O
gel	O
is	O
not	O
recommended	O
until	O
the	O
skin	O
is	O
healed	O
from	O
any	O
previous	O
drug	O
or	O
surgical	O
treatment	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
A	O
theoretical	O
risk	O
for	O
transmission	O
of	O
Creutzfeldt-Jakob	B
disease	I
(	O
CJD	B
)	O
is	O
also	O
considered	O
extremely	O
remote	O
.	O
	
The	O
most	O
common	O
medical	O
interventions	O
required	O
during	O
AFINITOR	O
treatment	O
were	O
for	O
infections	B
,	O
anemia	B
,	O
and	O
stomatitis	B
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
for	O
subjects	O
taking	O
OTEZLA	O
were	O
nausea	B
(	O
1.6	O
%	O
)	O
,	O
diarrhea	B
(	O
1.0	O
%	O
)	O
,	O
and	O
headache	B
(	O
0.8	O
%	O
)	O
.	O
	
A	O
dose-dependent	O
increase	O
in	O
the	O
risk	O
of	O
macular	B
edema	I
occurred	O
in	O
the	O
GILENYA	O
clinical	O
development	O
program	O
.	O
	
In	O
Studies	O
102	O
and	O
103	O
,	O
bone	B
fractures	I
occurred	O
in	O
27	O
subjects	O
(	O
3.9	O
%	O
)	O
in	O
the	O
STRIBILD	O
group	O
,	O
8	O
subjects	O
(	O
2.3	O
%	O
)	O
in	O
the	O
ATRIPLA	O
group	O
,	O
and	O
19	O
subjects	O
(	O
5.4	O
%	O
)	O
in	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
ENTEREG	O
is	O
not	O
recommended	O
in	O
this	O
population	O
.	O
	
Caution	O
is	O
warranted	O
when	O
prescribing	O
FANAPT	O
with	O
drugs	O
that	O
inhibit	O
FANAPT	O
metabolism	O
[	O
see	O
Drug	O
Interaction	O
s	O
(	O
7.1	O
)	O
]	O
,	O
and	O
in	O
patients	O
with	O
reduced	O
activity	O
of	O
CYP2D6	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
(	O
5.12	O
)	O
*	O
Priapism	B
:	O
Cases	O
have	O
been	O
reported	O
in	O
association	O
with	O
FANAPT	O
treatment	O
.	O
	
Overall	O
,	O
55	O
%	O
of	O
the	O
patients	O
were	O
men	O
.	O
	
Therefore	O
,	O
ENTEREG	O
is	O
not	O
recommended	O
for	O
use	O
in	O
these	O
patients	O
.	O
	
In	O
treatment-naive	O
subjects	O
,	O
a	O
mean	O
change	O
from	O
baseline	O
of	O
0.15	O
mg	O
per	O
dL	O
(	O
range	O
:	O
-0.32	O
mg	O
per	O
dL	O
to	O
0.65	O
mg	O
per	O
dL	O
)	O
was	O
observed	O
after	O
96	O
weeks	O
of	O
treatment	O
.	O
	
DYSPORT	O
(	O
r	O
)	O
is	O
approved	O
only	O
for	O
intramuscular	O
injection	O
.	O
	
(	O
5.1	O
)	O
*	O
Serious	O
Infections	B
:	O
Serious	O
and	O
sometimes	O
fatal	B
infections	B
have	O
been	O
reported	O
in	O
patients	O
receiving	O
immunosuppressive	O
agents	O
,	O
including	O
BENLYSTA	O
.	O
	
In	O
patients	O
who	O
develop	O
severe	O
hepatic	O
impairment	O
while	O
taking	O
GILOTRIF	O
,	O
treatment	O
should	O
be	O
discontinued	O
.	O
	
5.5	O
Pre-existing	O
Neuromuscular	O
Disorders	O
and	O
other	O
Special	O
Populations	O
Individuals	O
with	O
peripheral	O
motor	O
neuropathic	O
diseases	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
or	O
neuromuscular	O
junctional	O
disorders	O
(	O
e.g.	O
,	O
myasthenia	O
gravis	O
or	O
Lambert-Eaton	O
syndrome	O
)	O
should	O
be	O
monitored	O
particularly	O
closely	O
when	O
given	O
botulinum	O
toxin	O
.	O
	
c	O
Includes	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
pulmonary	B
fibrosis	I
and	O
restrictive	B
pulmonary	I
disease	I
.	O
	
Instances	O
of	O
suicidal	B
ideation	I
have	O
been	O
observed	O
in	O
0.2	O
%	O
(	O
3/1441	O
)	O
of	O
subjects	O
while	O
receiving	O
OTEZLA	O
,	O
compared	O
to	O
none	O
in	O
placebo	O
treated	O
subjects	O
(	O
0/495	O
)	O
.	O
	
5	O
(	O
tartrazine	O
)	O
which	O
may	O
cause	O
allergic-type	B
reactions	I
(	O
including	O
bronchial	B
asthma	I
)	O
in	O
certain	O
susceptible	O
persons	O
.	O
	
Posterior	O
reversible	O
encephalopathy	O
syndrome	O
(	O
PRES	O
)	O
,	O
formerly	O
termed	O
Reversible	O
Posterior	O
Leukoencephalopathy	O
Syndrome	O
(	O
RPLS	O
)	O
,	O
is	O
a	O
neurological	O
disorder	O
which	O
can	O
present	O
with	O
seizure	O
,	O
headache	O
,	O
lethargy	O
,	O
confusion	O
,	O
blindness	O
,	O
altered	O
consciousness	O
,	O
and	O
other	O
visual	O
and	O
neurological	O
disturbances	O
,	O
along	O
with	O
hypertension	O
,	O
and	O
the	O
diagnosis	O
is	O
confirmed	O
by	O
neuro-radiological	O
imaging	O
(	O
MRI	O
)	O
.	O
	
No	O
association	O
between	O
anti-icatibant	O
antibodies	O
and	O
efficacy	O
was	O
observed	O
.	O
	
Table	O
5	O
lists	O
treatment-emergent	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
patients	O
with	O
PHN	O
treated	O
with	O
HORIZANT	O
1,200	O
mg/day	O
and	O
numerically	O
greater	O
than	O
placebo	O
.	O
	
Stop	O
Kyprolis	O
for	O
Grade	O
3	O
or	O
4	O
dyspnea	O
until	O
resolved	O
or	O
returned	O
to	O
baseline	O
.	O
	
ARCAPTA	O
NEOHALER	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
asthma	O
[	O
See	O
B	O
oxed	O
Warning	O
and	O
W	O
arning	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
observed	O
in	O
the	O
other	O
trials	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
confirmatory	O
trials	O
.	O
	
One	O
patient	O
with	O
a	O
history	O
of	O
Wolff-Parkinson-White	O
syndrome	O
experienced	O
a	O
serious	O
adverse	O
reaction	O
of	O
supraventricular	B
tachycardia	I
.	O
	
5.10	O
Thrombocytopenia	O
Kyprolis	O
causes	O
thrombocytopenia	B
with	O
platelet	B
nadirs	I
observed	O
between	O
Day	O
8	O
and	O
Day	O
15	O
of	O
each	O
28-day	O
cycle	O
with	O
recovery	O
to	O
baseline	O
platelet	O
count	O
usually	O
by	O
the	O
start	O
of	O
the	O
next	O
cycle	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
*	O
Somnolence/sedation	O
and	O
dizziness	B
:	O
May	O
impair	B
the	I
patient	I
's	I
ability	I
to	I
operate	I
complex	I
machinery	I
.	O
	
Before	O
initiating	O
therapy	O
with	O
ZERBAXA	O
,	O
make	O
careful	O
inquiry	O
about	O
previous	O
hypersensitivity	O
reactions	O
to	O
other	O
cephalosporins	O
,	O
penicillins	O
,	O
or	O
other	O
beta-lactams	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
,	O
regardless	O
of	O
causality	O
,	O
occurring	O
in	O
at	O
least	O
3	O
%	O
of	O
patients	O
with	O
SLE	O
who	O
received	O
BENLYSTA	O
10	O
mg/kg	O
and	O
at	O
an	O
incidence	O
at	O
least	O
1	O
%	O
greater	O
than	O
that	O
observed	O
with	O
placebo	O
in	O
the	O
3	O
controlled	O
studies	O
.	O
	
Contact	O
lens	O
use	O
is	O
also	O
a	O
risk	O
factor	O
for	O
keratitis	O
and	O
ulceration	O
.	O
	
Patients	O
experiencing	O
seizure	B
were	O
permanently	O
discontinued	O
from	O
therapy	O
and	O
all	O
seizure	O
events	O
resolved	O
.	O
	
System	O
Organ	O
Class/Preferred	O
Term	O
Placebo	O
N=203	O
%	O
SAPHRIS	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily*	O
N=379	O
%	O
Gastrointestinal	O
disorders	O
Dry	B
mouth	I
1	O
3	O
Dyspepsia	B
2	O
4	O
Oral	B
hypoesthesia	I
<	O
1	O
4	O
Toothache	B
2	O
3	O
General	O
disorders	O
Fatigue	B
2	O
4	O
Investigations	O
Increased	B
weight	I
<	O
1	O
5	O
Metabolism	O
disorders	O
Increased	B
appetite	I
1	O
4	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Arthralgia	B
1	O
3	O
Pain	B
in	I
extremity	I
<	O
1	O
2	O
Nervous	O
system	O
disorders	O
Akathisia	B
2	O
4	O
Dizziness	B
3	O
11	O
Dysgeusia	B
<	O
1	O
3	O
Headache	B
11	O
12	O
Other	O
extrapyramidal	B
symptoms	I
(	O
excluding	O
akathisia	B
)	O
2	O
7	O
Somnolence	B
?	O
	
Higher	O
than	O
recommended	O
dosing	O
or	O
repeat	O
dosing	O
appear	O
to	O
increase	O
the	O
risk	O
.	O
	
All	O
second	B
degree	I
AV	I
blocks	I
on	I
placebo	I
were	I
Mobitz	I
Type	I
I	I
and	O
occurred	O
after	O
the	O
first	O
12	O
hours	O
postdose	O
.	O
	
In	O
placebo-controlled	O
trials	O
,	O
the	O
most	O
frequent	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=10	O
%	O
and	O
>	O
placebo	O
)	O
for	O
GILENYA	O
0.5	O
mg	O
were	O
headache	B
,	O
liver	B
transaminase	I
elevation	I
,	O
diarrhea	B
,	O
cough	B
,	O
influenza	B
,	O
sinusitis	B
,	O
back	B
pain	I
,	O
abdominal	B
pain	I
,	O
and	O
pain	B
in	I
extremity	I
.	O
	
Monitor	O
for	O
evidence	O
of	O
TLS	O
during	O
treatment	O
and	O
manage	O
promptly	O
including	O
interruption	O
of	O
Kyprolis	O
until	O
TLS	O
is	O
resolved	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
During	O
the	O
initial	O
phase	O
of	O
combination	O
antiretroviral	O
treatment	O
,	O
patients	O
whose	O
immune	O
systems	O
respond	O
may	O
develop	O
an	O
inflammatory	B
response	I
to	O
indolent	O
or	O
residual	B
opportunistic	I
infections	I
(	O
such	O
as	O
Mycobacterium	B
avium	I
infection	I
,	O
cytomegalovirus	B
,	O
Pneumocystis	B
jirovecii	I
pneumonia	I
[	O
PCP	B
]	O
,	O
or	O
tuberculosis	B
)	O
,	O
which	O
may	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
In	O
several	O
exploratory	O
trials	O
of	O
other	O
TNF-blockers	O
in	O
the	O
treatment	O
of	O
CHF	O
,	O
there	O
were	O
greater	O
proportions	O
of	O
TNF-blocker	O
treated	O
patients	O
who	O
had	O
CHF	B
exacerbations	I
requiring	O
hospitalization	O
or	O
increased	B
mortality	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
5	O
%	O
or	O
greater	O
in	O
either	O
indication	O
)	O
occurring	O
in	O
patients	O
receiving	O
ZERBAXA	O
were	O
nausea	B
,	O
diarrhea	B
,	O
headache	B
,	O
and	O
pyrexia	B
.	O
	
breathing	B
difficulties	I
can	O
be	O
life	O
threatening	O
and	O
there	O
have	O
been	O
reports	O
of	O
death	B
.	O
	
5.2	O
Infections	O
Risk	O
of	O
Infections	O
GILENYA	O
causes	O
a	O
dose-dependent	O
reduction	B
in	I
peripheral	I
lymphocyte	I
count	I
to	O
20	O
%	O
-30	O
%	O
of	O
baseline	O
values	O
because	O
of	O
reversible	O
sequestration	B
of	I
lymphocytes	I
in	I
lymphoid	I
tissues	I
.	O
	
No	O
unconfounded	O
cases	O
of	O
NSF	B
have	O
been	O
reported	O
with	O
DOTAREM	O
.	O
	
For	O
moderate	O
to	O
severe	O
proteinuria	O
,	O
reduce	O
the	O
dose	O
or	O
temporarily	O
interrupt	O
treatment	O
with	O
INLYTA	O
.	O
	
The	O
incidence	O
of	O
Grade	O
3	O
or	O
greater	O
non-hematologic	O
,	O
non-infectious	O
adverse	O
reactions	O
occurring	O
with	O
ERWINAZE	O
in	O
Study	O
1	O
,	O
Study	O
2	O
and	O
EMTP	O
trial	O
is	O
provided	O
in	O
Table	O
2	O
.	O
	
The	O
patients	O
had	O
no	O
other	O
identified	O
systemic	O
medical	O
conditions	O
resulting	O
in	O
compromised	B
immune	I
system	I
function	O
and	O
had	O
not	O
previously	O
been	O
treated	O
with	O
natalizumab	O
,	O
which	O
has	O
a	O
known	O
association	O
with	O
PML	B
.	O
	
It	O
is	O
unknown	O
whether	O
this	O
finding	O
applies	O
to	O
younger	O
postmenopausal	O
women	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
In	O
the	O
absence	O
of	O
comparable	O
data	O
,	O
these	O
risks	O
should	O
be	O
assumed	O
to	O
be	O
similar	O
for	O
other	O
doses	O
of	O
conjugated	O
estrogens	O
and	O
other	O
dosage	O
forms	O
of	O
estrogens	O
.	O
	
(	O
2.1	O
)	O
Monitor	O
for	O
TLS	O
,	O
including	O
uric	O
acid	O
levels	O
and	O
treat	O
promptly	O
.	O
	
Nearly	O
all	O
of	O
the	O
reported	O
TNF-blocker	O
associated	O
cases	O
have	O
occurred	O
in	O
patients	O
with	O
Crohn	O
's	O
disease	O
or	O
ulcerative	O
colitis	O
.	O
	
(	O
5.1	O
)	O
*	O
venous	B
thrombotic	I
events	I
have	O
been	O
observed	O
and	O
can	O
be	O
fatal	B
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
ERWINAZE	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
a	O
6-dose	O
regimen	O
of	O
Coartem	O
Tablets	O
in	O
1,979	O
patients	O
including	O
647	O
adults	O
(	O
older	O
than	O
16	O
years	O
)	O
and	O
1,332	O
children	O
(	O
16	O
years	O
and	O
younger	O
)	O
.	O
	
Use	O
with	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
may	O
cause	O
additive	O
QT	B
prolongation	I
.	O
	
In	O
controlled	O
clinical	O
studies	O
,	O
98	O
%	O
of	O
patients	O
completed	O
>	O
=	O
90	O
%	O
of	O
the	O
intended	O
patch	O
application	O
duration	O
.	O
	
Use	O
with	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
may	O
cause	O
additive	B
QT	I
prolongation	I
.	O
	
(	O
5.2	O
,	O
5.3	O
)	O
*	O
Transient	O
increases	B
in	I
blood	I
pressure	I
may	O
occur	O
in	O
patients	O
during	O
and	O
shortly	O
after	O
the	O
Qutenza	O
treatment	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Gastrointestinal	O
Toxicity	O
Diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
and	O
abdominal	B
pain	I
occur	O
with	O
BOSULIF	O
treatment	O
.	O
	
Approximately	O
80	O
%	O
of	O
these	O
patients	O
had	O
>	O
10	O
weeks	O
exposure	O
to	O
Toviaz	O
in	O
these	O
trials	O
.	O
	
5.4	O
Application	O
Associated	O
Pain	O
Even	O
following	O
use	O
of	O
a	O
local	O
anesthetic	O
prior	O
to	O
administration	O
of	O
Qutenza	O
,	O
patients	O
may	O
experience	O
substantial	O
procedural	B
pain	I
.	O
	
Decreases	O
in	O
Bone	O
Mineral	O
Density	O
Bone	O
mineral	O
density	O
(	O
BMD	O
)	O
was	O
measured	O
by	O
dual-energy	O
X-ray	O
absorptiometry	O
in	O
a	O
clinical	O
trial	O
of	O
714	O
older	O
adults	O
(	O
mean	O
age	O
64	O
years	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
permanent	O
discontinuation	O
in	O
XALKORI-treated	O
patients	O
were	O
elevated	B
transaminases	I
(	O
1.2	O
%	O
)	O
,	O
hepatotoxicity	B
(	O
1.2	O
%	O
)	O
,	O
and	O
ILD	B
(	O
1.2	O
%	O
)	O
.	O
	
Fatal	B
adverse	O
reactions	O
in	O
XALKORI-treated	O
patients	O
in	O
Study	O
2	O
occurred	O
in	O
9	O
(	O
5	O
%	O
)	O
patients	O
,	O
consisting	O
of	O
:	O
acute	B
respiratory	I
distress	I
syndrome	I
,	O
arrhythmia	B
,	O
dyspnea	B
,	O
pneumonia	B
,	O
pneumonitis	B
,	O
pulmonary	B
embolism	I
,	O
ILD	B
,	O
respiratory	B
failure	I
and	O
sepsis	B
.	O
	
The	O
adverse	O
reactions	O
described	O
in	O
this	O
section	O
reflect	O
Gadavist	O
exposure	O
in	O
6,330	O
subjects	O
(	O
including	O
184	O
pediatric	O
patients	O
,	O
ages	O
0	O
to	O
17	O
years	O
)	O
with	O
the	O
majority	O
receiving	O
the	O
recommended	O
dose	O
.	O
	
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
trials	O
,	O
the	O
mean	O
percent	O
change	B
in	I
serum	I
magnesium	I
levels	I
was	O
8.1	O
%	O
and	O
9.3	O
%	O
with	O
INVOKANA	O
100	O
mg	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
,	O
compared	O
to	O
-0.6	O
%	O
with	O
placebo	O
.	O
	
Data	O
from	O
a	O
large	O
placebo-controlled	O
US	O
study	O
that	O
compared	O
the	O
safety	O
of	O
another	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonist	O
(	O
salmeterol	O
)	O
or	O
placebo	O
added	O
to	O
usual	O
asthma	O
therapy	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
patients	O
receiving	O
salmeterol	O
.	O
	
The	O
safety	O
profile	O
of	O
SAPHRIS	O
in	O
the	O
maintenance	O
treatment	O
of	O
schizophrenia	O
in	O
adults	O
was	O
similar	O
to	O
that	O
seen	O
with	O
acute	O
treatment	O
.	O
	
Table	O
4	O
identifies	O
the	O
clinically	O
relevant	O
or	O
severe	O
Grade	O
3/4	O
laboratory	O
test	O
abnormalities	O
for	O
the	O
Phase	O
1/2	O
CML	O
safety	O
population	O
.	O
	
All	O
patients	O
were	O
treated	O
with	O
antihistamines	O
prior	O
to	O
each	O
infusion	O
.	O
	
Patients	O
with	O
hypovolemia	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
changes	O
.	O
	
The	O
data	O
described	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
reflect	O
exposure	O
to	O
INLYTA	O
in	O
359	O
patients	O
with	O
advanced	O
RCC	O
who	O
participated	O
in	O
a	O
randomized	O
clinical	O
study	O
versus	O
sorafenib	O
[	O
seeClinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Decrease	B
of	I
Hemoglobin	I
in	O
Patients	O
with	O
WM	O
(	O
N=63	O
)	O
Percent	O
of	O
Patients	O
(	O
N=63	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
Platelets	B
Decreased	I
43	O
13	O
Neutrophils	B
Decreased	I
44	O
19	O
Hemoglobin	B
Decreased	I
13	O
8	O
6	O
.	O
	
During	O
the	O
clinical	O
trial	O
,	O
the	O
patient	O
experienced	O
prolonged	O
lymphopenia	B
(	O
lymphocyte	O
counts	O
predominantly	O
<	O
0.5x10	O
9	O
/L	O
for	O
3.5	O
years	O
)	O
while	O
taking	O
TECFIDERA	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Consider	O
interruption	O
of	O
TECFIDERA	O
if	O
lymphocyte	O
counts	O
<	O
0.5	O
x	O
10	O
9	O
/L	O
persist	O
for	O
more	O
than	O
six	O
months	O
.	O
	
In	O
the	O
event	O
of	O
treatment-related	O
myelosuppression	O
,	O
monitor	O
leukocytes	O
,	O
platelets	O
,	O
hemoglobin	O
(	O
Hgb	O
)	O
,	O
and	O
neutrophils	O
frequently	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
in	O
the	O
WM	O
trial	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
rash	B
,	O
nausea	B
,	O
muscle	B
spasms	I
,	O
and	O
fatigue	B
.	O
	
The	O
use	O
of	O
NESINA	O
as	O
add-on	O
therapy	O
to	O
glyburide	O
or	O
insulin	O
did	O
not	O
increase	O
the	O
incidence	O
of	O
hypoglycemia	B
compared	O
to	O
placebo	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
in	O
patients	O
with	O
B-cell	O
malignancies	O
(	O
MCL	O
,	O
CLL	O
,	O
WM	O
)	O
were	O
thrombocytopenia	B
,	O
neutropenia	B
,	O
diarrhea	B
,	O
anemia	B
,	O
fatigue	B
,	O
musculoskeletal	B
pain	I
,	O
bruising	B
,	O
nausea	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
and	O
rash	B
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
adverse	O
reactions	O
most	O
commonly	O
(	O
>	O
=1	O
%	O
in	O
any	O
APTIOM	O
treatment	O
group	O
,	O
and	O
greater	O
than	O
placebo	O
)	O
leading	O
to	O
discontinuation	O
,	O
in	O
descending	O
order	O
of	O
frequency	O
,	O
were	O
dizziness	B
,	O
nausea	B
,	O
vomiting	B
,	O
ataxia	B
,	O
diplopia	B
,	O
somnolence	B
,	O
headache	B
,	O
blurred	B
vision	I
,	O
vertigo	B
,	O
asthenia	B
,	O
fatigue	B
,	O
rash	B
,	O
dysarthria	B
,	O
and	O
tremor	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
below	O
and	O
elsewhere	O
in	O
labeling	O
:	O
*	O
Distant	B
Spread	I
of	I
Toxin	I
Effect	I
[	O
seeBoxed	O
Warning	O
]	O
*	O
Lack	O
of	O
Interchangeability	O
between	O
Botulinum	O
Toxin	O
Products	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Spread	B
of	I
Effects	I
from	I
Toxin	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Dysphagia	B
and	O
Breathing	B
Difficulties	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Facial	O
Anatomy	O
in	O
the	O
Treatment	O
of	O
Glabellar	O
Lines	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Pre-existing	O
Neuromuscular	O
Disorders	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Human	O
Albumin	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Intradermal	B
Immune	I
Reaction	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5	O
.	O
	
Patients	O
with	O
myelosuppression	B
following	O
treatment	O
with	O
TREANDA	O
are	O
more	O
susceptible	O
to	O
infections	B
.	O
	
Of	O
the	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
,	O
5	O
%	O
(	O
14/304	O
)	O
developed	O
NODAT	B
by	O
the	O
end	O
of	O
one	O
year	O
compared	O
to	O
10	O
%	O
(	O
27/280	O
)	O
of	O
patients	O
on	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
25	O
%	O
)	O
were	O
increased	B
AST	I
,	O
increased	B
ALT	I
,	O
lymphopenia	B
,	O
increased	B
ALP	I
,	O
hypocalcemia	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
hypophosphatemia	B
,	O
and	O
hyperbilirubinemia	B
.	O
	
*	O
Dulaglutide	O
causes	O
thyroid	B
C-cell	I
tumors	I
in	O
rats	O
.	O
	
Pre-existing	O
hypertension	O
should	O
be	O
controlled	O
before	O
initiating	O
treatment	O
with	O
PRISTIQ	O
.	O
	
In	O
all	O
controlled	O
and	O
uncontrolled	O
trials	O
across	O
various	O
patient	O
populations	O
,	O
more	O
than	O
2,300	O
patients	O
have	O
received	O
HORIZANT	O
orally	O
in	O
daily	O
doses	O
ranging	O
from	O
600	O
to	O
3,600	O
mg	O
.	O
	
These	O
metabolic	O
changes	O
include	O
hyperglycemia	B
,	O
dyslipidemia	B
,	O
and	O
body	B
weight	I
gain	I
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17.3	O
)	O
]	O
.	O
	
The	O
rate	O
of	O
progression	O
of	O
retinal	B
abnormalities	I
and	O
the	O
reversibility	O
after	O
drug	O
discontinuation	O
are	O
unknown	O
.	O
	
If	O
significant	O
reductions	O
in	O
BMD	O
are	O
seen	O
and	O
BREO	O
ELLIPTA	O
is	O
still	O
considered	O
medically	O
important	O
for	O
that	O
patient	O
's	O
COPD	O
therapy	O
,	O
use	O
of	O
medicine	O
to	O
treat	O
or	O
prevent	O
osteoporosis	O
should	O
be	O
strongly	O
considered	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
occurring	O
in	O
>	O
=	O
5	O
%	O
of	O
CIMZIA-treated	O
patients	O
,	O
and	O
with	O
a	O
higher	O
incidence	O
compared	O
to	O
placebo	O
)	O
in	O
controlled	O
clinical	O
studies	O
with	O
CIMZIA	O
were	O
upper	B
respiratory	I
infections	I
(	O
e.g	O
.	O
	
Use	O
of	O
ocular	O
steroids	O
may	O
prolong	O
the	O
course	O
and	O
may	O
exacerbate	B
the	I
severity	I
of	I
many	I
viral	I
infections	I
of	I
the	I
eye	I
)	O
.	O
	
5.7	O
Discontinuation	O
Syndrome	O
Discontinuation	O
symptoms	O
have	O
been	O
systematically	O
and	O
prospectively	O
evaluated	O
in	O
patients	O
treated	O
with	O
PRISTIQ	O
during	O
clinical	O
studies	O
in	O
Major	O
Depressive	O
Disorder	O
.	O
	
Other	O
immune-mediated	B
adverse	I
reactions	I
,	O
including	O
ocular	B
manifestations	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Of	O
the	O
patients	O
who	O
developed	O
tuberculosis	B
through	O
3	O
years	O
,	O
all	O
but	O
one	O
NULOJIX	O
patient	O
lived	O
in	O
countries	O
with	O
a	O
high	O
prevalence	O
of	O
tuberculosis	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
The	O
ophthalmologic	O
monitoring	O
program	O
should	O
include	O
visual	O
acuity	O
testing	O
and	O
dilated	O
fundus	O
photography	O
.	O
	
Treatment	O
with	O
Edarbi	O
was	O
well-tolerated	O
with	O
an	O
overall	O
incidence	O
of	O
adverse	O
reactions	O
similar	O
to	O
placebo	O
.	O
	
Of	O
these	O
29	O
patients	O
,	O
5	O
(	O
17	O
%	O
)	O
required	O
catheterization	O
,	O
with	O
post-voiding	O
residuals	O
of	O
up	O
to	O
1,500	O
mL	O
.	O
	
Vascular	O
disorders	O
:	O
Thrombophlebitis	B
,	O
vasculitis	B
.	O
	
Trial	O
1	O
included	O
197	O
control-treated	O
patients	O
and	O
463	O
SIMPONI	O
ARIA-treated	O
patients	O
(	O
which	O
includes	O
control-treated	O
patients	O
who	O
switched	O
to	O
SIMPONI	O
ARIA	O
at	O
Week	O
16	O
)	O
.	O
	
Infusion	B
reactions	I
have	O
occurred	O
with	O
the	O
BLINCYTO	O
infusion	O
and	O
may	O
be	O
clinically	O
indistinguishable	O
from	O
manifestations	O
of	O
CRS	O
.	O
	
If	O
this	O
product	O
is	O
used	O
for	O
10	O
days	O
or	O
longer	O
,	O
intraocular	O
pressure	O
should	O
be	O
monitored	O
.	O
	
Of	O
these	O
,	O
806	O
received	O
FANAPT	O
for	O
at	O
least	O
6	O
months	O
,	O
with	O
463	O
exposed	O
to	O
FANAPT	O
for	O
at	O
least	O
12	O
months	O
.	O
	
Study	O
1	O
:	O
Metastatic	O
CRPC	O
Following	O
Chemotherapy	O
Study	O
1	O
enrolled	O
1195	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
received	O
prior	O
docetaxel	O
chemotherapy	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
CORPORAL	B
RUPTURE	I
(	O
PENILE	B
FRACTURE	I
)	O
OR	O
OTHER	O
SERIOUS	O
PENILE	B
INJURY	I
IN	O
THE	O
TREATMENT	O
OF	O
PEYRONIE	O
'S	O
DISEASE	O
WARNING	O
:	O
CORPORAL	B
RUPTURE	I
(	O
PENILE	B
FRACTURE	I
)	O
OR	O
OTHER	O
SERIOUS	O
PENILE	B
INJURY	I
IN	O
THE	O
TREATMENT	O
OF	O
PEYRONIE	O
'S	O
DISEASE	O
Corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
5	O
of	O
1044	O
(	O
0.5	O
%	O
)	O
XIAFLEX-treated	O
patients	O
in	O
clinical	O
studies	O
.	O
	
Grade	O
3	O
or	O
greater	O
thrombocytopenia	B
occurred	O
in	O
1	O
%	O
(	O
7/503	O
)	O
of	O
patients	O
.	O
	
Figure	O
1	O
Gastrointestinal	O
Adverse	O
Reactions	O
Patients	O
on	O
PRADAXA	O
150	O
mg	O
had	O
an	O
increased	O
incidence	O
of	O
gastrointestinal	B
adverse	I
reactions	I
(	O
35	O
%	O
vs.	O
24	O
%	O
on	O
warfarin	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Forest	O
Laboratories	O
,	O
LLC	O
,	O
at	O
1-800-678-1605	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Patients	O
with	O
bilirubin	O
>	O
1.5	O
*	O
ULN	O
also	O
had	O
a	O
higher	O
incidence	O
of	O
Grade	O
4	O
neutropenia	B
and	O
febrile	B
neutropenia	I
.	O
	
Neutralizing	O
antibodies	O
to	O
AUX-I	O
or	O
AUX-II	O
,	O
were	O
detected	O
in	O
10	O
%	O
and	O
21	O
%	O
,	O
respectively	O
,	O
of	O
patients	O
treated	O
with	O
XIAFLEX	O
.	O
	
Monitor	O
and	O
manage	O
patients	O
using	O
standards	O
of	O
care	O
,	O
including	O
anti-diarrheals	O
,	O
anti-emetics	O
,	O
or	O
fluid	O
replacement	O
,	O
as	O
indicated	O
.	O
	
Dyslipidemia	O
Mean	O
values	O
of	O
total	O
cholesterol	O
,	O
HDL	O
,	O
LDL	O
,	O
and	O
triglycerides	O
were	O
reported	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
Patients	O
should	O
be	O
closely	O
monitored	O
during	O
treatment	O
for	O
the	O
emergence	O
of	O
possible	O
bacterial	O
,	O
fungal	O
,	O
or	O
viral	O
infections	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
2338	O
patients	O
to	O
FARXIGA	O
with	O
a	O
mean	O
exposure	O
duration	O
of	O
21	O
weeks	O
.	O
	
Fatal	B
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
ZYKADIA	O
occurred	O
in	O
5	O
%	O
of	O
patients	O
,	O
consisting	O
of	O
:	O
pneumonia	B
(	O
4	O
patients	O
)	O
,	O
respiratory	B
failure	I
,	O
ILD/pneumonitis	O
,	O
pneumothorax	B
,	O
gastric	B
hemorrhage	I
,	O
general	B
physical	I
health	I
deterioration	I
,	O
pulmonary	B
tuberculosis	I
,	O
cardiac	B
tamponade	I
,	O
and	O
sepsis	B
(	O
1	O
patient	O
each	O
)	O
.	O
	
*	O
Women	O
over	O
35	O
years	O
old	O
who	O
smoke	O
should	O
not	O
use	O
Natazia	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
patients	O
treated	O
with	O
AMPYRA	O
10	O
mg	O
twice	O
daily	O
,	O
and	O
more	O
frequently	O
than	O
in	O
placebo-treated	O
patients	O
,	O
in	O
controlled	O
clinical	O
trials	O
.	O
	
Risk	O
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
Placebo	O
Patients	O
with	O
Events	O
per	O
1000	O
Patients	O
Drug	O
Patients	O
with	O
Events	O
per	O
1000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Drug	O
Events	O
in	O
Drug	O
Patients/Incidencein	O
Placebo	O
Patients	O
Risk	O
Difference	O
:	O
Additional	O
Drug	O
Patients	O
with	O
Events	O
per	O
1000	O
Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
for	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
for	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
the	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
There	O
have	O
been	O
reports	O
of	O
anaphylactic	B
reactions	I
in	O
patients	O
with	O
severe	O
milk	O
protein	O
allergy	O
after	O
inhalation	O
of	O
other	O
powder	O
medications	O
containing	O
lactose	O
;	O
therefore	O
,	O
patients	O
with	O
severe	O
milk	O
protein	O
allergy	O
should	O
not	O
use	O
BREO	O
ELLIPTA	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
bAnnual	O
event	O
rate	O
per	O
100	O
pt-years	O
=	O
100	O
*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O
.	O
	
Hypersensitivity	B
reactions	I
including	O
Drug	B
Rash	I
with	I
Eosinophilia	I
and	I
Systemic	I
Symptoms	I
(	O
DRESS	B
)	O
have	O
also	O
been	O
reported	O
and	O
were	O
characterized	O
by	O
rash	B
,	O
constitutional	O
findings	O
,	O
and	O
sometimes	O
organ	B
dysfunction	I
,	O
including	O
hepatic	B
failure	I
.	O
	
Studies	O
1	O
and	O
2	O
were	O
not	O
designed	O
to	O
support	O
comparative	O
claims	O
for	O
NULOJIX	O
for	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
table	O
.	O
	
5.3	O
Hematologic	O
Toxicities	O
Prolonged	O
(	O
>	O
=1	O
week	O
)	O
severe	O
neutropenia	B
and	O
Grade	O
3	O
or	O
Grade	O
4	O
thrombocytopenia	B
or	O
anemia	B
can	O
occur	O
with	O
ADCETRIS	O
.	O
	
Blood	O
and	O
lymphatic	O
system	O
disorders	O
:	O
thrombocytosis	B
,	O
pancytopenia	B
.	O
	
Autoimmune	B
disorders	I
(	O
such	O
as	O
Graves	B
'	I
disease	I
,	O
polymyositis	B
,	O
and	O
Guillain-Barre	B
syndrome	I
)	O
have	O
also	O
been	O
reported	O
to	O
occur	O
in	O
the	O
setting	O
of	O
immune	O
reconstitution	O
;	O
however	O
,	O
the	O
time	O
to	O
onset	O
is	O
more	O
variable	O
,	O
and	O
can	O
occur	O
many	O
months	O
after	O
initiation	O
of	O
treatment	O
.	O
	
5.11	O
Hypersensitivity	O
Reactions	O
,	O
Including	O
Anaphylaxis	O
Hypersensitivity	B
reactions	I
such	O
as	O
anaphylaxis	B
,	O
angioedema	B
,	O
rash	B
,	O
and	O
urticaria	B
may	O
occur	O
after	O
administration	O
of	O
BREO	O
ELLIPTA	O
.	O
	
6.1	O
Controlled	O
Clinical	O
Trials	O
Experience	O
In	O
three	O
placebo-controlled	O
clinical	O
trials	O
of	O
up	O
to	O
14	O
weeks	O
duration	O
,	O
4	O
%	O
(	O
15/400	O
)	O
of	O
patients	O
treated	O
with	O
AMPYRA	O
10	O
mg	O
twice	O
daily	O
experienced	O
one	O
or	O
more	O
treatment	O
emergent	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
,	O
compared	O
to	O
2	O
%	O
(	O
5/238	O
)	O
of	O
placebo-treated	O
patients	O
.	O
	
Table	O
2	O
shows	O
absolute	O
and	O
relative	O
risk	O
by	O
indication	O
for	O
all	O
evaluated	O
AEDs	O
.	O
	
[	O
See	O
Contraindications	O
(	O
4	O
)	O
.	O
]	O
	
Monitor	O
closely	O
and	O
take	O
appropriate	O
measures	O
.	O
	
Complete	O
blood	O
counts	O
should	O
be	O
monitored	O
prior	O
to	O
each	O
dose	O
of	O
ADCETRIS	O
and	O
more	O
frequent	O
monitoring	O
should	O
be	O
considered	O
for	O
patients	O
with	O
Grade	O
3	O
or	O
4	O
neutropenia	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
Ferriprox	O
.	O
	
Other	O
Adverse	O
Reactions	O
Adverse	O
reactions	O
that	O
occurred	O
at	O
a	O
frequency	O
of	O
>	O
=10	O
%	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
or	O
cyclosporine	O
control	O
regimen	O
in	O
Studies	O
1	O
and	O
2	O
through	O
three	O
years	O
are	O
summarized	O
by	O
preferred	O
term	O
in	O
decreasing	O
order	O
of	O
frequency	O
within	O
Table	O
4	O
.	O
	
5.3	O
Radiation	O
Risks	O
Choline	O
C	O
11	O
Injection	O
contributes	O
to	O
a	O
patient	O
's	O
overall	O
long-term	O
cumulative	O
radiation	O
exposure	O
.	O
	
Adverse	O
reactions	O
were	O
predominantly	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O
	
Patients	O
,	O
their	O
caregivers	O
,	O
and	O
families	O
should	O
be	O
informed	O
that	O
AEDs	O
increase	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
and	O
behavior	O
and	O
should	O
be	O
advised	O
of	O
the	O
need	O
to	O
be	O
alert	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
depression	O
,	O
any	O
unusual	O
changes	O
in	O
mood	O
or	O
behavior	O
,	O
or	O
the	O
emergence	O
of	O
suicidal	O
thoughts	O
,	O
behavior	O
,	O
or	O
thoughts	O
about	O
self-harm	O
.	O
	
(	O
5.1	O
)	O
5.1	O
Severe	O
Skin	O
and	O
Hypersensitivity	O
Reactions	O
Severe	O
,	O
potentially	O
life-threatening	O
,	O
and	O
fatal	B
skin	B
reactions	I
have	O
been	O
reported	O
.	O
	
In	O
case	O
of	O
recurrent	O
events	O
of	O
the	O
same	O
category	O
,	O
the	O
first	O
event	O
was	O
considered	O
.	O
	
Somnolence	B
was	O
reported	O
in	O
22	O
%	O
of	O
patients	O
treated	O
with	O
POTIGA	O
and	O
12	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
(	O
See	O
the	O
respective	O
package	O
inserts	O
for	O
complete	O
VZIG	O
and	O
IG	O
prescribing	O
information	O
.	O
)	O
	
Dose	O
reduction	O
due	O
to	O
neutropenia	B
was	O
required	O
in	O
12	O
%	O
(	O
62/503	O
)	O
of	O
patients	O
and	O
discontinuation	O
was	O
required	O
in	O
<	O
1	O
%	O
of	O
patients	O
.	O
	
Severe	O
penile	B
hematoma	I
was	O
also	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
39	O
of	O
1044	O
(	O
3.7	O
%	O
)	O
XIAFLEX-treated	O
patients	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
reported	O
in	O
the	O
two	O
randomized	O
clinical	O
trials	O
that	O
occurred	O
more	O
commonly	O
(	O
>	O
2	O
%	O
)	O
in	O
the	O
abiraterone	O
acetate	O
arm	O
were	O
fatigue	B
,	O
joint	B
swelling	I
,	O
edema	B
,	O
hot	B
flush	I
,	O
diarrhea	B
,	O
vomiting	B
,	O
cough	B
,	O
hypertension	B
,	O
dyspnea	B
,	O
urinary	B
tract	I
infection	I
and	O
contusion	B
.	O
	
The	O
most	O
common	O
reasons	O
for	O
dose	O
reductions	O
were	O
elevated	B
transaminases	I
,	O
diarrhea	B
or	O
colitis	B
,	O
and	O
rash	B
.	O
	
The	O
conditions	O
and	O
duration	O
of	O
treatment	O
with	O
FANAPT	O
varied	O
greatly	O
and	O
included	O
(	O
in	O
overlapping	O
categories	O
)	O
,	O
open-label	O
and	O
double-blind	O
phases	O
of	O
studies	O
,	O
inpatients	O
and	O
outpatients	O
,	O
fixed-dose	O
and	O
flexible-dose	O
studies	O
,	O
and	O
short-term	O
and	O
longer-term	O
exposure	O
.	O
	
(	O
5.1	O
,	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
ApoPharma	O
Inc.	O
at	O
:	O
Telephone	O
:	O
1-866-949-0995	O
Email	O
:	O
medicalsafety	O
@	O
apopharma.com	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
}	O
}	O
6.1	O
Clinical	O
Trial	O
Experience	O
The	O
following	O
adverse	O
reactions	O
are	O
also	O
discussed	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
Agranulocytosis/Neutropenia	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.13	O
,	O
7.1	O
)	O
5.1	O
Thromboembolic	O
Disorders	O
and	O
Other	O
Vascular	O
Problems	O
Stop	O
Natazia	O
if	O
an	O
arterial	O
or	O
venous	O
thrombotic	O
event	O
(	O
VTE	O
)	O
occurs	O
.	O
	
In	O
Study	O
5	O
,	O
treatment	O
of	O
recurrent	O
contractures	O
with	O
XIAFLEX	O
resulted	O
in	O
similar	O
immunogenicity	O
results	O
as	O
seen	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
Avoid	O
in	O
patients	O
with	O
congenital	O
long	O
QT	O
syndrome	O
(	O
5.4	O
)	O
5.1	O
Neutropenia	O
Severe	O
neutropenia	B
(	O
ANC	O
<	O
500/mm	O
3	O
)	O
lasting	O
more	O
than	O
one	O
week	O
occurred	O
in	O
12	O
%	O
(	O
62/503	O
)	O
of	O
patients	O
in	O
Study	O
1	O
,	O
leading	O
to	O
discontinuation	O
in	O
<	O
1	O
%	O
of	O
patients	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Cleviprex	O
was	O
infused	O
for	O
<	O
24	O
hours	O
in	O
the	O
majority	O
of	O
patients	O
(	O
n=1199	O
)	O
;	O
it	O
was	O
infused	O
as	O
a	O
continuous	O
infusion	O
in	O
an	O
additional	O
93	O
patients	O
for	O
durations	O
between	O
24	O
and	O
72	O
hours	O
.	O
	
More	O
rapid	O
titration	O
would	O
be	O
expected	O
to	O
increase	O
the	O
rate	O
of	O
orthostatic	O
hypotension	O
and	O
syncope	O
.	O
	
Median	O
exposure	O
in	O
days	O
for	O
pooled	O
studies	O
:	O
1203	O
for	O
NULOJIX	O
recommended	O
regimen	O
and	O
1163	O
for	O
cyclosporine	O
in	O
Studies	O
1	O
and	O
2.	O
?	O
	
(	O
5.5	O
)	O
5.1	O
Tendon	O
Rupture	O
or	O
Other	O
Serious	O
Injury	O
to	O
the	O
Injected	O
Finger/Hand	O
in	O
the	O
Treatment	O
of	O
Dupuytren	O
's	O
Contracture	O
In	O
the	O
controlled	O
and	O
uncontrolled	O
portions	O
of	O
clinical	O
trials	O
in	O
Dupuytren	O
's	O
contracture	O
,	O
flexor	B
tendon	I
ruptures	I
occurred	O
after	O
XIAFLEX	O
injection	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Immune-mediated	B
endocrinopathies	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
5.5	O
Viral	O
Infections	O
Employment	O
of	O
a	O
corticosteroid	O
medication	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
a	O
history	O
of	O
herpes	O
simplex	O
requires	O
great	O
caution	O
.	O
	
PRISTIQ	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
patients	O
with	O
a	O
seizure	O
disorder	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Gilead	O
Sciences	O
,	O
Inc.	O
at	O
1-800-GILEAD-5	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
(	O
5.6	O
)	O
*	O
Preparation	O
and	O
Administration	O
Errors	O
:	O
Strictly	O
follow	O
instructions	O
for	O
preparation	O
(	O
including	O
admixing	O
)	O
and	O
administration	O
.	O
	
#	O
Most	O
herpes	B
infections	I
were	O
non-serious	O
and	O
1	O
led	O
to	O
treatment	O
discontinuation	O
.	O
	
The	O
protocol	O
included	O
provisions	O
for	O
patients	O
taking	O
placebo	O
to	O
receive	O
treatment	O
with	O
SIMPONI	O
ARIA	O
at	O
Week	O
16	O
or	O
Week	O
24	O
either	O
by	O
patient	O
response	O
(	O
based	O
on	O
uncontrolled	O
disease	O
activity	O
)	O
or	O
by	O
design	O
,	O
so	O
that	O
adverse	O
events	O
can	O
not	O
always	O
be	O
unambiguously	O
attributed	O
to	O
a	O
given	O
treatment	O
.	O
	
Two	O
patients	O
continued	O
treatment	O
with	O
POTIGA	O
and	O
were	O
able	O
to	O
void	O
spontaneously	O
after	O
catheter	O
removal	O
.	O
	
The	O
mean	O
age	O
of	O
the	O
population	O
was	O
59	O
years	O
and	O
4	O
%	O
were	O
older	O
than	O
75	O
years	O
.	O
	
Table	O
2	O
:	O
Change	O
in	O
Glucose	O
Mean	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
3-6	O
months	O
6-12	O
months	O
>	O
12	O
months	O
FANAPT	O
10-16	O
mg/day	O
1.8	O
(	O
N=773	O
)	O
5.4	O
(	O
N=723	O
)	O
5.4	O
(	O
N=425	O
)	O
FANAPT	O
20-24	O
mg/day	O
-3.6	O
(	O
N=34	O
)	O
-9.0	O
(	O
N=31	O
)	O
-18.0	O
(	O
N=20	O
)	O
Dyslipidemia	O
Undesirable	B
alterations	I
in	I
lipids	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
HORIZANT	O
in	O
the	O
treatment	O
of	O
RLS	O
was	O
studied	O
primarily	O
in	O
placebo-controlled	O
trials	O
(	O
n	O
=	O
642	O
)	O
,	O
and	O
in	O
long-term	O
follow-up	O
studies	O
.	O
	
Treatment	O
with	O
PRISTIQ	O
and	O
any	O
concomitant	O
serotonergic	O
agents	O
should	O
be	O
discontinued	O
immediately	O
if	O
the	O
above	O
events	O
occur	O
and	O
supportive	O
symptomatic	O
treatment	O
should	O
be	O
initiated	O
.	O
	
Fatal	B
adverse	O
reactions	O
occurred	O
in	O
6	O
%	O
of	O
patients	O
receiving	O
COMETRIQ	O
and	O
resulted	O
from	O
hemorrhage	B
,	O
pneumonia	B
,	O
septicemia	B
,	O
fistulas	B
,	O
cardiac	B
arrest	I
,	O
respiratory	B
failure	I
,	O
and	O
unspecified	O
death	B
.	O
	
In	O
patients	O
receiving	O
BLINCYTO	O
in	O
clinical	O
trials	O
,	O
Grade	O
3	O
or	O
greater	O
elevations	B
in	I
liver	I
enzymes	I
occurred	O
in	O
approximately	O
6	O
%	O
of	O
patients	O
outside	O
the	O
setting	O
of	O
CRS	B
and	O
resulted	O
in	O
treatment	O
discontinuation	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
.	O
	
Activation	B
of	I
mania	I
has	O
also	O
been	O
reported	O
in	O
a	O
small	O
proportion	O
of	O
patients	O
with	O
major	O
affective	O
disorder	O
who	O
were	O
treated	O
with	O
other	O
marketed	O
antidepressants	O
.	O
	
It	O
is	O
unknown	O
whether	O
TRULICITY	O
will	O
cause	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
,	O
as	O
the	O
human	O
relevance	O
of	O
dulaglutide-induced	O
rodent	O
thyroid	B
C-cell	I
tumors	I
has	O
not	O
been	O
determined	O
.	O
	
Serious	O
adverse	O
reactions	O
reported	O
include	O
anaphylactic	B
shock	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
,	O
myelosuppression	B
,	O
gastrointestinal	B
toxicity	I
(	O
diarrhea	B
)	O
,	O
fluid	B
retention	I
,	O
hepatotoxicity	B
and	O
rash	B
.	O
	
bladder	B
infection	I
,	O
bacteriuria	B
,	O
cystitis	B
)	O
in	O
7	O
%	O
of	O
CIMZIA-treated	O
patients	O
and	O
in	O
6	O
%	O
of	O
placebo-treated	O
patients	O
,	O
and	O
arthralgia	B
(	O
6	O
%	O
CIMZIA	O
,	O
4	O
%	O
placebo	O
)	O
.	O
	
Consider	O
measures	O
to	O
prevent	O
severe	O
reactions	O
,	O
including	O
antihistamines	O
,	O
antipyretics	O
and	O
corticosteroids	O
in	O
subsequent	O
cycles	O
in	O
patients	O
who	O
have	O
experienced	O
Grade	O
1	O
or	O
2	O
infusion	O
reactions	O
.	O
	
Table	O
3	O
gives	O
the	O
incidence	O
of	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
subjects	O
with	O
partial-onset	O
seizures	O
in	O
any	O
APTIOM	O
treatment	O
group	O
and	O
for	O
which	O
the	O
incidence	O
was	O
greater	O
than	O
placebo	O
during	O
the	O
controlled	O
clinical	O
trials	O
.	O
	
If	O
liver	O
injury	O
is	O
detected	O
,	O
promptly	O
interrupt	O
NESINA	O
and	O
assess	O
patient	O
for	O
probable	O
cause	O
,	O
then	O
treat	O
cause	O
if	O
possible	O
,	O
to	O
resolution	O
or	O
stabilization	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
.	O
	
(	O
6.1	O
)	O
Glabellar	O
Lines	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
are	O
:	O
nasopharyngitis	B
,	O
headache	B
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
reaction	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
sinusitis	B
,	O
and	O
nausea	B
.	O
	
5.3	O
Anaphylaxis	O
and	O
Infusion	O
Reactions	O
Infusion	B
reactions	I
to	O
TREANDA	O
have	O
occurred	O
commonly	O
in	O
clinical	O
trials	O
.	O
	
Table	O
7	O
:	O
Non-Hematologic	O
Adverse	O
Reactions	O
in	O
>	O
=	O
10	O
%	O
of	O
Patients	O
with	O
Waldenstrom	O
's	O
Macroglobulinemia	O
(	O
N=63	O
)	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
The	O
system	O
organ	O
class	O
and	O
individual	O
ADR	O
terms	O
are	O
sorted	O
in	O
descending	O
frequency	O
order	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
1	O
%	O
)	O
were	O
ingrown	B
toenails	I
,	O
application	B
site	I
dermatitis	I
,	O
application	B
site	I
vesicles	I
,	O
and	O
application	B
site	I
pain	I
.	O
	
The	O
system	O
organ	O
class	O
and	O
individual	O
ADR	O
terms	O
are	O
sorted	O
in	O
descending	O
frequency	O
order	O
in	O
the	O
IMBRUVICA	O
arm	O
.	O
	
(	O
5.1	O
)	O
*	O
Progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
:	O
Withhold	O
TECFIDERA	O
at	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
.	O
	
The	O
mean	O
baseline	O
hemoglobin	O
value	O
was	O
approximately	O
14.1	O
g/dL	O
across	O
treatment	O
groups	O
.	O
	
Adult	O
Patients	O
:	O
Pooled	O
data	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
In	O
these	O
two	O
studies	O
combined	O
,	O
554	O
patients	O
received	O
Toviaz	O
4	O
mg/day	O
and	O
566	O
patients	O
received	O
Toviaz	O
8	O
mg/day	O
.	O
	
In	O
the	O
single-arm	O
Phase	O
1/2	O
clinical	O
trial	O
,	O
the	O
median	O
time	O
to	O
onset	O
for	O
diarrhea	O
(	O
all	O
grades	O
)	O
was	O
2	O
days	O
and	O
the	O
median	O
duration	O
per	O
event	O
was	O
1	O
day	O
.	O
	
The	O
population	O
was	O
19	O
to	O
97	O
years	O
old	O
,	O
64	O
%	O
were	O
female	O
,	O
and	O
84	O
%	O
were	O
Caucasian	O
;	O
64	O
%	O
were	O
undergoing	O
a	O
surgery	O
that	O
included	O
bowel	O
resection	O
.	O
	
They	O
represent	O
an	O
evaluation	O
of	O
the	O
adverse	O
reaction	O
data	O
from	O
870	O
patients	O
with	O
Ph+	O
leukemia	O
who	O
received	O
at	O
least	O
1	O
dose	O
of	O
single-agent	O
BOSULIF	O
.	O
	
These	O
adverse	O
reactions	O
are	O
:	O
hypersensitivity	B
reactions	I
,	O
paradoxical	B
bronchospasm	I
,	O
tachycardia/heart	O
rate	B
increase/palpitations	O
,	O
pruritus/rash	O
and	O
dizziness	B
.	O
	
Inhalation	O
of	O
airborne	O
capsaicin	O
can	O
result	O
in	O
coughing	B
or	O
sneezing	B
.	O
	
The	O
average	O
age	O
was	O
55	O
years	O
(	O
range	O
from1	O
week	O
to	O
93	O
years	O
)	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
64	O
patients	O
(	O
37.2	O
%	O
)	O
treated	O
with	O
XALKORI	O
and	O
40	O
patients	O
(	O
23.4	O
%	O
)	O
in	O
the	O
chemotherapy	O
arm	O
.	O
	
Male	B
patients	I
who	I
developed	I
genital	I
mycotic	I
infections	I
on	O
INVOKANA	O
were	O
more	O
likely	O
to	O
experience	O
recurrent	O
infections	O
(	O
22	O
%	O
on	O
INVOKANA	O
versus	O
none	O
on	O
placebo	O
)	O
,	O
and	O
require	O
treatment	O
with	O
oral	O
or	O
topical	O
antifungal	O
agents	O
and	O
anti-microbial	O
agents	O
than	O
patients	O
on	O
comparators	O
.	O
	
(	O
5.1	O
)	O
Growth	O
of	O
Resistant	O
Organisms	O
with	O
Prolonged	O
Use	O
.	O
	
Only	O
use	O
SIRTURO	O
when	O
an	O
effective	O
treatment	O
regimen	O
can	O
not	O
otherwise	O
be	O
provided	O
.	O
	
Across	O
all	O
controlled	O
and	O
uncontrolled	O
trials	O
,	O
more	O
than	O
1,600	O
patients	O
have	O
received	O
Qutenza	O
.	O
	
The	O
6-dose	O
Coartem	O
Tablets	O
population	O
was	O
patients	O
with	O
malaria	O
between	O
ages	O
2	O
months	O
and	O
71	O
years	O
:	O
67	O
%	O
(	O
1,332	O
)	O
were	O
16	O
years	O
and	O
younger	O
and	O
33	O
%	O
(	O
647	O
)	O
were	O
older	O
than	O
16	O
years	O
.	O
	
Only	O
use	O
SIRTURO	O
when	O
an	O
effective	O
treatment	O
regimen	O
can	O
not	O
otherwise	O
be	O
provided	O
[	O
see	O
Indications	O
and	O
Usage	O
(	O
1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Excessive	O
use	O
or	O
use	O
in	O
conjunction	O
with	O
other	O
medications	O
containing	O
LABA	O
can	O
result	O
in	O
clinically	O
significant	O
cardiovascular	B
effects	I
and	O
may	O
be	O
fatal	B
(	O
5.3	O
)	O
*	O
Immediate	O
hypersensitivity	B
reactions	I
may	O
occur	O
.	O
	
Anaphylaxis	B
was	O
reported	O
in	O
4	O
%	O
of	O
patients	O
with	O
HAE	O
.	O
	
The	O
incidence	O
of	O
nonfatal	O
serious	O
adverse	O
events	O
was	O
24.2	O
%	O
in	O
the	O
placebo	O
group	O
and	O
25.0	O
%	O
in	O
the	O
Prolia	O
group	O
.	O
	
DUAVEE	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
endometrial	B
hyperplasia	I
,	O
which	O
may	O
be	O
a	O
precursor	O
to	O
endometrial	O
cancer	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
were	O
hot	B
flush	I
,	O
abdominal	B
pain	I
upper	I
,	O
and	O
nausea	B
.	O
	
5.2	O
Spread	O
of	O
Toxin	O
Effect	O
Post-marketing	O
safety	O
data	O
from	O
DYSPORT	O
(	O
r	O
)	O
and	O
other	O
approved	O
botulinum	O
toxins	O
suggest	O
that	O
botulinum	O
toxin	B
effects	I
may	I
,	I
in	I
some	I
cases	I
,	I
be	I
observed	I
beyond	I
the	I
site	I
of	I
local	I
injection	I
.	O
	
The	O
forms	O
specifically	O
requested	O
information	O
on	O
occurrence	O
of	O
allergic	B
reactions	I
,	O
thrombotic	B
events	I
,	O
hemorrhagic	B
events	I
,	O
hepatobiliary	B
disorders	I
,	O
pancreatic	B
disorders	I
,	O
and	O
hyperglycemia	B
.	O
	
When	O
distant	O
effects	O
occur	O
,	O
additional	O
respiratory	O
muscles	O
may	O
be	O
involved	O
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Monitor	O
ALT	O
,	O
AST	O
and	O
bilirubin	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
.	O
	
Of	O
these	O
4	O
patients	O
who	O
developed	O
anti-ERWINAZE	O
antibodies	O
,	O
3	O
experienced	O
hypersensitivity	B
reactions	I
(	O
10	O
%	O
,	O
3	O
of	O
30	O
)	O
during	O
the	O
study	O
.	O
	
EXCERPT	O
:	O
Commonly	O
observed	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=5	O
%	O
and	O
at	O
least	O
twice	O
that	O
for	O
placebo	O
)	O
were	O
(	O
6.1	O
)	O
:	O
*	O
Schizophrenia	O
Adults	O
:	O
akathisia	B
,	O
oral	B
hypoesthesia	I
,	O
somnolence	B
.	O
	
5.9	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
INVOKANA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
If	O
a	O
decision	O
is	O
made	O
to	O
administer	O
SIMPONI	O
ARIA	O
to	O
RA	O
patients	O
with	O
CHF	O
,	O
these	O
patients	O
should	O
be	O
closely	O
monitored	O
during	O
therapy	O
,	O
and	O
SIMPONI	O
ARIA	O
should	O
be	O
discontinued	O
if	O
new	O
or	O
worsening	O
symptoms	O
of	O
CHF	O
appear	O
.	O
	
*	O
Do	O
not	O
use	O
estrogens	O
to	O
prevent	O
heart	O
disease	O
,	O
heart	O
attacks	O
,	O
strokes	O
or	O
dementia	O
(	O
decline	O
in	O
brain	O
function	O
)	O
.	O
	
In	O
the	O
EMTP	O
trial	O
,	O
the	O
planned	O
number	O
of	O
doses	O
of	O
ERWINAZE	O
ranged	O
from	O
3	O
to	O
48	O
doses	O
.	O
	
5.1	O
Spread	O
of	O
Toxin	O
Effect	O
Postmarketing	O
safety	O
data	O
from	O
XEOMIN	O
and	O
other	O
approved	O
botulinum	O
toxins	O
suggest	O
that	O
botulinum	O
toxin	B
effects	I
may	I
,	I
in	I
some	I
cases	I
,	I
be	I
observed	I
beyond	I
the	I
site	I
of	I
local	I
injection	I
.	O
	
Postmarketing	O
Experience	O
In	O
the	O
postmarketing	O
setting	O
,	O
third-degree	B
AV	I
block	I
and	O
AV	B
block	I
with	O
junctional	B
escape	I
have	O
been	O
observed	O
during	O
the	O
first-dose	O
6-hour	O
observation	O
period	O
with	O
GILENYA	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
need	O
of	O
emergency	O
cardiorespiratory	O
support	O
.	O
	
Limited	O
safety	O
data	O
are	O
available	O
in	O
patients	O
with	O
predisposing	O
factors	O
for	O
seizure	O
because	O
these	O
patients	O
were	O
generally	O
excluded	O
from	O
the	O
trials	O
.	O
	
Avoid	O
use	O
of	O
GBCAs	O
in	O
these	O
patients	O
unless	O
the	O
diagnostic	O
information	O
is	O
essential	O
and	O
not	O
available	O
with	O
non-contrasted	O
MRI	O
or	O
other	O
modalities	O
.	O
	
Before	O
initiating	O
treatment	O
with	O
GILENYA	O
,	O
a	O
recent	O
CBC	O
(	O
i.e.	O
,	O
within	O
6	O
months	O
or	O
after	O
discontinuation	O
of	O
prior	O
therapy	O
)	O
should	O
be	O
available	O
.	O
	
The	O
effects	O
of	O
XEOMIN	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	O
produce	O
symptoms	O
consistent	O
with	O
botulinum	O
toxin	B
effects	I
.	O
	
In	O
an	O
exploratory	O
clinical	O
trial	O
evaluating	O
the	O
use	O
of	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
in	O
patients	O
with	O
severe	O
persistent	O
asthma	O
,	O
more	O
patients	O
treated	O
with	O
golimumab	O
reported	O
malignancies	B
compared	O
with	O
control	O
patients	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Common	O
adverse	O
reactions	O
that	O
occurred	O
in	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
of	O
subjects	O
switching	O
to	O
STRIBILD	O
were	O
nausea	B
(	O
4	O
%	O
)	O
,	O
flatulence	B
(	O
2	O
%	O
)	O
,	O
and	O
headache	B
(	O
2	O
%	O
)	O
.	O
	
A	O
total	O
of	O
2,034	O
subjects	O
with	O
COPD	O
received	O
at	O
least	O
1	O
dose	O
of	O
BREO	O
ELLIPTA	O
100/25	O
,	O
and	O
1,087	O
subjects	O
received	O
a	O
higher	O
strength	O
of	O
fluticasone	O
furoate/vilanterol	O
.	O
	
Patients	O
should	O
be	O
counseled	O
about	O
the	O
possibility	O
of	O
delayed-onset	O
hypersensitivity	O
reactions	O
and	O
given	O
proper	O
follow-up	O
instructions	O
.	O
	
5.6	O
Dyspnea	O
Dyspnea	B
was	O
reported	O
in	O
28	O
%	O
of	O
patients	O
treated	O
with	O
Kyprolis	O
and	O
was	O
Grade	O
3	O
or	O
greater	O
in	O
4	O
%	O
of	O
patients	O
.	O
	
(	O
1	O
,	O
5.2	O
,	O
7.1	O
,	O
7.3	O
,	O
12.3	O
)	O
*	O
Neuroleptic	B
Malignant	I
Syndrome	I
:	O
Manage	O
with	O
immediate	O
discontinuation	O
of	O
drug	O
and	O
close	O
monitoring	O
.	O
	
The	O
safety	O
of	O
reinitiating	O
Kyprolis	O
therapy	O
in	O
patients	O
previously	O
experiencing	O
TTP/HUS	O
is	O
not	O
known	O
.	O
	
Careful	O
consideration	O
should	O
be	O
given	O
to	O
this	O
potential	O
risk	O
prior	O
to	O
initiating	O
therapy	O
in	O
patients	O
with	O
these	O
conditions	O
.	O
	
Treatment	O
with	O
antibacterial	O
agents	O
alters	O
the	O
normal	O
flora	O
of	O
the	O
colon	O
and	O
may	O
permit	O
overgrowth	O
of	O
C	O
.	O
	
Afatinib	O
was	O
embryotoxic	B
and	O
,	O
in	O
animals	O
with	O
maternal	O
toxicity	O
,	O
led	O
to	O
abortions	B
at	I
late	I
gestational	I
stages	I
in	O
rabbits	O
at	O
doses	O
of	O
5	O
mg/kg	O
(	O
approximately	O
0.2	O
times	O
the	O
human	O
exposure	O
at	O
the	O
recommended	O
dose	O
of	O
40	O
mg	O
daily	O
)	O
or	O
greater	O
.	O
	
If	O
supine	O
hypertension	O
is	O
not	O
well-managed	O
,	O
NORTHERA	O
may	O
increase	O
the	O
risk	O
of	O
cardiovascular	O
events	O
.	O
	
Monitor	O
CrCl	O
at	O
least	O
daily	O
in	O
patients	O
with	O
changing	O
renal	O
function	O
and	O
adjust	O
the	O
dosage	O
of	O
ZERBAXA	O
accordingly	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Administer	O
dexamethasone	O
prior	O
to	O
Kyprolis	O
to	O
reduce	O
the	O
incidence	O
and	O
severity	O
of	O
infusion	O
reactions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
6.2	O
Adverse	O
Events	O
Associated	O
With	O
Gabapentin	O
The	O
following	O
adverse	O
events	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
gabapentin	O
,	O
either	O
in	O
clinical	O
trials	O
or	O
postmarketing	O
:	O
breast	B
enlargement	I
,	O
gynecomastia	B
,	O
and	O
elevated	B
creatine	I
kinase	I
.	O
	
Monitor	O
blood	O
pressure	O
regularly	O
in	O
all	O
patients	O
.	O
	
Two	O
patients	O
receiving	O
alglucosidase	O
alfa	O
discontinued	O
the	O
trial	O
due	O
to	O
anaphylactic	B
reactions	I
.	O
	
Appropriate	O
laboratory	O
testing	O
prior	O
to	O
initiating	O
therapy	O
and	O
monitoring	O
for	O
hepatotoxicity	O
during	O
therapy	O
with	O
TIVICAY	O
is	O
recommended	O
in	O
patients	O
with	O
underlying	O
hepatic	O
disease	O
such	O
as	O
hepatitis	O
B	O
or	O
C.	O
(	O
5.2	O
)	O
*	O
accumulation	B
of	I
body	I
fat	I
and	O
immune	B
reconstitution	I
syndrome	I
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
combination	O
antiretroviral	O
therapy	O
.	O
	
ENTEREG	O
is	O
not	O
recommended	O
for	O
use	O
in	O
these	O
patients	O
.	O
	
5.4	O
Macular	O
Edema	O
Fingolimod	O
increases	O
the	O
risk	O
of	O
macular	B
edema	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
irrespective	O
of	O
causality	O
)	O
leading	O
to	O
treatment	O
discontinuation	O
were	O
pneumonitis	B
and	O
dyspnea	B
.	O
	
Table	O
3	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=1	O
%	O
of	O
Subjects	O
on	O
OTEZLA	O
and	O
With	O
Greater	O
Frequency	O
Than	O
in	O
Subjects	O
on	O
Placebo	O
;	O
up	O
to	O
Day	O
112	O
(	O
Week	O
16	O
)	O
*	O
Two	O
subjects	O
treated	O
with	O
OTEZLA	O
experienced	O
serious	O
adverse	O
reaction	O
of	O
abdominal	B
pain	I
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Reported	O
>	O
=	O
10	O
%	O
of	O
Patients	O
with	O
Advanced	O
PNET	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Includes	O
stomatitis	B
,	O
aphthous	B
stomatitis	I
,	O
gingival	B
pain	I
,	O
glossitis	B
,	O
glossodynia	B
,	O
lip	B
ulceration	I
,	O
mouth	B
ulceration	I
,	O
tongue	B
ulceration	I
,	O
and	O
mucosal	B
inflammation	I
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Zylera	O
Pharmaceuticals	O
,	O
LLC	O
.	O
	
5.6	O
Corneal	O
Exposure	O
,	O
Corneal	O
Ulceration	O
,	O
and	O
Ectropion	O
in	O
Patients	O
Treated	O
with	O
XEOMIN	O
for	O
Blepharospasm	O
Reduced	B
blinking	I
from	O
injection	O
of	O
botulinum	O
toxin	O
products	O
in	O
the	O
orbicularis	O
muscle	O
can	O
lead	O
to	O
corneal	B
exposure	I
and	O
corneal	B
ulceration	I
,	O
especially	O
in	O
patients	O
with	O
VII	O
nerve	O
disorders	O
.	O
	
Symptoms	O
of	O
macular	B
edema	I
included	O
blurred	B
vision	I
and	O
decreased	B
visual	I
acuity	I
.	O
	
Exercise	O
caution	O
in	O
patients	O
with	O
known	O
hypersensitivity	O
to	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
Changes	O
in	O
Serum	O
Creatinine	O
Dolutegravir	O
has	O
been	O
shown	O
to	O
increase	B
serum	I
creatinine	I
due	O
to	O
inhibition	O
of	O
tubular	O
secretion	O
of	O
creatinine	O
without	O
affecting	O
renal	O
glomerular	O
function	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
In	O
Studies	O
102	O
and	O
103	O
,	O
increases	B
in	I
serum	I
creatinine	I
and	O
decreases	B
in	I
estimated	I
creatinine	I
clearance	I
occurred	O
early	O
in	O
treatment	O
with	O
STRIBILD	O
,	O
after	O
which	O
they	O
stabilized	O
.	O
	
The	O
incidence	O
of	O
adverse	O
reactions	O
associated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
and	O
BREO	O
ELLIPTA	O
200/25	O
is	O
shown	O
in	O
Table	O
3	O
.	O
	
No	O
new	O
safety	O
findings	O
were	O
observed	O
following	O
the	O
switch	O
to	O
4000	O
L	O
scale	O
of	O
alglucosidase	O
alfa	O
.	O
	
Patients	O
with	O
a	O
pre-existing	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
or	O
a	O
history	O
of	O
leukopenia/neutropenia	O
should	O
have	O
their	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
monitored	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
and	O
should	O
discontinue	O
FANAPT	O
at	O
the	O
first	O
sign	O
of	O
a	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
Exposure	O
to	O
sunlight	O
and	O
ultraviolet	O
(	O
UV	O
)	O
light	O
should	O
be	O
limited	O
by	O
wearing	O
protective	O
clothing	O
and	O
using	O
a	O
sunscreen	O
with	O
a	O
high	O
protection	O
factor	O
.	O
	
Discontinue	O
trametinib	O
if	O
no	O
improvement	O
after	O
3	O
weeks	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
ELIQUIS	O
can	O
cause	O
serious	O
,	O
potentially	O
fatal	B
bleeding	B
.	O
	
If	O
the	O
patient	O
is	O
known	O
or	O
strongly	O
suspected	O
of	O
having	O
had	O
a	O
hypersensitivity	O
reaction	O
to	O
DaTscan	O
,	O
the	O
decision	O
to	O
administer	O
DaTscan	O
should	O
be	O
based	O
upon	O
an	O
assessment	O
of	O
the	O
expected	O
benefits	O
compared	O
to	O
the	O
potential	O
hypersensitivity	O
risks	O
.	O
	
It	O
is	O
unknown	O
whether	O
TANZEUM	O
(	O
r	O
)	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
Of	O
the	O
total	O
population	O
across	O
the	O
three	O
trials	O
,	O
229	O
patients	O
received	O
a	O
dose	O
of	O
125	O
mg	O
twice	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
141	O
days	O
,	O
69	O
patients	O
received	O
a	O
dose	O
of	O
250	O
mg	O
twice	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
139	O
days	O
,	O
102	O
patients	O
received	O
a	O
dose	O
of	O
250	O
mg	O
four	O
times	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
14	O
days	O
,	O
54	O
patients	O
received	O
a	O
dose	O
of	O
500	O
mg	O
twice	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
146	O
days	O
,	O
and	O
242	O
patients	O
received	O
a	O
dose	O
of	O
500	O
mg	O
four	O
times	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
14	O
days	O
.	O
	
Neonates	O
(	O
i.e	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Interstitial	B
Lung	I
Disease/Pneumonitis	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
QT	B
Interval	I
Prolongation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Bradycardia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Severe	O
Visual	B
Loss	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
are	O
vision	B
disorders	I
,	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
edema	B
,	O
elevated	B
transaminases	I
,	O
upper	B
respiratory	I
infection	I
,	O
decreased	B
appetite	I
,	O
and	O
dysgeusia	B
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
65	O
%	O
of	O
patients	O
.	O
	
(	O
5.5	O
)	O
*	O
Impaired	B
wound	I
healing	I
:	O
Increased	O
risk	O
of	O
wound-related	B
complications	I
.	O
	
Physicians	O
should	O
consider	O
PTLD	O
in	O
patients	O
reporting	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
or	O
symptoms	O
.	O
	
If	O
anticoagulation	O
with	O
ELIQUIS	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
RPED	B
occurred	O
in	O
2	O
%	O
(	O
1/55	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
These	O
studies	O
did	O
not	O
show	O
an	O
increase	O
in	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
antidepressant	O
use	O
in	O
patients	O
over	O
age	O
24	O
;	O
there	O
was	O
a	O
reduction	O
in	O
risk	O
with	O
antidepressant	O
use	O
in	O
patients	O
aged	O
65	O
and	O
older	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Fatal	B
outcomes	O
have	O
been	O
observed	O
.	O
	
The	O
discontinuation	O
rate	O
due	O
to	O
bleeding	B
events	O
was	O
0.7	O
%	O
in	O
the	O
ELIQUIS-treated	O
patients	O
compared	O
to	O
1.7	O
%	O
in	O
enoxaparin/warfarin-treated	O
patients	O
in	O
the	O
AMPLIFY	O
study	O
.	O
	
(	O
2.3	O
)	O
*	O
JEVTANA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
As	O
such	O
,	O
reliability	O
in	O
estimating	O
their	O
frequency	O
or	O
in	O
establishing	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
is	O
not	O
always	O
possible	O
.	O
	
5	O
.	O
	
Additional	O
safety	O
information	O
was	O
collected	O
from	O
clinical	O
records	O
submitted	O
by	O
treating	O
physicians	O
.	O
	
*	O
Progressive	B
multifocal	I
leukoencephalopathy	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
SJIA	O
Study	O
2	O
was	O
a	O
two-part	O
study	O
with	O
an	O
open-label	O
,	O
single-arm	O
active	O
treatment	O
period	O
(	O
Part	O
I	O
)	O
followed	O
by	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
event-driven	O
withdrawal	O
design	O
(	O
Part	O
II	O
)	O
.	O
	
*	O
b	O
In	O
this	O
trial	O
,	O
no	O
documented	O
symptomatic	O
or	O
severe	O
hypoglycemia	B
were	O
reported	O
for	O
TANZEUM	O
50	O
mg	O
and	O
these	O
data	O
are	O
omitted	O
from	O
the	O
table	O
.	O
	
Eye	B
disorders	I
,	O
including	O
severe	O
eye	B
pain	I
,	O
chemical	B
conjunctivitis	I
,	O
corneal	B
burn	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
periorbital	B
edema	I
can	O
occur	O
after	O
exposure	O
.	O
	
Withhold	O
treatment	O
with	O
trametinib	O
and	O
continue	O
TAFINLAR	O
at	O
the	O
same	O
dose	O
if	O
absolute	O
LVEF	O
value	O
decreases	O
by	O
10	O
%	O
from	O
pretreatment	O
values	O
and	O
is	O
less	O
than	O
the	O
lower	O
limit	O
of	O
normal	O
.	O
	
If	O
an	O
infection	O
develops	O
,	O
monitor	O
carefully	O
,	O
and	O
stop	O
CIMZIA	O
if	O
infection	O
becomes	O
serious	O
(	O
5.1	O
)	O
*	O
Invasive	B
fungal	I
infections	I
-	O
for	O
patients	O
who	O
develop	O
a	O
systemic	O
illness	O
on	O
CIMZIA	O
,	O
consider	O
empiric	O
antifungal	O
therapy	O
for	O
those	O
who	O
reside	O
or	O
travel	O
to	O
regions	O
where	O
mycoses	O
are	O
endemic	O
(	O
5.1	O
)	O
*	O
Cases	O
of	O
lymphoma	B
and	O
other	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF	O
blockers	O
(	O
5.2	O
)	O
*	O
Heart	B
failure	I
,	I
worsening	I
may	O
occur	O
(	O
5.3	O
)	O
*	O
Anaphylaxis	B
or	O
serious	O
allergic	B
reactions	I
may	O
occur	O
(	O
5.4	O
)	O
*	O
Hepatitis	B
B	I
virus	I
reactivation	I
-	O
test	O
for	O
HBV	O
infection	O
before	O
starting	O
CIMZIA	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
postmarketing	O
use	O
of	O
Gadavist	O
.	O
	
Some	O
deaths	B
due	O
to	O
renal	B
failure	I
did	O
not	O
have	O
a	O
clear	O
etiology	O
.	O
	
Bipolar	O
I	O
Disorder	O
(	O
3-weeks	O
)	O
Placebo	O
SAPHRIS2.5	O
mgtwice	O
daily	O
SAPHRIS5	O
mgtwice	O
daily	O
SAPHRIS10	O
mgtwice	O
daily	O
Change	O
from	O
Baseline	O
(	O
kg	O
)	O
(	O
N*	O
)	O
0.5	O
(	O
89	O
)	O
1.7	O
(	O
92	O
)	O
1.6	O
(	O
90	O
)	O
1.4	O
(	O
87	O
)	O
Proportion	O
of	O
Subjects	O
with	O
a	O
>	O
=7	O
%	O
Increase	B
in	I
Body	I
Weight	I
%	O
with	O
>	O
=7	O
%	O
increase	B
in	I
body	I
weight	I
1.1	O
%	O
12.0	O
%	O
8.9	O
%	O
8.0	O
%	O
5.6	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
The	O
concomitant	O
use	O
of	O
a	O
TNF-blocker	O
and	O
abatacept	O
or	O
anakinra	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
serious	O
infections	O
;	O
therefore	O
,	O
the	O
concomitant	O
use	O
of	O
SIMPONI	O
ARIA	O
and	O
these	O
biologic	O
products	O
is	O
not	O
recommended	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
,	O
5.6	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
infections	B
-	O
Do	O
not	O
start	O
SIMPONI	O
ARIA	O
during	O
an	O
active	O
infection	O
.	O
	
5.2	O
Paradoxical	O
Bronchospasm	O
Inhaled	O
medicines	O
,	O
including	O
TUDORZA	O
PRESSAIR	O
,	O
may	O
cause	O
paradoxical	B
bronchospasm	I
.	O
	
30.6	O
%	O
had	O
diabetes	O
mellitus	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
EYLEA	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Possible	O
risk	O
factors	O
for	O
leukopenia/neutropenia	O
include	O
pre-existing	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
/absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
and	O
history	O
of	O
drug	O
induced	O
leukopenia/neutropenia	O
.	O
	
All	O
patients	O
also	O
received	O
basiliximab	O
induction	O
,	O
mycophenolate	O
mofetil	O
,	O
and	O
corticosteroids	O
.	O
	
Congestive	O
Heart	O
Failure	O
No	O
serious	O
adverse	O
reactions	O
to	O
AdreView	O
were	O
observed	O
in	O
clinical	O
studies	O
.	O
	
Details	O
of	O
the	O
study	O
treatment	O
are	O
described	O
in	O
Section	O
14.1	O
.	O
	
C.	O
difficile	O
produces	O
toxins	O
A	O
and	O
B	O
which	O
contribute	O
to	O
the	O
development	O
of	O
CDAD	O
.	O
	
Patients	O
greater	O
than	O
65	O
years	O
of	O
age	O
,	O
patients	O
with	O
co-morbid	O
conditions	O
,	O
and/or	O
patients	O
taking	O
concomitant	O
immunosuppressants	O
(	O
e.g	O
.	O
	
Mineralization	O
Defects	O
:	O
Cases	O
of	O
osteomalacia	B
associated	O
with	O
proximal	B
renal	I
tubulopathy	I
,	O
manifested	O
as	O
bone	B
pain	I
or	O
pain	B
in	I
extremities	I
and	O
which	O
may	O
contribute	O
to	O
fractures	B
,	O
have	O
been	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
tenofovir	O
DF	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
A	O
majority	O
of	O
reported	O
events	O
occurred	O
in	O
patients	O
who	O
had	O
experienced	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
or	O
dehydration	B
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TANZEUM	O
.	O
	
Most	O
,	O
but	O
not	O
all	O
,	O
of	O
these	O
patients	O
had	O
underlying	O
anatomic	O
or	O
vascular	O
risk	O
factors	O
for	O
developing	O
NAION	O
,	O
including	O
but	O
not	O
necessarily	O
limited	O
to	O
:	O
low	O
cup	O
to	O
disc	O
ratio	O
(	O
``	O
crowded	O
disc	O
''	O
)	O
,	O
age	O
over	O
50	O
,	O
diabetes	O
,	O
hypertension	O
,	O
coronary	O
artery	O
disease	O
,	O
hyperlipidemia	O
,	O
and	O
smoking	O
.	O
	
Reported	O
infections	O
with	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
include	O
:	O
*	O
Active	B
tuberculosis	I
,	O
including	O
reactivation	B
of	I
latent	I
tuberculosis	I
.	O
	
transfusion	O
)	O
if	O
clinically	O
indicated	O
.	O
	
Immunogenicity	O
assay	O
results	O
are	O
highly	O
dependent	O
on	O
several	O
factors	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Stroke	O
In	O
the	O
WHI	O
estrogen-alone	O
substudy	O
,	O
a	O
statistically	O
significant	O
increased	O
risk	O
of	O
stroke	B
was	O
reported	O
in	O
women	O
50	O
to	O
79	O
years	O
of	O
age	O
receiving	O
daily	O
conjugated	O
estrogens	O
(	O
CE	O
)	O
(	O
0.625	O
mg	O
)	O
-alone	O
compared	O
to	O
women	O
in	O
the	O
same	O
age	O
group	O
receiving	O
placebo	O
(	O
45	O
versus	O
33	O
per	O
10,000	O
women-years	O
)	O
.	O
	
In	O
the	O
extension	O
trial	O
,	O
cataracts	B
developed	O
or	O
worsened	O
in	O
4	O
%	O
of	O
patients	O
who	O
underwent	O
ocular	O
examination	O
prior	O
to	O
therapy	O
with	O
PROMACTA	O
.	O
	
The	O
anti-brentuximab	O
antibodies	O
were	O
directed	O
against	O
the	O
antibody	O
component	O
of	O
brentuximab	O
vedotin	O
in	O
all	O
patients	O
with	O
transiently	O
or	O
persistently	O
positive	O
antibodies	O
.	O
	
5.10	O
Hyperprolactinemia	O
Like	O
other	O
drugs	O
that	O
antagonize	O
dopamine	O
D2receptors	O
,	O
SAPHRIS	O
can	O
elevate	B
prolactin	I
levels	I
,	O
and	O
the	O
elevation	O
can	O
persist	O
during	O
chronic	O
administration	O
.	O
	
For	O
more	O
information	O
,	O
go	O
to	O
www.DUAVEE.com	O
,	O
or	O
call	O
1-800-438-1985	O
.	O
	
Consider	O
lowering	O
sulfonylurea	O
or	O
insulin	O
dosage	O
when	O
starting	O
TANZEUM	O
.	O
	
The	O
adverse	O
events	O
reported	O
in	O
the	O
long	O
term	O
safety	O
trials	O
were	O
similar	O
to	O
those	O
occurring	O
in	O
the	O
placebo-controlled	O
trials	O
of	O
3	O
to	O
6	O
months	O
.	O
	
Table	O
1	O
Adverse	O
Reactions	O
Reaction	O
Rate	O
(	O
%	O
)	O
n	O
=	O
1581	O
Nausea	B
1.1	O
Headache	B
1.1	O
Feeling	B
hot	I
0.8	O
Dizziness	B
0.6	O
Back	B
pain	I
0.6	O
Vomiting	B
0.4	O
Blood	B
pressure	I
increased	I
0.4	O
Injection	B
site	I
reactions	I
)	O
0.4	O
Dysgeusia	B
0.4	O
Paresthesia	B
0.3	O
Flushing	B
0.3	O
Parosmia	B
0.3	O
Pruritus	B
(	I
generalized	I
)	O
0.3	O
Rash	B
0.3	O
Respiratory	B
disorders	I
(	O
dyspnea	B
,	O
respiratory	B
distress	I
)	O
0.2	O
Fatigue	B
0.2	O
Chest	B
pain	I
0.1	O
Vertigo	B
0.1	O
Dry	B
mouth	I
0.1	O
Chills	B
0.1	O
Feeling	B
abnormal	I
0.1	O
Adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
of	O
<	O
0.1	O
%	O
in	O
subjects	O
who	O
received	O
EOVIST	O
include	O
:	O
tremor	B
,	O
akathisia	B
,	O
bundle	B
branch	I
block	I
,	O
palpitation	B
,	O
oral	B
discomfort	I
,	O
salivary	B
hypersecretion	I
,	O
maculopapular	B
rash	I
,	O
hyperhidrosis	B
,	O
discomfort	B
,	O
and	O
malaise	B
.	O
	
(	O
5.1	O
)	O
*	O
Rapid	O
intravenous	O
infusion	B
of	I
glycopeptide	I
antibacterial	I
agents	I
can	I
cause	I
reactions	I
.	O
	
Anti-tuberculosis	O
therapy	O
should	O
also	O
be	O
considered	O
prior	O
to	O
initiation	O
of	O
CIMZIA	O
in	O
patients	O
with	O
a	O
past	O
history	O
of	O
latent	O
or	O
active	O
tuberculosis	O
in	O
whom	O
an	O
adequate	O
course	O
of	O
treatment	O
can	O
not	O
be	O
confirmed	O
,	O
and	O
for	O
patients	O
with	O
a	O
negative	O
test	O
for	O
latent	O
tuberculosis	O
but	O
having	O
risk	O
factors	O
for	O
tuberculosis	O
infection	O
.	O
	
This	O
list	O
also	O
includes	O
adverse	O
reactions	O
(	O
less	O
than	O
1	O
%	O
of	O
subjects	O
)	O
associated	O
with	O
organ	O
systems	O
from	O
Warnings	O
and	O
Precautions	O
.	O
	
Patients	O
with	O
thyroid	O
nodules	O
noted	O
on	O
physical	O
examination	O
or	O
neck	O
imaging	O
should	O
also	O
be	O
further	O
evaluated	O
.	O
	
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
Gadavist	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
prior	O
to	O
re-administration	O
.	O
	
(	O
5.2	O
)	O
*	O
Hypoglycemia	B
:	O
Can	O
occur	O
when	O
used	O
in	O
combination	O
with	O
insulin	O
secretagogues	O
(	O
e.g.	O
,	O
sulfonylureas	O
)	O
or	O
insulin	O
.	O
	
SAPHRIS	O
should	O
also	O
be	O
avoided	O
in	O
patients	O
with	O
a	O
history	O
of	O
cardiac	O
arrhythmias	O
and	O
in	O
other	O
circumstances	O
that	O
may	O
increase	O
the	O
risk	O
of	O
the	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
and/or	O
sudden	O
death	O
in	O
association	O
with	O
the	O
use	O
of	O
drugs	O
that	O
prolong	O
the	O
QTc	O
interval	O
,	O
including	O
bradycardia	O
;	O
hypokalemia	O
or	O
hypomagnesemia	O
;	O
and	O
presence	O
of	O
congenital	O
prolongation	O
of	O
the	O
QT	O
interval	O
.	O
	
In	O
the	O
two	O
controlled	O
clinical	O
trials	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
and	O
thrombocytopenia	O
,	O
cataracts	B
developed	O
or	O
worsened	O
in	O
8	O
%	O
patients	O
treated	O
with	O
PROMACTA	O
and	O
5	O
%	O
patients	O
treated	O
with	O
placebo	O
.	O
	
If	O
hemoglobin	O
is	O
less	O
than	O
10	O
g	O
per	O
dL	O
,	O
a	O
decrease	O
in	O
dosage	O
of	O
ribavirin	O
is	O
recommended	O
;	O
and	O
if	O
hemoglobin	O
is	O
less	O
than	O
8.5	O
g	O
per	O
dL	O
,	O
discontinuation	O
of	O
ribavirin	O
is	O
recommended	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
In	O
Phase	O
2	O
and	O
3	O
clinical	O
studies	O
the	O
following	O
adverse	O
reactions	O
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
and	O
in	O
more	O
than	O
one	O
subject	O
treated	O
with	O
doses	O
ranging	O
from	O
40	O
mg	O
to	O
240	O
mg	O
of	O
ULORIC	O
.	O
	
If	O
serum	O
calcitonin	O
is	O
measured	O
and	O
found	O
to	O
be	O
elevated	O
,	O
the	O
patient	O
should	O
be	O
further	O
evaluated	O
.	O
	
Induration	O
of	O
5	O
mm	O
or	O
greater	O
with	O
tuberculin	O
skin	O
testing	O
should	O
be	O
considered	O
a	O
positive	O
test	O
result	O
when	O
assessing	O
if	O
treatment	O
for	O
latent	O
tuberculosis	O
is	O
needed	O
prior	O
to	O
initiating	O
CIMZIA	O
,	O
even	O
for	O
patients	O
previously	O
vaccinated	O
with	O
Bacille	O
Calmette-Guerin	O
(	O
BCG	O
)	O
.	O
	
Elevation	B
of	I
serum	I
iron	I
laboratory	O
values	O
were	O
reported	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
after	O
administration	O
of	O
EOVIST	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
skin	B
reactions	I
have	O
been	O
reported	O
with	O
glycopeptide	O
antibacterial	O
agents	O
,	O
including	O
DALVANCE	O
;	O
exercise	O
caution	O
in	O
patients	O
with	O
known	O
hypersensitivity	O
to	O
glycopeptides	O
.	O
	
Some	O
of	O
these	O
events	O
were	O
reported	O
in	O
patients	O
without	O
known	O
underlying	O
renal	O
disease	O
.	O
	
Treatment	O
with	O
CIMZIA	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
with	O
an	O
active	O
infection	O
,	O
including	O
clinically	O
important	O
localized	O
infections	O
.	O
	
Arthralgias	B
and	O
muscle	B
pain	I
have	O
also	O
been	O
reported	O
in	O
cases	O
of	O
proximal	B
renal	I
tubulopathy	I
.	O
	
Treatment	O
with	O
antibacterial	O
agents	O
can	O
alter	O
the	O
normal	O
flora	O
of	O
the	O
colon	O
,	O
and	O
may	O
permit	O
overgrowth	O
of	O
C.	O
difficile	O
.	O
	
Certain	O
adverse	O
reactions	O
consistent	O
with	O
symptoms	O
of	O
anemia	B
,	O
such	O
as	O
dyspnea	B
,	O
exertional	B
dyspnea	I
,	O
dizziness	B
and	O
syncope	B
were	O
reported	O
more	O
frequently	O
in	O
subjects	O
who	O
received	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
than	O
in	O
those	O
treated	O
with	O
PegIntron/REBETOL	O
alone	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
increase	O
in	O
risk	O
was	O
demonstrated	O
in	O
year	O
1	O
and	O
persisted	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.5	O
)	O
]	O
.	O
	
The	O
effect	O
of	O
anti-brentuximab	O
vedotin	O
antibodies	O
on	O
safety	O
and	O
efficacy	O
is	O
not	O
known	O
.	O
	
5.3	O
Thrombotic/Thromboembolic	O
Complications	O
In	O
two	O
controlled	O
clinical	O
trials	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
and	O
thrombocytopenia	O
,	O
3	O
%	O
(	O
31/955	O
)	O
treated	O
with	O
PROMACTA	O
experienced	O
a	O
thrombotic	B
event	I
(	O
1	O
%	O
in	O
patients	O
treated	O
with	O
PROMACTA	O
versus	O
less	O
than	O
1	O
%	O
for	O
placebo	O
)	O
.	O
	
If	O
drug-induced	O
hemolytic	O
anemia	O
is	O
suspected	O
,	O
discontinuation	O
of	O
Teflaro	O
should	O
be	O
considered	O
and	O
supportive	O
care	O
should	O
be	O
administered	O
to	O
the	O
patient	O
(	O
i.e	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
Ophthalmologic	O
:	O
Non-arteritic	B
anterior	I
ischemic	I
optic	I
neuropathy	I
(	O
NAION	B
)	O
,	O
a	O
cause	O
of	O
decreased	B
vision	I
including	O
permanent	B
loss	I
of	I
vision	I
,	O
has	O
been	O
reported	O
rarely	O
post-marketing	O
in	O
temporal	O
association	O
with	O
the	O
use	O
of	O
phosphodiesterase	O
type	O
5	O
(	O
PDE5	O
)	O
inhibitors	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
for	O
MTC	O
with	O
the	O
use	O
of	O
TANZEUM	O
and	O
inform	O
them	O
of	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g.	O
,	O
a	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
or	O
persistent	O
hoarseness	O
)	O
.	O
	
The	O
detection	O
of	O
an	O
immune	O
response	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assays	O
used	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
The	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
for	O
patients	O
treated	O
with	O
STENDRA	O
50	O
mg	O
,	O
100	O
mg	O
,	O
or	O
200	O
mg	O
was	O
1.4	O
%	O
,	O
2.0	O
%	O
,	O
and	O
2.0	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
1.7	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
If	O
this	O
occurs	O
,	O
treatment	O
with	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
stopped	O
and	O
other	O
treatments	O
considered	O
.	O
	
If	O
an	O
infection	O
develops	O
,	O
monitor	O
carefully	O
,	O
and	O
stop	O
SIMPONI	O
ARIA	O
if	O
infection	O
becomes	O
serious	O
(	O
5.1	O
)	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
initiated	O
was	O
22	O
cycles	O
for	O
the	O
KRd	O
arm	O
and	O
14	O
cycles	O
for	O
the	O
Rd	O
arm	O
.	O
	
Appropriate	O
measures	O
should	O
be	O
taken	O
to	O
identify	O
causes	O
of	O
renal	O
failure	O
and	O
treat	O
aggressively	O
.	O
	
(	O
8.4	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
infections	B
-	O
do	O
not	O
start	O
CIMZIA	O
during	O
an	O
active	O
infection	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
,	O
age	O
>	O
60	O
years	O
,	O
diabetes	O
mellitus	O
or	O
chronic	O
hypertension	O
)	O
,	O
estimate	O
the	O
GFR	O
through	O
laboratory	O
testing	O
.	O
	
5.7	O
Plasmodium	O
vivax	O
Infection	O
Coartem	O
Tablets	O
have	O
been	O
shown	O
in	O
limited	O
data	O
(	O
43	O
patients	O
)	O
to	O
be	O
effective	O
in	O
treating	O
the	O
erythrocytic	O
stage	O
of	O
P.	O
vivax	O
infection	O
.	O
	
Treatment	O
with	O
SIMPONI	O
ARIA	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
with	O
an	O
active	O
infection	O
,	O
including	O
clinically	O
important	O
localized	O
infections	O
.	O
	
The	O
most	O
frequent	O
(	O
>	O
=2	O
%	O
)	O
adverse	O
reactions	O
leading	O
to	O
dose	O
reduction	O
of	O
TAFINLAR	O
were	O
pyrexia	B
(	O
9	O
%	O
)	O
,	O
PPES	B
(	O
3	O
%	O
)	O
,	O
chills	B
(	O
3	O
%	O
)	O
,	O
fatigue	B
(	O
2	O
%	O
)	O
,	O
and	O
headache	B
(	O
2	O
%	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Avoid	O
treatment	O
in	O
the	O
periocular	O
area	O
.	O
	
Patients	O
in	O
SJIA	O
Study	O
1	O
received	O
a	O
single	O
dose	O
of	O
ILARIS	O
4	O
mg/kg	O
(	O
n=43	O
)	O
or	O
placebo	O
(	O
n=41	O
)	O
via	O
subcutaneous	O
injection	O
and	O
were	O
assessed	O
at	O
Day	O
15	O
for	O
the	O
efficacy	O
endpoints	O
and	O
had	O
a	O
safety	O
analysis	O
up	O
to	O
Day	O
29	O
.	O
	
*	O
Lymphopenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
For	O
symptomatic	O
cardiomyopathy	O
or	O
persistent	O
,	O
asymptomatic	O
LV	O
dysfunction	O
that	O
does	O
not	O
resolve	O
within	O
4	O
weeks	O
,	O
permanently	O
discontinue	O
trametinib	O
and	O
withhold	O
TAFINLAR	O
.	O
	
The	O
development	O
of	O
pneumonitis	B
has	O
been	O
reported	O
even	O
at	O
a	O
reduced	O
dose	O
.	O
	
For	O
the	O
purposes	O
of	O
assessing	O
Response-Guided	O
Therapy	O
milestones	O
,	O
a	O
confirmed	O
``	O
detectable	O
but	O
below	O
limit	O
of	O
quantification	O
''	O
HCV-RNA	O
result	O
should	O
not	O
be	O
considered	O
equivalent	O
to	O
an	O
``	O
undetectable	O
''	O
HCV-RNA	O
result	O
(	O
reported	O
as	O
``	O
Target	O
Not	O
Detected	O
''	O
or	O
``	O
HCV-RNA	O
Not	O
Detected	O
''	O
)	O
.	O
	
One	O
additional	O
patient	O
's	O
death	B
was	O
attributed	O
to	O
neutropenia	B
without	O
a	O
documented	O
infection	B
.	O
	
Hypersensitivity	B
reactions	I
(	O
dyspnea	B
,	O
angioedema	B
,	O
rash	B
,	O
and	O
pruritus	B
)	O
have	O
been	O
reported	O
.	O
	
(	O
5.5	O
)	O
(	O
6	O
)	O
(	O
8.5	O
)	O
*	O
Hepatic	B
impairment	I
:	O
Reduce	O
the	O
JEVTANA	O
dose	O
to	O
20	O
mg/m	O
2	O
in	O
patients	O
with	O
mild	O
hepatic	O
impairment	O
and	O
to	O
15	O
mg/m	O
2	O
in	O
patients	O
with	O
moderate	O
hepatic	O
impairment	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
bleeding	B
occurred	O
in	O
417	O
(	O
15.6	O
%	O
)	O
ELIQUIS-treated	O
patients	O
compared	O
to	O
661	O
(	O
24.6	O
%	O
)	O
enoxaparin/warfarin-treated	O
patients	O
.	O
	
Consider	O
a	O
diagnosis	O
of	O
non-infectious	O
pneumonitis	O
in	O
patients	O
presenting	O
with	O
non-specific	O
respiratory	O
signs	O
and	O
symptoms	O
such	O
as	O
hypoxia	O
,	O
pleural	O
effusion	O
,	O
cough	O
,	O
or	O
dyspnea	O
,	O
and	O
in	O
whom	O
infectious	O
,	O
neoplastic	O
,	O
and	O
other	O
causes	O
have	O
been	O
excluded	O
by	O
means	O
of	O
appropriate	O
investigations	O
.	O
	
This	O
information	O
was	O
abstracted	O
and	O
categorized	O
using	O
the	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
``	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
''	O
(	O
CTCAE	O
)	O
version	O
3	O
scale	O
.	O
	
Adverse	O
reactions	O
are	O
listed	O
according	O
to	O
MedDRA	O
version	O
15.0	O
system	O
organ	O
class	O
.	O
	
*	O
Impaired	B
wound	I
healing	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
pyrexia	B
(	O
62	O
%	O
)	O
,	O
headache	B
(	O
36	O
%	O
)	O
,	O
peripheral	B
edema	I
(	O
25	O
%	O
)	O
,	O
febrile	B
neutropenia	I
(	O
25	O
%	O
)	O
,	O
nausea	B
(	O
25	O
%	O
)	O
,	O
hypokalemia	B
(	O
23	O
%	O
)	O
,	O
and	O
constipation	B
(	O
20	O
%	O
)	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
administered	O
in	O
combination	O
with	O
trametinib	O
(	O
N	O
=	O
202	O
)	O
,	O
the	O
incidence	O
of	O
RPED	B
was	O
1	O
%	O
(	O
2/202	O
)	O
.	O
	
As	O
the	O
total	O
burden	O
of	O
immunosuppression	O
is	O
a	O
risk	O
factor	O
for	O
PTLD	O
,	O
higher	O
than	O
the	O
recommended	O
doses	O
or	O
more	O
frequent	O
dosing	O
of	O
NULOJIX	O
and	O
higher	O
than	O
recommended	O
doses	O
of	O
concomitant	O
immunosuppressive	O
agents	O
are	O
not	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Monitor	O
signs	O
and	O
symptoms	O
.	O
	
5.5	O
Effect	O
of	O
P-gp	O
Inducers	O
and	O
Inhibitors	O
on	O
Dabigatran	O
Exposure	O
The	O
concomitant	O
use	O
of	O
PRADAXA	O
with	O
P-gp	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
)	O
reduces	O
exposure	O
to	O
dabigatran	O
and	O
should	O
generally	O
be	O
avoided	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
?	O
	
Uveitis	O
and	O
Iritis	O
:	O
Uveitis	B
and	O
iritis	B
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
5.3	O
Other	O
Malignancies	O
Patients	O
receiving	O
immunosuppressants	O
,	O
including	O
NULOJIX	O
,	O
are	O
at	O
increased	O
risk	O
of	O
developing	O
PTLD	B
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
patients	O
less	O
than	O
1	O
month	O
of	O
age	O
or	O
preterm	O
infants	O
with	O
a	O
corrected	O
age	O
of	O
less	O
than	O
44	O
weeks	O
)	O
could	O
be	O
at	O
risk	O
for	O
gasping	B
syndrome	I
if	O
treated	O
with	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
]	O
.	O
	
A	O
total	O
of	O
696	O
HIV-positive	O
patients	O
in	O
three	O
placebo-controlled	O
trials	O
received	O
FULYZAQ	O
for	O
a	O
mean	O
duration	O
of	O
78	O
days	O
.	O
	
*	O
TANZEUM	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
or	O
in	O
patients	O
with	O
Multiple	O
Endocrine	O
Neoplasia	O
syndrome	O
type	O
2	O
(	O
MEN	O
2	O
)	O
.	O
	
Prior	O
to	O
administration	O
,	O
question	O
the	O
patient	O
for	O
a	O
history	O
of	O
prior	O
reactions	O
to	O
DaTscan	O
.	O
	
Routine	O
ophthalmological	O
examination	O
detected	O
macular	B
edema	I
in	O
some	O
patients	O
with	O
no	O
visual	B
symptoms	I
.	O
	
(	O
5.2	O
)	O
*	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
with	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
ZERBAXA	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
NORTHERA	O
can	O
cause	O
supine	B
hypertension	I
and	O
may	O
increase	O
cardiovascular	B
risk	I
if	O
supine	B
hypertension	I
is	O
not	O
well-managed	O
(	O
5.1	O
)	O
.	O
	
Careful	O
testing	O
of	O
corneal	O
sensation	O
in	O
eyes	O
previously	O
operated	O
upon	O
,	O
avoidance	O
of	O
injection	O
into	O
the	O
lower	O
lid	O
area	O
to	O
avoid	O
ectropion	O
,	O
and	O
vigorous	O
treatment	O
of	O
any	O
epithelial	O
defect	O
should	O
be	O
employed	O
.	O
	
at	O
1-866-416-9637	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
During	O
the	O
clinical	O
trials	O
,	O
0.1	O
%	O
(	O
1/1308	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
discontinued	O
treatment	O
due	O
to	O
depression	B
compared	O
with	O
none	O
in	O
placebo-treated	O
subjects	O
(	O
0/506	O
)	O
.	O
	
Table	O
4	O
compares	O
the	O
incidence	O
of	O
treatment-emergent	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
10	O
mg	O
daily	O
versus	O
placebo	O
.	O
	
(	O
5.8	O
)	O
*	O
Suicide	B
:	O
Close	O
supervision	O
of	O
high	O
risk	O
patients	O
.	O
	
Of	O
the	O
1,039	O
subjects	O
,	O
60	O
%	O
were	O
female	O
and	O
88	O
%	O
were	O
white	O
;	O
the	O
mean	O
age	O
was	O
46	O
years	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
frequent	O
(	O
>	O
=	O
0.2	O
%	O
)	O
adverse	O
reactions	O
in	O
clinical	O
studies	O
were	O
nausea	B
,	O
headache	B
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
coldness	I
,	O
and	O
burning	B
sensation	I
.	O
	
Increases	B
in	I
serum	I
creatinine	I
occurred	O
within	O
the	O
first	O
4	O
weeks	O
of	O
treatment	O
and	O
remained	O
stable	O
through	O
48	O
to	O
96	O
weeks	O
.	O
	
Laboratory	O
Abnormalities	O
The	O
frequency	O
of	O
laboratory	O
abnormalities	O
(	O
Grades	O
3-4	O
)	O
occurring	O
in	O
at	O
least	O
2	O
%	O
of	O
subjects	O
receiving	O
STRIBILD	O
in	O
Studies	O
102	O
and	O
103	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
5.5	O
End-Stage	O
Renal	O
Disease	O
No	O
studies	O
have	O
been	O
conducted	O
in	O
patients	O
with	O
end-stage	O
renal	O
disease	O
.	O
	
The	O
rates	O
of	O
treatment-emergent	O
adverse	O
events	O
(	O
irrespective	O
of	O
causality	O
)	O
resulting	O
in	O
permanent	O
discontinuation	O
were	O
14	O
%	O
and	O
3	O
%	O
for	O
the	O
AFINITOR	O
and	O
placebo	O
treatment	O
groups	O
,	O
respectively	O
.	O
	
Perform	O
an	O
examination	O
of	O
the	O
fundus	O
including	O
the	O
macula	O
in	O
all	O
patients	O
before	O
starting	O
treatment	O
,	O
again	O
3-4	O
months	O
after	O
starting	O
treatment	O
,	O
and	O
again	O
at	O
any	O
time	O
after	O
a	O
patient	O
reports	O
visual	O
disturbances	O
while	O
on	O
GILENYA	O
therapy	O
.	O
	
These	O
reactions	O
can	O
occur	O
immediately	O
following	O
or	O
up	O
to	O
24	O
hours	O
after	O
administration	O
of	O
Kyprolis	O
.	O
	
Table	O
4	O
:	O
Clinical	O
Cure	O
Rates	O
in	O
a	O
Phase	O
3	O
Trial	O
of	O
cIAI	O
by	O
Baseline	O
Renal	O
Function	O
(	O
MITT	O
Population	O
)	O
Baseline	O
Renal	O
Function	O
ZERBAXA	O
plus	O
metronidazolen/N	O
(	O
%	O
)	O
Meropenemn/N	O
(	O
%	O
)	O
Normal/mild	O
impairment	O
(	O
CrCl	O
>	O
=50	O
mL/min	O
)	O
312/366	O
(	O
85.2	O
)	O
355/404	O
(	O
87.9	O
)	O
Moderate	O
impairment	O
(	O
CrCl	O
30	O
to	O
<	O
=50	O
mL/min	O
)	O
11/23	O
(	O
47.8	O
)	O
9/13	O
(	O
69.2	O
)	O
5.2	O
Hypersensitivity	O
Reactions	O
Serious	O
and	O
occasionally	O
fatal	B
anaphylactic	B
)	I
reactions	I
have	O
been	O
reported	O
in	O
patients	O
receiving	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
The	O
reported	O
frequency	O
for	O
the	O
group	O
receiving	O
10	O
mg/kg	O
may	O
underestimate	O
the	O
actual	O
frequency	O
due	O
to	O
lower	O
assay	O
sensitivity	O
in	O
the	O
presence	O
of	O
high	O
drug	O
concentrations	O
.	O
	
5.2	O
Hyperpyrexia	O
and	O
Confusion	O
Post-marketing	O
cases	O
of	O
a	O
symptom	O
complex	O
resembling	O
neuroleptic	B
malignant	I
syndrome	I
(	O
NMS	B
)	O
have	O
been	O
reported	O
with	O
NORTHERA	O
use	O
during	O
post-marketing	O
surveillance	O
in	O
Japan	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
(	O
5.3	O
,	O
5.4	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	O
have	O
been	O
reported	O
and	O
were	O
characterized	O
by	O
rash	B
,	O
constitutional	O
findings	O
,	O
and	O
sometimes	O
organ	B
dysfunction	I
,	O
including	O
liver	B
injury	I
.	O
	
Some	O
of	O
these	O
events	O
have	O
been	O
fatal	B
.	O
	
Serious	O
adverse	O
reactions	O
reported	O
with	O
alglucosidase	O
alfa	O
included	O
anaphylaxis	B
,	O
which	O
presented	O
as	O
angioedema	B
,	O
throat	B
tightness	I
and	O
chest	B
pain	I
.	O
	
(	O
5.3	O
)	O
*	O
Tardive	B
dyskinesia	I
:	O
Discontinue	O
if	O
clinically	O
appropriate	O
.	O
	
Table	O
3	O
summarizes	O
the	O
most	O
common	O
adverse	O
reactions	O
that	O
occurred	O
in	O
at	O
least	O
3	O
%	O
of	O
alglucosidase	O
alfa-treated	O
patients	O
and	O
with	O
a	O
higher	O
incidence	O
than	O
the	O
placebo-treated	O
patients	O
during	O
the	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
described	O
above	O
.	O
	
Withhold	O
Kyprolis	O
for	O
pulmonary	O
hypertension	O
until	O
resolved	O
or	O
returned	O
to	O
baseline	O
and	O
consider	O
whether	O
to	O
restart	O
Kyprolis	O
based	O
on	O
a	O
benefit/risk	O
assessment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
L	O
ong	O
-	O
acting	O
beta	O
2	O
-adrenergic	O
agonists	O
,	O
such	O
as	O
A	O
RCAPTA	O
NEOHALER	O
,	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
in	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
The	O
clinical	O
program	O
for	O
BREO	O
ELLIPTA	O
included	O
7,700	O
subjects	O
with	O
COPD	O
in	O
two	O
6-month	O
lung	O
function	O
trials	O
,	O
two	O
12-month	O
exacerbation	O
trials	O
,	O
and	O
6	O
other	O
trials	O
of	O
shorter	O
duration	O
.	O
	
In	O
a	O
combined	O
analysis	O
of	O
Studies	O
115	O
and	O
121	O
,	O
the	O
frequency	O
of	O
adverse	O
reactions	O
(	O
all	O
grades	O
)	O
was	O
24	O
%	O
in	O
subjects	O
switching	O
to	O
STRIBILD	O
compared	O
to	O
6	O
%	O
of	O
subjects	O
in	O
either	O
group	O
who	O
stayed	O
on	O
their	O
baseline	O
antiretroviral	O
regimen	O
,	O
RTV-boosted	O
PI	O
+	O
TRUVADA	O
or	O
NNRTI	O
+	O
TRUVADA	O
.	O
	
Pool	O
of	O
Placebo-Controlled	O
Trials	O
The	O
data	O
in	O
Table	O
1	O
is	O
derived	O
from	O
four	O
26-week	O
placebo-controlled	O
trials	O
.	O
	
difficile	O
.	O
	
5.4	O
Allergic	O
Reactions	O
This	O
product	O
contains	O
FD	O
&	O
C	O
Yellow	O
No	O
.	O
	
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
in	O
this	O
trial	O
for	O
the	O
1,200	O
mg	O
dose	O
of	O
HORIZANT	O
were	O
dizziness	B
,	O
somnolence	B
,	O
and	O
headache	B
(	O
see	O
Table	O
5	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Laryngeal	O
attacks	O
:	O
Following	O
treatment	O
of	O
laryngeal	O
attacks	O
with	O
FIRAZYR	O
,	O
advise	O
patients	O
to	O
seek	O
immediate	O
medical	O
attention	O
.	O
	
If	O
the	O
diagnosis	O
of	O
TTP/HUS	O
is	O
excluded	O
,	O
Kyprolis	O
may	O
be	O
restarted	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
reported	O
for	O
AFINITOR	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
was	O
stomatitis	B
.	O
	
Vascular	O
Disorders	O
superficial	B
phlebitis	I
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
GILENYA	O
may	O
therefore	O
increase	O
the	O
risk	O
of	O
infections	B
,	O
some	O
serious	O
in	O
nature	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
In	O
controlled	O
trials	O
of	O
other	O
TNF-blockers	O
in	O
patients	O
at	O
higher	O
risk	O
for	O
malignancies	O
(	O
e.g.	O
,	O
patients	O
with	O
COPD	O
,	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
treated	O
with	O
concomitant	O
cyclophosphamide	O
)	O
a	O
greater	O
portion	O
of	O
malignancies	B
occurred	O
in	O
the	O
TNF-blocker	O
group	O
compared	O
to	O
the	O
controlled	O
group	O
.	O
	
Your	O
healthcare	O
provider	O
should	O
check	O
any	O
unusual	O
vaginal	O
bleeding	O
to	O
find	O
out	O
the	O
cause	O
.	O
	
SIMPONI	O
ARIA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
a	O
history	O
of	O
CHF	O
and	O
SIMPONI	O
ARIA	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
CHF	O
.	O
	
There	O
is	O
no	O
clinical	O
trial	O
experience	O
re-administering	O
XTANDI	O
to	O
patients	O
who	O
experienced	O
seizure	O
.	O
	
The	O
conduction	B
abnormalities	I
were	O
usually	O
transient	O
and	O
asymptomatic	O
,	O
and	O
resolved	O
within	O
the	O
first	O
24	O
hours	O
on	O
treatment	O
,	O
but	O
they	O
occasionally	O
required	O
treatment	O
with	O
atropine	O
or	O
isoproterenol	O
.	O
	
(	O
5.1	O
)	O
*	O
Hypersensitivity	B
:	O
anaphylactic	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
,	O
including	O
death	B
,	O
have	O
uncommonly	O
occurred	O
.	O
	
Glabellar	O
Lines	O
(	O
5.7	O
)	O
:	O
*	O
Risk	O
of	O
ptosis	B
(	O
5.7	O
)	O
.	O
	
Seventy-eight	O
percent	O
of	O
patients	O
(	O
693	O
of	O
893	O
)	O
were	O
able	O
to	O
receive	O
all	O
planned	O
doses	O
to	O
complete	O
their	O
prescribed	O
treatment	O
regimen	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
who	O
are	O
at	O
increased	O
risk	O
for	O
these	O
events	O
.	O
	
(	O
5.11	O
)	O
*	O
Thrombotic	B
thrombocytopenic	I
purpura/hemolytic	O
uremic	B
syndrome	I
(	O
TTP/HUS	O
)	O
.	O
	
The	O
symptoms	O
are	O
consistent	O
with	O
the	O
mechanism	O
of	O
action	O
of	O
botulinum	O
toxin	O
and	O
may	O
include	O
asthenia	B
,	O
generalized	B
muscle	I
weakness	I
,	O
diplopia	B
,	O
blurred	B
vision	I
,	O
ptosis	B
,	O
dysphagia	B
,	O
dysphonia	B
,	O
dysarthria	B
,	O
urinary	B
incontinence	I
and	O
breathing	B
difficulties	I
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
treatment	O
due	O
to	O
adverse	O
reactions	O
was	O
7.5	O
%	O
in	O
the	O
DUAVEE	O
group	O
and	O
10.0	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
ENDOMETRIAL	B
CANCER	I
,	O
CARDIOVASCULAR	B
DISORDERS	I
,	O
AND	O
PROBABLE	O
DEMENTIA	B
WARNING	O
:	O
ENDOMETRIAL	B
CANCER	I
,	O
CARDIOVASCULAR	B
DISORDERS	I
,	O
AND	O
PROBABLE	O
DEMENTIA	B
*	O
Women	O
taking	O
DUAVEE	O
should	O
not	O
take	O
additional	O
estrogens	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
There	O
is	O
an	O
increased	O
risk	O
of	O
endometrial	B
cancer	I
in	O
a	O
woman	O
with	O
a	O
uterus	O
who	O
uses	O
unopposed	O
estrogens	O
.	O
	
If	O
hypertension	O
can	O
not	O
be	O
adequately	O
controlled	O
,	O
a	O
risk-benefit	O
decision	O
on	O
continued	O
Kyprolis	O
therapy	O
is	O
needed	O
.	O
	
(	O
5.10	O
)	O
*	O
Liver	B
enzyme	I
elevation	I
has	O
been	O
observed	O
during	O
treatment	O
with	O
INLYTA	O
.	O
	
In	O
most	O
cases	O
,	O
this	O
is	O
a	O
consequence	O
of	O
weakening	O
of	O
muscles	O
in	O
the	O
area	O
of	O
injection	O
that	O
are	O
involved	O
in	O
breathing	O
or	O
swallowing	O
.	O
	
The	O
incidence	O
of	O
non-hematologic	O
,	O
non-infectious	O
,	O
adverse	O
events	O
(	O
all	O
Grades	O
)	O
in	O
Study	O
1	O
,	O
Study	O
2	O
,	O
and	O
the	O
EMTP	O
trial	O
is	O
provided	O
in	O
Table	O
1	O
.	O
	
Discontinue	O
immediately	O
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
adverse	O
events	O
was	O
2.1	O
%	O
and	O
2.4	O
%	O
for	O
the	O
placebo	O
and	O
Prolia	O
groups	O
,	O
respectively	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bausch	O
&	O
Lomb	O
Incorporated	O
at	O
1-800-323-0000	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Topical	O
Ophthalmic	O
Use	O
Only	O
.	O
	
Male	B
genital	I
mycotic	I
infections	I
occurred	O
more	O
commonly	O
in	O
uncircumcised	O
males	O
and	O
in	O
males	O
with	O
a	O
prior	O
history	O
of	O
balanitis	O
or	O
balanoposthitis	O
.	O
	
For	O
the	O
6-dose	O
regimen	O
,	O
Coartem	O
Tablets	O
was	O
studied	O
in	O
active-controlled	O
(	O
366	O
patients	O
)	O
and	O
non-controlled	O
,	O
open-label	O
trials	O
(	O
1,613	O
patients	O
)	O
.	O
	
A	O
total	O
of	O
394	O
patients	O
received	O
more	O
than	O
one	O
treatment	O
application	O
and	O
274	O
patients	O
were	O
followed	O
for	O
48	O
weeks	O
or	O
longer	O
.	O
	
Flush	O
eyes	O
and	O
mucous	O
membranes	O
with	O
cool	O
water	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
L	O
ong-acting	O
beta	O
2	O
-adrenergic	O
agonist	O
s	O
(	O
LABA	O
)	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
The	O
first	O
dose	O
of	O
ENTEREG	O
was	O
administered	O
30	O
minutes	O
to	O
5	O
hours	O
before	O
the	O
scheduled	O
start	O
of	O
surgery	O
and	O
then	O
twice	O
daily	O
until	O
hospital	O
discharge	O
(	O
or	O
for	O
a	O
maximum	O
of	O
7	O
days	O
of	O
postoperative	O
treatment	O
)	O
.	O
	
The	O
most	O
frequent	O
serious	O
adverse	O
reactions	O
reported	O
in	O
patients	O
treated	O
with	O
XALKORI	O
were	O
pneumonia	B
(	O
4.1	O
%	O
)	O
,	O
pulmonary	B
embolism	I
(	O
3.5	O
%	O
)	O
,	O
dyspnea	B
(	O
2.3	O
%	O
)	O
,	O
and	O
ILD	B
(	O
2.9	O
%	O
)	O
.	O
	
However	O
,	O
epidemiological	O
studies	O
suggest	O
an	O
increased	O
risk	O
of	O
treatment-emergent	O
hyperglycemia-related	O
adverse	O
events	O
in	O
patients	O
treated	O
with	O
the	O
atypical	O
antipsychotics	O
included	O
in	O
these	O
studies	O
.	O
	
In	O
these	O
patients	O
,	O
increases	B
in	I
potassium	I
were	O
more	O
commonly	O
seen	O
in	O
those	O
with	O
elevated	O
potassium	O
at	O
baseline	O
.	O
	
TABLE	O
2	O
:	O
Changes	O
in	O
Fasting	O
Glucose	O
in	O
Pediatric	O
Subjects	O
Bipolar	O
I	O
Disorder	O
(	O
3-weeks	O
)	O
Placebo	O
SAPHRIS2.5	O
mgtwice	O
daily	O
SAPHRIS5	O
mgtwice	O
daily	O
SAPHRIS10	O
mgtwice	O
daily	O
Mean	O
Change	O
from	O
Baseline	O
in	O
Fasting	O
Glucose	O
at	O
Endpoint	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
(	O
N*	O
)	O
-2.24	O
(	O
56	O
)	O
1.43	O
(	O
51	O
)	O
-0.45	O
(	O
57	O
)	O
0.34	O
(	O
52	O
)	O
Proportion	O
of	O
Subjects	O
with	O
Shifts	O
from	O
Baseline	O
to	O
Endpoint	O
Normal	O
to	O
High	O
>	O
45	O
&	O
<	O
100	O
to	O
>	O
=126	O
mg/dL	O
0	O
%	O
0	O
%	O
1.8	O
%	O
0	O
%	O
(	O
n/N*	O
)	O
(	O
0/56	O
)	O
(	O
0/51	O
)	O
(	O
1/57	O
)	O
(	O
0/52	O
)	O
Dyslipidemia	B
Undesirable	B
alterations	I
in	I
lipids	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
Increases	O
in	O
Hemoglobin	O
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
trials	O
,	O
mean	O
changes	B
(	I
percent	I
changes	I
)	I
from	I
baseline	I
in	I
hemoglobin	I
were	O
-0.18	O
g/dL	O
(	O
-1.1	O
%	O
)	O
with	O
placebo	O
,	O
0.47	O
g/dL	O
(	O
3.5	O
%	O
)	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
0.51	O
g/dL	O
(	O
3.8	O
%	O
)	O
with	O
INVOKANA	O
300	O
mg	O
.	O
	
Permanent	O
discontinuation	O
of	O
XALKORI	O
treatment	O
for	O
adverse	O
reactions	O
was	O
8.2	O
%	O
.	O
	
Among	O
the	O
patients	O
who	O
experienced	O
diarrhea	O
,	O
the	O
median	O
number	O
of	O
episodes	O
of	O
diarrhea	O
per	O
patient	O
during	O
treatment	O
with	O
BOSULIF	O
was	O
3	O
(	O
range	O
1-221	O
)	O
.	O
	
A	O
total	O
of	O
1964	O
patients	O
participated	O
in	O
two	O
12-week	O
,	O
Phase	O
3	O
efficacy	O
and	O
safety	O
studies	O
and	O
subsequent	O
open-label	O
extension	O
studies	O
.	O
	
The	O
imbalance	O
in	O
deaths	B
is	O
unexplained	O
;	O
no	O
discernible	O
pattern	O
between	O
death	B
and	O
sputum	O
conversion	O
,	O
relapse	O
,	O
sensitivity	O
to	O
other	O
drugs	O
used	O
to	O
treat	O
tuberculosis	O
,	O
HIV	O
status	O
,	O
and	O
severity	O
of	O
disease	O
was	O
observed	O
.	O
	
(	O
5.2	O
)	O
*	O
Lymphopenia	B
:	O
Obtain	O
a	O
CBC	O
including	O
lymphocyte	O
count	O
before	O
initiating	O
TECFIDERA	O
,	O
after	O
6	O
months	O
,	O
and	O
every	O
6	O
to	O
12	O
months	O
thereafter	O
.	O
	
Table	O
5	O
:	O
Non-Hematologic	O
Adverse	O
Reactions	O
>	O
=	O
10	O
%	O
Reported	O
in	O
Study	O
2	O
IMBRUVICA	O
(	O
N=195	O
)	O
Ofatumumab	O
(	O
N=191	O
)	O
System	O
Organ	O
Class	O
ADR	O
Term	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
Subjects	O
with	O
multiple	O
events	O
for	O
a	O
given	O
ADR	O
term	O
are	O
counted	O
once	O
only	O
for	O
each	O
ADR	O
term	O
.	O
	
Adult	O
Patients	O
:	O
Pooled	O
data	O
on	O
mean	O
changes	O
in	O
body	O
weight	O
and	O
the	O
proportion	O
of	O
subjects	O
meeting	O
a	O
weight	B
gain	I
criterion	O
of	O
>	O
=7	O
%	O
of	O
body	O
weight	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
PML	O
is	O
an	O
opportunistic	O
viral	O
infection	O
of	O
the	O
brain	O
caused	O
by	O
the	O
JC	O
virus	O
(	O
JCV	O
)	O
that	O
typically	O
only	O
occurs	O
in	O
patients	O
who	O
are	O
immunocompromised	O
,	O
and	O
that	O
usually	O
leads	O
to	O
death	O
or	O
severe	O
disability	O
.	O
	
Of	O
the	O
176	O
patients	O
,	O
65	O
%	O
were	O
White	O
,	O
23	O
%	O
Asian	O
,	O
3	O
%	O
Black	O
,	O
and	O
10	O
%	O
Other	O
race	O
.	O
	
Do	O
not	O
restart	O
NESINA	O
if	O
liver	O
injury	O
is	O
confirmed	O
and	O
no	O
alternative	O
etiology	O
can	O
be	O
found	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
in	O
Study	O
1	O
and	O
Study	O
2	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
thrombocytopenia	B
,	O
neutropenia	B
,	O
diarrhea	B
,	O
anemia	B
,	O
fatigue	B
,	O
musculoskeletal	B
pain	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
rash	B
,	O
nausea	B
,	O
and	O
pyrexia	B
.	O
	
Eosinophilia	O
A	O
transient	O
increase	B
in	I
mean	I
eosinophil	I
counts	I
was	O
seen	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
.	O
	
Symptoms	O
include	O
fever	B
,	O
chills	B
,	O
pruritus	B
and	O
rash	B
.	O
	
7	O
)	O
]	O
EXCERPT	O
:	O
Cervical	O
Dystonia	O
Most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
5	O
%	O
of	O
patients	O
)	O
are	O
:	O
muscular	B
weakness	I
,	O
dysphagia	B
,	O
dry	B
mouth	I
,	O
injection	B
site	I
discomfort	I
,	O
fatigue	B
,	O
headache	B
,	O
neck	B
pain	I
,	O
musculoskeletal	B
pain	I
,	O
dysphonia	B
,	O
injection	B
site	I
pain	I
,	O
and	O
eye	B
disorders	I
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
in	O
patients	O
receiving	O
APTIOM	O
at	O
doses	O
of	O
800	O
mg	O
or	O
1200	O
mg	O
(	O
>	O
=4	O
%	O
and	O
>	O
=2	O
%	O
greater	O
than	O
placebo	O
)	O
were	O
dizziness	B
,	O
somnolence	B
,	O
nausea	B
,	O
headache	B
,	O
diplopia	B
,	O
vomiting	B
,	O
fatigue	B
,	O
vertigo	B
,	O
ataxia	B
,	O
blurred	B
vision	I
,	O
and	O
tremor	B
.	O
	
Discontinue	O
TREANDA	O
for	O
patients	O
with	O
Grade	O
4	O
infusion	O
reactions	O
.	O
	
Glucagon-like	O
peptide	O
(	O
GLP-1	O
)	O
receptor	O
agonists	O
have	O
induced	O
thyroid	B
C-cell	I
adenomas	I
in	O
mice	O
and	O
rats	O
at	O
clinically	O
relevant	O
exposures	O
.	O
	
As	O
with	O
all	O
antidepressants	O
,	O
PRISTIQ	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
or	O
family	O
history	O
of	O
mania	O
or	O
hypomania	O
.	O
	
Other	O
Adverse	O
Reactions	O
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
in	O
controlled	O
trials	O
of	O
Crohn	O
's	O
disease	O
were	O
described	O
above	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Restless	O
Legs	O
Syndrome	O
:	O
The	O
exposure	O
to	O
HORIZANT	O
in	O
1,201	O
patients	O
with	O
RLS	O
included	O
613	O
exposed	O
for	O
at	O
least	O
6	O
months	O
and	O
371	O
exposed	O
for	O
at	O
least	O
1	O
year	O
.	O
	
It	O
is	O
unknown	O
whether	O
TRULICITY	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
as	O
the	O
human	O
relevance	O
of	O
dulaglutide-induced	O
rodent	O
thyroid	B
C-cell	I
tumors	I
has	O
not	O
been	O
determined	O
(	O
5.1	O
,	O
13.1	O
)	O
.	O
	
BK	B
virus-associated	I
nephropathy	I
was	O
reported	O
in	O
6	O
NULOJIX	O
patients	O
(	O
4	O
of	O
which	O
resulted	O
in	O
graft	O
loss	O
)	O
and	O
6	O
cyclosporine	O
patients	O
(	O
none	O
of	O
which	O
resulted	O
in	O
graft	O
loss	O
)	O
by	O
Year	O
3	O
.	O
	
(	O
5.9	O
)	O
5.1	O
Cytokine	O
Release	O
Syndrome	O
Cytokine	B
Release	I
Syndrome	I
(	O
CRS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
5.2	O
Cataracts	O
Use	O
of	O
corticosteroids	O
may	O
result	O
in	O
posterior	B
subcapsular	I
cataract	I
formation	O
.	O
	
Summary	O
of	O
Clinical	O
Trials	O
in	O
Chronic	O
Lymphocytic	O
Leukemia	O
The	O
safety	O
data	O
reflect	O
subject	O
exposure	O
to	O
Zydelig	O
from	O
Study	O
1	O
,	O
in	O
which	O
218	O
subjects	O
with	O
relapsed	O
CLL	O
received	O
up	O
to	O
8	O
doses	O
of	O
rituximab	O
with	O
or	O
without	O
Zydelig	O
150	O
mg	O
twice	O
daily	O
.	O
	
5.9	O
Hyponatremia	O
Hyponatremia	B
may	O
occur	O
as	O
a	O
result	O
of	O
treatment	O
with	O
SSRIs	O
and	O
SNRIs	O
,	O
including	O
PRISTIQ	O
.	O
	
Data	O
from	O
a	O
placebo-controlled	O
,	O
4-week	O
,	O
fixed-dose	O
study	O
,	O
in	O
which	O
fasting	O
blood	O
samples	O
were	O
drawn	O
,	O
in	O
adult	O
subjects	O
with	O
schizophrenia	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
Fifty-eight	O
percent	O
(	O
58	O
%	O
)	O
of	O
the	O
population	O
were	O
male	O
;	O
84	O
%	O
were	O
White	O
,	O
9	O
%	O
were	O
Asian	O
,	O
and	O
3	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
Hydronephrosis	B
occurred	O
in	O
2	O
patients	O
,	O
one	O
of	O
whom	O
had	O
associated	O
renal	B
function	I
impairment	I
that	O
resolved	O
upon	O
discontinuation	O
of	O
POTIGA	O
.	O
	
The	O
safety	O
data	O
described	O
below	O
are	O
based	O
on	O
one	O
,	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
Phase	O
3	O
trial	O
in	O
patients	O
with	O
RA	O
receiving	O
SIMPONI	O
ARIA	O
by	O
intravenous	O
infusion	O
(	O
Trial	O
1	O
)	O
.	O
	
5.2	O
Urinary	O
Retention	O
POTIGA	O
caused	O
urinary	B
retention	I
in	O
clinical	O
trials	O
.	O
	
(	O
5.4	O
)	O
*	O
Patients	O
with	O
abnormal	O
coagulation	O
:	O
Use	O
with	O
caution	O
,	O
including	O
in	O
patients	O
who	O
have	O
received	O
anticoagulant	O
medications	O
other	O
than	O
low-dose	O
aspirin	O
within	O
7	O
days	O
of	O
the	O
injection	O
.	O
	
Table	O
3	O
:	O
Overall	O
Infections	B
and	O
Select	O
Infections	B
with	O
Identified	O
Etiology	O
by	O
Treatment	O
Group	O
following	O
One	O
and	O
Three	O
Years	O
of	O
Treatment	O
in	O
Studies	O
1	O
and	O
2*	O
Up	O
to	O
Year	O
1	O
Up	O
to	O
Year	O
3	O
NULOJIX	O
Recommended	O
Regimen	O
N=401	O
n	O
(	O
%	O
)	O
Cyclosporine	O
N=405	O
n	O
(	O
%	O
)	O
NULOJIX	O
Recommended	O
Regimen	O
N=401	O
n	O
(	O
%	O
)	O
Cyclosporine	O
N=405	O
n	O
(	O
%	O
)	O
*	O
Studies	O
1	O
and	O
2	O
were	O
not	O
designed	O
to	O
support	O
comparative	O
claims	O
for	O
NULOJIX	O
for	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
table	O
.	O
	
(	O
2.3	O
)	O
,	O
(	O
5.1	O
)	O
*	O
Neurological	B
toxicities	I
,	O
which	O
may	O
be	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
In	O
the	O
Peyronie	O
's	O
disease	O
clinical	O
studies	O
,	O
at	O
6	O
weeks	O
after	O
the	O
first	O
treatment	O
cycle	O
of	O
XIAFLEX	O
0.58	O
mg	O
,	O
approximately	O
75	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-I	O
and	O
approximately	O
55	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-II	O
.	O
	
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
If	O
a	O
patient	O
is	O
exposed	O
to	O
measles	O
,	O
prophylaxis	O
with	O
pooled	O
intramuscular	O
immunoglobulin	O
(	O
IG	O
)	O
may	O
be	O
indicated	O
.	O
	
In	O
placebo-controlled	O
trials	O
in	O
patients	O
with	O
epilepsy	O
,	O
dizziness	B
was	O
reported	O
in	O
23	O
%	O
of	O
patients	O
treated	O
with	O
POTIGA	O
and	O
9	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
Elevated	B
ALT	I
(	O
5.3	O
)	O
,	O
Decreased	B
plasma	I
zinc	I
concentrations	I
(	O
5.3	O
)	O
.	O
	
All	O
of	O
these	O
patients	O
who	O
received	O
FANAPT	O
were	O
participating	O
in	O
multiple-dose	O
clinical	O
trials	O
.	O
	
Table	O
2	O
and	O
Table	O
3	O
summarize	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
reported	O
for	O
Zydelig	O
+	O
rituximab	O
and	O
placebo	O
+	O
rituximab	O
arms	O
.	O
	
Placebo	O
plus	O
prednisone	O
5	O
mg	O
twice	O
daily	O
was	O
given	O
to	O
control	O
patients	O
.	O
	
*	O
Ferriprox	O
can	O
cause	O
agranulocytosis	B
that	O
can	O
lead	O
to	O
serious	O
infections	B
and	O
death	B
.	O
	
Signs	O
or	O
symptoms	O
that	O
may	O
reflect	O
serious	O
penile	O
injury	O
should	O
be	O
promptly	O
evaluated	O
to	O
assess	O
for	O
corporal	O
rupture	O
or	O
severe	O
penile	O
hematoma	O
which	O
may	O
require	O
surgical	O
intervention	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Long-term	O
cumulative	O
radiation	O
exposure	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
cancer	B
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
>	O
=10	O
%	O
of	O
Patients	O
Treated	O
with	O
Either	O
the	O
NULOJIX	O
Recommended	O
Regimen	O
or	O
Control	O
in	O
Studies	O
1	O
and	O
2	O
Through	O
Three	O
Years*	O
,	O
Adverse	O
Reaction	O
NULOJIX	O
Recommended	O
Regimen	O
N=401	O
%	O
Cyclosporine	O
N=405	O
%	O
*	O
All	O
randomized	O
and	O
transplanted	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Mineralocorticoid	B
excess	I
:	O
Use	O
ZYTIGA	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
cardiovascular	O
disease	O
.	O
	
Chromaturia	B
(	O
reddish/brown	O
discoloration	O
of	O
the	O
urine	O
)	O
is	O
a	O
result	O
of	O
the	O
excretion	O
of	O
the	O
iron	O
in	O
the	O
urine	O
.	O
	
Prednisone	O
reduction	O
can	O
be	O
accomplished	O
by	O
reducing	O
the	O
daily	O
prednisone	O
dose	O
by	O
2.5	O
mg	O
on	O
a	O
weekly	O
basis	O
during	O
therapy	O
with	O
BREO	O
ELLIPTA	O
.	O
	
cDefined	O
as	O
bleeding	B
accompanied	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
a	O
decrease	B
in	I
hemoglobin	I
of	O
>	O
=2	O
g/dL	O
,	O
a	O
transfusion	O
of	O
2	O
or	O
more	O
units	O
of	O
packed	O
red	O
blood	O
cells	O
,	O
bleeding	B
at	I
a	I
critical	I
site	I
or	O
with	O
fatal	B
outcome	O
.	O
	
Immediately	O
discontinue	O
treatment	O
if	O
severe	O
hypersensitivity	O
,	O
severe	O
rash	O
or	O
rash	O
with	O
systemic	O
symptoms	O
or	O
liver	O
transaminase	O
elevations	O
develops	O
and	O
monitor	O
clinical	O
status	O
,	O
including	O
liver	O
transaminases	O
closely	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=	O
0.1	O
%	O
of	O
subjects	O
treated	O
with	O
EOVIST	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Acorda	O
Therapeutics	O
at	O
1-800-367-5109	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
If	O
paradoxical	O
bronchospasm	O
occurs	O
following	O
dosing	O
with	O
BREO	O
ELLIPTA	O
,	O
it	O
should	O
be	O
treated	O
immediately	O
with	O
an	O
inhaled	O
,	O
short-acting	O
bronchodilator	O
;	O
BREO	O
ELLIPTA	O
should	O
be	O
discontinued	O
immediately	O
;	O
and	O
alternative	O
therapy	O
should	O
be	O
instituted	O
.	O
	
During	O
the	O
initial	O
phase	O
of	O
combination	O
antiretroviral	O
treatment	O
,	O
patients	O
whose	O
immune	O
system	O
responds	O
may	O
develop	O
an	O
inflammatory	B
response	I
to	O
indolent	O
or	O
residual	O
opportunistic	B
infections	I
(	O
such	O
as	O
Mycobacterium	B
avium	I
infection	I
,	O
cytomegalovirus	B
,	O
Pneumocystis	B
jiroveci	I
pneumonia	I
(	O
PCP	B
)	O
or	O
tuberculosis	B
)	O
,	O
which	O
may	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
5.6	O
Increased	O
Toxicity	O
in	O
the	O
Presence	O
of	O
Severe	O
Renal	O
Impairment	O
The	O
frequency	O
of	O
>	O
=Grade	O
3	O
adverse	O
reactions	O
and	O
deaths	B
was	O
greater	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
compared	O
to	O
patients	O
with	O
normal	O
renal	O
function	O
.	O
	
In	O
4	O
studies	O
FARXIGA	O
was	O
used	O
as	O
monotherapy	O
,	O
and	O
in	O
8	O
studies	O
FARXIGA	O
was	O
used	O
as	O
add-on	O
to	O
background	O
antidiabetic	O
therapy	O
or	O
as	O
combination	O
therapy	O
with	O
metformin	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Tables	O
2	O
and	O
3	O
summarize	O
the	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
observed	O
in	O
ZYKADIA-treated	O
patients	O
.	O
	
Patients	O
were	O
not	O
eligible	O
if	O
AST	O
and/or	O
ALT	O
>	O
=2.5*	O
ULN	O
in	O
the	O
absence	O
of	O
liver	O
metastases	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
collagenase	O
clostridium	O
histolyticum	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
most	O
frequent	O
serious	O
adverse	O
reactions	O
that	O
occurred	O
were	O
pneumonia	B
(	O
15	O
%	O
)	O
,	O
diarrhea	B
(	O
11	O
%	O
)	O
,	O
and	O
pyrexia	B
(	O
9	O
%	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
during	O
clinical	O
trials	O
were	O
chromaturia	B
,	O
nausea	B
,	O
vomiting	B
,	O
abdominal	B
pain	I
,	O
alanine	B
aminotransferase	I
increased	I
,	O
arthralgia	B
and	O
neutropenia	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Cleviprex	O
clinical	O
development	O
included	O
19	O
studies	O
,	O
with	O
99	O
healthy	O
subjects	O
and	O
1307	O
hypertensive	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
clevidipine	O
(	O
1406	O
total	O
exposures	O
)	O
.	O
	
5.4	O
Neuropsychiatric	O
Symptoms	O
Confusional	B
state	I
,	O
psychotic	B
symptoms	I
,	O
and	O
hallucinations	B
were	O
reported	O
more	O
frequently	O
as	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
POTIGA	O
than	O
in	O
those	O
treated	O
with	O
placebo	O
in	O
placebo-controlled	O
epilepsy	O
trials	O
(	O
see	O
Table	O
2	O
)	O
.	O
	
These	O
patients	O
should	O
also	O
be	O
instructed	O
to	O
carry	O
a	O
warning	O
card	O
indicating	O
that	O
they	O
may	O
need	O
supplementary	O
systemic	O
corticosteroids	O
during	O
periods	O
of	O
stress	O
,	O
a	O
severe	O
COPD	O
exacerbation	O
,	O
or	O
a	O
severe	O
asthma	O
attack	O
.	O
	
If	O
feasible	O
,	O
stop	O
Natazia	O
at	O
least	O
4	O
weeks	O
before	O
and	O
through	O
2	O
weeks	O
after	O
major	O
surgery	O
or	O
other	O
surgeries	O
known	O
to	O
have	O
an	O
elevated	O
risk	O
of	O
thromboembolism	O
.	O
	
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
:	O
acute	B
respiratory	I
distress	I
syndrome	I
,	O
epistaxis	B
,	O
hemoptysis	B
,	O
pulmonary	B
embolism	I
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
:	O
The	O
following	O
additional	O
adverse	O
reactions	O
were	O
reported	O
in	O
>	O
=5	O
%	O
to	O
<	O
10	O
%	O
of	O
the	O
HALAVEN-treated	O
group	O
:	O
*	O
Eye	O
Disorders	O
:	O
increased	B
lacrimation	I
*	O
Gastrointestinal	O
Disorders	O
:	O
dyspepsia	B
,	O
abdominal	B
pain	I
,	O
stomatitis	B
,	O
dry	B
mouth	I
*	O
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
peripheral	B
edema	I
*	O
Infections	O
and	O
Infestations	O
:	O
upper	B
respiratory	I
tract	I
infection	I
*	O
Metabolism	O
and	O
Nutrition	O
Disorders	O
:	O
hypokalemia	B
*	O
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
muscle	B
spasms	I
,	O
muscular	B
weakness	I
*	O
Nervous	O
System	O
Disorders	O
:	O
dysgeusia	B
,	O
dizziness	B
*	O
Psychiatric	O
Disorders	O
:	O
insomnia	B
,	O
depression	B
*	O
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
rash	B
6	O
.	O
	
Neutralizing	O
antibodies	O
to	O
AUX-I	O
or	O
AUX-II	O
,	O
were	O
detected	O
in	O
60	O
%	O
and	O
51.8	O
%	O
,	O
respectively	O
,	O
of	O
patients	O
tested	O
.	O
	
If	O
a	O
hypersensitivity	O
reaction	O
occurs	O
,	O
the	O
patient	O
should	O
discontinue	O
TRULICITY	O
and	O
promptly	O
seek	O
medical	O
advice	O
.	O
	
(	O
2.2	O
,	O
5.1	O
)	O
*	O
Hepatotoxicity	B
:	O
ZYKADIA	O
can	O
cause	O
hepatotoxicity	B
.	O
	
Grade	O
3-4	O
cardiac	B
failure	I
occurred	O
in	O
0.2	O
%	O
of	O
patients	O
taking	O
placebo	O
.	O
	
Avoid	O
the	O
use	O
of	O
ADCETRIS	O
in	O
patients	O
with	O
moderate	O
(	O
Child-Pugh	O
B	O
)	O
or	O
severe	O
(	O
Child-Pugh	O
C	O
)	O
hepatic	O
impairment	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
]	O
.	O
	
c	O
not	O
applicable	O
;	O
(	O
grading	O
system	O
does	O
not	O
specify	O
>	O
Grade	O
2	O
for	O
alopecia	B
)	O
.	O
	
Hypertension	O
Blood	O
pressure	O
and	O
use	O
of	O
antihypertensive	O
medications	O
were	O
reported	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
5.2	O
Fat	O
Redistribution	O
buffalo	B
hump	I
,	O
facial	B
wasting	I
,	O
breast	B
enlargement	I
,	O
and	O
``	O
cushingoid	B
appearance	I
''	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O
	
It	O
is	O
possible	O
that	O
systemic	O
corticosteroid	O
effects	O
such	O
as	O
hypercorticism	B
and	O
adrenal	B
suppression	I
(	O
including	O
adrenal	B
crisis	I
)	O
may	O
appear	O
in	O
a	O
small	O
number	O
of	O
patients	O
who	O
are	O
sensitive	O
to	O
these	O
effects	O
.	O
	
In	O
Phase	O
3	O
clinical	O
trials	O
,	O
Grade	O
3	O
and	O
4	O
rashes	B
were	O
reported	O
in	O
1.3	O
%	O
of	O
subjects	O
receiving	O
INTELENCE	O
(	O
r	O
)	O
compared	O
to	O
0.2	O
%	O
of	O
placebo	O
subjects	O
.	O
	
Major	O
bleeding	B
events	O
within	O
each	O
subcategory	O
were	O
counted	O
once	O
per	O
patient	O
,	O
but	O
patients	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
subcategories	O
.	O
	
During	O
withdrawal	O
from	O
oral	O
corticosteroids	O
,	O
some	O
patients	O
may	O
experience	O
symptoms	O
of	O
systemically	O
active	O
corticosteroid	O
withdrawal	O
(	O
e.g.	O
,	O
joint	O
and/or	O
muscular	O
pain	O
,	O
lassitude	O
,	O
depression	O
)	O
despite	O
maintenance	O
or	O
even	O
improvement	O
of	O
respiratory	O
function	O
.	O
	
Premedication	O
may	O
include	O
acetaminophen	O
,	O
an	O
antihistamine	O
,	O
and	O
a	O
corticosteroid	O
.	O
	
Cardiac	O
disorders	O
:	O
atrial	B
fibrillation	I
,	O
cardiac	B
failure	I
.	O
	
Do	O
not	O
use	O
NULOJIX	O
in	O
transplant	O
recipients	O
who	O
are	O
EBV	O
seronegative	O
or	O
with	O
unknown	O
EBV	O
serostatus	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Sustained	O
blood	B
pressure	I
increases	I
could	O
have	O
adverse	O
consequences	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
leading	O
to	O
permanent	O
discontinuation	O
in	O
patients	O
treated	O
with	O
COMETRIQ	O
were	O
:	O
hypocalcemia	B
,	O
increased	B
lipase	I
,	O
PPES	B
,	O
diarrhea	B
,	O
fatigue	B
,	O
hypertension	B
,	O
nausea	B
,	O
pancreatitis	B
,	O
tracheal	B
fistula	I
formation	I
and	O
vomiting	B
.	O
	
*	O
Pancreatitis	B
:	O
Has	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O
	
(	O
6.1	O
)	O
*	O
PHN	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
were	O
dizziness	B
,	O
somnolence	B
,	O
and	O
headache	B
.	O
	
During	O
controlled	O
clinical	O
studies	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
serious	O
adverse	O
reactions	O
was	O
10	O
%	O
for	O
CIMZIA	O
and	O
9	O
%	O
for	O
placebo	O
.	O
	
Monitor	O
and	O
treat	O
promptly	O
per	O
standard	O
of	O
care	O
until	O
signs	O
and	O
symptoms	O
resolve	O
(	O
5.4	O
)	O
.	O
	
[	O
See	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
are	O
fatigue	B
,	O
diarrhea	B
,	O
pruritus	B
,	O
rash	B
,	O
and	O
colitis	B
.	O
	
Sustained	O
decreases	O
in	O
eGFR	O
were	O
seen	O
in	O
patients	O
with	O
moderate	O
renal	O
impairment	O
(	O
eGFR	O
30	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
This	O
reflects	O
its	O
alpha1-adrenergic	O
antagonist	O
properties	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reaction	O
in	O
adults	O
was	O
diarrhea	B
(	O
2	O
%	O
)	O
.	O
	
Patients	O
who	O
can	O
not	O
be	O
monitored	O
should	O
usually	O
not	O
be	O
treated	O
with	O
POTIGA	O
.	O
	
Across	O
all	O
short-	O
and	O
long-term	O
studies	O
,	O
the	O
overall	O
mean	O
change	O
from	O
baseline	O
at	O
endpoint	O
was	O
2.1	O
kg	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
volume	B
depletion	I
(	O
including	O
reports	O
of	O
dehydration	B
,	O
hypovolemia	B
,	O
orthostatic	B
hypotension	I
,	O
or	O
hypotension	B
)	O
are	O
shown	O
in	O
Table	O
2	O
for	O
the	O
12-study	O
and	O
13-study	O
,	O
short-term	O
,	O
placebo-controlled	O
pools	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.6	O
)	O
}	O
}	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Alcon	O
Laboratories	O
,	O
Inc.	O
at	O
1-800-757-9195	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
have	O
been	O
associated	O
with	O
Zydelig	O
in	O
clinical	O
trials	O
and	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
prescribing	O
information	O
.	O
	
In	O
some	O
cases	O
,	O
disseminated	B
intravascular	I
coagulation	I
(	O
DIC	B
)	O
,	O
capillary	B
leak	I
syndrome	I
(	O
CLS	B
)	O
,	O
and	O
hemophagocytic	B
lymphohistiocytosis/macrophage	O
activation	B
syndrome	I
(	O
HLH/MAS	O
)	O
have	O
been	O
reported	O
in	O
the	O
setting	O
of	O
CRS	B
.	O
	
Infusion	O
Reactions	O
There	O
were	O
no	O
reports	O
of	O
anaphylaxis	B
or	O
drug	B
hypersensitivity	I
in	O
patients	O
treated	O
with	O
NULOJIX	O
in	O
Studies	O
1	O
and	O
2	O
through	O
three	O
years	O
.	O
	
Table	O
1	O
summarizes	O
the	O
most	O
common	O
adverse	O
reactions	O
that	O
occurred	O
in	O
the	O
placebo-controlled	O
trial	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
in	O
patients	O
treated	O
with	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
and	O
with	O
a	O
higher	O
incidence	O
than	O
in	O
the	O
placebo-treated	O
patients	O
.	O
	
Adverse	O
reactions	O
reported	O
within	O
48	O
weeks	O
of	O
treatment	O
and	O
in	O
at	O
least	O
1	O
%	O
of	O
subjects	O
treated	O
with	O
JUBLIA	O
and	O
those	O
reported	O
in	O
subjects	O
treated	O
with	O
the	O
vehicle	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
The	O
patient	O
was	O
also	O
not	O
taking	O
any	O
immunosuppressive	O
or	O
immunomodulatory	O
medications	O
concomitantly	O
.	O
	
2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
IMBRUVICA	O
.	O
	
The	O
following	O
risks	O
,	O
including	O
appropriate	O
action	O
to	O
be	O
taken	O
,	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1-5.13	O
)	O
]	O
:	O
hypertension	B
,	O
arterial	B
thromboembolic	I
events	I
,	O
venous	B
thromboembolic	I
events	I
,	O
hemorrhage	B
,	O
cardiac	B
failure	I
,	O
gastrointestinal	B
perforation	I
and	O
fistula	B
formation	I
,	O
thyroid	B
dysfunction	I
,	O
wound	B
healing	I
complications	I
,	O
RPLS	B
,	O
proteinuria	B
,	O
elevation	B
of	I
liver	I
enzymes	I
,	O
hepatic	B
impairment	I
and	O
fetal	O
development	O
.	O
	
When	O
treating	O
pediatric	O
patients	O
,	O
weight	O
gain	O
should	O
be	O
monitored	O
and	O
assessed	O
against	O
that	O
expected	O
for	O
normal	O
growth	O
.	O
	
These	O
included	O
infections	B
,	O
subdural	B
hematomas	I
and	O
diarrhea	B
.	O
	
Approximately	O
1162	O
patients	O
have	O
received	O
more	O
than	O
2	O
years	O
of	O
treatment	O
with	O
TECFIDERA	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
Life-threatening	O
anaphylactic	B
reactions	I
have	O
occurred	O
in	O
some	O
patients	O
during	O
Vimizim	O
infusions	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
neutropenia	B
,	O
anemia	B
,	O
fatigue	B
,	O
musculoskeletal	B
pain	I
,	O
peripheral	B
edema	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
nausea	B
,	O
bruising	B
,	O
dyspnea	B
,	O
constipation	B
,	O
rash	B
,	O
abdominal	B
pain	I
,	O
vomiting	B
and	O
decreased	B
appetite	I
(	O
see	O
Tables	O
1	O
and	O
2	O
)	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
the	O
postmarketing	O
use	O
of	O
NESINA	O
.	O
	
Preventive	O
measures	O
include	O
vigorous	O
hydration	O
and	O
close	O
monitoring	O
of	O
blood	O
chemistry	O
,	O
particularly	O
potassium	O
and	O
uric	O
acid	O
levels	O
.	O
	
Cervical	O
Dystonia	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
DYSPORT	O
(	O
r	O
)	O
in	O
357	O
cervical	O
dystonia	O
patients	O
in	O
6	O
studies	O
.	O
	
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
(	O
2.3	O
)	O
]	O
5.2	O
Infections	O
Infection	B
,	O
including	O
pneumonia	B
,	O
sepsis	B
,	O
septic	B
shock	I
,	O
and	O
death	B
have	O
occurred	O
in	O
adult	O
and	O
pediatric	O
patients	O
in	O
clinical	O
trials	O
and	O
in	O
postmarketing	O
reports	O
.	O
	
In	O
such	O
cases	O
,	O
promptly	O
discontinue	O
NESINA	O
,	O
assess	O
for	O
other	O
potential	O
causes	O
,	O
institute	O
appropriate	O
monitoring	O
and	O
treatment	O
and	O
initiate	O
alternative	O
treatment	O
for	O
diabetes	O
.	O
	
The	O
most	O
common	O
cause	O
of	O
death	B
as	O
reported	O
by	O
the	O
investigator	O
was	O
TB	O
(	O
9	O
subjects	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
in	O
children	O
(	O
>	O
12	O
%	O
)	O
are	O
pyrexia	B
,	O
cough	B
,	O
vomiting	B
,	O
anorexia	B
,	O
and	O
headache	B
.	O
	
DALVANCE	O
was	O
discontinued	O
due	O
to	O
an	O
adverse	O
reaction	O
in	O
53/1778	O
(	O
3	O
%	O
)	O
patients	O
and	O
the	O
comparator	O
was	O
discontinued	O
due	O
to	O
an	O
adverse	O
reaction	O
in	O
35/1224	O
(	O
2.8	O
%	O
)	O
patients	O
.	O
	
Dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
were	O
required	O
in	O
6.4	O
%	O
of	O
XALKORI-treated	O
patients	O
.	O
	
If	O
skin	O
reactions	O
are	O
severe	O
or	O
progressive	O
,	O
withhold	O
or	O
discontinue	O
TREANDA	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Besivance	O
in	O
approximately	O
1,000	O
patients	O
between	O
1	O
and	O
98	O
years	O
old	O
with	O
clinical	O
signs	O
and	O
symptoms	O
of	O
bacterial	O
conjunctivitis	O
.	O
	
Laboratory	O
and	O
Imaging	O
Tests	O
Increases	O
in	O
Serum	O
Potassium	O
In	O
a	O
pooled	O
population	O
of	O
patients	O
(	O
N=723	O
)	O
with	O
moderate	O
renal	O
impairment	O
(	O
eGFR	O
45	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
increases	B
in	I
serum	I
potassium	I
to	O
greater	O
than	O
5.4	O
mEq/L	O
and	O
15	O
%	O
above	O
baseline	O
occurred	O
in	O
5.3	O
%	O
,	O
5.0	O
%	O
,	O
and	O
8.8	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
A	O
total	O
of	O
3876	O
women	O
were	O
exposed	O
to	O
placebo	O
and	O
3886	O
women	O
were	O
exposed	O
to	O
Prolia	O
administered	O
subcutaneously	O
once	O
every	O
6	O
months	O
as	O
a	O
single	O
60	O
mg	O
dose	O
.	O
	
S	O
Includes	O
patients	O
treated	O
with	O
flexible	O
dose	O
of	O
SAPHRIS	O
5	O
or	O
10	O
mg	O
twice	O
daily	O
(	O
N=90	O
)	O
.	O
	
In	O
a	O
trial	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
serum	B
magnesium	I
levels	I
increased	I
by	O
0.2	O
%	O
,	O
9.2	O
%	O
,	O
and	O
14.8	O
%	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
The	O
median	O
duration	O
of	O
study	O
treatment	O
was	O
7.1	O
months	O
for	O
patients	O
who	O
received	O
XALKORI	O
and	O
2.8	O
months	O
for	O
patients	O
who	O
received	O
chemotherapy	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
compared	O
directly	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
No	O
deaths	B
,	O
intubations	O
,	O
or	O
serious	O
adverse	O
reactions	O
related	O
to	O
asthma	B
exacerbation	I
were	O
reported	O
in	O
this	O
trial	O
.	O
	
(	O
5.4	O
,	O
5.5	O
)	O
5.1	O
Eye	O
and	O
Mucous	O
Membrane	O
Exposure	O
Do	O
not	O
apply	O
Qutenza	O
to	O
the	O
face	O
or	O
scalp	O
to	O
avoid	O
risk	O
of	O
exposure	O
to	O
the	O
eyes	O
or	O
mucous	O
membranes	O
.	O
	
Laboratory	O
abnormalities	O
are	O
described	O
separately	O
in	O
Table	O
11	O
.	O
	
(	O
5.1	O
)	O
5.1	O
Seizure	O
In	O
Study	O
1	O
,	O
which	O
enrolled	O
patients	O
who	O
previously	O
received	O
docetaxel	O
,	O
7	O
of	O
800	O
(	O
0.9	O
%	O
)	O
patients	O
treated	O
with	O
XTANDI	O
experienced	O
a	O
seizure	B
and	O
no	O
patients	O
treated	O
with	O
placebo	O
experienced	O
a	O
seizure	B
.	O
	
Prescribers	O
should	O
exercise	O
caution	O
in	O
considering	O
the	O
use	O
of	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
in	O
patients	O
with	O
central	O
or	O
peripheral	O
nervous	O
system	O
demyelinating	O
disorders	O
.	O
	
Three	O
additional	O
subjects	O
tested	O
positive	O
for	O
binding	O
antibodies	O
after	O
receiving	O
DYSPORT	O
(	O
r	O
)	O
treatment	O
.	O
	
This	O
drop	O
in	O
body	O
estrogen	O
levels	O
causes	O
the	O
``	O
change	O
of	O
life	O
''	O
or	O
menopause	O
(	O
the	O
end	O
of	O
monthly	O
menstrual	O
periods	O
)	O
.	O
	
A	O
risk	O
for	O
the	O
development	O
for	O
hepatosplenic	O
T-cell	O
lymphoma	O
in	O
patients	O
treated	O
with	O
TNF-blockers	O
can	O
not	O
be	O
excluded	O
.	O
	
Instruct	O
patients	O
receiving	O
GILENYA	O
to	O
report	O
symptoms	O
of	O
infections	O
to	O
a	O
physician	O
.	O
	
*	O
Screen	O
patients	O
for	O
acute	O
kidney	O
injury	O
and	O
other	O
conditions	O
that	O
may	O
reduce	O
renal	O
function	O
.	O
	
The	O
risk	O
of	O
symptoms	O
is	O
probably	O
greatest	O
in	O
children	O
treated	O
for	O
spasticity	O
but	O
symptoms	O
can	O
also	O
occur	O
in	O
adults	O
,	O
particularly	O
in	O
those	O
patients	O
who	O
have	O
underlying	O
conditions	O
that	O
would	O
predispose	O
them	O
to	O
these	O
symptoms	O
.	O
	
The	O
most	O
common	O
key	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
50	O
%	O
)	O
were	O
hypercholesterolemia	B
and	O
elevated	B
partial	I
thromboplastin	I
time	I
.	O
	
In	O
Study	O
1	O
,	O
all	O
Grades	O
of	O
adverse	O
events	O
were	O
reported	O
for	O
the	O
following	O
adverse	O
events	O
of	O
special	O
interest	O
:	O
allergy	B
,	O
pancreatitis	B
,	O
coagulopathy	B
(	O
hemorrhage	B
,	O
thrombosis	B
or	O
infarct	B
)	O
,	O
hyperbilirubinemia	B
,	O
hyperglycemia	B
,	O
hyperlipidemia	B
,	O
ketoacidosis	B
,	O
and	O
CNS	B
events	I
,	O
and	O
cerebral	B
venous	I
thrombosis	I
)	O
and	O
only	O
Grade	O
3	O
and	O
4	O
events	O
were	O
reported	O
for	O
other	O
adverse	O
events	O
.	O
	
(	O
5.8	O
)	O
*	O
Reversible	B
Posterior	I
Leukoencephalopathy	I
Syndrome	I
(	O
RPLS	B
)	O
has	O
been	O
observed	O
.	O
	
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
5	O
%	O
)	O
more	O
frequently	O
reported	O
in	O
women	O
treated	O
with	O
DUAVEE	O
than	O
placebo	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
(	O
5.1	O
)	O
*	O
Acute	B
Renal	I
Failure	I
:	O
Monitor	O
serum	O
creatinine	O
regularly	O
(	O
5.2	O
)	O
*	O
Tumor	B
Lysis	I
Syndrome	I
(	O
TLS	B
)	O
:	O
Administer	O
pre-treatment	O
hydration	O
.	O
	
In	O
unapproved	O
uses	O
,	O
including	O
spasticity	O
in	O
children	O
and	O
in	O
approved	O
indications	O
,	O
symptoms	O
consistent	O
with	O
spread	B
of	I
toxin	I
effect	I
have	O
been	O
reported	O
at	O
doses	O
comparable	O
to	O
or	O
lower	O
than	O
the	O
maximum	O
recommended	O
total	O
dose	O
.	O
	
Consider	O
factors	O
that	O
contribute	O
to	O
fracture	O
risk	O
prior	O
to	O
initiating	O
INVOKANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
(	O
5.13	O
)	O
*	O
Embryo-fetal	B
Toxicity	I
:	O
Kyprolis	O
can	O
cause	O
fetal	B
harm	I
.	O
	
Patients	O
treated	O
with	O
botulinum	O
toxin	O
may	O
require	O
immediate	O
medical	O
attention	O
should	O
they	O
develop	O
problems	O
with	O
swallowing	O
,	O
speech	O
or	O
respiratory	O
disorders	O
.	O
	
Administer	O
this	O
product	O
in	O
a	O
setting	O
with	O
resuscitation	O
equipment	O
and	O
other	O
agents	O
necessary	O
to	O
treat	O
anaphylaxis	O
.	O
	
Monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
cardiac	O
failure	O
throughout	O
treatment	O
with	O
INLYTA	O
.	O
	
*	O
Bipolar	O
Disorder	O
Adults	O
(	O
Adjunctive	O
)	O
:	O
somnolence	B
,	O
oral	B
hypoesthesia	I
.	O
	
At	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
,	O
withhold	O
GILENYA	O
and	O
perform	O
an	O
appropriate	O
diagnostic	O
evaluation	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
were	O
infections	B
,	O
dyspnea	B
,	O
fatigue	B
,	O
stomatitis	B
,	O
dehydration	B
,	O
pneumonitis	B
,	O
abdominal	B
pain	I
,	O
and	O
asthenia	B
.	O
	
If	O
unexplained	O
or	O
clinically	O
significant	O
weight	O
loss	O
occurs	O
,	O
evaluate	O
weight	O
loss	O
and	O
consider	O
discontinuation	O
of	O
OTEZLA	O
(	O
5.2	O
)	O
*	O
Drug	O
Interactions	O
:	O
Use	O
with	O
strong	O
cytochrome	O
P450	O
enzyme	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
phenobarbital	O
,	O
carbamazepine	O
,	O
phenytoin	O
)	O
is	O
not	O
recommended	O
because	O
loss	O
of	O
efficacy	O
may	O
occur	O
(	O
5.3,7.1	O
)	O
5.1	O
Depression	O
Treatment	O
with	O
OTEZLA	O
is	O
associated	O
with	O
an	O
increase	O
in	O
adverse	O
reactions	O
of	O
depression	B
.	O
	
Based	O
on	O
effective	O
donor	O
screening	O
and	O
product	O
manufacturing	O
processes	O
,	O
it	O
carries	O
an	O
extremely	O
remote	O
risk	O
for	O
transmission	B
of	I
viral	I
diseases	I
.	O
	
BREO	O
ELLIPTA	O
100/25	O
was	O
studied	O
in	O
2,369	O
subjects	O
and	O
BREO	O
ELLIPTA	O
200/25	O
was	O
studied	O
in	O
956	O
subjects	O
.	O
	
Therefore	O
,	O
if	O
ENTEREG	O
is	O
administered	O
to	O
these	O
patients	O
,	O
they	O
should	O
be	O
monitored	O
for	O
gastrointestinal	O
adverse	O
reactions	O
.	O
	
Seventy-seven	O
subjects	O
initiated	O
a	O
lipid-lowering	O
agent	O
post-baseline	O
;	O
their	O
last	O
fasted	O
on-treatment	O
values	O
(	O
prior	O
to	O
starting	O
the	O
agent	O
)	O
were	O
used	O
regardless	O
if	O
they	O
discontinued	O
the	O
agent	O
(	O
SPRING-2	O
:	O
TIVICAY	O
n	O
=	O
9	O
,	O
raltegravir	O
n	O
=	O
13	O
;	O
SINGLE	O
:	O
TIVICAY	O
n	O
=	O
25	O
and	O
ATRIPLA	O
:	O
n	O
=	O
30	O
)	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
treatment	O
with	O
STRIBILD	O
,	O
the	O
RTV-boosted	O
PI	O
,	O
or	O
the	O
NNRTI	O
due	O
to	O
adverse	O
events	O
,	O
was	O
2	O
%	O
,	O
3	O
%	O
and	O
1	O
%	O
,	O
respectively	O
.	O
	
Overall	O
,	O
the	O
safety	O
profile	O
in	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
C	O
virus	O
co-infection	O
was	O
similar	O
to	O
that	O
observed	O
in	O
subjects	O
without	O
hepatitis	O
B	O
or	O
C	O
co-infection	O
,	O
although	O
the	O
rates	O
of	O
ALT	B
abnormalities	I
were	O
higher	O
in	O
the	O
subgroup	O
with	O
hepatitis	O
B	O
and/or	O
C	O
virus	O
co-infection	O
for	O
all	O
treatment	O
groups	O
.	O
	
Serum	O
Lipids	O
:	O
In	O
the	O
clinical	O
trials	O
of	O
STRIBILD	O
,	O
a	O
similar	O
percentage	O
of	O
subjects	O
receiving	O
STRIBILD	O
,	O
ATRIPLA	O
,	O
and	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
were	O
on	O
lipid	O
lowering	O
agents	O
at	O
baseline	O
(	O
12	O
%	O
,	O
12	O
%	O
,	O
and	O
13	O
%	O
,	O
respectively	O
)	O
.	O
	
5.1	O
Increased	O
Risks	O
in	O
Elderly	O
Patients	O
with	O
Dementia-Related	O
Psychosis	O
Increased	O
Mortality	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
atypical	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
compared	O
to	O
placebo	O
.	O
	
5.2	O
Concomitant	O
Use	O
with	O
CYP3A	O
Inducers	O
Use	O
of	O
KALYDECO	O
with	O
strong	O
CYP3A	O
inducers	O
,	O
such	O
as	O
rifampin	O
,	O
substantially	O
decreases	O
the	O
exposure	O
of	O
ivacaftor	O
,	O
which	O
may	O
reduce	O
the	O
therapeutic	O
effectiveness	O
of	O
KALYDECO	O
.	O
	
Ecchymosis	O
easily	O
occurs	O
in	O
the	O
soft	O
tissues	O
of	O
the	O
eyelid	O
.	O
	
All	O
subjects	O
were	O
queried	O
about	O
the	O
presence	O
of	O
skin	O
and	O
scalp	O
symptoms	O
;	O
the	O
results	O
are	O
presented	O
in	O
Table	O
2	O
.	O
	
Continuation	O
of	O
GILENYA	O
in	O
patients	O
who	O
develop	O
macular	B
edema	I
has	O
not	O
been	O
evaluated	O
.	O
	
Reduce	O
or	O
withhold	O
dose	O
as	O
appropriate	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Overall	O
,	O
the	O
mean	O
age	O
of	O
patients	O
in	O
the	O
PHN	O
studies	O
ranged	O
from	O
61	O
to	O
64	O
years	O
of	O
age	O
across	O
dose	O
groups	O
;	O
the	O
majority	O
of	O
patients	O
were	O
male	O
(	O
45	O
%	O
to	O
61	O
%	O
)	O
and	O
Caucasian	O
(	O
80	O
%	O
to	O
98	O
%	O
)	O
.	O
	
If	O
CDAD	O
is	O
confirmed	O
,	O
discontinue	O
antibacterials	O
not	O
directed	O
against	O
C.	O
difficile	O
,	O
if	O
possible	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
in	O
COPD	B
or	O
loss	B
of	I
efficacy	I
.	O
	
6-Month	O
Trials	O
The	O
incidence	O
of	O
adverse	O
reactions	O
associated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
in	O
Table	O
1	O
is	O
based	O
on	O
2	O
placebo-controlled	O
,	O
6-month	O
clinical	O
trials	O
(	O
Trials	O
1	O
and	O
2	O
;	O
n	O
=	O
1,224	O
and	O
n	O
=	O
1,030	O
,	O
respectively	O
)	O
.	O
	
Some	O
events	O
have	O
been	O
fatal	B
.	O
	
(	O
5.7	O
)	O
*	O
Leukopenia	B
,	O
Neutropenia	B
,	O
and	O
Agranulocytosis	B
have	O
been	O
reported	O
with	O
antipsychotics	O
.	O
	
5.8	O
Venous	O
Thrombosis	O
Venous	B
thromboembolic	I
events	I
(	O
including	O
deep	B
venous	I
thrombosis	I
and	O
pulmonary	B
embolism	I
)	O
have	O
been	O
observed	O
with	O
Kyprolis	O
.	O
	
Patients	O
should	O
be	O
advised	O
to	O
elevate	O
the	O
head	O
of	O
the	O
bed	O
when	O
resting	O
or	O
sleeping	O
.	O
	
GILOTRIF	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
keratitis	O
,	O
ulcerative	O
keratitis	O
,	O
or	O
severe	O
dry	O
eye	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Decreased	O
Efficacy	O
in	O
Patients	O
with	O
Baseline	O
Creatinine	O
Clearance	O
of	O
30	O
to	O
<	O
=50	O
mL/min	O
In	O
a	O
subgroup	O
analysis	O
of	O
a	O
Phase	O
3	O
cIAI	O
trial	O
,	O
clinical	O
cure	O
rates	O
were	O
lower	O
in	O
patients	O
with	O
baseline	O
creatinine	O
clearance	O
(	O
CrCl	O
)	O
of	O
30	O
to	O
<	O
=50	O
mL/min	O
compared	O
to	O
those	O
with	O
CrCl	O
>	O
=50	O
mL/min	O
(	O
Table	O
4	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
resulting	O
in	O
discontinuation	O
of	O
treatment	O
(	O
>	O
=1	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
or	O
placebo	O
)	O
were	O
infusion	B
reactions	I
(	O
1.6	O
%	O
BENLYSTA	O
and	O
0.9	O
%	O
placebo	O
)	O
,	O
lupus	B
nephritis	I
(	O
0.7	O
%	O
BENLYSTA	O
and	O
1.2	O
%	O
placebo	O
)	O
,	O
and	O
infections	B
(	O
0.7	O
%	O
BENLYSTA	O
and	O
1.0	O
%	O
placebo	O
)	O
.	O
	
Table	O
8	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=	O
10	O
%	O
of	O
AFINITOR-treated	O
Patients	O
with	O
Renal	O
Angiomyolipoma	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Includes	O
stomatitis	B
,	O
aphthous	B
stomatitis	I
,	O
mouth	B
ulceration	I
,	O
gingival	B
pain	I
,	O
glossitis	B
,	O
and	O
glossodynia	B
.	O
	
Thrombocytopenia	B
was	O
reported	O
in	O
approximately	O
40	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
Kyprolis	O
.	O
	
ULESFIA	O
(	O
r	O
)	O
Lotion	O
may	O
cause	O
eye	B
irritation	I
.	O
	
(	O
5.2	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
following	O
DaTscan	O
administration	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
6.3	O
Immunogenicity	O
A	O
biosensor	O
binding	O
assay	O
or	O
a	O
bridging	O
immunoassay	O
was	O
used	O
to	O
detect	O
antibodies	O
directed	O
against	O
canakinumab	O
in	O
patients	O
who	O
received	O
ILARIS	O
.	O
	
Presence	O
of	O
antibody	O
did	O
not	O
correlate	O
with	O
reduced	O
efficacy	O
as	O
measured	O
by	O
HbA1c	O
and	O
fasting	O
plasma	O
glucose	O
or	O
specific	O
adverse	O
reactions	O
.	O
	
Patients	O
with	O
pre-VORAXAZE	O
methotrexate	O
concentrations	O
>	O
100	O
mumol/L	O
were	O
to	O
receive	O
a	O
second	O
dose	O
of	O
VORAXAZE	O
48	O
hours	O
after	O
the	O
first	O
dose	O
.	O
	
Withhold	O
trametinib	O
and	O
continue	O
TAFINLAR	O
at	O
the	O
same	O
dose	O
for	O
uncomplicated	O
DVT	O
or	O
PE	O
;	O
if	O
improved	O
within	O
3	O
weeks	O
,	O
trametinib	O
may	O
be	O
resumed	O
at	O
a	O
lower	O
dose	O
level	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
*	O
Renal	B
failure	I
,	O
including	O
cases	O
with	O
fatal	B
outcomes	O
,	O
has	O
been	O
reported	O
.	O
	
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
-	O
Asthenia	B
.	O
	
(	O
5.2	O
)	O
*	O
Development	O
of	O
drug-resistant	O
bacteria	O
:	O
Only	O
use	O
DIFICID	O
for	O
infection	O
proven	O
or	O
strongly	O
suspected	O
to	O
be	O
caused	O
by	O
C.	O
difficile	O
.	O
	
If	O
toxicity	O
recurs	O
at	O
Grade	O
3	O
,	O
consider	O
discontinuation	O
of	O
AFINITOR	O
.	O
	
Table	O
7	O
:	O
Bleeding	B
Results	O
in	O
the	O
AMPLIFY-EXT	O
Study	O
ELIQUIS	O
2.5	O
mg	O
bidN=840n	O
(	O
%	O
)	O
ELIQUIS	O
5	O
mg	O
bidN=811n	O
(	O
%	O
)	O
PlaceboN=826n	O
(	O
%	O
)	O
*	O
CRNM	B
=	O
clinically	B
relevant	I
nonmajor	I
bleeding.Events	O
associated	O
with	O
each	O
endpoint	O
were	O
counted	O
once	O
per	O
subject	O
,	O
but	O
subjects	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
endpoints	O
.	O
	
Patients	O
should	O
be	O
observed	O
for	O
an	O
appropriate	O
period	O
of	O
time	O
after	O
administration	O
of	O
KALBITOR	O
,	O
taking	O
into	O
account	O
the	O
time	O
to	O
onset	O
of	O
anaphylaxis	O
seen	O
in	O
clinical	O
trials	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
More	O
cases	O
of	O
pneumonia	B
in	O
the	O
group	O
receiving	O
TANZEUM	O
were	O
serious	O
(	O
0.4	O
%	O
for	O
TANZEUM	O
versus	O
0.1	O
%	O
for	O
all	O
comparators	O
)	O
.	O
	
A	O
total	O
of	O
108	O
subjects	O
treated	O
with	O
Picato	O
(	O
r	O
)	O
gel	O
on	O
the	O
face/scalp	O
and	O
38	O
subjects	O
treated	O
on	O
the	O
trunk/extremities	O
were	O
followed	O
for	O
12	O
months	O
.	O
	
To	O
decrease	O
thyroid	O
accumulation	O
of	O
iodine	O
123	O
,	O
block	O
the	O
thyroid	O
gland	O
before	O
administration	O
of	O
DaTscan	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Advise	O
pregnant	O
women	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
(	O
5.12	O
)	O
.	O
	
Consider	O
discontinuing	O
use	O
if	O
severe	O
symptoms	O
develop	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17.8	O
)	O
]	O
.	O
	
This	O
proteinuria	B
was	O
not	O
associated	O
with	O
increases	B
in	I
BUN	I
and	O
was	O
generally	O
transient	O
.	O
	
The	O
incidence	O
of	O
Common	O
Terminology	O
Criteria	O
(	O
CTC	O
)	O
Grade	O
3	O
and	O
4	O
non-infectious	B
pneumonitis	I
was	O
up	O
to	O
4.0	O
%	O
and	O
up	O
to	O
0.2	O
%	O
,	O
respectively	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
If	O
diagnosed	O
,	O
withhold	O
TAFINLAR	O
for	O
up	O
to	O
6	O
weeks	O
until	O
uveitis/iritis	O
resolves	O
to	O
Grade	O
0-1	O
.	O
	
Consider	O
these	O
risks	O
when	O
scheduling	O
patients	O
for	O
spinal	O
procedures	O
.	O
	
5.6	O
Ocular	O
Toxicities	O
Retinal	O
Pigment	O
Epithelial	O
Detachment	O
(	O
RPED	O
)	O
:	O
Retinal	B
pigment	I
epithelial	I
detachments	I
(	O
RPED	B
)	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
and	O
with	O
trametinib	O
as	O
a	O
single	O
agent	O
[	O
refer	O
to	O
Full	O
Prescribing	O
Information	O
for	O
trametinib	O
]	O
.	O
	
*	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Table	O
3	O
presents	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
study	O
.	O
	
Across	O
8	O
Phase	O
III	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
MTC	B
was	O
diagnosed	O
in	O
1	O
patient	O
receiving	O
TANZEUM	O
and	O
1	O
patient	O
receiving	O
placebo	O
.	O
	
JC	B
virus	I
infection	I
resulting	O
in	O
PML	B
and	O
death	B
can	O
occur	O
in	O
patients	O
receiving	O
ADCETRIS	O
(	O
5.9	O
,	O
6.2	O
)	O
.	O
	
An	O
increased	O
risk	O
of	O
stroke	B
and	O
DVT	B
has	O
been	O
reported	O
with	O
estrogen-alone	O
therapy	O
.	O
	
5.11	O
Seizures	O
Seizures	B
were	O
reported	O
in	O
0	O
%	O
and	O
0.3	O
%	O
(	O
0/572	O
,	O
1/379	O
)	O
of	O
adult	O
patients	O
treated	O
with	O
doses	O
of	O
5	O
mg	O
and	O
10	O
mg	O
twice	O
daily	O
of	O
SAPHRIS	O
,	O
respectively	O
,	O
compared	O
to	O
0	O
%	O
(	O
0/503	O
,	O
0/203	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
in	O
short-term	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
,	O
respectively	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
received	O
an	O
ESA	O
was	O
43	O
%	O
in	O
those	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
24	O
%	O
in	O
those	O
treated	O
with	O
PegIntron/REBETOL	O
alone	O
.	O
	
Stopping	O
or	O
slowing	O
the	O
infusion	O
may	O
result	O
in	O
cessation	O
of	O
these	O
reactions	O
.	O
	
Monitor	O
HBV	O
carriers	O
during	O
and	O
several	O
months	O
after	O
therapy	O
.	O
	
Evaluate	O
if	O
diarrhea	O
occurs	O
.	O
	
After	O
initiation	O
of	O
TANZEUM	O
,	O
observe	O
patients	O
carefully	O
for	O
signs	O
and	O
symptoms	O
of	O
pancreatitis	O
(	O
including	O
persistent	O
severe	O
abdominal	O
pain	O
,	O
sometimes	O
radiating	O
to	O
the	O
back	O
and	O
which	O
may	O
or	O
may	O
not	O
be	O
accompanied	O
by	O
vomiting	O
)	O
.	O
	
Ear	O
and	O
Labyrinth	O
Disorders	O
:	O
deafness	B
,	O
tinnitus	B
,	O
vertigo	B
.	O
	
Monitoring	O
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
CIMZIA	O
,	O
including	O
the	O
development	O
of	O
tuberculosis	O
in	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
.	O
	
Routine	O
monthly	O
pregnancy	O
tests	O
must	O
be	O
performed	O
during	O
this	O
time	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
Five	O
of	O
the	O
six	O
patients	O
in	O
the	O
group	O
that	O
received	O
PROMACTA	O
experienced	O
a	O
thrombotic	B
complication	I
within	O
30	O
days	O
of	O
completing	O
treatment	O
with	O
PROMACTA	O
and	O
at	O
a	O
platelet	O
count	O
above	O
200	O
x	O
10	O
9	O
/L	O
.	O
	
Consider	O
the	O
diagnosis	O
of	O
pancreatitis	O
for	O
patients	O
presenting	O
with	O
severe	O
abdominal	O
pain	O
.	O
	
As	O
with	O
other	O
PDE5	O
inhibitors	O
STENDRA	O
has	O
systemic	O
vasodilatory	O
properties	O
and	O
may	O
augment	O
the	O
blood	O
pressure-lowering	O
effect	O
of	O
other	O
anti-hypertensive	O
medications	O
.	O
	
(	O
5.4	O
)	O
*	O
Renal	B
Impairment	I
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
reporting	O
severe	O
adverse	O
gastrointestinal	O
reactions	O
.	O
	
5.7	O
Orthostatic	O
Hypotension	O
,	O
Syncope	O
,	O
and	O
Other	O
Hemodynamic	O
Effects	O
SAPHRIS	O
may	O
induce	O
orthostatic	B
hypotension	I
and	O
syncope	B
in	O
some	O
patients	O
,	O
especially	O
early	O
in	O
treatment	O
,	O
because	O
of	O
its	O
alpha1-adrenergic	O
antagonist	O
activity	O
.	O
	
5.1	O
Serious	O
Infections	O
Patients	O
treated	O
with	O
SIMPONI	O
ARIA	O
are	O
at	O
increased	O
risk	O
for	O
developing	O
serious	O
infections	B
involving	O
various	O
organ	O
systems	O
and	O
sites	O
that	O
may	O
lead	O
to	O
hospitalization	O
or	O
death	B
.	O
	
In	O
addition	O
,	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
severe	O
hypersensitivity	O
to	O
milk	O
proteins	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
The	O
data	O
described	O
below	O
primarily	O
derive	O
from	O
two	O
randomized	O
,	O
active-controlled	O
three-year	O
trials	O
of	O
NULOJIX	O
in	O
de	O
novo	O
kidney	O
transplant	O
patients	O
.	O
	
Antiemetic	O
prophylaxis	O
is	O
recommended	O
.	O
	
ALT	B
elevations	I
were	O
reversible	O
in	O
all	O
subjects	O
.	O
	
Higher	O
than	O
recommended	O
dosing	O
or	O
repeated	O
dosing	O
appears	O
to	O
increase	O
the	O
risk	O
(	O
5.1	O
)	O
*	O
Hypersensitivity	O
:	O
hypersensitivity	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
reactions	O
including	O
shock	B
can	O
occur	O
.	O
	
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
CIMZIA	O
,	O
including	O
the	O
possible	O
development	O
of	O
tuberculosis	O
in	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
.	O
	
*	O
Malignancies	B
-	O
More	O
cases	O
of	O
lymphoma	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF-blockers	O
compared	O
with	O
patients	O
in	O
the	O
control	O
groups	O
.	O
	
SAPHRIS	O
should	O
be	O
used	O
with	O
caution	O
in	O
(	O
1	O
)	O
patients	O
with	O
known	O
cardiovascular	O
disease	O
(	O
history	O
of	O
myocardial	O
infarction	O
or	O
ischemic	O
heart	O
disease	O
,	O
heart	O
failure	O
or	O
conduction	O
abnormalities	O
)	O
,	O
cerebrovascular	O
disease	O
,	O
or	O
conditions	O
which	O
would	O
predispose	O
patients	O
to	O
hypotension	O
(	O
dehydration	O
,	O
hypovolemia	O
,	O
and	O
treatment	O
with	O
antihypertensive	O
medications	O
)	O
;	O
and	O
(	O
2	O
)	O
in	O
the	O
elderly	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
No	O
comparator-treated	O
subject	O
with	O
normal	O
baseline	O
transaminases	O
had	O
post-baseline	O
ALT	B
elevation	I
greater	O
than	O
10	O
times	O
ULN	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
has	O
occurred	O
in	O
patients	O
with	O
impaired	O
elimination	O
of	O
GBCAs	O
.	O
	
(	O
6	O
)	O
The	O
most	O
common	O
adverse	O
events	O
occurring	O
in	O
at	O
least	O
20	O
%	O
of	O
patients	O
treated	O
with	O
Kyprolis	O
in	O
the	O
combination	O
therapy	O
trial	O
:	O
decreased	B
lymphocytes	I
,	O
decreased	B
absolute	I
neutrophil	I
count	I
,	O
decreased	B
phosphorus	I
,	O
anemia	B
,	O
neutropenia	B
,	O
decreased	B
total	I
white	I
blood	I
cell	I
count	I
,	O
decreased	B
platelets	I
,	O
diarrhea	B
,	O
fatigue	B
,	O
thrombocytopenia	B
,	O
pyrexia	B
,	O
muscle	B
spasm	I
,	O
cough	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
decreased	B
hemoglobin	I
,	O
hypokalemia	B
.	O
	
Intensive	O
measures	O
may	O
be	O
required	O
for	O
severe	O
diarrhea	O
and	O
electrolyte	O
imbalance	O
.	O
	
SAPHRIS	O
should	O
be	O
used	O
cautiously	O
when	O
treating	O
patients	O
who	O
receive	O
treatment	O
with	O
other	O
drugs	O
that	O
can	O
induce	O
hypotension	O
,	O
bradycardia	O
,	O
respiratory	O
or	O
central	O
nervous	O
system	O
depression	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
6.2	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
a	O
potential	O
for	O
an	O
immune	O
response	O
in	O
patients	O
treated	O
with	O
EYLEA	O
.	O
	
If	O
reactivation	O
occurs	O
,	O
stop	O
SIMPONI	O
ARIA	O
and	O
begin	O
anti-viral	O
therapy	O
(	O
5.1	O
)	O
.	O
	
Given	O
the	O
similar	O
structural	O
formula	O
of	O
atropine	O
to	O
aclidinium	O
,	O
patients	O
with	O
a	O
history	O
of	O
hypersensitivity	O
reactions	O
to	O
atropine	O
should	O
be	O
closely	O
monitored	O
for	O
similar	O
hypersensitivity	O
reactions	O
to	O
TUDORZA	O
PRESSAIR	O
.	O
	
In	O
short-term	O
schizophrenia	O
adult	O
trials	O
,	O
syncope	B
was	O
reported	O
in	O
0.2	O
%	O
(	O
1/572	O
)	O
of	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
(	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
)	O
of	O
SAPHRIS	O
,	O
compared	O
to	O
0.3	O
%	O
(	O
1/378	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
The	O
population	O
exposed	O
to	O
TAFINLAR	O
was	O
60	O
%	O
male	O
,	O
99	O
%	O
white	O
,	O
and	O
had	O
a	O
median	O
age	O
of	O
53	O
years	O
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
Oral	O
contraceptives	O
containing	O
lower	O
doses	O
of	O
norethindrone	O
and	O
other	O
forms	O
of	O
hormonal	O
contraception	O
have	O
not	O
been	O
studied	O
or	O
are	O
contraindicated	O
.	O
	
Tests	O
for	O
latent	O
tuberculosis	O
infection	O
may	O
also	O
be	O
falsely	O
negative	O
while	O
on	O
therapy	O
with	O
CIMZIA	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
TANZEUM	O
.	O
	
Eye	O
Disorders	O
:	O
vision	B
blurred	I
.	O
	
Long-term	O
Safety	O
Trials	O
TUDORZA	O
PRESSAIR	O
was	O
studied	O
in	O
three	O
long	O
term	O
safety	O
trials	O
,	O
two	O
double	O
blind	O
and	O
one	O
open	O
label	O
,	O
ranging	O
from	O
40	O
to	O
52	O
weeks	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
COPD	O
.	O
	
(	O
5.5	O
)	O
*	O
Macrovascular	O
Outcomes	O
:	O
There	O
have	O
been	O
no	O
clinical	O
trials	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TANZEUM	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
SIMPONI	O
ARIA	O
,	O
including	O
the	O
possible	O
development	O
of	O
tuberculosis	O
in	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Inactive	O
Ingredients	O
:	O
calcium	O
phosphate	O
tribasic	O
,	O
hydroxypropyl	O
cellulose	O
,	O
microcrystalline	O
cellulose	O
,	O
powdered	O
cellulose	O
,	O
hypromellose	O
,	O
lactose	O
monohydrate	O
,	O
magnesium	O
stearate	O
,	O
polyethylene	O
glycol	O
,	O
sucrose	O
,	O
ascorbic	O
acid	O
,	O
sucrose	O
palmitic	O
acid	O
ester	O
,	O
hydroxyethylcellulose	O
,	O
titanium	O
dioxide	O
,	O
red	O
iron	O
oxide	O
,	O
yellow	O
iron	O
oxide	O
,	O
black	O
iron	O
oxide	O
,	O
povidone	O
,	O
polydextrose	O
,	O
maltitol	O
,	O
poloxamer	O
188	O
,	O
propylene	O
glycol	O
,	O
isopropyl	O
alcohol	O
.	O
	
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
:	O
noninfectious	B
pulmonary	I
toxicity	I
including	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
and	O
ARDS	B
(	O
some	O
with	O
fatal	B
outcomes	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.10	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Symptoms	O
of	O
PVT	B
included	O
abdominal	B
pain	I
,	O
nausea	B
,	O
vomiting	B
,	O
and	O
diarrhea	B
.	O
	
During	O
adult	O
pre-marketing	O
clinical	O
trials	O
with	O
SAPHRIS	O
,	O
including	O
long-term	O
trials	O
without	O
comparison	O
to	O
placebo	O
,	O
seizures	B
were	O
reported	O
in	O
0.3	O
%	O
(	O
5/1953	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Peripheral	B
neuropathy	I
:	O
Monitor	O
patients	O
for	O
neuropathy	O
and	O
institute	O
dose	O
modifications	O
accordingly	O
(	O
5.1	O
)	O
.	O
	
Consider	O
the	O
potential	O
for	O
an	O
increased	O
risk	O
of	O
thromboembolism	O
when	O
administering	O
PROMACTA	O
to	O
patients	O
with	O
known	O
risk	O
factors	O
for	O
thromboembolism	O
(	O
e.g.	O
,	O
Factor	O
V	O
Leiden	O
,	O
ATIII	O
deficiency	O
,	O
antiphospholipid	O
syndrome	O
,	O
chronic	O
liver	O
disease	O
)	O
.	O
	
Both	O
patients	O
had	O
markedly	O
elevated	O
serum	O
calcitonin	O
levels	O
at	O
baseline	O
.	O
	
If	O
reactivation	O
occurs	O
,	O
stop	O
CIMZIA	O
and	O
begin	O
anti-viral	O
therapy	O
(	O
5.5	O
)	O
*	O
Demyelinating	B
disease	I
,	O
exacerbation	O
or	O
new	O
onset	O
,	O
may	O
occur	O
(	O
5.6	O
)	O
*	O
Cytopenias	B
,	O
pancytopenia	B
-	O
advise	O
patients	O
to	O
seek	O
immediate	O
medical	O
attention	O
if	O
symptoms	O
develop	O
,	O
and	O
consider	O
stopping	O
CIMZIA	O
(	O
5.7	O
)	O
*	O
Lupus-like	B
syndrome	I
-	O
stop	O
CIMZIA	O
if	O
syndrome	O
develops	O
(	O
5.9	O
)	O
5.1	O
Risk	O
of	O
Serious	O
Infections	O
[	O
see	O
Boxed	O
Warning	O
]	O
Patients	O
treated	O
with	O
CIMZIA	O
are	O
at	O
an	O
increased	O
risk	O
for	O
developing	O
serious	O
infections	B
involving	O
various	O
organ	O
systems	O
and	O
sites	O
that	O
may	O
lead	O
to	O
hospitalization	O
or	O
death	B
.	O
	
5.4	O
Hypersensitivity	O
Reactions	O
Across	O
8	O
Phase	O
III	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
a	O
serious	O
hypersensitivity	B
reaction	I
with	O
pruritus	B
,	O
rash	B
,	O
and	O
dyspnea	B
occurred	O
in	O
a	O
patient	O
treated	O
with	O
TANZEUM	O
.	O
	
5.3	O
Hepatic	O
Effects	O
In	O
Phase	O
2	O
and	O
3	O
clinical	O
trials	O
,	O
more	O
DALVANCE-	O
than	O
comparator-treated	O
subjects	O
with	O
normal	O
baseline	O
transaminase	O
levels	O
had	O
post-baseline	O
ALT	B
)	I
elevation	I
greater	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O
	
Transplant	O
recipients	O
who	O
are	O
EBV	O
seronegative	O
,	O
or	O
with	O
unknown	O
serostatus	O
,	O
should	O
not	O
receive	O
NULOJIX	O
[	O
see	O
Boxed	O
Warning	O
and	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Factors	O
that	O
can	O
increase	O
the	O
risk	O
of	O
developing	O
spinal	B
hematomas	I
in	O
these	O
patients	O
include	O
:	O
*	O
?	O
use	O
of	O
indwelling	O
epidural	O
catheters	O
*	O
?	O
concomitant	O
use	O
of	O
other	O
drugs	O
that	O
affect	O
hemostasis	O
,	O
such	O
as	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
platelet	O
inhibitors	O
,	O
other	O
anticoagulants	O
*	O
?	O
a	O
history	O
of	O
traumatic	O
or	O
repeated	O
epidural	O
or	O
spinal	O
punctures	O
*	O
?	O
a	O
history	O
of	O
spinal	O
deformity	O
or	O
spinal	O
surgery	O
*	O
?	O
optimal	O
timing	O
between	O
the	O
administration	O
of	O
ELIQUIS	O
and	O
neuraxial	O
procedures	O
is	O
not	O
known	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
Monitor	O
patients	O
frequently	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
impairment	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Thyroid	B
C-cell	I
Tumors	I
:	O
See	O
Boxed	O
Warning	O
.	O
	
This	O
is	O
supplemented	O
with	O
information	O
on	O
adverse	O
drug	O
reactions	O
in	O
1326	O
patients	O
with	O
ALK-positive	O
metastatic	O
NSCLC	O
who	O
received	O
XALKORI	O
250	O
mg	O
twice	O
daily	O
across	O
clinical	O
trials	O
,	O
for	O
a	O
total	O
of	O
1669	O
patients	O
across	O
all	O
clinical	O
studies	O
.	O
	
*	O
Embryo-fetal	B
toxicity	I
:	O
Fetal	B
harm	I
can	O
occur	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
are	O
upper	B
respiratory	I
tract	I
infection	I
,	O
bronchitis	B
,	O
cough	B
,	O
flatulence	B
and	O
increased	B
bilirubin	I
.	O
	
Avoid	O
the	O
use	O
of	O
Potassium	O
Iodide	O
Oral	O
Solution	O
or	O
Lugol	O
's	O
Solution	O
in	O
patients	O
who	O
are	O
sensitive	O
to	O
such	O
products	O
.	O
	
5.2	O
Management	O
of	O
Immunosuppression	O
Only	O
physicians	O
experienced	O
in	O
management	O
of	O
systemic	O
immunosuppressant	O
therapy	O
in	O
transplantation	O
should	O
prescribe	O
NULOJIX	O
.	O
	
(	O
2.4	O
,	O
5.1	O
,	O
14.1	O
)	O
(	O
B	O
)	O
SPINAL/EPIDURAL	O
HEMATOMA	O
:	O
spinal	B
hematomas	I
may	O
occur	O
in	O
patients	O
treated	O
with	O
ELIQUIS	O
who	O
are	O
receiving	O
neuraxial	O
anesthesia	O
or	O
undergoing	O
spinal	O
puncture	O
.	O
	
Monitor	O
patients	O
for	O
visual	O
signs	O
and	O
symptoms	O
of	O
uveitis	O
(	O
e.g.	O
,	O
change	O
in	O
vision	O
,	O
photophobia	O
,	O
eye	O
pain	O
)	O
.	O
	
Non-infectious	B
pneumonitis	I
was	O
reported	O
in	O
up	O
to	O
19	O
%	O
of	O
patients	O
treated	O
with	O
AFINITOR	O
in	O
clinical	O
trials	O
.	O
	
Table	O
4	O
:	O
Incidence	O
(	O
%	O
)	O
of	O
Patients	O
With	O
Lipid	B
Abnormalities	I
of	O
Potential	O
Clinical	O
Significance*	O
PRISTIQ	O
Placebo	O
50	O
mg	O
100	O
mg	O
200	O
mg	O
400	O
mg	O
Total	B
Cholesterol*	I
(	I
Increase	I
of	I
>	I
=	I
50	I
mg/dl	I
and	I
an	I
absolute	I
value	I
of	I
>	I
=	I
261	I
mg/dl	I
)	O
2	O
3	O
4	O
4	O
10	O
LDL	B
Cholesterol*	I
(	I
Increase	I
>	I
=	I
50	I
mg/dl	I
and	I
an	I
absolute	I
value	I
of	I
>	I
=	I
190	I
mg/dl	I
)	O
0	O
1	O
0	O
1	O
2	O
Triglycerides	B
,	I
fasting*	I
(	I
Fasting	I
:	I
>	I
=	I
327	I
mg/dl	I
)	O
3	O
2	O
1	O
4	O
6	O
Proteinuria	O
Proteinuria	B
,	O
greater	O
than	O
or	O
equal	O
to	O
trace	O
,	O
was	O
observed	O
in	O
the	O
pre-marketing	O
fixed-dose	O
controlled	O
studies	O
(	O
see	O
Table	O
5	O
)	O
.	O
	
5.9	O
Suppression	O
of	O
Bone	O
Turnover	O
In	O
clinical	O
trials	O
in	O
women	O
with	O
postmenopausal	O
osteoporosis	O
,	O
treatment	O
with	O
Prolia	O
resulted	O
in	O
significant	O
suppression	B
of	I
bone	I
remodeling	I
as	O
evidenced	O
by	O
markers	O
of	O
bone	O
turnover	O
and	O
bone	O
histomorphometry	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
and	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
Major	O
2	O
(	O
0.2	O
)	O
1	O
(	O
0.1	O
)	O
4	O
(	O
0.5	O
)	O
CRNM*	O
25	O
(	O
3.0	O
)	O
34	O
(	O
4.2	O
)	O
19	O
(	O
2.3	O
)	O
Major	O
+	O
CRNM	B
27	O
(	O
3.2	O
)	O
35	O
(	O
4.3	O
)	O
22	O
(	O
2.7	O
)	O
Minor	O
75	O
(	O
8.9	O
)	O
98	O
(	O
12.1	O
)	O
58	O
(	O
7.0	O
)	O
All	O
94	O
(	O
11.2	O
)	O
121	O
(	O
14.9	O
)	O
74	O
(	O
9.0	O
)	O
Adverse	O
reactions	O
occurring	O
in	O
>	O
=1	O
%	O
of	O
patients	O
in	O
the	O
AMPLIFY-EXT	O
study	O
are	O
listed	O
in	O
Table	O
8	O
.	O
	
Other	O
adverse	O
reactions	O
indicative	O
of	O
hypersensitivity	B
reactions	O
included	O
the	O
following	O
:	O
pruritus	B
(	O
5	O
%	O
)	O
,	O
rash	B
(	O
3	O
%	O
)	O
,	O
and	O
urticaria	B
(	O
2	O
%	O
)	O
.	O
	
AFINITOR	O
may	O
be	O
re-introduced	O
at	O
a	O
daily	O
dose	O
approximately	O
50	O
%	O
lower	O
than	O
the	O
dose	O
previously	O
administered	O
depending	O
on	O
the	O
individual	O
clinical	O
circumstances	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
5.7	O
Laboratory	O
Tests	O
HCV-RNA	O
levels	O
should	O
be	O
monitored	O
at	O
Treatment	O
Weeks	O
4	O
,	O
8	O
,	O
12	O
,	O
and	O
24	O
,	O
at	O
the	O
end	O
of	O
treatment	O
,	O
during	O
treatment	O
follow-up	O
,	O
and	O
for	O
other	O
time	O
points	O
as	O
clinically	O
indicated	O
.	O
	
Monitoring	O
of	O
complete	O
blood	O
counts	O
is	O
essential	O
on	O
a	O
weekly	O
basis	O
during	O
cycle	O
1	O
and	O
before	O
each	O
treatment	O
cycle	O
thereafter	O
so	O
that	O
the	O
dose	O
can	O
be	O
adjusted	O
,	O
if	O
needed	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Pneumonia	O
In	O
the	O
pool	O
of	O
7	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
the	O
adverse	O
reaction	O
of	O
pneumonia	B
was	O
reported	O
more	O
frequently	O
in	O
patients	O
receiving	O
TANZEUM	O
(	O
1.8	O
%	O
)	O
than	O
in	O
patients	O
in	O
the	O
all-comparators	O
group	O
(	O
0.8	O
%	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Biogen	O
at	O
1-800-456-2255	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
None	O
of	O
these	O
antibodies	O
were	O
shown	O
to	O
neutralize	O
the	O
activity	O
of	O
albiglutide	O
in	O
an	O
in	O
vitro	O
bioassay	O
.	O
	
VORAXAZE	O
was	O
given	O
at	O
a	O
dose	O
of	O
50	O
Units/kg	O
as	O
an	O
intravenous	O
injection	O
over	O
5	O
minutes	O
.	O
	
The	O
reactions	O
have	O
generally	O
consisted	O
of	O
skin	B
erythema	I
and	O
pruritis	B
and	O
have	O
either	O
resolved	O
spontaneously	O
or	O
following	O
the	O
administration	O
of	O
corticosteroids	O
and	O
anti-histamines	O
.	O
	
5.2	O
Eye	O
Irritation	O
Avoid	O
eye	O
exposure	O
.	O
	
In	O
the	O
event	O
of	O
a	O
severe	O
reaction	O
,	O
discontinue	O
DIFICID	O
.	O
	
Identify	O
cause	O
and	O
manage	O
aggressively	O
.	O
	
Permanently	O
discontinue	O
TAFINLAR	O
and	O
trametinib	O
for	O
life-threatening	O
PE	O
.	O
	
Patients	O
who	O
develop	O
radiological	O
changes	O
suggestive	O
of	O
non-infectious	O
pneumonitis	O
and	O
have	O
few	O
or	O
no	O
symptoms	O
may	O
continue	O
AFINITOR	O
therapy	O
without	O
dose	O
alteration	O
.	O
	
The	O
youngest	O
alglucosidase	O
alfa-treated	O
patient	O
was	O
16	O
years	O
of	O
age	O
,	O
and	O
the	O
youngest	O
placebo-treated	O
patient	O
was	O
10	O
years	O
of	O
age	O
.	O
	
In	O
the	O
combination	O
study	O
,	O
the	O
incidence	O
of	O
venous	B
thromboembolic	I
events	I
in	O
the	O
first	O
12	O
cycles	O
was	O
13	O
%	O
in	O
the	O
Kyprolis	O
combination	O
arm	O
versus	O
6	O
%	O
in	O
the	O
control	O
arm	O
.	O
	
(	O
5.6	O
)	O
*	O
Orthostatic	B
hypotension	I
:	O
Dizziness	B
,	O
tachycardia	B
,	O
and	O
syncope	B
can	O
occur	O
with	O
standing	O
.	O
	
(	O
5.3	O
)	O
*	O
Suicidal	B
thoughts	I
:	O
HORIZANT	O
is	O
a	O
prodrug	O
of	O
gabapentin	O
,	O
an	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=5	O
%	O
of	O
GD1	O
Patients	O
Switching	O
from	O
Enzyme	O
Replacement	O
Therapy	O
to	O
CERDELGA	O
and	O
More	O
Frequently	O
than	O
Imiglucerase	O
(	O
Trial	O
2	O
)	O
Trial	O
2	O
was	O
not	O
designed	O
to	O
support	O
comparative	O
claims	O
for	O
CERDELGA	O
for	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
table	O
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
discontinued	O
treatment	O
due	O
to	O
any	O
adverse	O
reaction	O
during	O
the	O
controlled	O
clinical	O
trials	O
was	O
6.2	O
%	O
for	O
patients	O
receiving	O
BENLYSTA	O
and	O
7.1	O
%	O
for	O
patients	O
receiving	O
placebo	O
.	O
	
If	O
keratitis	O
is	O
diagnosed	O
,	O
the	O
benefits	O
and	O
risks	O
of	O
continuing	O
treatment	O
should	O
be	O
carefully	O
considered	O
.	O
	
*	O
Hyperpyrexia	B
and	O
confusion	B
(	O
5.2	O
)	O
*	O
May	O
exacerbate	B
symptoms	I
in	I
patients	I
with	I
existing	I
ischemic	I
heart	I
disease	I
(	O
5.3	O
)	O
*	O
Allergic	B
reactions	I
(	O
5.4	O
)	O
5.1	O
Supine	O
Hypertension	O
NORTHERA	O
therapy	O
may	O
cause	O
or	O
exacerbate	O
supine	B
hypertension	I
in	O
patients	O
with	O
NOH	O
.	O
	
5	O
(	O
tartrazine	O
)	O
sensitivity	O
in	O
the	O
general	O
population	O
is	O
low	O
,	O
it	O
is	O
frequently	O
seen	O
in	O
patients	O
who	O
also	O
have	O
aspirin	O
hypersensitivity	O
.	O
	
Postherpetic	O
Neuralgia	O
:	O
The	O
exposure	O
to	O
HORIZANT	O
in	O
417	O
patients	O
with	O
PHN	O
included	O
207	O
patients	O
exposed	O
for	O
at	O
least	O
3	O
months	O
.	O
	
5.12	O
Thrombotic	O
Thrombocytopenic	O
Purpura/Hemolytic	O
Uremic	O
Syndrome	O
Cases	O
of	O
thrombotic	B
thrombocytopenic	I
purpura/hemolytic	O
uremic	B
syndrome	I
(	O
TTP/HUS	O
)	O
including	O
fatal	B
outcome	O
have	O
been	O
reported	O
in	O
patients	O
who	O
received	O
Kyprolis	O
.	O
	
Patients	O
who	O
have	O
experienced	O
anaphylaxis	O
or	O
hypersensitivity	O
reactions	O
should	O
be	O
treated	O
with	O
caution	O
when	O
they	O
are	O
re-administered	O
alglucosidase	O
alfa	O
.	O
	
Of	O
the	O
2,254	O
subjects	O
,	O
70	O
%	O
were	O
male	O
and	O
84	O
%	O
were	O
white	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Patients	O
received	O
INVOKANA	O
100	O
mg	O
(	O
N=833	O
)	O
,	O
INVOKANA	O
300	O
mg	O
(	O
N=834	O
)	O
or	O
placebo	O
(	O
N=646	O
)	O
once	O
daily	O
.	O
	
Therefore	O
,	O
co-administration	O
of	O
KALYDECO	O
with	O
strong	O
CYP3A	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
St.	O
John	O
's	O
wort	O
)	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
GBCAs	O
have	O
been	O
associated	O
with	O
a	O
risk	O
for	O
NSF	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
While	O
receiving	O
study	O
drug	O
through	O
Week	O
144	O
,	O
an	O
additional	O
11	O
%	O
of	O
STRIBILD	O
subjects	O
were	O
started	O
on	O
lipid	O
lowering	O
agents	O
,	O
compared	O
to	O
13	O
%	O
of	O
ATRIPLA	O
and	O
12	O
%	O
of	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
subjects	O
.	O
	
Macular	B
edema	I
has	O
also	O
been	O
reported	O
in	O
patients	O
taking	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
postmarketing	O
setting	O
,	O
usually	O
within	O
the	O
first	O
6	O
months	O
of	O
treatment	O
.	O
	
To	O
prevent	O
ectropion	O
,	O
botulinum	O
toxin	O
products	O
should	O
not	O
be	O
injected	O
into	O
the	O
medial	O
lower	O
eyelid	O
area	O
.	O
	
During	O
the	O
clinical	O
trials	O
,	O
0.3	O
%	O
(	O
4/1441	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
discontinued	O
treatment	O
due	O
to	O
depression	B
or	O
depressed	B
mood	I
compared	O
with	O
none	O
in	O
placebo	O
treated	O
subjects	O
(	O
0/495	O
)	O
.	O
	
Key	O
observed	O
laboratory	O
abnormalities	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
5.8	O
Human	O
Albumin	O
and	O
Transmission	O
of	O
Viral	O
Diseases	O
This	O
product	O
contains	O
albumin	O
,	O
a	O
derivative	O
of	O
human	O
blood	O
.	O
	
The	O
patients	O
were	O
also	O
not	O
taking	O
any	O
immunosuppressive	O
or	O
immunomodulatory	O
medications	O
concomitantly	O
.	O
	
ENTEREG	O
is	O
contraindicated	O
in	O
patients	O
who	O
have	O
taken	O
therapeutic	O
doses	O
of	O
opioids	O
for	O
more	O
than	O
7	O
consecutive	O
days	O
immediately	O
prior	O
to	O
taking	O
ENTEREG	O
.	O
	
The	O
effect	O
of	O
FANAPT	O
on	O
the	O
QT	O
interval	O
was	O
augmented	O
by	O
the	O
presence	O
of	O
CYP450	O
2D6	O
or	O
3A4	O
metabolic	O
inhibition	O
(	O
paroxetine	O
20	O
mg	O
once	O
daily	O
and	O
ketoconazole	O
200	O
mg	O
twice	O
daily	O
,	O
respectively	O
)	O
.	O
	
(	O
5.12	O
)	O
*	O
Posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
:	O
Consider	O
neuro-radiological	O
imaging	O
(	O
MRI	O
)	O
for	O
onset	O
of	O
visual	O
or	O
neurological	O
symptoms	O
;	O
discontinue	O
Kyprolis	O
if	O
suspected	O
.	O
	
5.7	O
Bone	O
Fracture	O
An	O
increased	O
risk	O
of	O
bone	B
fracture	I
,	O
occurring	O
as	O
early	O
as	O
12	O
weeks	O
after	O
treatment	O
initiation	O
,	O
was	O
observed	O
in	O
patients	O
using	O
INVOKANA	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Forest	O
Laboratories	O
,	O
LLC	O
.	O
	
(	O
5.5	O
)	O
*	O
Gastrointestinal	B
perforation	I
,	O
including	O
death	B
,	O
have	O
occurred	O
.	O
	
Perform	O
appropriate	O
monitoring	O
and	O
treat	O
hyperglycemia	O
with	O
insulin	O
,	O
as	O
necessary	O
(	O
5.3	O
)	O
*	O
Thrombosis	B
,	O
hemorrhage	B
:	O
discontinue	O
ERWINAZE	O
until	O
resolved	O
(	O
5.4	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Grade	O
3	O
and	O
4	O
hypersensitivity	B
reactions	I
after	O
the	O
use	O
of	O
ERWINAZE	O
have	O
occurred	O
in	O
5	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
Study	O
1	O
and	O
Study	O
2	O
,	O
safety	O
information	O
was	O
prospectively	O
and	O
systematically	O
collected	O
.	O
	
The	O
risk	O
of	O
the	O
symptoms	O
is	O
probably	O
greatest	O
in	O
children	O
treated	O
for	O
spasticity	O
but	O
symptoms	O
can	O
also	O
occur	O
in	O
adults	O
treated	O
for	O
spasticity	O
and	O
other	O
conditions	O
,	O
and	O
particularly	O
in	O
those	O
patients	O
who	O
have	O
underlying	O
conditions	O
that	O
would	O
predispose	O
them	O
to	O
these	O
symptoms	O
.	O
	
Withhold	O
Kyprolis	O
and	O
evaluate	O
promptly	O
.	O
	
Melanoma	B
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF-blocking	O
agents	O
,	O
including	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
.	O
	
Sometimes	O
both	O
ovaries	O
are	O
removed	O
during	O
an	O
operation	O
before	O
natural	O
menopause	O
takes	O
place	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
For	O
All	O
Indications	O
:	O
*	O
The	O
potency	O
Units	O
of	O
XEOMIN	O
are	O
not	O
interchangeable	O
with	O
other	O
preparations	O
of	O
botulinum	O
toxin	O
products	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
e.g	O
.	O
	
Seizure	B
occurred	O
from	O
31	O
to	O
603	O
days	O
after	O
initiation	O
of	O
XTANDI	O
.	O
	
Table	O
10	O
compares	O
the	O
incidence	O
of	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
occurring	O
more	O
frequently	O
with	O
AFINITOR	O
than	O
with	O
placebo	O
.	O
	
*	O
Limiting	O
the	O
dose	O
injected	O
into	O
the	O
sternocleidomastoid	O
muscle	O
may	O
decrease	O
the	O
occurrence	O
of	O
dysphagia	O
.	O
	
Two	O
subjects	O
(	O
0.13	O
%	O
)	O
tested	O
positive	O
for	O
binding	O
antibodies	O
at	O
baseline	O
.	O
	
Discontinuation	O
of	O
SIMPONI	O
ARIA	O
should	O
be	O
considered	O
if	O
these	O
disorders	O
develop	O
.	O
	
Patients	O
in	O
the	O
chemotherapy	O
arm	O
received	O
pemetrexed	O
unless	O
they	O
had	O
received	O
pemetrexed	O
as	O
part	O
of	O
first-line	O
or	O
maintenance	O
treatment	O
.	O
	
Hypersensitivity	B
reactions	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Increases	O
in	O
Serum	O
Phosphate	O
Dose-related	O
increases	B
in	I
serum	I
phosphate	I
levels	O
were	O
observed	O
with	O
INVOKANA	O
.	O
	
5.2	O
Aerosolization	O
of	O
Capsaicin	O
Aerosolization	O
of	O
capsaicin	O
can	O
occur	O
upon	O
rapid	O
removal	O
of	O
Qutenza	O
patches	O
.	O
	
The	O
adult	O
information	O
below	O
is	O
derived	O
from	O
a	O
clinical	O
trial	O
database	O
for	O
SAPHRIS	O
consisting	O
of	O
over	O
4565	O
patients	O
and/or	O
healthy	O
subjects	O
exposed	O
to	O
one	O
or	O
more	O
sublingual	O
doses	O
of	O
SAPHRIS	O
.	O
	
In	O
addition	O
,	O
a	O
two-week	O
dose-ranging	O
trial	O
was	O
conducted	O
in	O
511	O
adult	O
patients	O
with	O
mild	O
persistent	O
asthma	O
taking	O
inhaled	O
corticosteroids	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Merck	O
Sharp	O
&	O
Dohme	O
Corp.	O
,	O
a	O
subsidiary	O
of	O
Merck	O
&	O
Co.	O
,	O
Inc.	O
,	O
at	O
1-877-888-4231	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Withhold	O
,	O
dose	O
reduce	O
,	O
or	O
discontinue	O
BOSULIF	O
.	O
	
Monitor	O
blood	O
pressure	O
periodically	O
during	O
the	O
treatment	O
and	O
provide	O
adequate	O
support	O
for	O
treatment	O
related	O
pain	O
.	O
	
Dose-related	O
increases	B
in	I
non-HDL-C	I
with	O
INVOKANA	O
were	O
observed	O
.	O
	
(	O
6.2	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Serious	O
Adverse	O
Reactions	O
The	O
following	O
serious	O
and	O
otherwise	O
important	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
labeling	O
:	O
*	O
Hypersensitivity	B
Reactions	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.3	O
)	O
]	O
.	O
	
All	O
but	O
one	O
subject	O
who	O
died	B
of	O
TB	O
had	O
not	O
converted	O
or	O
had	O
relapsed	O
.	O
	
5.6	O
Other	O
Malignancies	O
There	O
are	O
reports	O
of	O
malignant	B
diseases	I
that	O
have	O
developed	O
in	O
patients	O
who	O
have	O
been	O
treated	O
with	O
TREANDA	O
,	O
including	O
myelodysplastic	B
syndrome	I
,	O
myeloproliferative	B
disorders	I
,	O
acute	B
myeloid	I
leukemia	I
and	O
bronchial	B
carcinoma	I
.	O
	
Serious	O
Adverse	O
Reactions	O
and	O
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
Serious	O
adverse	O
reactions	O
occurred	O
in	O
109/1778	O
(	O
6.1	O
%	O
)	O
of	O
patients	O
treated	O
with	O
DALVANCE	O
and	O
in	O
80/1224	O
(	O
6.5	O
%	O
)	O
of	O
patients	O
treated	O
with	O
comparator	O
.	O
	
Prior	O
to	O
the	O
initiation	O
of	O
the	O
next	O
cycle	O
of	O
therapy	O
,	O
the	O
ANC	O
should	O
be	O
>	O
=	O
1	O
x	O
10	O
9	O
/L	O
and	O
the	O
platelet	O
count	O
should	O
be	O
>	O
=	O
75	O
x	O
10	O
9	O
/L	O
.	O
	
Of	O
these	O
,	O
two	O
studies	O
were	O
randomized	O
,	O
double-blind	O
,	O
single	O
treatment	O
,	O
placebo	O
controlled	O
studies	O
with	O
subsequent	O
optional	O
open	O
label	O
treatment	O
in	O
which	O
dose	O
optimization	O
(	O
250	O
to	O
1000	O
Units	O
per	O
treatment	O
)	O
over	O
the	O
course	O
of	O
5	O
treatment	O
cycles	O
was	O
allowed	O
.	O
	
Laboratory	O
Tests	O
No	O
clinically	O
meaningful	O
changes	O
in	O
hematology	O
,	O
serum	O
chemistry	O
or	O
urinalysis	O
were	O
observed	O
in	O
patients	O
treated	O
with	O
NESINA	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Mantle	O
Cell	O
Lymphoma	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
IMBRUVICA	O
in	O
a	O
clinical	O
trial	O
that	O
included	O
111	O
patients	O
with	O
previously	O
treated	O
MCL	O
treated	O
with	O
560	O
mg	O
daily	O
with	O
a	O
median	O
treatment	O
duration	O
of	O
8.3	O
months	O
.	O
	
Anaphylaxis	B
,	O
presenting	O
as	O
cough	B
,	O
erythema	B
,	O
throat	B
tightness	I
,	O
urticaria	B
,	O
flushing	B
,	O
cyanosis	B
,	O
hypotension	B
,	O
rash	B
,	O
dyspnea	B
,	O
chest	B
discomfort	I
,	O
and	O
gastrointestinal	B
symptoms	I
(	O
e.g.	O
,	O
nausea	B
,	O
abdominal	B
pain	I
,	O
retching	B
,	O
and	O
vomiting	B
)	O
in	O
conjunction	O
with	O
urticaria	B
,	O
have	O
been	O
reported	O
to	O
occur	O
during	O
Vimizim	O
infusions	O
,	O
regardless	O
of	O
duration	O
of	O
the	O
course	O
of	O
treatment	O
.	O
	
Dizziness	B
,	O
nausea	B
,	O
somnolence	B
,	O
and	O
fatigue	B
were	O
all	O
reported	O
at	O
lower	O
incidences	O
during	O
the	O
AED	O
Withdrawal	O
Phase	O
and	O
Monotherapy	O
Phase	O
compared	O
with	O
the	O
Titration	O
Phase	O
.	O
	
The	O
data	O
described	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
and	O
below	O
reflect	O
exposure	O
to	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
onset	O
tends	O
to	O
be	O
within	O
the	O
first	O
treatment	O
cycle	O
of	O
TREANDA	O
and	O
,	O
without	O
intervention	O
,	O
may	O
lead	O
to	O
acute	B
renal	I
failure	I
and	O
death	B
.	O
	
Adverse	O
Reactions	O
in	O
Placebo-Controlled	O
and	O
Uncontrolled	O
Studies	O
In	O
placebo-controlled	O
and	O
uncontrolled	O
clinical	O
studies	O
,	O
a	O
total	O
of	O
2513	O
patients	O
have	O
received	O
TECFIDERA	O
and	O
been	O
followed	O
for	O
periods	O
up	O
to	O
4	O
years	O
with	O
an	O
overall	O
exposure	O
of	O
4603	O
person-years	O
.	O
	
After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
to	O
endpoint	O
in	O
weight	O
z-score	O
for	O
SAPHRS	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
was	O
0.11	O
,	O
0.08	O
and	O
0.09	O
SD	O
versus	O
0.02	O
SD	O
for	O
placebo	O
,	O
respectively	O
.	O
	
The	O
patient	O
had	O
no	O
other	O
identified	O
systemic	O
medical	O
conditions	O
resulting	O
in	O
compromised	O
immune	O
system	O
function	O
and	O
had	O
not	O
previously	O
been	O
treated	O
with	O
natalizumab	O
,	O
which	O
has	O
a	O
known	O
association	O
with	O
PML	O
.	O
	
Volume	O
Depletion	O
FARXIGA	O
causes	O
an	O
osmotic	B
diuresis	I
,	O
which	O
may	O
lead	O
to	O
reductions	B
in	I
intravascular	I
volume	I
.	O
	
Clinical	O
monitoring	O
of	O
weight	O
is	O
recommended	O
.	O
	
Because	O
of	O
the	O
increased	O
risk	O
of	O
urinary	O
retention	O
on	O
POTIGA	O
,	O
urologic	O
symptoms	O
should	O
be	O
carefully	O
monitored	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
serious	O
adverse	O
reactions	O
were	O
:	O
*	O
Serious	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Malignancies	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=3	O
%	O
)	O
are	O
:	O
upper	B
respiratory	I
tract	I
infection	I
,	O
viral	B
infection	I
,	O
bronchitis	B
,	O
hypertension	B
,	O
and	O
rash	B
(	O
6.1	O
)	O
.	O
	
Infusion-related	B
reactions	I
within	O
one	O
hour	O
of	O
infusion	O
were	O
reported	O
in	O
5	O
%	O
of	O
patients	O
treated	O
with	O
the	O
recommended	O
dose	O
of	O
NULOJIX	O
,	O
similar	O
to	O
the	O
placebo	O
rate	O
.	O
	
Life-threatening	O
or	O
fatal	B
CRS	B
was	O
infrequently	O
reported	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
5.1	O
IOP	O
Increase	O
Prolonged	O
use	O
of	O
corticosteroids	O
may	O
result	O
in	O
glaucoma	B
with	O
damage	B
to	I
the	I
optic	I
nerve	I
,	O
defects	B
in	I
visual	I
acuity	I
.	O
	
Fungal	O
culture	O
should	O
be	O
taken	O
when	O
appropriate	O
.	O
	
Fungal	B
infections	I
were	O
reported	O
in	O
18	O
%	O
of	O
patients	O
receiving	O
NULOJIX	O
compared	O
to	O
22	O
%	O
receiving	O
cyclosporine	O
,	O
primarily	O
due	O
to	O
mucocutaneous	B
fungal	I
infections	I
.	O
	
The	O
best	O
method	O
of	O
detection	O
of	O
these	O
abnormalities	O
and	O
the	O
optimal	O
frequency	O
of	O
periodic	O
ophthalmologic	O
monitoring	O
are	O
unknown	O
.	O
	
5.7	O
Orthostatic	O
Hypotension	O
and	O
Syncope	O
FANAPT	O
can	O
induce	O
orthostatic	B
hypotension	I
associated	O
with	O
dizziness	B
,	O
tachycardia	B
,	O
and	O
syncope	B
.	O
	
Elderly	O
patients	O
and	O
patients	O
with	O
impaired	O
renal	O
function	O
were	O
more	O
susceptible	O
to	O
these	O
adverse	O
reactions	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
The	O
majority	O
of	O
patients	O
in	O
the	O
active	O
group	O
were	O
between	O
the	O
ages	O
of	O
18	O
and	O
64	O
.	O
	
*	O
Renal	B
Impairment	I
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
reporting	O
severe	O
adverse	O
gastrointestinal	O
reactions	O
(	O
5.5	O
)	O
.	O
	
Bleeding	B
events	O
related	O
to	O
SSRIs	O
and	O
SNRIs	O
have	O
ranged	O
from	O
ecchymosis	B
,	O
hematoma	B
,	O
epistaxis	B
,	O
and	O
petechiae	B
to	O
life-threatening	O
hemorrhages	B
.	O
	
Monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
TLS	O
.	O
	
c	O
Underlying	O
etiology	O
not	O
established	O
.	O
	
Adverse	O
reactions	O
led	O
to	O
study	O
treatment	O
discontinuation	O
in	O
16	O
%	O
of	O
patients	O
receiving	O
COMETRIQ	O
and	O
in	O
8	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Cases	O
of	O
elevated	B
blood	I
pressure	I
requiring	O
immediate	O
treatment	O
have	O
been	O
reported	O
with	O
PRISTIQ	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
XenoPort	O
at	O
1-877-XENOPRT	O
(	O
1-877-936-6778	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Table	O
displays	O
adverse	O
reactions	O
that	O
were	O
reported	O
in	O
greater	O
than	O
5	O
%	O
of	O
patients	O
in	O
the	O
NORTHERA	O
group	O
and	O
with	O
at	O
least	O
a	O
3	O
%	O
greater	O
incidence	O
in	O
the	O
NORTHERA	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O
	
5.8	O
Hypercorticism	O
and	O
Adrenal	O
Suppression	O
Inhaled	O
fluticasone	O
furoate	O
is	O
absorbed	O
into	O
the	O
circulation	O
and	O
can	O
be	O
systemically	O
active	O
.	O
	
Table	O
2	O
Adjudicated	O
Major	O
Bleeding	B
Events	O
in	O
Treated	O
Patientsa	O
aPatients	O
during	O
treatment	O
or	O
within	O
2	O
days	O
of	O
stopping	O
study	O
treatment	O
.	O
	
A	O
total	O
of	O
2.2	O
%	O
of	O
HIV-1-infected	O
subjects	O
receiving	O
INTELENCE	O
(	O
r	O
)	O
discontinued	O
from	O
Phase	O
3	O
trials	O
due	O
to	O
rash	B
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Recipients	O
without	O
immunity	O
to	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
are	O
at	O
a	O
particularly	O
increased	O
risk	O
;	O
therefore	O
,	O
use	O
in	O
EBV	O
seropositive	O
patients	O
only	O
.	O
	
Congenital	O
,	O
familial	O
and	O
genetic	O
disorders	O
:	O
hypospadias	B
.	O
	
Patients	O
who	O
have	O
experienced	O
a	O
prior	O
infusion-related	O
reaction	O
should	O
be	O
premedicated	O
for	O
subsequent	O
infusions	O
.	O
	
However	O
,	O
by	O
the	O
end	O
of	O
the	O
third	O
year	O
,	O
the	O
cumulative	O
incidence	O
of	O
NODAT	B
was	O
8	O
%	O
(	O
24/304	O
)	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
and	O
10	O
%	O
(	O
29/280	O
)	O
in	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
regimen	O
.	O
	
5.9	O
Preparation	O
and	O
Administration	O
Errors	O
Preparation	O
and	O
administration	O
errors	O
have	O
occurred	O
with	O
BLINCYTO	O
treatment	O
.	O
	
Cytopenias	O
:	O
Grade	O
3	O
neutropenia	B
occurred	O
in	O
28	O
%	O
(	O
143/503	O
)	O
of	O
patients	O
who	O
received	O
HALAVEN	O
in	O
Study	O
1	O
,	O
and	O
29	O
%	O
(	O
144/503	O
)	O
of	O
patients	O
experienced	O
Grade	O
4	O
neutropenia	B
.	O
	
5.7	O
Increased	O
Toxicity	O
in	O
the	O
Presence	O
of	O
Moderate	O
or	O
Severe	O
Hepatic	O
Impairment	O
The	O
frequency	O
of	O
>	O
=Grade	O
3	O
adverse	O
reactions	O
and	O
deaths	B
was	O
greater	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
hepatic	O
impairment	O
compared	O
to	O
patients	O
with	O
normal	O
hepatic	O
function	O
.	O
	
There	O
were	O
no	O
treatment	O
discontinuations	O
and	O
one	O
death	B
due	O
to	O
cardiac	B
failure	I
in	O
the	O
placebo	O
group	O
.	O
	
Withhold	O
if	O
not	O
responsive	O
to	O
anti-emetics	O
or	O
anti-diarrheals	O
,	O
then	O
dose	O
reduce	O
ZYKADIA	O
.	O
	
Because	O
most	O
trials	O
included	O
in	O
the	O
analysis	O
did	O
not	O
extend	O
beyond	O
24	O
weeks	O
,	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
beyond	O
24	O
weeks	O
could	O
not	O
be	O
assessed	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Patients	O
requiring	O
oral	O
corticosteroids	O
should	O
be	O
weaned	O
slowly	O
from	O
systemic	O
corticosteroid	O
use	O
after	O
transferring	O
to	O
BREO	O
ELLIPTA	O
.	O
	
Discontinuations	O
resulting	O
from	O
these	O
reactions	O
were	O
more	O
common	O
in	O
the	O
drug-treated	O
group	O
(	O
see	O
Table	O
2	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
The	O
Medicines	O
Company	O
at	O
1-888-977-MDCO	O
(	O
6326	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Teflaro	O
was	O
evaluated	O
in	O
four	O
controlled	O
comparative	O
Phase	O
3	O
clinical	O
trials	O
(	O
two	O
in	O
ABSSSI	O
and	O
two	O
in	O
CABP	O
)	O
which	O
included	O
1300	O
adult	O
patients	O
treated	O
with	O
Teflaro	O
(	O
600	O
mg	O
administered	O
by	O
IV	O
over	O
1	O
hour	O
every	O
12h	O
)	O
and	O
1297	O
patients	O
treated	O
with	O
comparator	O
(	O
vancomycin	O
plus	O
aztreonam	O
or	O
ceftriaxone	O
)	O
for	O
a	O
treatment	O
period	O
up	O
to	O
21	O
days	O
.	O
	
2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
drug	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
of	O
HALAVEN	O
.	O
	
Skin	O
,	O
subcutaneous	O
tissue	O
disorders	O
:	O
hyperhidrosis	B
,	O
periorbital	B
edema	I
,	O
photosensitivity	B
reaction	I
,	O
pruritis	B
,	O
urticaria	B
,	O
rash	B
,	O
Henoch-Schonlein	B
purpura	I
.	O
	
For	O
each	O
subject	O
in	O
whom	O
a	O
Week	O
12	O
sample	O
was	O
selected	O
,	O
the	O
corresponding	O
Week	O
6	O
,	O
18	O
,	O
24	O
,	O
and	O
52	O
samples	O
were	O
assayed	O
if	O
they	O
were	O
also	O
binding	O
antibody	O
positive	O
.	O
	
Safe	O
handling	O
should	O
be	O
ensured	O
to	O
minimize	O
radiation	O
exposure	O
to	O
the	O
patient	O
and	O
health	O
care	O
workers	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
.	O
	
The	O
most	O
serious	O
adverse	O
reaction	O
reported	O
in	O
clinical	O
trials	O
with	O
Ferriprox	O
was	O
agranulocytosis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
73	O
(	O
50	O
%	O
)	O
subjects	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trial	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Peripheral	O
Neuropathy	O
:	O
In	O
Study	O
1	O
,	O
17	O
%	O
of	O
enrolled	O
patients	O
had	O
Grade	O
1	O
peripheral	B
neuropathy	I
and	O
3	O
%	O
of	O
patients	O
had	O
Grade	O
2	O
peripheral	B
neuropathy	I
at	O
baseline	O
.	O
	
Patients	O
with	O
liver	O
metastases	O
were	O
excluded	O
if	O
AST	O
and/or	O
ALT	O
>	O
5*	O
ULN	O
.	O
	
Six	O
weeks	O
after	O
the	O
eighth	O
injection	O
(	O
fourth	O
treatment	O
cycle	O
)	O
of	O
XIAFLEX	O
,	O
>	O
99	O
%	O
of	O
XIAFLEX-treated	O
patients	O
developed	O
high	O
titers	O
of	O
antibodies	O
to	O
both	O
AUX-I	O
and	O
AUX-II	O
.	O
	
Patients	O
received	O
5-10	O
days	O
of	O
an	O
approved	O
parenteral	O
anticoagulant	O
therapy	O
followed	O
by	O
6	O
months	O
,	O
with	O
mean	O
exposure	O
of	O
164	O
days	O
,	O
of	O
oral	O
only	O
treatment	O
;	O
warfarin	O
was	O
overlapped	O
with	O
parenteral	O
therapy	O
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
with	O
ZYTIGA	O
was	O
8	O
months	O
.	O
	
Hold	O
ADCETRIS	O
dosing	O
for	O
any	O
suspected	O
case	O
of	O
PML	O
and	O
discontinue	O
ADCETRIS	O
dosing	O
if	O
a	O
diagnosis	O
of	O
PML	O
is	O
confirmed	O
.	O
	
Four	O
percent	O
(	O
20/503	O
)	O
of	O
patients	O
experienced	O
peripheral	B
motor	I
neuropathy	I
of	O
any	O
grade	O
and	O
2	O
%	O
(	O
8/503	O
)	O
of	O
patients	O
developed	O
Grade	O
3	O
peripheral	B
motor	I
neuropathy	I
.	O
	
In	O
vitro	O
studies	O
showed	O
no	O
evidence	O
of	O
cross-reactivity	O
between	O
anti-drug-antibody	O
positive	O
patient	O
sera	O
and	O
a	O
series	O
of	O
relevant	O
MMPs	O
.	O
	
After	O
five	O
years	O
more	O
than	O
90	O
percent	O
of	O
patients	O
remained	O
seropositive	O
for	O
anti-AUX-I	O
and	O
anti-AUX-II	O
antibody	O
(	O
Study	O
4	O
)	O
.	O
	
Gastrointestinal	O
disorders	O
:	O
enterocolitis	B
,	O
rectal	B
hemorrhage	I
,	O
gastric	B
ulcer	I
,	O
pancreatitis	B
,	O
parotid	B
gland	I
enlargement	I
.	O
	
If	O
anaphylaxis	O
occurs	O
,	O
immediately	O
and	O
permanently	O
discontinue	O
administration	O
of	O
ADCETRIS	O
and	O
administer	O
appropriate	O
medical	O
therapy	O
.	O
	
Only	O
physicians	O
experienced	O
in	O
immunosuppressive	O
therapy	O
and	O
management	O
of	O
kidney	O
transplant	O
patients	O
should	O
prescribe	O
NULOJIX	O
.	O
	
Other	O
serious	O
adverse	O
reactions	O
included	O
thromboembolic	B
complications	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
The	O
incidence	O
of	O
rash	B
was	O
higher	O
in	O
females	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
Discontinue	O
INTELENCE	O
(	O
r	O
)	O
immediately	O
if	O
signs	O
or	O
symptoms	O
of	O
severe	O
skin	O
reactions	O
or	O
hypersensitivity	O
reactions	O
develop	O
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
severe	O
rash	O
or	O
rash	O
accompanied	O
by	O
fever	O
,	O
general	O
malaise	O
,	O
fatigue	O
,	O
muscle	O
or	O
joint	O
aches	O
,	O
blisters	O
,	O
oral	O
lesions	O
,	O
conjunctivitis	O
,	O
facial	O
edema	O
,	O
hepatitis	O
,	O
eosinophilia	O
,	O
angioedema	O
)	O
.	O
	
Major	O
bleeding	B
is	O
defined	O
as	O
bleeding	B
accompanied	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
a	O
decrease	B
in	I
hemoglobin	I
of	O
>	O
=2	O
g/dL	O
,	O
a	O
transfusion	O
of	O
>	O
=2	O
units	O
of	O
packed	O
red	O
blood	O
cells	O
,	O
bleeding	B
at	I
a	I
critical	I
site	I
or	O
with	O
a	O
fatal	B
outcome	O
.	O
	
5.3	O
Immune	O
Reconstitution	O
Syndrome	O
Immune	B
reconstitution	I
syndrome	I
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
combination	O
antiretroviral	O
therapy	O
,	O
including	O
INTELENCE	O
(	O
r	O
)	O
.	O
	
5.10	O
Paradoxical	O
Bronchospasm	O
As	O
with	O
other	O
inhaled	O
medicines	O
,	O
BREO	O
ELLIPTA	O
can	O
produce	O
paradoxical	B
bronchospasm	I
,	O
which	O
may	O
be	O
life	O
threatening	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
=2	O
%	O
and	O
at	O
a	O
rate	O
greater	O
than	O
the	O
placebo	O
rate	O
)	O
for	O
AMPYRA	O
were	O
urinary	B
tract	I
infection	I
,	O
insomnia	B
,	O
dizziness	B
,	O
headache	B
,	O
nausea	B
,	O
asthenia	B
,	O
back	B
pain	I
,	O
balance	B
disorder	I
,	O
multiple	B
sclerosis	I
relapse	I
,	O
paresthesia	B
,	O
nasopharyngitis	B
,	O
constipation	B
,	O
dyspepsia	B
,	O
and	O
pharyngolaryngeal	B
pain	I
(	O
6.1	O
)	O
.	O
	
This	O
risk	O
increases	O
with	O
age	O
,	O
particularly	O
in	O
women	O
over	O
35	O
years	O
of	O
age	O
,	O
and	O
with	O
the	O
number	O
of	O
cigarettes	O
smoked	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
AstraZeneca	O
at	O
1-800-	O
236-9933	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
AdreView	O
may	O
increase	O
release	O
of	O
norepinephrine	O
from	O
chromaffin	O
granules	O
and	O
produce	O
a	O
transient	B
episode	I
of	I
hypertension	I
,	O
although	O
this	O
was	O
not	O
observed	O
in	O
the	O
clinical	O
studies	O
.	O
	
By	O
Year	O
3	O
,	O
one	O
or	O
more	O
antihypertensive	O
medications	O
were	O
used	O
in	O
85	O
%	O
of	O
NULOJIX-treated	O
patients	O
and	O
92	O
%	O
of	O
cyclosporine-treated	O
patients	O
.	O
	
5.8	O
Leukoencephalopathy	O
Cranial	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
changes	O
showing	O
leukoencephalopathy	B
have	O
been	O
observed	O
in	O
patients	O
receiving	O
BLINCYTO	O
,	O
especially	O
in	O
patients	O
with	O
prior	O
treatment	O
with	O
cranial	O
irradiation	O
and	O
antileukemic	O
chemotherapy	O
(	O
including	O
systemic	O
high-dose	O
methotrexate	O
or	O
intrathecal	O
cytarabine	O
)	O
.	O
	
*	O
Fatal	B
and	O
serious	O
pneumonitis	B
can	O
occur	O
in	O
Zydelig-treated	O
patients	O
.	O
	
Of	O
56	O
patients	O
who	O
tested	O
negative	O
for	O
antibodies	O
during	O
treatment	O
and	O
reassessed	O
approximately	O
7	O
half-lives	O
after	O
discontinuation	O
of	O
NULOJIX	O
,	O
1	O
tested	O
antibody	O
positive	O
.	O
	
*	O
Hypersensitivity	B
Reactions	O
:	O
Discontinue	O
TRULICITY	O
if	O
suspected	O
.	O
	
(	O
N	O
for	O
males	O
:	O
Placebo=716	O
,	O
FARXIGA	O
5	O
mg=564	O
,	O
FARXIGA	O
10	O
mg=595	O
)	O
.	O
	
Patients	O
who	O
develop	O
symptoms	O
of	O
hyperglycemia	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
should	O
undergo	O
fasting	O
blood	O
glucose	O
testing	O
.	O
	
Adverse	O
Reactions	O
N	O
(	O
Percent	O
of	O
patients	O
)	O
Headache	B
10	O
(	O
1.8	O
%	O
)	O
Musculoskeletal	B
pain	I
4	O
(	O
0.7	O
%	O
)	O
Blood	B
pressure	I
increased	I
a	O
4	O
(	O
0.7	O
%	O
)	O
Nausea	B
4	O
(	O
0.7	O
%	O
)	O
Fatigue	B
3	O
(	O
0.5	O
%	O
)	O
Injection	B
site	I
reaction	I
b	O
3	O
(	O
0.5	O
%	O
)	O
Anxiety	B
2	O
(	O
0.4	O
%	O
)	O
Back	B
pain	I
2	O
(	O
0.4	O
%	O
)	O
Claustrophobia	B
2	O
(	O
0.4	O
%	O
)	O
Dizziness	B
2	O
(	O
0.4	O
%	O
)	O
Feeling	B
cold	I
c	O
2	O
(	O
0.4	O
%	O
)	O
Insomnia	B
2	O
(	O
0.4	O
%	O
)	O
Neck	B
pain	I
2	O
(	O
0.4	O
%	O
)	O
Other	O
adverse	O
reactions	O
occurred	O
at	O
lower	O
frequencies	O
and	O
included	O
infusion	B
site	I
rash	I
,	O
dysgeusia	B
,	O
pruritis	B
,	O
urticaria	B
,	O
and	O
flushing	B
.	O
	
[	O
See	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
.	O
]	O
	
The	O
abnormalities	O
seen	O
in	O
patients	O
treated	O
with	O
POTIGA	O
have	O
funduscopic	B
features	I
similar	I
to	I
those	I
seen	I
in	I
retinal	I
pigment	I
dystrophies	I
that	O
are	O
known	O
to	O
result	O
in	O
damage	B
to	I
photoreceptors	I
and	O
vision	B
loss	I
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
in	O
more	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
of	O
the	O
label	O
:	O
*	O
Somnolence/sedation	O
and	O
dizziness	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
RLS	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
and	O
at	O
least	O
2	O
times	O
the	O
rate	O
of	O
placebo	O
)	O
were	O
somnolence/sedation	O
and	O
dizziness	B
.	O
	
For	O
patients	O
who	O
experience	O
a	O
sustained	O
increase	O
in	O
blood	O
pressure	O
while	O
receiving	O
PRISTIQ	O
,	O
either	O
dose	O
reduction	O
or	O
discontinuation	O
should	O
be	O
considered	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Severe	O
Diarrhea	B
or	O
Colitis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Pneumonitis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Intestinal	B
Perforation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Severe	O
Cutaneous	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Anaphylaxis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Neutropenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=20	O
%	O
)	O
are	O
diarrhea	B
,	O
pyrexia	B
,	O
fatigue	B
,	O
nausea	B
,	O
cough	B
,	O
pneumonia	B
,	O
abdominal	B
pain	I
,	O
chills	B
,	O
and	O
rash	B
(	O
6.1	O
)	O
.	O
	
Six	O
patients	O
out	O
of	O
the	O
403	O
who	O
were	O
treated	O
with	O
the	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
in	O
Studies	O
1	O
and	O
2	O
(	O
1.5	O
%	O
)	O
were	O
reported	O
to	O
have	O
developed	O
CNS	B
infections	I
,	O
including	O
2	O
cases	O
of	O
cryptococcal	B
meningitis	I
,	O
one	O
case	O
of	O
Chagas	B
encephalitis	I
with	O
cryptococcal	B
meningitis	I
,	O
one	O
case	O
of	O
cerebral	B
aspergillosis	I
,	O
one	O
case	O
of	O
West	B
Nile	I
encephalitis	I
,	O
and	O
one	O
case	O
of	O
PML	B
(	O
discussed	O
above	O
)	O
.	O
	
Hydronephrosis	B
was	O
not	O
reported	O
in	O
placebo	O
patients	O
.	O
	
As	O
with	O
other	O
antipsychotics	O
,	O
FANAPT	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
conditions	O
that	O
potentially	O
lower	O
the	O
seizure	O
threshold	O
,	O
e.g.	O
,	O
Alzheimer	O
's	O
dementia	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Arbor	O
Pharmaceuticals	O
,	O
LLC	O
at	O
1-866-516-4950	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Other	O
Adverse	O
Reactions	O
Other	O
infrequent	O
adverse	O
reactions	O
(	O
occurring	O
in	O
less	O
than	O
3	O
%	O
of	O
RA	O
patients	O
)	O
were	O
similar	O
to	O
those	O
seen	O
in	O
Crohn	O
's	O
disease	O
patients	O
.	O
	
The	O
overall	O
trial	O
population	O
had	O
a	O
median	O
age	O
of	O
61	O
years	O
;	O
61	O
%	O
of	O
patients	O
in	O
the	O
GILOTRIF	O
arm	O
and	O
60	O
%	O
of	O
patients	O
in	O
the	O
pemetrexed/cisplatin	O
arm	O
were	O
younger	O
than	O
65	O
years	O
.	O
	
The	O
causative	O
organisms	O
for	O
these	O
reactions	O
are	O
identified	O
when	O
provided	O
by	O
the	O
physician	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
CYTOKINE	B
RELEASE	I
SYNDROME	I
and	O
NEUROLOGICAL	B
TOXICITIES	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
The	O
clinical	O
development	O
program	O
excluded	O
patients	O
with	O
active	O
autoimmune	O
disease	O
or	O
those	O
receiving	O
systemic	O
immunosuppression	O
for	O
organ	O
transplantation	O
.	O
	
5.6	O
Fungal	O
Infections	O
Fungal	B
infections	I
of	I
the	I
cornea	I
are	O
particularly	O
prone	O
to	O
develop	O
coincidentally	O
with	O
long-term	O
local	O
steroid	O
application	O
.	O
	
*	O
Perforations	B
and	O
Fistulas	B
:	O
Gastrointestinal	B
perforations	I
occurred	O
in	O
3	O
%	O
and	O
fistula	B
formation	I
in	O
1	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TRULICITY	O
[	O
see	O
Contraindications	O
(	O
4.1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Table	O
2	O
Investigator	O
Assessment	O
of	O
Maximal	O
Local	B
Skin	I
Reactions	I
in	O
the	O
Treatment	O
Area	O
during	O
the	O
57	O
Days	O
Post	O
Treatment	O
Period	O
(	O
trunk/extremities	O
trials	O
)	O
Trunk	O
and	O
Extremities	O
(	O
n=457	O
)	O
Picato	O
(	O
r	O
)	O
gel	O
,	O
0.05	O
%	O
once	O
daily	O
for	O
2	O
days	O
Skin	B
reactions	I
Any	I
Gradea	I
>	I
Baseline	I
Grade	I
4	I
58	O
(	O
26	O
%	O
)	O
6	O
(	O
3	O
%	O
)	O
2	O
(	O
1	O
%	O
)	O
0	O
(	O
0	O
%	O
)	O
a	O
Mild	O
(	O
grade	O
1	O
)	O
,	O
Moderate	O
(	O
grade	O
2-3	O
)	O
or	O
Severe	O
(	O
grade	O
4	O
)	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
genital	O
mycotic	O
infections	O
and	O
uncircumcised	O
males	O
were	O
more	O
likely	O
to	O
develop	O
genital	B
mycotic	I
infections	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Table	O
2	O
:	O
Risk	O
of	O
Suicidal	B
Thoughts	I
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
Placebo	O
Patients	O
with	O
Events	O
Per	O
1000	O
Patients	O
Drug	O
Patients	O
with	O
Events	O
Per	O
1000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Events	O
in	O
Drug	O
Patients/Incidence	O
in	O
Placebo	O
Patients	O
Risk	O
Differences	O
:	O
Additional	O
Drug	O
Patients	O
with	O
Events	O
Per	O
1000	O
Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
The	O
adverse	O
reaction	O
profile	O
of	O
TECFIDERA	O
in	O
the	O
uncontrolled	O
clinical	O
studies	O
was	O
consistent	O
with	O
the	O
experience	O
in	O
the	O
placebo-controlled	O
clinical	O
trials	O
.	O
	
Pre-medicate	O
in	O
subsequent	O
cycles	O
for	O
milder	O
reactions	O
.	O
	
At	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
,	O
withhold	O
TECFIDERA	O
and	O
perform	O
an	O
appropriate	O
diagnostic	O
evaluation	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
median	O
duration	O
of	O
treatment	O
was	O
6.4	O
months	O
(	O
range	O
0.03	O
to	O
22.0	O
)	O
for	O
patients	O
who	O
received	O
INLYTA	O
and	O
5.0	O
months	O
(	O
range	O
0.03	O
to	O
20.1	O
)	O
for	O
patients	O
who	O
received	O
sorafenib	O
.	O
	
A	O
single	O
event	O
of	O
serum	B
sickness	I
was	O
reported	O
in	O
a	O
patient	O
treated	O
with	O
NESINA	O
25	O
mg.	O
Hypoglycemia	O
Hypoglycemic	B
events	I
were	O
documented	O
based	O
upon	O
a	O
blood	O
glucose	O
value	O
and/or	O
clinical	O
signs	O
and	O
symptoms	O
of	O
hypoglycemia	B
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Acute	B
pancreatitis	I
:	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
pancreatitis	I
.	O
	
Hematologic	O
nadirs	O
were	O
observed	O
predominantly	O
in	O
the	O
third	O
week	O
of	O
therapy	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Ipsen	O
Biopharmaceuticals	O
,	O
Inc.	O
at	O
877-397-7671	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Consider	O
discontinuation	O
for	O
Grade	O
3	O
infusions	O
reactions	O
as	O
clinically	O
appropriate	O
considering	O
individual	O
benefits	O
,	O
risks	O
,	O
and	O
supportive	O
care	O
.	O
	
TAFINLAR	O
was	O
studied	O
in	O
open-label	O
,	O
single-arm	O
trials	O
and	O
in	O
an	O
open-label	O
,	O
randomized	O
,	O
active-controlled	O
trial	O
.	O
	
Adverse	O
reactions	O
observed	O
in	O
these	O
studies	O
were	O
generally	O
similar	O
to	O
those	O
observed	O
and	O
attributed	O
to	O
drug	O
in	O
adjunctive	O
placebo-controlled	O
studies	O
.	O
	
in	O
Placebo	O
and	O
Active-Controlled	O
Studies	O
when	O
NESINA	O
Was	O
Used	O
as	O
Add-On	O
Therapy	O
to	O
Glyburide	O
,	O
Insulin	O
,	O
Metformin	O
,	O
Pioglitazone	O
or	O
Compared	O
to	O
Glipizide	O
Add-On	O
to	O
Glyburide	O
(	O
26	O
Weeks	O
)	O
NESINA	O
25	O
mg+	O
Glyburide	O
Placebo+	O
Glyburide	O
N=198	O
N=99	O
Overall	O
(	O
%	O
)	O
19	O
(	O
9.6	O
)	O
11	O
(	O
11.1	O
)	O
Severe	O
(	O
%	O
)	O
Severe	O
events	O
of	O
hypoglycemia	B
were	O
defined	O
as	O
those	O
events	O
requiring	O
medical	O
assistance	O
or	O
exhibiting	O
depressed	O
level	O
or	O
loss	O
of	O
consciousness	O
or	O
seizure	O
.	O
	
Monitor	O
ECGs	O
and	O
discontinue	O
SIRTURO	O
if	O
significant	O
ventricular	O
arrhythmia	O
or	O
QTcF	O
interval	O
>	O
500	O
ms	O
develops	O
.	O
	
In	O
non-clinical	O
studies	O
in	O
rats	O
and	O
rabbits	O
,	O
cabazitaxel	O
was	O
embryotoxic	B
,	O
fetotoxic	B
,	O
and	O
abortifacient	B
at	O
exposures	O
significantly	O
lower	O
than	O
those	O
expected	O
at	O
the	O
recommended	O
human	O
dose	O
level	O
.	O
	
Pain	B
in	I
extremity	I
and	O
musculoskeletal	B
pain	I
have	O
also	O
been	O
reported	O
in	O
clinical	O
trials	O
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Amgen	O
Inc.	O
at	O
1-800-77-AMGEN	O
(	O
1-800-772-6436	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Hyperglycemia	O
and	O
Diabetes	O
Mellitus	O
Hyperglycemia	B
,	O
in	O
some	O
cases	O
extreme	O
and	O
associated	O
with	O
ketoacidosis	B
or	O
hyperosmolar	B
coma	I
or	O
death	B
,	O
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
one	O
clinical	O
trial	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
the	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
the	O
same	O
or	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Acorda	O
Therapeutics	O
at	O
1-877-900-6479	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNINGS	O
:	O
INCREASED	B
MORTALITY	I
;	O
QT	B
PROLONGATION	I
WARNINGS	O
:	O
INCREASED	B
MORTALITY	I
;	O
QT	B
PROLONGATION	I
EXCERPT	O
:	O
WARNINGS	O
:	O
INCREASED	B
MORTALITY	I
;	O
QT	B
PROLONGATION	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
in	O
adults	O
(	O
>	O
30	O
%	O
)	O
are	O
headache	B
,	O
anorexia	B
,	O
dizziness	B
,	O
asthenia	B
,	O
arthralgia	B
and	O
myalgia	B
.	O
	
In	O
a	O
3-week	O
monotherapy	O
trial	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
and	O
at	O
least	O
twice	O
the	O
rate	O
of	O
placebo	O
)	O
reported	O
in	O
pediatric	O
patients	O
with	O
bipolar	O
I	O
disorder	O
treated	O
with	O
SAPHRIS	O
were	O
somnolence	B
,	O
dizziness	B
,	O
dysgeusia	B
,	O
oral	B
paresthesia	I
,	O
nausea	B
,	O
increased	B
appetite	I
,	O
fatigue	B
,	O
and	O
increased	B
weight	I
.	O
	
For	O
those	O
patients	O
who	O
require	O
the	O
use	O
of	O
opioids	O
to	O
treat	O
pain	O
during	O
or	O
following	O
the	O
procedure	O
,	O
their	O
ability	O
to	O
perform	O
potentially	O
hazardous	O
activities	O
such	O
as	O
driving	O
or	O
operating	O
machinery	O
may	O
be	O
affected	O
.	O
	
In	O
a	O
trial	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
the	O
mean	O
serum	B
phosphate	I
levels	I
increased	I
by	O
1.2	O
%	O
,	O
5.0	O
%	O
,	O
and	O
9.3	O
%	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
Across	O
the	O
347	O
patients	O
who	O
were	O
randomized	O
to	O
study	O
treatment	O
(	O
343	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
treatment	O
)	O
,	O
the	O
median	O
age	O
was	O
50	O
years	O
;	O
14	O
%	O
of	O
patients	O
were	O
older	O
than	O
65	O
years	O
.	O
	
Atypical	O
Subtrochanteric	O
and	O
Diaphyseal	O
Fractures	O
In	O
the	O
osteoporosis	O
clinical	O
trial	O
program	O
,	O
atypical	B
femoral	I
fractures	I
were	O
reported	O
in	O
patients	O
treated	O
with	O
Prolia	O
.	O
	
N**	O
=	O
Number	O
of	O
patients	O
at	O
risk	O
at	O
Baseline	O
with	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
The	O
changes	O
averaged	O
less	O
than	O
10	O
mm	O
Hg	O
,	O
although	O
some	O
patients	O
had	O
greater	O
increases	O
and	O
these	O
changes	O
lasted	O
for	O
approximately	O
two	O
hours	O
after	O
patch	O
removal	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
frequently	O
reported	O
adverse	O
events	O
(	O
>	O
=4	O
%	O
)	O
for	O
Toviaz	O
were	O
:	O
dry	B
mouth	I
(	O
placebo	O
,	O
7	O
%	O
;	O
Toviaz	O
4	O
mg	O
,	O
19	O
%	O
;	O
Toviaz	O
8	O
mg	O
,	O
35	O
%	O
)	O
and	O
constipation	B
(	O
placebo	O
,	O
2	O
%	O
;	O
Toviaz	O
4	O
mg	O
,	O
4	O
%	O
;	O
Toviaz	O
8	O
mg	O
,	O
6	O
%	O
)	O
.	O
	
(	O
2.3	O
,	O
5.3	O
)	O
*	O
Fluid	B
Retention	I
:	O
Monitor	O
patients	O
and	O
manage	O
using	O
standard	O
of	O
care	O
treatment	O
.	O
	
*	O
The	O
risk	O
for	O
NSF	B
appears	O
highest	O
among	O
patients	O
with	O
:	O
Chronic	O
,	O
severe	O
kidney	O
disease	O
(	O
GFR	O
<	O
30	O
mL/min/1.73	O
m2	O
)	O
,	O
orAcute	O
kidney	O
injury	O
.	O
	
Because	O
the	O
elimination	O
of	O
fingolimod	O
after	O
discontinuation	O
may	O
take	O
up	O
to	O
2	O
months	O
,	O
continue	O
monitoring	O
for	O
infections	O
throughout	O
this	O
period	O
.	O
	
System	O
Organ	O
Class/	O
Preferred	O
Term	O
Placebo	O
N=378	O
%	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
N=274	O
%	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
N=208	O
%	O
All	O
SAPHRIS	O
S	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
N=572	O
%	O
Gastrointestinal	O
disorders	O
Constipation	B
6	O
7	O
4	O
5	O
Dry	B
mouth	I
1	O
3	O
1	O
2	O
Oral	B
hypoesthesia	I
1	O
6	O
7	O
5	O
Salivary	B
hypersecretion	I
0	O
<	O
1	O
4	O
2	O
Stomach	B
discomfort	I
1	O
<	O
1	O
3	O
2	O
Vomiting	B
5	O
4	O
7	O
5	O
General	O
disorders	O
Fatigue	B
3	O
4	O
3	O
3	O
Irritability	B
<	O
1	O
2	O
1	O
2	O
Investigations	O
Increased	B
weight	I
<	O
1	O
2	O
2	O
3	O
Metabolism	O
disorders	O
Increased	B
appetite	I
<	O
1	O
3	O
0	O
2	O
Nervous	O
system	O
disorders	O
Akathisia*	O
3	O
4	O
11	O
6	O
Dizziness	B
4	O
7	O
3	O
5	O
Extrapyramidal	B
symptoms	I
(	O
excluding	O
akathisia	B
)	O
7	O
9	O
12	O
10	O
Somnolence	B
?	O
	
*	O
Immediate	O
medical	O
attention	O
may	O
be	O
required	O
in	O
cases	O
of	O
respiratory	O
,	O
speech	O
or	O
swallowing	O
difficulties	O
(	O
5.1	O
,	O
5.4	O
)	O
.	O
	
The	O
median	O
duration	O
of	O
blinded	O
study	O
treatment	O
was	O
52	O
weeks	O
(	O
range	O
24	O
to	O
89	O
weeks	O
)	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
47	O
weeks	O
(	O
range	O
14	O
to	O
88	O
weeks	O
)	O
for	O
those	O
receiving	O
placebo	O
.	O
	
Monitor	O
for	O
hypertension	O
and	O
treat	O
as	O
needed	O
.	O
	
5.2	O
Acute	O
Renal	O
Failure	O
Cases	O
of	O
acute	B
renal	I
failure	I
have	O
occurred	O
in	O
patients	O
receiving	O
Kyprolis	O
.	O
	
Almost	O
all	O
these	O
patients	O
had	O
received	O
treatment	O
with	O
azathioprine	O
(	O
AZA	O
)	O
or	O
6-mercaptopurine	O
(	O
6-MP	O
)	O
concomitantly	O
with	O
a	O
TNF-blocker	O
at	O
or	O
prior	O
to	O
diagnosis	O
.	O
	
Cases	O
of	O
central	B
demyelination	I
,	O
MS	B
,	O
optic	B
neuritis	I
,	O
and	O
peripheral	B
demyelinating	I
polyneuropathy	I
have	O
rarely	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
.	O
	
*	O
Lower	O
lid	O
injections	O
should	O
not	O
be	O
repeated	O
if	O
diplopia	O
occurred	O
with	O
previous	O
botulinum	O
toxin	O
injections	O
.	O
	
Discontinuations	O
due	O
to	O
adverse	O
drug	O
reactions	O
(	O
ADRs	O
)	O
were	O
5.2	O
%	O
in	O
the	O
INTELENCE	O
(	O
r	O
)	O
arm	O
and	O
2.6	O
%	O
in	O
the	O
placebo	O
arm	O
.	O
	
Atrioventricular	O
Blocks	O
Initiation	O
of	O
GILENYA	O
treatment	O
has	O
resulted	O
in	O
transient	O
AV	B
conduction	I
delays	I
.	O
	
Permanently	O
discontinue	O
XTANDI	O
in	O
patients	O
who	O
develop	O
a	O
seizure	O
during	O
treatment	O
.	O
	
If	O
a	O
serious	O
hypersensitivity	O
reaction	O
occurs	O
,	O
discontinue	O
ERWINAZE	O
and	O
initiate	O
appropriate	O
therapy	O
.	O
	
(	O
5.4	O
)	O
*	O
Cardiac	B
failure	I
has	O
been	O
observed	O
and	O
can	O
be	O
fatal	B
.	O
	
*	O
Bipolar	O
Disorder	O
Pediatric	O
Patients	O
(	O
Monotherapy	O
)	O
:	O
somnolence	B
,	O
dizziness	B
,	O
dysgeusia	B
,	O
oral	B
paresthesia	I
,	O
nausea	B
,	O
increased	B
appetite	I
,	O
fatigue	B
,	O
increased	B
weight	I
.	O
	
In	O
unapproved	O
uses	O
,	O
including	O
spasticity	O
in	O
children	O
,	O
and	O
in	O
approved	O
indications	O
,	O
cases	O
of	O
spread	O
of	O
effect	O
have	O
been	O
reported	O
at	O
doses	O
comparable	O
to	O
or	O
lower	O
than	O
the	O
maximum	O
recommended	O
total	O
dose	O
.	O
	
Antipsychotic	O
treatment	O
itself	O
,	O
however	O
,	O
may	O
suppress	O
(	O
or	O
partially	O
suppress	O
)	O
the	O
signs	O
and	O
symptoms	O
of	O
the	O
syndrome	O
and	O
thereby	O
may	O
possibly	O
mask	O
the	O
underlying	O
process	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
TTP/HUS	O
.	O
	
Due	O
to	O
the	O
low	O
rate	O
of	O
events	O
in	O
both	O
groups	O
,	O
it	O
is	O
not	O
possible	O
to	O
conclude	O
that	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
with	O
DUAVEE	O
is	O
different	O
from	O
that	O
seen	O
with	O
other	O
estrogen	O
therapies	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Monotherapy	O
Historical	O
Control	O
Trials	O
In	O
the	O
monotherapy	O
epilepsy	O
trials	O
(	O
Study	O
1	O
and	O
Study	O
2	O
)	O
,	O
13	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
APTIOM	O
at	O
the	O
recommended	O
doses	O
of	O
1200	O
mg	O
and	O
1600	O
mg	O
once	O
daily	O
discontinued	O
from	O
the	O
trials	O
as	O
a	O
result	O
of	O
an	O
adverse	O
event	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
dehydration	B
,	O
thrombotic	B
thrombocytopenic	I
purpura/hemolytic	O
uremic	B
syndrome	I
(	O
TTP/HUS	O
)	O
,	O
tumor	B
lysis	I
syndrome	I
including	O
fatal	B
outcomes	O
,	O
and	O
posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
.	O
	
5.3	O
Dysphagia	O
and	O
Breathing	O
Difficulties	O
Treatment	O
with	O
DYSPORT	O
(	O
r	O
)	O
and	O
other	O
botulinum	O
toxin	O
products	O
can	O
result	O
in	O
breathing	B
difficulties	I
.	O
	
In	O
Study	O
2	O
all	O
adverse	O
events	O
of	O
all	O
Grades	O
were	O
prospectively	O
collected	O
.	O
	
(	O
5.7	O
)	O
*	O
Stop	O
INLYTA	O
at	O
least	O
24	O
hours	O
prior	O
to	O
scheduled	O
surgery	O
.	O
	
Prescribers	O
should	O
carefully	O
evaluate	O
the	O
risks	O
and	O
benefits	O
of	O
continuing	O
treatment	O
with	O
OTEZLA	O
if	O
such	O
events	O
occur	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
was	O
61	O
years	O
(	O
range	O
27-85	O
)	O
,	O
88	O
%	O
were	O
Caucasian	O
,	O
and	O
78	O
%	O
were	O
male	O
.	O
	
This	O
may	O
require	O
protective	O
drops	O
,	O
ointment	O
,	O
therapeutic	O
soft	O
contact	O
lenses	O
,	O
or	O
closure	O
of	O
the	O
eye	O
by	O
patching	O
or	O
other	O
means	O
.	O
	
Grades	O
2	O
to	O
4	O
ALT	B
abnormalities	I
in	O
hepatitis	O
B	O
and/or	O
C	O
co-infected	O
compared	O
with	O
HIV	O
mono-infected	O
subjects	O
receiving	O
TIVICAY	O
were	O
observed	O
in	O
18	O
%	O
vs.	O
3	O
%	O
with	O
the	O
50-mg	O
once-daily	O
dose	O
and	O
13	O
%	O
vs.	O
8	O
%	O
with	O
the	O
50-mg	O
twice-daily	O
dose	O
.	O
	
Hypersensitivity	B
reactions	I
and	O
acute	B
kidney	I
injury	I
are	O
described	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
and	O
(	O
5.3	O
)	O
]	O
.	O
	
FANAPT	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
[	O
s	O
ee	O
Boxed	O
Warning	O
]	O
.	O
	
Although	O
other	O
risk	O
factors	O
were	O
present	O
in	O
some	O
cases	O
(	O
such	O
as	O
corticosteroid	O
use	O
and/or	O
exposure	O
to	O
radiation	O
)	O
,	O
a	O
possible	O
risk	O
attributable	O
to	O
KALYDECO	O
can	O
not	O
be	O
excluded	O
.	O
	
Do	O
not	O
exceed	O
the	O
recommended	O
dosage	O
and	O
frequency	O
of	O
administration	O
of	O
DYSPORT	O
(	O
r	O
)	O
.	O
	
Laboratory	O
abnormalities	O
observed	O
in	O
the	O
FLAMINGO	O
trial	O
were	O
generally	O
consistent	O
with	O
observations	O
in	O
SPRING-2	O
and	O
SINGLE	O
.	O
	
The	O
mechanism	O
and	O
clinical	O
significance	O
are	O
unknown	O
.	O
	
Discontinue	O
GILOTRIF	O
in	O
patients	O
who	O
develop	O
life-threatening	O
bullous	O
,	O
blistering	O
,	O
or	O
exfoliating	O
lesions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
MRI	O
signs	O
may	O
be	O
apparent	O
before	O
clinical	O
symptoms	O
.	O
	
In	O
order	O
to	O
reduce	O
the	O
complication	O
of	O
ptosis	O
the	O
following	O
steps	O
should	O
be	O
taken	O
:	O
*	O
Avoid	O
injection	O
near	O
the	O
levator	O
palpebrae	O
superioris	O
,	O
particularly	O
in	O
patients	O
with	O
larger	O
brow	O
depressor	O
complexes	O
.	O
	
Three	O
of	O
these	O
patients	O
had	O
subsequent	O
tests	O
which	O
were	O
negative	O
.	O
	
Keratitis	B
was	O
reported	O
in	O
5	O
(	O
2.2	O
%	O
)	O
patients	O
in	O
Study	O
1	O
,	O
with	O
Grade	O
3	O
in	O
1	O
(	O
0.4	O
%	O
)	O
.	O
	
The	O
reduction	O
in	O
clinical	O
cure	O
rates	O
was	O
more	O
marked	O
in	O
the	O
ZERBAXA	O
plus	O
metronidazole	O
arm	O
compared	O
to	O
the	O
meropenem	O
arm	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
were	O
serious	O
infections	B
(	O
6.0	O
%	O
and	O
5.2	O
%	O
in	O
the	O
groups	O
receiving	O
BENLYSTA	O
and	O
placebo	O
,	O
respectively	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Monitor	O
for	O
suicidal	O
thoughts	O
or	O
behaviors	O
.	O
	
5.11	O
Hepatic	O
Toxicity	O
and	O
Hepatic	O
Failure	O
Cases	O
of	O
hepatic	B
failure	I
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
(	O
<	O
1	O
%	O
)	O
during	O
treatment	O
with	O
Kyprolis	O
.	O
	
Thromboprophylaxis	O
is	O
recommended	O
and	O
should	O
be	O
based	O
on	O
an	O
assessment	O
of	O
the	O
patient	O
's	O
underlying	O
risks	O
,	O
treatment	O
regimen	O
,	O
and	O
clinical	O
status	O
.	O
	
Patients	O
were	O
randomized	O
in	O
a	O
2:1	O
ratio	O
and	O
received	O
alglucosidase	O
alfa	O
or	O
placebo	O
every	O
other	O
week	O
for	O
78	O
weeks	O
(	O
18	O
months	O
)	O
.	O
	
In	O
one	O
trial	O
INVOKANA	O
was	O
used	O
as	O
monotherapy	O
and	O
in	O
three	O
trials	O
INVOKANA	O
was	O
used	O
as	O
add-on	O
therapy	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
At	O
screening	O
,	O
the	O
mean	O
postbronchodilator	O
percent	O
predicted	O
FEV1was	O
48	O
%	O
(	O
range	O
:	O
14	O
%	O
to	O
87	O
%	O
)	O
,	O
the	O
mean	O
postbronchodilator	O
FEV1/forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
ratio	O
was	O
47	O
%	O
(	O
range	O
:	O
17	O
%	O
to	O
88	O
%	O
)	O
,	O
and	O
the	O
mean	O
percent	O
reversibility	O
was	O
14	O
%	O
(	O
range	O
:	O
-41	O
%	O
to	O
152	O
%	O
)	O
.	O
	
Evaluate	O
with	O
cardiac	O
imaging	O
and/or	O
other	O
tests	O
as	O
indicated	O
.	O
	
Subjects	O
ranged	O
in	O
age	O
from	O
18	O
to	O
83	O
years	O
,	O
with	O
an	O
overall	O
median	O
age	O
of	O
46	O
years	O
.	O
	
(	O
5.1	O
)	O
5.1	O
Laryngeal	O
Attacks	O
Given	O
the	O
potential	O
for	O
airway	O
obstruction	O
during	O
acute	O
laryngeal	O
HAE	O
attacks	O
,	O
patients	O
should	O
be	O
advised	O
to	O
seek	O
medical	O
attention	O
in	O
an	O
appropriate	O
healthcare	O
facility	O
immediately	O
in	O
addition	O
to	O
treatment	O
with	O
FIRAZYR	O
.	O
	
If	O
the	O
diagnosis	O
is	O
suspected	O
,	O
stop	O
Kyprolis	O
and	O
evaluate	O
.	O
	
All	O
events	O
resolved	O
with	O
continued	O
treatment	O
with	O
ILARIS	O
.	O
	
*	O
Flushing	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
The	O
risks	O
and	O
benefits	O
of	O
treatment	O
should	O
be	O
considered	O
prior	O
to	O
prescribing	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
to	O
patients	O
who	O
are	O
carriers	O
of	O
HBV	O
.	O
	
Atrial	O
Fibrillation/Flutte	O
r	O
In	O
the	O
pool	O
of	O
7	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
adverse	O
reactions	O
of	O
atrial	B
fibrillation	I
(	O
1.0	O
%	O
)	O
and	O
atrial	B
flutter	I
(	O
0.2	O
%	O
)	O
were	O
reported	O
more	O
frequently	O
for	O
TANZEUM	O
than	O
for	O
all	O
comparators	O
(	O
0.5	O
%	O
and	O
0	O
%	O
,	O
respectively	O
)	O
.	O
	
Primary	O
prophylaxis	O
with	O
G-CSF	O
should	O
be	O
considered	O
in	O
patients	O
with	O
high-risk	O
clinical	O
features	O
(	O
age	O
>	O
65	O
years	O
,	O
poor	O
performance	O
status	O
,	O
previous	O
episodes	O
of	O
febrile	O
neutropenia	O
,	O
extensive	O
prior	O
radiation	O
ports	O
,	O
poor	O
nutritional	O
status	O
,	O
or	O
other	O
serious	O
comorbidities	O
)	O
that	O
predispose	O
them	O
to	O
increased	O
complications	O
from	O
prolonged	O
neutropenia	O
.	O
	
The	O
assay	O
should	O
have	O
a	O
lower	O
limit	O
of	O
HCV-RNA	O
quantification	O
of	O
equal	O
to	O
or	O
less	O
than	O
25	O
IU	O
per	O
mL	O
,	O
and	O
a	O
limit	O
of	O
HCV-RNA	O
detection	O
of	O
approximately	O
10	O
to	O
15	O
IU	O
per	O
mL	O
.	O
	
For	O
cases	O
of	O
Grade	O
4	O
non-infectious	O
pneumonitis	O
,	O
discontinue	O
AFINITOR	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Table	O
2	O
Adverse	O
Reactions	O
with	O
a	O
Frequency	O
>	O
=0.5	O
%	O
Reported	O
in	O
Clinical	O
Trials	O
(	O
n	O
=	O
978	O
Administrations	O
in	O
872	O
Subjects	O
)	O
Adverse	O
drug	O
reaction	O
n	O
(	O
%	O
)	O
application	B
site	I
erythema	I
17	O
(	O
1.7	O
)	O
Injection	B
site	I
irritation	I
12	O
(	O
1.2	O
)	O
Injection	B
site	I
pain	I
38	O
(	O
3.9	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Image	O
interpretation	O
errors	O
(	O
especially	O
false	O
positives	O
)	O
have	O
been	O
observed	O
(	O
5.1	O
)	O
.	O
	
If	O
symptoms	O
are	O
moderate	O
,	O
consider	O
interrupting	O
therapy	O
until	O
symptoms	O
improve	O
.	O
	
Delay	O
or	O
discontinue	O
JEVTANA	O
.	O
	
Investigations	O
-	O
Weight	B
increased	I
,	O
liver	B
function	I
test	I
abnormal	I
,	O
blood	B
prolactin	I
increased	I
.	O
	
(	O
5.3	O
)	O
5.1	O
Not	O
for	O
Systemic	O
Infections	O
Since	O
there	O
is	O
minimal	O
systemic	O
absorption	O
of	O
fidaxomicin	O
,	O
DIFICID	O
is	O
not	O
effective	O
for	O
treatment	O
of	O
systemic	O
infections	O
.	O
	
ILARIS	O
should	O
not	O
be	O
administered	O
to	O
any	O
patients	O
with	O
known	O
clinical	O
hypersensitivity	O
to	O
ILARIS	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
All	O
other	O
patients	O
were	O
eligible	O
for	O
these	O
studies	O
if	O
the	O
plasma	O
methotrexate	O
level	O
was	O
greater	O
than	O
10	O
mumol/L	O
more	O
than	O
42	O
hours	O
after	O
the	O
start	O
of	O
the	O
methotrexate	O
or	O
the	O
plasma	O
level	O
was	O
greater	O
than	O
2	O
standard	O
deviations	O
above	O
the	O
mean	O
methotrexate	O
excretion	O
curve	O
at	O
least	O
12	O
hours	O
following	O
methotrexate	O
and	O
the	O
serum	O
creatinine	O
was	O
greater	O
than	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
the	O
creatinine	O
clearance	O
was	O
less	O
than	O
60	O
mL/min	O
at	O
least	O
12	O
hours	O
following	O
methotrexate	O
administration	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
another	O
section	O
of	O
the	O
label	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
]	O
:	O
*	O
Non-infectious	B
pneumonitis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=1	O
%	O
of	O
ULORIC-Treated	O
Patients	O
and	O
at	O
Least	O
0.5	O
%	O
Greater	O
than	O
Seen	O
in	O
Patients	O
Receiving	O
Placebo	O
in	O
Controlled	O
Studies	O
Adverse	O
Reactions	O
Placebo	O
ULORIC	O
allopurinolOf	O
the	O
subjects	O
who	O
received	O
allopurinol	O
,	O
10	O
received	O
100	O
mg	O
,	O
145	O
received	O
200	O
mg	O
,	O
and	O
1122	O
received	O
300	O
mg	O
,	O
based	O
on	O
level	O
of	O
renal	O
impairment	O
.	O
	
In	O
clinical	O
trials	O
,	O
121	O
patients	O
who	O
received	O
one	O
(	O
n=99	O
)	O
,	O
two	O
(	O
n=21	O
)	O
,	O
or	O
three	O
(	O
n=1	O
)	O
doses	O
of	O
VORAXAZE	O
were	O
evaluated	O
for	O
anti-glucarpidase	O
antibodies	O
.	O
	
If	O
signs	O
or	O
symptoms	O
of	O
spinal	O
hematoma	O
are	O
suspected	O
,	O
initiate	O
urgent	O
diagnosis	O
and	O
treatment	O
including	O
consideration	O
for	O
spinal	O
cord	O
decompression	O
even	O
though	O
such	O
treatment	O
may	O
not	O
prevent	O
or	O
reverse	O
neurological	O
sequelae	O
.	O
	
Retinal	B
detachments	I
resulting	O
from	O
trametinib	O
are	O
often	O
bilateral	O
and	O
multifocal	O
,	O
occurring	O
in	O
the	O
macular	O
region	O
of	O
the	O
retina	O
.	O
	
EBV	O
seropositive	O
patients	O
are	O
defined	O
as	O
having	O
evidence	O
of	O
acquired	O
immunity	O
shown	O
by	O
the	O
presence	O
of	O
IgG	O
antibodies	O
to	O
viral	O
capsid	O
antigen	O
(	O
VCA	O
)	O
and	O
EBV	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
who	O
have	O
a	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
cabazitaxel	O
or	O
to	O
other	O
drugs	O
formulated	O
with	O
polysorbate	O
80	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
,	O
Contraindications	O
(	O
4	O
)	O
,	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
If	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
do	O
not	O
modify	O
the	O
dose	O
of	O
trametinib	O
.	O
	
Patients	O
who	O
are	O
EBV	O
seropositive	O
and	O
CMV	O
seronegative	O
may	O
be	O
at	O
increased	O
risk	O
for	O
PTLD	O
compared	O
to	O
patients	O
who	O
are	O
EBV	O
seropositive	O
and	O
CMV	O
seropositive	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.5	O
Urinary	O
Tract	O
Infections	O
JARDIANCE	O
increases	O
the	O
risk	O
for	O
urinary	B
tract	I
infections	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Gastrointestinal	O
disorders	O
:	O
Pancreatitis	B
(	O
including	O
fatal	B
outcomes	O
)	O
.	O
	
Monitor	O
and	O
treat	O
promptly	O
per	O
standard	O
of	O
care	O
until	O
signs	O
and	O
symptoms	O
resolve	O
.	O
	
In	O
these	O
trials	O
,	O
891	O
patients	O
were	O
treated	O
with	O
TUDORZA	O
PRESSAIR	O
at	O
the	O
recommended	O
dose	O
of	O
400	O
mcg	O
twice	O
daily	O
.	O
	
Before	O
using	O
DALVANCE	O
,	O
inquire	O
carefully	O
about	O
previous	O
hypersensitivity	O
reactions	O
to	O
glycopeptides	O
,	O
and	O
due	O
to	O
the	O
possibility	O
of	O
cross-sensitivity	O
,	O
exercise	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
glycopeptide	O
allergy	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17	O
)	O
]	O
.	O
	
Cardiac	O
Disorders	O
:	O
angina	B
pectoris	I
,	O
atrial	B
fibrillation	I
,	O
cardiac	B
murmur	I
,	O
ECG	B
abnormal	I
,	O
palpitations	B
,	O
sinus	B
bradycardia	I
,	O
tachycardia	B
.	O
	
TANZEUM	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
a	O
history	O
of	O
pancreatitis	O
to	O
determine	O
whether	O
these	O
patients	O
are	O
at	O
increased	O
risk	O
for	O
pancreatitis	O
.	O
	
Women	O
of	O
childbearing	O
potential	O
and	O
men	O
must	O
use	O
at	O
least	O
two	O
forms	O
of	O
effective	O
contraception	O
during	O
treatment	O
and	O
for	O
at	O
least	O
6	O
months	O
after	O
treatment	O
has	O
concluded	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
use	O
effective	O
contraception	O
during	O
treatment	O
with	O
XALKORI	O
and	O
for	O
at	O
least	O
45	O
days	O
following	O
the	O
final	O
dose	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
,	O
8.3	O
)	O
]	O
.	O
	
In	O
clinical	O
trials	O
with	O
VICTRELIS	O
,	O
dose	O
modifications	O
(	O
generally	O
of	O
PegIntron/REBETOL	O
)	O
due	O
to	O
anemia	B
occurred	O
twice	O
as	O
often	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
(	O
26	O
%	O
)	O
compared	O
to	O
PegIntron/REBETOL	O
(	O
13	O
%	O
)	O
.	O
	
If	O
the	O
QTc	O
Bazett	O
interval	O
is	O
>	O
=500	O
ms	O
,	O
discontinue	O
MULTAQ	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
5.5	O
Renal	O
Impairment	O
In	O
patients	O
treated	O
with	O
GLP-1	O
receptor	O
agonists	O
,	O
there	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
renal	I
failure	I
and	O
worsening	B
of	I
chronic	I
renal	I
failure	I
,	O
which	O
may	O
sometimes	O
require	O
hemodialysis	O
.	O
	
Patients	O
have	O
frequently	O
presented	O
with	O
disseminated	O
rather	O
than	O
localized	O
disease	O
.	O
	
It	O
is	O
unknown	O
whether	O
TANZEUM	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
MTC	B
,	O
in	O
humans	O
[	O
see	O
Boxed	O
Warning	O
,	O
Contraindications	O
(	O
4.1	O
)	O
]	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
PROGRESSIVE	B
MULTIFOCAL	I
LEUKOENCEPHALOPATHY	I
(	O
PML	B
)	O
WARNING	O
:	O
PROGRESSIVE	B
MULTIFOCAL	I
LEUKOENCEPHALOPATHY	I
(	O
PML	B
)	O
JC	B
virus	I
infection	I
resulting	O
in	O
PML	B
and	O
death	B
can	O
occur	O
in	O
patients	O
receiving	O
ADCETRIS	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
EXCERPT	O
:	O
WARNING	O
:	O
PROGRESSIVE	B
MULTIFOCAL	I
LEUKOENCEPHALOPATHY	I
(	O
PML	B
)	O
See	O
Full	O
Prescribing	O
Information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
thromboembolic	B
complications	I
may	O
result	O
from	O
increases	B
in	I
platelet	I
counts	I
with	O
PROMACTA	O
.	O
	
Cases	O
of	O
other	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF-blockers	O
(	O
5.2	O
)	O
.	O
	
Diabetic	O
Macular	O
Edema	O
(	O
DME	O
)	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
EYLEA	O
in	O
578	O
patients	O
with	O
DME	O
treated	O
with	O
the	O
2-mg	O
dose	O
in	O
2	O
double-masked	O
,	O
controlled	O
clinical	O
studies	O
(	O
VIVID	O
and	O
VISTA	O
)	O
from	O
baseline	O
to	O
week	O
52	O
and	O
from	O
baseline	O
to	O
week	O
100	O
[	O
seeClinical	O
Studies	O
(	O
14.4	O
)	O
]	O
.	O
	
It	O
may	O
harm	O
them	O
.	O
	
5.8	O
Leukopenia	O
,	O
Neutropenia	O
,	O
and	O
Agranulocytosis	O
In	O
clinical	O
trial	O
and	O
postmarketing	O
experience	O
,	O
leukopenia	B
and	O
neutropenia	B
have	O
been	O
reported	O
temporally	O
related	O
to	O
antipsychotic	O
agents	O
,	O
including	O
SAPHRIS	O
.	O
	
Reproductive	O
System	O
and	O
Breast	O
Changes	O
:	O
breast	B
pain	I
,	O
erectile	B
dysfunction	I
,	O
gynecomastia	B
.	O
	
5.3	O
Neutropenia	O
(	O
Use	O
with	O
Ribavirin	O
and	O
Peginterferon	O
Alfa	O
)	O
In	O
Phase	O
2	O
and	O
3	O
clinical	O
trials	O
,	O
seven	O
percent	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
had	O
neutrophil	B
counts	I
of	I
less	I
than	I
0.5	I
*	I
10	I
9	I
per	I
L	I
compared	O
to	O
4	O
%	O
of	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
If	O
the	O
abnormalities	O
are	O
confirmed	O
,	O
monitor	O
serum	O
liver	O
tests	O
weekly	O
until	O
resolved	O
or	O
stabilized	O
.	O
	
The	O
trial	O
excluded	O
patients	O
with	O
abnormal	O
left	O
ventricular	O
ejection	O
fraction	O
or	O
cardiac	O
valve	O
morphology	O
(	O
>	O
=Grade	O
2	O
)	O
,	O
corrected	O
QT	O
interval	O
>	O
=480	O
milliseconds	O
on	O
electrocardiogram	O
,	O
or	O
a	O
known	O
history	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
deficiency	O
.	O
	
Dose	O
modifications	O
Adverse	O
reactions	O
that	O
led	O
to	O
dose	O
delays	O
in	O
more	O
than	O
5	O
%	O
of	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
were	O
neutropenia	B
(	O
14	O
%	O
)	O
and	O
peripheral	B
sensory	I
neuropathy	I
(	O
11	O
%	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Opportunistic	B
infections	I
organisms	O
including	O
aspergillosis	B
,	O
blastomycosis	B
,	O
candidiasis	B
,	O
coccidioidomycosis	B
,	O
histoplasmosis	B
,	O
legionellosis	B
,	O
listeriosis	B
,	O
pneumocystosis	B
,	O
and	O
tuberculosis	B
have	O
been	O
reported	O
with	O
TNF-blockers	O
.	O
	
Three	O
subjects	O
experienced	O
severe	O
or	O
life-threatening	O
infections	B
associated	O
with	O
neutropenia	B
,	O
and	O
two	O
subjects	O
experienced	O
life-threatening	O
neutropenia	B
while	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
.	O
	
In	O
short-term	O
bipolar	O
mania	O
adult	O
trials	O
,	O
syncope	B
was	O
reported	O
in	O
0.3	O
%	O
(	O
1/379	O
)	O
of	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
(	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
)	O
of	O
SAPHRIS	O
,	O
compared	O
to	O
0	O
%	O
(	O
0/203	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
were	O
pneumonia	B
(	O
4	O
%	O
)	O
,	O
pyrexia	B
(	O
4	O
%	O
)	O
,	O
vomiting	B
(	O
3	O
%	O
)	O
,	O
nausea	B
(	O
2	O
%	O
)	O
,	O
hepatotoxicity	B
(	O
2	O
%	O
)	O
and	O
peripheral	B
sensory	I
neuropathy	I
(	O
2	O
%	O
)	O
.	O
	
Discontinue	O
PROMACTA	O
if	O
ALT	O
levels	O
increase	O
to	O
greater	O
than	O
or	O
equal	O
to	O
3	O
x	O
ULN	O
in	O
patients	O
with	O
normal	O
liver	O
function	O
or	O
greater	O
than	O
or	O
equal	O
to	O
3	O
x	O
baseline	O
in	O
patients	O
with	O
pre-treatment	O
elevations	O
in	O
transaminases	O
and	O
are	O
:	O
*	O
progressively	O
increasing	O
,	O
or	O
*	O
persistent	O
for	O
greater	O
than	O
or	O
equal	O
to	O
4	O
weeks	O
,	O
or	O
*	O
accompanied	O
by	O
increased	O
direct	O
bilirubin	O
,	O
or	O
*	O
accompanied	O
by	O
clinical	O
symptoms	O
of	O
liver	O
injury	O
or	O
evidence	O
for	O
hepatic	O
decompensation	O
.	O
	
Monitoring	O
of	O
orthostatic	O
vital	O
signs	O
should	O
be	O
considered	O
in	O
all	O
such	O
patients	O
,	O
and	O
a	O
dose	O
reduction	O
should	O
be	O
considered	O
if	O
hypotension	O
occurs	O
.	O
	
This	O
Patient	O
Information	O
summarizes	O
the	O
most	O
important	O
information	O
about	O
DUAVEE	O
.	O
	
*	O
Heart	B
failure	I
,	O
may	O
occur	O
.	O
	
Renal	O
and	O
hematuria	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
serious	O
adverse	O
reactions	O
reported	O
with	O
NULOJIX	O
are	O
:	O
*	O
PTLD	B
,	O
predominantly	O
CNS	B
PTLD	I
,	O
and	O
other	O
malignancies	B
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.3	O
)	O
]	O
*	O
Serious	O
infections	B
,	O
including	O
JC	B
virus-associated	O
PML	B
and	O
polyoma	B
virus	I
nephropathy	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
,	O
5.5	O
,	O
5.6	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
on	O
NULOJIX	O
treatment	O
)	O
are	O
anemia	B
,	O
diarrhea	B
,	O
urinary	B
tract	I
infection	I
,	O
peripheral	B
edema	I
,	O
constipation	B
,	O
hypertension	B
,	O
pyrexia	B
,	O
graft	B
dysfunction	I
,	O
cough	B
,	O
nausea	B
,	O
vomiting	B
,	O
headache	B
,	O
hypokalemia	B
,	O
hyperkalemia	B
,	O
and	O
leukopenia	B
.	O
	
Opportunistic	B
infections	I
,	O
or	O
other	O
opportunistic	O
pathogens	O
including	O
aspergillosis	B
,	O
blastomycosis	B
,	O
candidiasis	B
,	O
coccidioidomycosis	B
,	O
histoplasmosis	B
,	O
legionellosis	B
,	O
listeriosis	B
,	O
pneumocystosis	B
and	O
tuberculosis	B
have	O
been	O
reported	O
with	O
TNF	O
blockers	O
.	O
	
If	O
hypersensitivity	O
reactions	O
occur	O
,	O
discontinue	O
use	O
of	O
TANZEUM	O
;	O
treat	O
promptly	O
per	O
standard	O
of	O
care	O
and	O
monitor	O
until	O
signs	O
and	O
symptoms	O
resolve	O
[	O
see	O
Contraindications	O
(	O
4.2	O
)	O
]	O
.	O
	
Overall	O
,	O
abnormalities	B
in	I
liver	I
tests	I
(	I
ALT	I
)	O
were	O
reported	O
with	O
similar	O
frequency	O
in	O
the	O
DALVANCE	O
and	O
comparator	O
arms	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
study	O
drug	O
due	O
to	O
anemia	B
was	O
1	O
%	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
and	O
1	O
%	O
in	O
subjects	O
who	O
received	O
PegIntron/REBETOL	O
.	O
	
Advise	O
pregnant	O
women	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus	O
.	O
	
Women	O
taking	O
DUAVEE	O
should	O
not	O
take	O
progestins	O
,	O
additional	O
estrogens	O
or	O
additional	O
estrogen	O
agonist/antagonists	O
.	O
	
Reported	O
thromboembolic	B
complications	I
and	O
were	O
observed	O
at	O
low	O
and	O
at	O
normal	O
platelet	O
counts	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
ADCETRIS	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
5.4	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
Teflaro	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
bacterial	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
increases	O
the	O
risk	O
of	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
Excluded	O
from	O
this	O
list	O
are	O
those	O
events	O
that	O
were	O
minor	O
,	O
those	O
with	O
no	O
plausible	O
relation	O
to	O
drug	O
use	O
,	O
and	O
reports	O
too	O
imprecise	O
to	O
be	O
meaningful	O
.	O
	
The	O
demographic	O
and	O
baseline	O
characteristics	O
of	O
the	O
long	O
term	O
safety	O
trials	O
were	O
similar	O
to	O
those	O
of	O
the	O
placebo-controlled	O
trials	O
.	O
	
(	O
5.3	O
)	O
*	O
Hypersensitivity	B
Reactions	I
:	O
Discontinue	O
TANZEUM	O
if	O
suspected	O
.	O
	
Conjugated	O
estrogens	O
are	O
a	O
mixture	O
of	O
sodium	O
estrone	O
sulfate	O
and	O
sodium	O
equilin	O
sulfate	O
and	O
other	O
components	O
,	O
including	O
sodium	O
sulfate	O
conjugates	O
,	O
17alpha-dihydroequilin	O
,	O
17alpha-estradiol	O
,	O
and	O
17beta-dihydroequilin	O
.	O
	
Pyrexia	B
,	O
chills	B
,	O
and	O
nausea	B
were	O
the	O
most	O
common	O
reasons	O
cited	O
for	O
dose	O
reductions	O
and	O
pyrexia	B
,	O
chills	B
,	O
and	O
decreased	B
ejection	I
fraction	I
were	O
the	O
most	O
common	O
reasons	O
cited	O
for	O
dose	O
interruptions	O
of	O
TAFINLAR	O
and	O
trametinib	O
when	O
used	O
in	O
combination	O
.	O
	
One	O
of	O
these	O
forms	O
of	O
contraception	O
can	O
be	O
a	O
combined	O
oral	O
contraceptive	O
product	O
containing	O
at	O
least	O
1	O
mg	O
of	O
norethindrone	O
.	O
	
Blood	O
and	O
Lymphatic	O
System	O
Disorders	O
:	O
anemia	B
,	O
idiopathic	B
thrombocytopenic	I
purpura	I
,	O
leukocytosis/leukopenia	O
,	O
neutropenia	B
,	O
pancytopenia	B
,	O
splenomegaly	B
,	O
thrombocytopenia	B
.	O
	
If	O
pancreatitis	O
is	O
confirmed	O
,	O
TANZEUM	O
should	O
not	O
be	O
restarted	O
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
If	O
an	O
allergic	O
reaction	O
occurs	O
,	O
treatment	O
with	O
DALVANCE	O
should	O
be	O
discontinued	O
.	O
	
The	O
risk	O
may	O
also	O
be	O
increased	O
by	O
traumatic	O
or	O
repeated	O
epidural	O
or	O
spinal	O
puncture	O
.	O
	
CMV	O
prophylaxis	O
is	O
recommended	O
for	O
at	O
least	O
3	O
months	O
after	O
transplantation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
These	O
hematomas	B
may	O
result	O
in	O
permanent	B
paralysis	I
.	O
	
5.7	O
Serious	O
Febrile	O
Reactions	O
Serious	O
febrile	B
reactions	I
and	O
fever	B
of	O
any	O
severity	O
complicated	O
by	O
hypotension	B
,	O
rigors	B
or	O
chills	B
,	O
dehydration	B
,	O
or	O
renal	B
failure	I
,	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
5.8	O
Musculoskeletal	O
Pain	O
In	O
post-marketing	O
experience	O
,	O
severe	O
and	O
occasionally	O
incapacitating	O
muscle	B
pain	I
has	O
been	O
reported	O
in	O
patients	O
taking	O
Prolia	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
for	O
FULYZAQ	O
that	O
occurred	O
in	O
at	O
least	O
2	O
%	O
of	O
patients	O
and	O
at	O
a	O
higher	O
incidence	O
than	O
placebo	O
are	O
provided	O
in	O
Table	O
1	O
.	O
	
Monitor	O
and	O
treat	O
as	O
appropriate	O
.	O
	
Failure	O
to	O
block	O
thyroid	O
uptake	O
of	O
iodine	O
123	O
may	O
result	O
in	O
an	O
increased	O
long	O
term	O
risk	O
for	O
thyroid	O
neoplasia	O
.	O
	
Twenty-five	O
of	O
these	O
121	O
patients	O
(	O
21	O
%	O
)	O
had	O
detectable	O
anti-glucarpidase	O
antibodies	O
following	O
VORAXAZE	O
administration	O
,	O
of	O
which	O
19	O
received	O
a	O
single	O
dose	O
of	O
VORAXAZE	O
and	O
6	O
received	O
two	O
doses	O
of	O
VORAXAZE	O
.	O
	
Table	O
1	O
summarizes	O
adverse	O
reactions	O
reported	O
at	O
a	O
rate	O
of	O
at	O
least	O
1	O
%	O
in	O
ULORIC	O
treatment	O
groups	O
and	O
at	O
least	O
0.5	O
%	O
greater	O
than	O
placebo	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
of	O
XALKORI	O
in	O
Studies	O
1	O
and	O
2	O
are	O
vision	B
disorders	I
,	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
edema	B
,	O
elevated	B
transaminases	I
,	O
upper	B
respiratory	I
infection	I
,	O
decreased	B
appetite	I
,	O
and	O
dysgeusia	B
.	O
	
Patients	O
should	O
receive	O
premedication	O
.	O
	
EBV	O
Serostatus	O
The	O
risk	O
of	O
PTLD	B
was	O
higher	O
in	O
EBV	O
seronegative	O
patients	O
compared	O
to	O
EBV	O
seropositive	O
patients	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
Acute	B
hypersensitivity	I
reactions	I
,	O
including	O
dyspnea	B
,	O
rash	B
pruritus	B
,	O
and	O
angioedema	B
of	I
the	I
mouth	I
have	O
been	O
reported	O
with	O
fidaxomicin	O
.	O
	
The	O
use	O
of	O
corticosteroids	O
may	O
be	O
indicated	O
.	O
	
Study	O
1	O
,	O
conducted	O
by	O
the	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
,	O
enrolled	O
184	O
patients	O
;	O
safety	O
information	O
is	O
available	O
for	O
149	O
patients	O
.	O
	
A	O
minority	O
of	O
patients	O
(	O
approximately	O
17	O
%	O
)	O
who	O
tested	O
positive	O
for	O
anti-albiglutide	O
antibodies	O
also	O
transiently	O
tested	O
positive	O
for	O
antibodies	O
to	O
human	O
albumin	O
.	O
	
If	O
irritation	O
persists	O
,	O
consult	O
a	O
physician	O
.	O
	
In	O
both	O
groups	O
,	O
patients	O
with	O
events	O
were	O
generally	O
male	O
,	O
older	O
,	O
and	O
had	O
underlying	O
renal	O
impairment	O
or	O
cardiac	O
disease	O
(	O
e.g.	O
,	O
history	O
of	O
arrhythmia	O
,	O
palpitations	O
,	O
congestive	O
heart	O
failure	O
,	O
cardiomyopathy	O
,	O
etc	O
.	O
	
)	O
.	O
	
For	O
patients	O
who	O
test	O
positive	O
for	O
hepatitis	O
B	O
surface	O
antigen	O
,	O
consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
hepatitis	O
B	O
is	O
recommended	O
before	O
initiating	O
TNF-blocker	O
therapy	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=10	O
%	O
and	O
>	O
=2	O
%	O
placebo	O
)	O
were	O
flushing	B
,	O
abdominal	B
pain	I
,	O
diarrhea	B
,	O
and	O
nausea	B
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
occurring	O
in	O
at	O
least	O
0.5	O
%	O
of	O
subjects	O
)	O
during	O
Neuraceq	O
clinical	O
trials	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
Treatment	O
of	O
CAPS	O
The	O
data	O
described	O
herein	O
reflect	O
exposure	O
to	O
ILARIS	O
in	O
104	O
adult	O
and	O
pediatric	O
CAPS	O
patients	O
,	O
including	O
20	O
FCAS	O
,	O
72	O
MWS	O
,	O
10	O
MWS/NOMID	O
(	O
Neonatal	O
Onset	O
Multisystem	O
Inflammatory	O
Disorder	O
)	O
overlap	O
,	O
1	O
non-FCAS	O
non-MWS	O
,	O
and	O
1	O
misdiagnosed	O
in	O
placebo-controlled	O
(	O
35	O
patients	O
)	O
and	O
uncontrolled	O
trials	O
.	O
	
Corticosteroids	O
may	O
be	O
indicated	O
until	O
clinical	O
symptoms	O
resolve	O
.	O
	
Use	O
of	O
a	O
sensitive	O
real-time	O
reverse-transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assay	O
for	O
monitoring	O
HCV-RNA	O
levels	O
during	O
treatment	O
is	O
recommended	O
.	O
	
G-CSF	O
may	O
be	O
administered	O
to	O
reduce	O
the	O
risks	O
of	O
neutropenia	O
complications	O
associated	O
with	O
JEVTANA	O
use	O
.	O
	
In	O
the	O
two	O
clinical	O
trials	O
in	O
infantile-onset	O
patients	O
,	O
the	O
majority	O
of	O
patients	O
(	O
34	O
of	O
38	O
;	O
89	O
%	O
)	O
tested	O
positive	O
for	O
IgG	O
antibodies	O
to	O
alglucosidase	O
alfa	O
.	O
	
They	O
had	O
a	O
mean	O
age	O
of	O
62	O
years	O
and	O
an	O
average	O
smoking	O
history	O
of	O
44	O
pack-years	O
,	O
with	O
54	O
%	O
identified	O
as	O
current	O
smokers	O
.	O
	
Of	O
these	O
patients	O
,	O
there	O
were	O
2	O
respiratory-related	O
deaths	B
in	O
the	O
ARCAPTA	O
NEOHALER	O
300	O
mcg	O
dose	O
group	O
.	O
	
5.4	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
ZERBAXA	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
bacterial	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
risks	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
The	O
principal	O
efficacy	O
study	O
evaluating	O
the	O
efficacy	O
and	O
safety	O
of	O
HORIZANT	O
in	O
the	O
management	O
of	O
PHN	O
was	O
a	O
12-week	O
,	O
double-blind	O
,	O
multicenter	O
study	O
comparing	O
1,200	O
mg/day	O
,	O
2,400	O
mg/day	O
and	O
3,600	O
mg/day	O
to	O
placebo	O
.	O
	
Diarrhea	B
,	O
nausea	B
,	O
and	O
upper	B
respiratory	I
tract	I
infection	I
were	O
the	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
.	O
	
(	O
5.4	O
)	O
5.1	O
Effects	O
on	O
Driving	O
HORIZANT	O
may	O
cause	O
significant	O
driving	B
impairment	I
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
.	O
	
The	O
most	O
commonly-reported	O
adverse	O
reactions	O
,	O
occurring	O
in	O
>	O
=5	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
were	O
nausea	B
,	O
diarrhea	B
,	O
pyrexia	B
,	O
nasopharyngitis	B
,	O
bronchitis	B
,	O
insomnia	B
,	O
pain	B
in	I
extremity	I
,	O
depression	B
,	O
migraine	B
,	O
and	O
pharyngitis	B
.	O
	
A	O
similar	O
trend	O
was	O
also	O
seen	O
in	O
the	O
cUTI	O
trial	O
.	O
	
Withhold	O
GILOTRIF	O
during	O
evaluation	O
of	O
patients	O
with	O
suspected	O
keratitis	O
,	O
and	O
if	O
diagnosis	O
of	O
ulcerative	O
keratitis	O
is	O
confirmed	O
,	O
treatment	O
with	O
GILOTRIF	O
should	O
be	O
interrupted	O
or	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Reduce	O
or	O
discontinue	O
NORTHERA	O
if	O
supine	O
hypertension	O
persists	O
.	O
	
The	O
study	O
population	O
included	O
34	O
males	O
and	O
26	O
females	O
(	O
n=60	O
)	O
in	O
the	O
alglucosidase	O
alfa	O
group	O
and	O
11	O
males	O
and	O
19	O
females	O
(	O
n=30	O
)	O
in	O
the	O
placebo	O
group	O
.	O
	
Skin	B
discoloration	I
has	O
been	O
reported	O
with	O
higher	O
frequency	O
among	O
emtricitabine-treated	O
subjects	O
;	O
it	O
was	O
manifested	O
by	O
hyperpigmentation	B
on	I
the	I
palms	I
and	O
was	O
generally	O
mild	O
and	O
asymptomatic	O
.	O
	
5.4	O
Facial	O
Anatomy	O
in	O
the	O
Treatment	O
of	O
Glabellar	O
Lines	O
Caution	O
should	O
be	O
exercised	O
when	O
administering	O
DYSPORT	O
(	O
r	O
)	O
to	O
patients	O
with	O
surgical	O
alterations	O
to	O
the	O
facial	O
anatomy	O
,	O
excessive	O
weakness	O
or	O
atrophy	O
in	O
the	O
target	O
muscle	O
(	O
s	O
)	O
,	O
marked	O
facial	O
asymmetry	O
,	O
inflammation	O
at	O
the	O
injection	O
site	O
(	O
s	O
)	O
,	O
ptosis	O
,	O
excessive	O
dermatochalasis	O
,	O
deep	O
dermal	O
scarring	O
,	O
thick	O
sebaceous	O
skin	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.3	O
]	O
or	O
the	O
inability	O
to	O
substantially	O
lessen	O
glabellar	O
lines	O
by	O
physically	O
spreading	O
them	O
apart	O
[	O
seeClinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Since	O
ENTEREG	O
acts	O
peripherally	O
,	O
clinical	O
signs	O
and	O
symptoms	O
of	O
increased	B
sensitivity	I
would	I
be	I
related	I
to	I
the	I
gastrointestinal	I
tract	I
(	O
e.g.	O
,	O
abdominal	B
pain	I
,	O
nausea	B
and	O
vomiting	B
,	O
diarrhea	B
)	O
.	O
	
No	O
hypersensitivity	B
or	O
anaphylactic	B
reactions	I
were	O
reported	O
with	O
FIRAZYR	O
.	O
	
*	O
Corrugator	O
injections	O
should	O
be	O
placed	O
at	O
least	O
1	O
cm	O
above	O
the	O
bony	O
supraorbital	O
ridge	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
were	O
lymphopenia	B
,	O
hyperglycemia	B
,	O
anemia	B
,	O
hypophosphatemia	B
,	O
and	O
hypercholesterolemia	B
.	O
	
Carefully	O
weigh	O
risks	O
and	O
benefits	O
of	O
treatment	O
with	O
OTEZLA	O
in	O
patients	O
with	O
a	O
history	O
of	O
depression	O
and/or	O
suicidal	O
thoughts	O
or	O
behavior	O
.	O
	
(	O
5.7	O
)	O
5.1	O
Mortality	O
There	O
were	O
more	O
deaths	B
reported	O
with	O
BENLYSTA	O
than	O
with	O
placebo	O
during	O
the	O
controlled	O
period	O
of	O
the	O
clinical	O
trials	O
.	O
	
Typical	O
symptoms	O
associated	O
with	O
PML	B
are	O
diverse	O
,	O
progress	O
over	O
days	O
to	O
weeks	O
,	O
and	O
include	O
progressive	B
weakness	I
on	I
one	I
side	I
of	I
the	I
body	I
or	O
clumsiness	B
of	I
limbs	I
,	O
disturbance	B
of	I
vision	I
,	O
and	O
changes	B
in	I
thinking	I
leading	O
to	O
confusion	B
and	O
personality	B
changes	I
.	O
	
For	O
patients	O
who	O
develop	O
prolonged	O
Grade	O
2	O
cutaneous	O
adverse	O
reactions	O
lasting	O
more	O
than	O
7	O
days	O
,	O
intolerable	O
Grade	O
2	O
,	O
or	O
Grade	O
3	O
cutaneous	O
reactions	O
,	O
withhold	O
GILOTRIF	O
until	O
the	O
adverse	O
reaction	O
resolves	O
to	O
Grade	O
1	O
or	O
less	O
,	O
and	O
resume	O
GILOTRIF	O
with	O
appropriate	O
dose	O
reduction	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
rates	O
of	O
adverse	O
reactions	O
below	O
were	O
derived	O
from	O
two	O
randomized	O
,	O
multi-center	O
,	O
vehicle-controlled	O
clinical	O
trials	O
and	O
one	O
open-label	O
study	O
in	O
subjects	O
with	O
head	O
lice	O
infestation	O
.	O
	
Because	O
of	O
its	O
anticholinergic	O
effects	O
,	O
XEOMIN	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
at	O
risk	O
of	O
developing	O
narrow	O
angle	O
glaucoma	O
.	O
	
Psoriatic	O
arthritis	O
:	O
During	O
the	O
0	O
to	O
16	O
week	O
placebo-controlled	O
period	O
of	O
the	O
3	O
controlled	O
clinical	O
trials	O
,	O
1.0	O
%	O
(	O
10/998	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
reported	O
depression	B
or	O
depressed	B
mood	I
compared	O
to	O
0.8	O
%	O
(	O
4/495	O
)	O
treated	O
with	O
placebo	O
.	O
	
Cerebrovascular	O
Adverse	O
Events	O
,	O
Including	O
Stroke	O
In	O
placebo-controlled	O
trials	O
with	O
risperidone	O
,	O
aripiprazole	O
,	O
and	O
olanzapine	O
in	O
elderly	O
patients	O
with	O
dementia	O
,	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
cerebrovascular	B
adverse	I
events	I
(	O
cerebrovascular	B
accidents	I
and	O
transient	B
ischemic	I
attacks	I
)	O
including	O
fatalities	B
compared	O
to	O
placebo-treated	O
patients	O
.	O
	
Changes	O
from	O
baseline	O
in	O
total	O
cholesterol	O
,	O
HDL-cholesterol	O
,	O
LDL-cholesterol	O
,	O
and	O
triglycerides	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
Liver	B
chemistry	I
elevations	I
consistent	O
with	O
immune	B
reconstitution	I
syndrome	I
were	O
observed	O
in	O
some	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
C	O
at	O
the	O
start	O
of	O
therapy	O
with	O
TIVICAY	O
,	O
particularly	O
in	O
the	O
setting	O
where	O
anti-hepatitis	O
therapy	O
was	O
withdrawn	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Patients	O
with	O
pre-	O
existing	O
swallowing	O
or	O
breathing	O
difficulties	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
complications	O
.	O
	
The	O
malignancies	O
occurred	O
after	O
a	O
median	O
of	O
30	O
months	O
(	O
range	O
1	O
to	O
84	O
months	O
)	O
after	O
the	O
first	O
dose	O
of	O
TNF-blocker	O
therapy	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Cardiac	B
toxicities	I
include	O
cardiac	B
failure	I
and	O
myocardial	B
infarction	I
with	O
fatal	B
outcome	O
,	O
and	O
myocardial	B
ischemia	I
.	O
	
Of	O
the	O
patients	O
in	O
those	O
trials	O
,	O
approximately	O
95	O
%	O
were	O
between	O
18	O
and	O
60	O
years	O
old	O
,	O
approximately	O
50	O
%	O
were	O
male	O
,	O
and	O
approximately	O
80	O
%	O
were	O
Caucasian	O
.	O
	
Adverse	O
reactions	O
of	O
venous	B
thromboembolism	I
were	O
reported	O
in	O
0.0	O
%	O
of	O
patients	O
treated	O
with	O
DUAVEE	O
and	O
0.1	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
Monitor	O
thyroid	O
function	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
.	O
	
In	O
the	O
EMTP	O
trial	O
,	O
safety	O
data	O
were	O
derived	O
from	O
case	O
report	O
forms	O
that	O
collected	O
adverse	O
event	O
information	O
.	O
	
*	O
Bipolar	O
Disorder	O
Adults	O
(	O
Monotherapy	O
)	O
:	O
somnolence	B
,	O
dizziness	B
,	O
extrapyramidal	B
symptoms	I
other	O
than	O
akathisia	B
,	O
increased	B
weight	I
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
evidence	O
of	O
untreated	O
brain	O
metastasis	O
or	O
recent	O
active	O
gastrointestinal	O
bleeding	O
and	O
should	O
not	O
be	O
used	O
in	O
those	O
patients	O
.	O
	
5.2	O
Pancreatitis	O
Pancreatitis	B
has	O
been	O
reported	O
in	O
4	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Discontinue	O
Kyprolis	O
if	O
suspected	O
.	O
	
There	O
is	O
no	O
known	O
treatment	O
for	O
established	O
cases	O
of	O
tardive	O
dyskinesia	O
,	O
although	O
the	O
syndrome	O
may	O
remit	O
,	O
partially	O
or	O
completely	O
,	O
if	O
antipsychotic	O
treatment	O
is	O
withdrawn	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
The	O
effects	O
of	O
DYSPORT	O
(	O
r	O
)	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	I
produce	I
symptoms	I
consistent	I
with	I
botulinum	I
toxin	I
effects	I
.	O
	
5.4	O
Demyelinating	O
Disorders	O
Use	O
of	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
has	O
been	O
associated	O
with	O
rare	O
cases	O
of	O
exacerbation	B
of	I
central	I
nervous	I
system	I
(	I
CNS	I
)	I
demyelinating	I
disorders	I
,	O
including	O
multiple	B
sclerosis	I
(	O
MS	B
)	O
and	O
peripheral	B
demyelinating	I
disorders	I
,	O
including	O
Guillain-Barre	B
syndrome	I
.	O
	
There	O
is	O
no	O
clinical	O
trial	O
experience	O
with	O
XTANDI	O
in	O
patients	O
who	O
have	O
had	O
a	O
seizure	O
.	O
	
The	O
most	O
frequently	O
reported	O
ADR	O
at	O
least	O
Grade	O
2	O
in	O
severity	O
was	O
rash	B
(	O
10.0	O
%	O
)	O
.	O
	
Blepharospasm	O
(	O
5.6	O
)	O
:	O
*	O
Corneal	B
exposure	I
*	O
Injection	O
of	O
XEOMIN	O
into	O
the	O
orbicularis	O
oculi	O
muscle	O
may	O
lead	O
to	O
reduced	B
blinking	I
and	O
corneal	B
exposure	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
for	O
AFINITOR	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
were	O
stomatitis	B
and	O
respiratory	B
tract	I
infection	I
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
Consider	O
suspending	O
treatment	O
with	O
GILENYA	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
,	O
and	O
reassess	O
the	O
benefits	O
and	O
risks	O
prior	O
to	O
reinitiation	O
of	O
therapy	O
.	O
	
The	O
majority	O
were	O
in	O
adolescent	O
and	O
young	O
adult	O
males	O
.	O
	
Renal	B
insufficiency	I
adverse	I
events	I
(	O
renal	B
impairment	I
,	O
acute	B
renal	I
failure	I
,	O
renal	B
failure	I
)	O
have	O
occurred	O
with	O
an	O
incidence	O
of	O
approximately	O
8	O
%	O
in	O
a	O
randomized	O
controlled	O
trial	O
.	O
	
TABLE	O
1	O
:	O
Changes	O
in	O
Fasting	O
Glucose	O
in	O
Adult	O
Patients	O
N*	O
=	O
Number	O
of	O
patients	O
who	O
had	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
The	O
duration	O
of	O
Prolia	O
exposure	O
to	O
time	O
of	O
atypical	B
femoral	I
fracture	I
diagnosis	O
was	O
as	O
early	O
as	O
21/2	O
years	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
Mean	O
changes	B
(	I
percent	I
changes	I
)	I
from	I
baseline	I
in	I
non-HDL-C	I
relative	O
to	O
placebo	O
were	O
2.1	O
mg/dL	O
(	O
1.5	O
%	O
)	O
and	O
5.1	O
mg/dL	O
(	O
3.6	O
%	O
)	O
with	O
INVOKANA	O
100	O
mg	O
and	O
300	O
mg	O
,	O
respectively	O
.	O
	
Monitor	O
blood	O
pressure	O
during	O
and	O
following	O
the	O
treatment	O
procedure	O
.	O
	
No	O
new	O
major	O
safety	O
findings	O
were	O
reported	O
from	O
a	O
50-week	O
,	O
open-label	O
,	O
uncontrolled	O
safety	O
trial	O
.	O
	
A	O
total	O
of	O
56	O
%	O
of	O
patients	O
were	O
female	O
and	O
45	O
%	O
of	O
patients	O
were	O
Asian	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
*	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
labeling	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
(	O
NSF	B
)	O
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
causes	O
of	O
death	B
in	O
the	O
remaining	O
subjects	O
varied	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
other	O
drugs	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
QT	B
prolongation	I
can	O
occur	O
with	O
SIRTURO	O
.	O
	
Patients	O
with	O
uncontrolled	O
or	O
significant	O
cardiovascular	O
disease	O
including	O
QT	O
interval	O
prolongation	O
were	O
excluded	O
by	O
protocol	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
in	O
pregnant	O
women	O
using	O
JEVTANA	O
.	O
	
The	O
adverse	O
reaction	O
most	O
commonly	O
(	O
>	O
=1	O
%	O
on	O
APTIOM	O
)	O
leading	O
to	O
discontinuation	O
was	O
hyponatremia	B
.	O
	
BRAF	O
V600E	O
Unresectable	O
or	O
Metastatic	O
Melanoma	O
:	O
The	O
safety	O
of	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
was	O
evaluated	O
in	O
586	O
patients	O
with	O
BRAF	O
V600	O
mutation-positive	O
unresectable	O
or	O
metastatic	O
melanoma	O
,	O
previously	O
treated	O
or	O
untreated	O
,	O
who	O
received	O
TAFINLAR	O
150	O
mg	O
orally	O
twice	O
daily	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
,	O
including	O
181	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months	O
and	O
86	O
additional	O
patients	O
treated	O
for	O
more	O
than	O
12	O
months	O
.	O
	
5.4	O
Tumor	O
Lysis	O
Syndrome	O
Tumor	B
lysis	I
syndrome	I
associated	O
with	O
TREANDA	O
treatment	O
has	O
occurred	O
in	O
patients	O
in	O
clinical	O
trials	O
and	O
in	O
postmarketing	O
reports	O
.	O
	
Fatal	B
and	O
serious	O
cases	O
of	O
renal	B
failure	I
have	O
occurred	O
with	O
IMBRUVICA	O
therapy	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
NESINA	O
.	O
	
(	O
6.1	O
)	O
Upper	O
Limb	O
Spasticity	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
are	O
:	O
urinary	B
tract	I
infection	I
,	O
nasopharyngitis	B
,	O
muscular	B
weakness	I
,	O
musculoskeletal	B
pain	I
,	O
dizziness	B
,	O
fall	B
and	O
depression	B
.	O
	
Myelosuppression	O
may	O
require	O
dose	O
delays	O
and/or	O
subsequent	O
dose	O
reductions	O
if	O
recovery	O
to	O
the	O
recommended	O
values	O
has	O
not	O
occurred	O
by	O
the	O
first	O
day	O
of	O
the	O
next	O
scheduled	O
cycle	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Pfizer	O
,	O
Inc	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Hypersensitivity	B
reactions	I
including	O
anaphylactic	B
shock	I
(	O
fatal	B
)	O
,	O
urticaria	B
,	O
and	O
angioedema	B
have	O
been	O
reported	O
.	O
	
Typical	O
symptoms	O
associated	O
with	O
PML	O
are	O
diverse	O
,	O
progress	O
over	O
days	O
to	O
weeks	O
,	O
and	O
include	O
progressive	O
weakness	O
on	O
one	O
side	O
of	O
the	O
body	O
or	O
clumsiness	O
of	O
limbs	O
,	O
disturbance	O
of	O
vision	O
,	O
and	O
changes	O
in	O
thinking	O
,	O
memory	O
,	O
and	O
orientation	O
leading	O
to	O
confusion	O
and	O
personality	O
changes	O
.	O
	
(	O
5.3	O
)	O
*	O
Tumor	B
Lysis	I
Syndrome	I
:	O
Acute	B
renal	I
failure	I
and	O
death	B
;	O
anticipate	O
and	O
use	O
supportive	O
measures	O
.	O
	
No	O
new	O
adverse	O
reactions	O
were	O
reported	O
.	O
	
Local	B
skin	I
reactions	I
typically	O
occurred	O
within	O
1	O
day	O
of	O
treatment	O
initiation	O
,	O
peaked	O
in	O
intensity	O
up	O
to	O
1	O
week	O
following	O
completion	O
of	O
treatment	O
,	O
and	O
resolved	O
within	O
2	O
weeks	O
for	O
areas	O
treated	O
on	O
the	O
face	O
and	O
scalp	O
,	O
and	O
within	O
4	O
weeks	O
for	O
areas	O
treated	O
on	O
the	O
trunk	O
and	O
extremities	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Anaphylaxis	B
and	O
angioedema	B
:	O
Discontinue	O
and	O
do	O
not	O
restart	O
TECFIDERA	O
if	O
these	O
occur	O
.	O
	
Study	O
1	O
Adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
from	O
the	O
CLL	O
trial	O
(	O
N=48	O
)	O
using	O
single	O
agent	O
IMBRUVICA	O
420	O
mg	O
daily	O
occurring	O
at	O
a	O
rate	O
of	O
>	O
=	O
10	O
%	O
are	O
presented	O
in	O
Tables	O
3	O
and	O
4	O
.	O
	
Patients	O
should	O
have	O
baseline	O
ophthalmologic	O
testing	O
by	O
an	O
ophthalmic	O
professional	O
and	O
follow-up	O
testing	O
every	O
6	O
months	O
.	O
	
The	O
median	O
exposure	O
was	O
11.0	O
months	O
for	O
patients	O
treated	O
with	O
GILOTRIF	O
and	O
3.4	O
months	O
for	O
patients	O
treated	O
with	O
pemetrexed/cisplatin	O
.	O
	
Psoriatic	O
Arthritis	O
Clinical	O
Study	O
CIMZIA	O
has	O
been	O
studied	O
in	O
409	O
patients	O
with	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
in	O
a	O
placebo-controlled	O
trial	O
.	O
	
Conditions	O
that	O
lower	O
the	O
seizure	O
threshold	O
may	O
be	O
more	O
prevalent	O
in	O
a	O
population	O
of	O
65	O
years	O
or	O
older	O
.	O
	
Renal-related	B
adverse	I
reactions	I
,	O
including	O
renal	B
failure	I
and	O
blood	B
creatinine	I
increase	I
,	O
were	O
more	O
frequent	O
in	O
patients	O
treated	O
with	O
FARXIGA	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
of	O
MTC	O
with	O
use	O
of	O
TRULICITY	O
and	O
inform	O
them	O
of	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g.	O
,	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
persistent	O
hoarseness	O
)	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
the	O
adverse	O
reaction	O
rates	O
observed	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
other	O
clinical	O
trials	O
or	O
experience	O
with	O
therapeutics	O
in	O
the	O
same	O
class	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
*	O
Cytokine	B
Release	I
Syndrome	I
(	O
CRS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
Bacterial	O
,	O
Mycobacterial	O
,	O
Viral	O
,	O
and	O
Fungal	O
Infections	O
Adverse	O
reactions	O
of	O
infectious	B
etiology	I
were	O
reported	O
based	O
on	O
clinical	O
assessment	O
by	O
physicians	O
.	O
	
All	O
infections	B
#	O
27	O
(	O
7	O
)	O
26	O
(	O
6	O
)	O
55	O
(	O
14	O
)	O
46	O
(	O
11	O
)	O
Tuberculosis	B
2	O
(	O
1	O
)	O
1	O
(	O
<	O
1	O
)	O
6	O
(	O
2	O
)	O
1	O
(	O
<	O
1	O
)	O
Infections	O
Reported	O
in	O
the	O
CNS	O
Following	O
three	O
years	O
of	O
treatment	O
in	O
Studies	O
1	O
and	O
2	O
,	O
cryptococcal	B
meningitis	I
was	O
reported	O
in	O
one	O
patient	O
out	O
of	O
401	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
(	O
0.2	O
%	O
)	O
and	O
one	O
patient	O
out	O
of	O
the	O
405	O
treated	O
with	O
the	O
cyclosporine	O
control	O
(	O
0.2	O
%	O
)	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=30	O
%	O
)	O
are	O
neutropenia	B
,	O
hypertriglyceridemia	B
,	O
hyperglycemia	B
,	O
ALT	B
elevations	I
,	O
and	O
AST	B
elevations	I
(	O
6.1	O
)	O
.	O
	
(	O
5.5	O
)	O
item	O
{	O
Fungal	O
infections-	O
Fungal	B
infections	I
of	I
the	I
cornea	I
are	O
particularly	O
prone	O
to	O
develop	O
coincidentally	O
with	O
long-term	O
local	O
steroid	O
application	O
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
in	O
88	O
%	O
of	O
patients	O
and	O
moderately	O
impaired	O
in	O
11	O
%	O
of	O
patients	O
(	O
mean	O
eGFR	O
82	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contactJanssen	O
Biotech	O
,	O
Inc.	O
at	O
1-800-JANSSEN	O
(	O
1-800-526-7736	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
median	O
number	O
of	O
dosing	O
delays	O
was	O
one	O
in	O
patients	O
receiving	O
COMETRIQ	O
compared	O
to	O
none	O
in	O
patients	O
receiving	O
placebo	O
.	O
	
5.4	O
Abnormal	O
Bleeding	O
SSRIs	O
and	O
SNRIs	O
,	O
including	O
PRISTIQ	O
,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	B
events	O
.	O
	
5.6	O
Activation	O
of	O
Mania/Hypomania	O
During	O
all	O
MDD	O
phase	O
2	O
and	O
phase	O
3	O
studies	O
,	O
mania	B
was	O
reported	O
for	O
approximately	O
0.02	O
%	O
of	O
patients	O
treated	O
with	O
PRISTIQ	O
.	O
	
In	O
the	O
patients	O
who	O
developed	O
antibodies	O
during	O
treatment	O
,	O
the	O
median	O
titer	O
(	O
by	O
dilution	O
method	O
)	O
was	O
8	O
,	O
with	O
a	O
range	O
of	O
5	O
to	O
80	O
.	O
	
The	O
retinal	B
abnormalities	I
observed	O
with	O
POTIGA	O
have	O
been	O
reported	O
in	O
patients	O
who	O
were	O
originally	O
enrolled	O
in	O
clinical	O
trials	O
with	O
POTIGA	O
and	O
who	O
have	O
generally	O
taken	O
the	O
drug	O
for	O
a	O
long	O
period	O
of	O
time	O
in	O
2	O
ongoing	O
extension	O
trials	O
.	O
	
c	O
Includes	O
the	O
terms	O
feeling	B
cold	I
and	O
chills	B
.	O
	
0.3	O
2.8	O
2.7	O
Nausea	B
2.4	O
2.8	O
2.5	O
Influenza	B
2.3	O
2.7	O
2.3	O
Dyslipidemia	B
1.5	O
2.1	O
2.5	O
Constipation	B
1.5	O
2.2	O
1.9	O
Discomfort	B
with	I
urination	I
0.7	O
1.6	O
2.1	O
Pain	B
in	I
extremity	I
1.4	O
2.0	O
1.7	O
Pool	O
of	O
13	O
Placebo-Controlled	O
Studies	O
for	O
FARXIGA	O
10	O
mg	O
The	O
safety	O
and	O
tolerability	O
of	O
FARXIGA	O
10	O
mg	O
was	O
also	O
evaluated	O
in	O
a	O
larger	O
placebo-controlled	O
study	O
pool	O
.	O
	
The	O
following	O
adverse	O
reactions	O
are	O
described	O
in	O
more	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
of	O
the	O
label	O
:	O
Seizures	B
,	O
Anaphylaxis	B
,	O
and	O
Urinary	B
Tract	I
Infections	I
.	O
	
The	O
risk	O
did	O
not	O
vary	O
substantially	O
by	O
age	O
(	O
5-100	O
years	O
)	O
in	O
the	O
clinical	O
trials	O
analyzed	O
.	O
	
5.9	O
Drug	O
Interactions	O
with	O
Strong	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
Caution	O
should	O
be	O
exercised	O
when	O
considering	O
the	O
coadministration	O
of	O
BREO	O
ELLIPTA	O
with	O
long-term	O
ketoconazole	O
and	O
other	O
known	O
strong	O
CYP3A4	O
inhibitors	O
(	O
e.g.	O
,	O
ritonavir	O
,	O
clarithromycin	O
,	O
conivaptan	O
,	O
indinavir	O
,	O
itraconazole	O
,	O
lopinavir	O
,	O
nefazodone	O
,	O
nelfinavir	O
,	O
saquinavir	O
,	O
telithromycin	O
,	O
troleandomycin	O
,	O
voriconazole	O
)	O
because	O
increased	O
systemic	O
corticosteroid	O
and	O
increased	O
cardiovascular	O
adverse	O
effects	O
may	O
occur	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
,	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Monitor	O
for	O
pulmonary	O
symptoms	O
and	O
bilateral	O
interstitial	O
infiltrates	O
.	O
	
Interrupt	O
BLINCYTO	O
if	O
the	O
transaminases	O
rise	O
to	O
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
if	O
bilirubin	O
rises	O
to	O
more	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O
	
Table	O
3	O
:	O
Key	O
Laboratory	O
Abnormalities	O
Occurring	O
in	O
>	O
10	O
%	O
(	O
All	O
NCI	O
CTCAE	O
Grades	O
)	O
of	O
ALK-Positive	O
Patients	O
Treated	O
with	O
ZYKADIA	O
in	O
Study	O
1	O
ZYKADIAN=255	O
All	O
Grades	O
Grade	O
3-4	O
%	O
%	O
Hemoglobin	B
decreased	I
84	O
5	O
ALT	B
)	I
increased	I
80	O
27	O
AST	B
)	I
increased	I
75	O
13	O
Creatinine	B
increased	I
58	O
2	O
Glucose	B
increased	I
49	O
13	O
Phosphate	B
decreased	I
36	O
7	O
Lipase	B
increased	I
28	O
10	O
Bilirubin	B
(	I
total	I
)	I
increased	I
15	O
1	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Severe	O
or	O
Persistent	O
Gastrointestinal	O
Toxicity	O
:	O
Dose	O
modification	O
due	O
to	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
or	O
abdominal	B
pain	I
occurred	O
in	O
38	O
%	O
of	O
patients	O
.	O
	
Prior	O
to	O
AdreView	O
administration	O
,	O
ensure	O
emergency	O
cardiac	O
and	O
anti-hypertensive	O
treatments	O
are	O
readily	O
available	O
.	O
	
Patients	O
receiving	O
the	O
drug	O
should	O
be	O
managed	O
in	O
facilities	O
equipped	O
and	O
staffed	O
with	O
adequate	O
laboratory	O
and	O
supportive	O
medical	O
resources	O
.	O
	
If	O
an	O
infusion-related	O
reaction	O
occurs	O
,	O
the	O
infusion	O
should	O
be	O
interrupted	O
and	O
appropriate	O
medical	O
management	O
instituted	O
.	O
	
Intracranial	B
hemorrhage	I
included	O
subdural	B
bleeds	I
.	O
	
Effects	O
of	O
fluticasone	O
furoate	O
on	O
the	O
HPA	O
axis	O
are	O
not	O
observed	O
with	O
the	O
therapeutic	O
doses	O
of	O
BREO	O
ELLIPTA	O
.	O
	
Chronic	O
Immune	O
(	O
Idiopathic	O
)	O
Thrombocytopenia	O
:	O
Adults	O
:	O
In	O
clinical	O
trials	O
,	O
hemorrhage	B
was	O
the	O
most	O
common	O
serious	O
adverse	O
reaction	O
and	O
most	O
hemorrhagic	B
reactions	I
followed	O
discontinuation	O
of	O
PROMACTA	O
.	O
	
Table	O
3	O
shows	O
the	O
number	O
of	O
patients	O
experiencing	O
bleeding	B
events	O
in	O
the	O
pooled	O
analysis	O
of	O
RE-COVER	O
and	O
RE-COVER	O
II	O
studies	O
during	O
the	O
full	O
treatment	O
including	O
parenteral	O
and	O
oral	O
only	O
treatment	O
periods	O
after	O
randomization	O
.	O
	
Table	O
1shows	O
all	O
adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
of	O
greater	O
than	O
or	O
equal	O
to	O
1	O
%	O
in	O
the	O
TUDORZA	O
PRESSAIR	O
group	O
in	O
the	O
two	O
3-month	O
and	O
one	O
6-month	O
placebo-controlled	O
trials	O
where	O
the	O
rates	O
in	O
the	O
TUDORZA	O
PRESSAIR	O
group	O
exceeded	O
placebo	O
.	O
	
Adverse	O
reaction	O
information	O
for	O
Ferriprox	O
represents	O
the	O
pooled	O
data	O
collected	O
from	O
642	O
patients	O
who	O
participated	O
in	O
single	O
arm	O
or	O
active-controlled	O
clinical	O
studies	O
.	O
	
The	O
median	O
duration	O
of	O
exposure	O
was	O
6.1	O
months	O
(	O
range	O
0.3	O
to	O
26.4	O
months	O
)	O
.	O
	
Dose	O
reduction	O
due	O
to	O
peripheral	B
neuropathy	I
was	O
required	O
by	O
3	O
%	O
(	O
14/503	O
)	O
of	O
patients	O
who	O
received	O
HALAVEN	O
.	O
	
In	O
addition	O
,	O
no	O
clinical	O
safety	O
concerns	O
related	O
to	O
the	O
inhibition	O
of	O
endogenous	O
MMPs	O
have	O
been	O
observed	O
.	O
	
5.10	O
Pulmonary	O
Toxicity	O
Events	O
of	O
noninfectious	B
pulmonary	I
toxicity	I
including	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
and	O
acute	B
respiratory	I
distress	I
syndrome	I
(	O
ARDS	B
)	O
,	O
some	O
with	O
fatal	B
outcomes	O
,	O
have	O
been	O
reported	O
.	O
	
Table	O
1	O
shows	O
adverse	O
reactions	O
on	O
the	O
ZYTIGA	O
arm	O
in	O
Study	O
1	O
that	O
occurred	O
with	O
a	O
>	O
=2	O
%	O
absolute	O
increase	O
in	O
frequency	O
compared	O
to	O
placebo	O
or	O
were	O
events	O
of	O
special	O
interest	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
treated	O
with	O
Teflaro	O
was	O
54	O
years	O
,	O
ranging	O
between	O
18	O
and	O
99	O
years	O
old	O
.	O
	
Neutralizing	O
antibodies	O
were	O
assayed	O
for	O
a	O
subset	O
of	O
70	O
samples	O
selected	O
to	O
be	O
representative	O
of	O
high	O
and	O
low	O
titer	O
binding	O
antibody	O
responses	O
at	O
week	O
12	O
of	O
treatment	O
.	O
